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Abstract  
 
Cytochrome P450 enzymes (P450s) are involved in cancer development and treatment due 
to their roles in the oxidative metabolism of various endogenous (e.g. oestrogen) and 
exogenous (e.g. tamoxifen) compounds.  It is well-known that intermediate P450 
metabolites derived from oestrogen metabolism are associated with breast carcinogenesis.  
The main aim of this project was to profile the cytochrome P450 and P450-regulatory 
nuclear receptor mRNAs in a series of breast cancer cell lines (BCCs) and compare this 
profile with normal breast cells.  This study used the qualitative reverse transcriptase-
polymerase chain reaction (RT-PCR) to detect mRNA expression of target genes.  Results 
showed CYP1B1, CYP2D6, CYP2J2, CYP2R1, CYP2U1 and CYP4X1 mRNA to be 
present in all cell lines.  CYP2A6, CYP2C8, CYP2C18, CYP2F1 and CYP4Z1 mRNA 
were expressed in oestrogen receptor (ER)-positive Caucasian and ER-negative Afro-
Caribbean BCCs.  Although no differences in P450 mRNA were observed between the 
different ethnic groups, these preliminary findings suggest potential similarities in the ER-
positive Caucasian and ER-negative Afro-Caribbean BCCs which warrant further 
investigation 
 
The CYP4Z1 PCR product was identified as two distinct bands.  Specific primer sets were 
used to demonstrate potential intron retention in CYP4Z1.  Using established in vitro 
models for the study of regulatory mechanisms of CYP4Z1, T47D and ZR-75-1 breast 
cancer cell lines were used to determine the appropriate nuclear receptors (i.e. progesterone 
receptor, glucocorticoid receptor or peroxisome proliferator-activated receptor alpha ).  
These findings suggest that there may be an alternative receptor mechanism involved in 
CYP4Z1 mRNA induction in these cells.  In conjunction, pre-treatment of these two cell 
lines with the RNA synthesis inhibitor actinomycin D followed by the agonists showed a 
significant reduction (p < 0.05) of CYP4Z1 mRNA levels and inhibited CYP4Z1 induction 
by either progesterone, dexamethasone or pirinixic acid, indicating that these agonists have 
effects on CYP4Z1 mRNA transcription or stability.  In contrast, cycloheximide 
differentially affected the level of CYP4Z1 mRNA induction by these agonists.  Taken 
together, these results suggest that CYP4Z1 mRNA induction in T47D and ZR-75-1 is 
mediated through differential cell type specific regulatory mechanisms and there is 
evidence for differential regulation of the splice variants. 
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Chapter 1 
General Introduction 
 
1.1 Introduction 
According to a recent report by Cancer Research UK, breast cancer is the second most 
common cause of cancer mortality in women (http://www.cancerresearchuk.org).  In 2005, 
it was responsible for more than 12,000 deaths in women and accounted for 17% of all 
female cancer deaths.  The most important prognostic factor related to survival and tumour 
recurrence following surgery is node-positive breast cancer patients.  The prognosis of 
these patients compared to patients with primary breast cancer is poor, despite 
improvements in chemotherapy (Wapnir et al. 2006).  In addition, ethnic differences in 
breast cancer survival between Caucasian and Afro-Caribbean women have been well 
documented.  A poorer prognosis and more aggressive breast cancer are found in Afro-
Caribbean compared to Caucasian women (Curtis et al. 2008).  However, it is unclear why, 
and there is an urgent need to identify the main factors involved in these differences.  
Clinically, the critical aspects concerning the use of chemotherapy associated with the poor 
prognosis of patients are tumour resistance and drug toxicity.  Some of this variability may 
be due to the clearance and metabolism of the anticancer drugs used in breast cancer 
treatment.  
 
Although antioestrogen therapy and aromatase inhibitors have long been shown to be 
effective in reducing the risk of recurrence and death in patients with oestrogen receptor 
(ER) positive tumours, the use of these treatments has been limited in patients with ER 
negative tumours (Chia et al. 2005).  ER-negative breast tumours are more aggressive and 
have a poorer prognosis when compared with ER-positive tumours and it is therefore, clear 
that targeted therapies for this patient population are needed (Rochefort et al. 2003).   
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At the present time, the progression and invasion of breast cancer is not fully understood.  
However, lifetime exposure to oestrogen correlates with increased risk of breast cancer in 
women, suggesting that oestrogen plays a crucial role in breast carcinogenesis (Henderson 
and Feigelson 2000).  Two main hypotheses have been discussed concerning oestrogen and 
breast cancer.  Firstly, binding of oestrogen to ER increases cell division and DNA 
synthesis, resulting in DNA mutations in mammary cells (Yager and Davidson 2006).  
Secondly, intermediate metabolites derived from oestrogen metabolism cause DNA 
damage by producing free radicals, leading to initiation and promotion of breast cancer 
(Deroo and Korach 2006).   
 
For the latter hypothesis, a better understanding of the mechanisms involved in biotrans- 
formation of endogenous and/or xenobiotic compounds by breast cancer cells is very 
important as it contributes to the development of new target therapies as well as the 
knowledge of breast cancer progression and invasion.  These compounds are usually 
detoxified into inactive forms by enzymes existing in local cells.  Cytochrome P450 
enzymes (P450s) are one of the key enzymes involved in the oxidative metabolism of a 
wide range of endogenous (e.g. oestrogen, vitamin A and vitamin D) and exogenous (e.g. 
tamoxifen, cyclophosphamide, paclitaxel and some carcinogens) compounds (Nebert and 
Nelson 2005).  It is important to note that certain chemicals which are not carcinogens 
(procarcinogens) can be transformed into carcinogens by cytochrome P450s (Guengerich 
2004). 
 
Currently, 57 functional cytochrome P450 enzymes have been classified in humans. 
The majority of these enzymes are predominantly expressed in the liver, but some 
cytochrome P450s are preferentially expressed in extrahepatic tissues such as the breast 
(Nebert and Nelson 2005).  Previous studies demonstrated a differential expression profile 
of cytochrome P450s between tumours and their corresponding normal tissues, and some 
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cytochrome P450s have been identified as having tumour-specific expression.  For 
instance, overexpression of CYP1B1 has been detected in various tumours including breast 
(Murray et al. 1997, McFadyen et al. 1999, Murray et al. 2001) and a novel member of the 
cytochrome P450 family 4, CYP4Z1 mRNA is preferentially expressed in breast 
carcinoma and associated with poor prognosis in primary ovarian cancer (Downie et al. 
2005).  More recently, CYP2W1 expression has been shown to be highly expressed in 
colon tumours (Karlgren et al. 2006).  The existence of tumour specific cytochrome P450 
expression suggests that these enzymes could be targets for cancer therapy, and a better 
understanding of their roles in tumour progression and invasion may be beneficial to 
cancer research as a whole. 
 
Several chemotherapeutic drugs used in breast cancer therapy (e.g. anthracyclines, taxane, 
cyclophosphamide, tamoxifen and aromatase inhibitors) are extensively biotransformed in 
the liver, thereby reducing the release of toxic metabolites present in the tumour cells.  
Previous studies investigated the expression of cytochrome P450s in breast cancer cells 
from patients-derived samples (Albin et al. 1993, Huang et al. 1996, Murray et al. 1997, 
Iscan et al. 2001, Modugno et al. 2003, Haas et al. 2006), in vitro [i.e. cell lines (Sonneveld 
et al. 1998, Spink et al. 1998, Soulez and Parker 2001, McFadyen et al. 2003, Rieger et al. 
2004, Savas et al. 2005, Fischer et al. 2007) and from xenografts (Smith et al. 1993)].  
However, only a few cytochrome P450s (i.e. CYP1A1, CYP1B1, CYP2B, CYP2C and 
CYP3A) have been identified in breast cancer cells and the current knowledge of 
cytochrome P450 expression related to tumour characteristics in breast cancer is extremely 
limited.  Therefore, this study was designed to identify the cytochrome P450 mRNA 
profile in a series of breast cancer cell lines derived from different tumour characteristics 
(i.e. ER status, invasive property and ethnicity) and compare this profile with a normal 
breast cell line.   
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1.2 Breast cancer 
1.2.1 Overview of breast cancer 
In the UK, breast cancer is the commonest cancer and the second most common cause of 
cancer death (after lung cancer) in women.  According to a recent report by Cancer 
Research UK, breast cancer accounted for 29% of all female cancers.  Each year more than 
40,000 women are diagnosed with breast cancer in the UK compared to 324 new cases of 
breast cancer annually in men.  In 2005, there were more than 12,000 deaths from breast 
cancer in the UK.  Risk of developing breast cancer in women significantly increases with 
age particularly in women older than 50 (http://www.cancerresearchuk.org).  The lifetime 
risk of being diagnosed with breast cancer in women is 1 in 9 (O'Halloran et al. 2004). 
 
Over the last two decades, the number of new cases of breast cancer diagnosed has 
increased from 75 (in 1975) to 116 (in 2003) per 100,000 in the UK.  Five year survival 
has also improved from 52% (1971-1975) to 80% (2001-2003).  Some of this improvement 
is as a consequence of the National Health Service Breast Screening Programme 
(NHSBSP) which targets the female population aged between 50 and 64 for routine 
mammography.  The service was set up in 1988 (Reddy and Given-Wilson 2004).   
 
In addition, the fourth worldwide meta-analysis (2000-2005) by the Early Breast Cancer 
Trialists' Collaborative Group (EBCTCG) reported that interethnic variation in the 
incidence and mortality rate of breast cancer in women is widening.  Caucasian women 
have a higher incidence of breast cancer whereas African women are more likely to die 
from breast cancer (Chia et al. 2005).  Recently, Morris and colleagues (Morris et al. 2007) 
demonstrated that African-American patients with breast cancer appear to have more high-
grade, more ER-negative and more aggressive tumours than Caucasian women.  These 
observations suggest that differences in survival by race/ethnicity may be due to breast 
carcinoma characteristics.  Further molecular studies are required to investigate this 
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correlation with survival and perhaps identify new therapeutic targets for this patient 
population. 
 
The aetiology of breast cancer remains complex with multiple risk factors including 
hormonal receptor status (positive/negative), duration of oestrogen exposure (early 
menarche/late menopause), age (pre-/post-menopausal status), lifestyle (high fat/low fibre 
diet), racial/ethnic groups and familial history of breast cancer (Dumitrescu and Cotarla 
2005).  Oestrogen mediates its effects on growth, differentiation and function of target 
tissues particularly reproductive organs by binding to ER found in the nucleus of those 
cells that are targets for oestrogen action.  The ER exists in two subtypes, ERα and ERβ 
which are highly homologous and have distinct target tissue.  ERα protein has been shown 
to be associated with breast cancer by several clinical and experimental studies, while the 
role of ERβ in relation to breast cancer remains controversial (Deroo and Korach 2006).  In 
addition, in vitro studies indicated that ERβ appears to inhibit ERα activity (McDonnell 
2004) and its expression is associated with the response of antioestrogen tamoxifen in ER-
negative breast cancer (Gruvberger-Saal et al. 2007).  Henceforth, the term ‘ER status’ in 
this thesis will refer to only ERα protein expression. 
 
The nuclear oestrogen-ER complex binds to oestrogen response elements (EREs), resulting 
in transcriptional activation of oestrogen-responsive genes and this leads to the production 
of protein and a physiological response (Deroo and Korach 2006).  In breast cancer cells, 
the ER signalling pathway is involved in increasing cell growth, cell division and DNA 
synthesis, and these can trigger DNA mutations in cells.  Mutant cells can lead to 
uncontrolled proliferation in response to oestrogen stimulation and increase the risk of 
developing cancer in breast tissue (Yager and Davidson 2006).  Therefore, targeting of the 
ER using antioestrogen therapy becomes an important therapeutic option in the treatment 
of breast cancer patients and this is described in the next section (McDonnell 2004).  
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The link between the metabolism of oestrogen and breast carcinogenesis is well 
documented.  It is known that the carcinogenic effect of oestrogen can be attributed to the 
initiation of oestrogen metabolism by cytochrome P450s.  A metabolite of 2-hydroxy-
oestradiol is primarily catalysed by CYP1A2 and CYP3A4 in the liver, and by CYP1A1 in 
extrahepatic tissues including the breast.  CYP1B1 which is mainly expressed in the breast, 
ovary and uterus catalyses the 4-hydroxylation of oestradiol.  The quinone metabolites of 
4-hydroxyoestradiol have been shown to act through the mechanisms that initiate and/or 
promote breast cancer by producing free radicals such as superoxides, and more reactive 
semiquinone-quinone intermediates, leading to the formation of DNA adducts (Tsuchiya et 
al. 2005, Yager and Davidson 2006). 
 
1.2.2 The treatment of breast cancer 
In general, breast cancer begins as a localised microscopic lesion which grows and spreads 
into the regional lymph nodes and metastases to other organs of the body, particularly the 
liver and lung, and may eventually lead to death.  Traditional strategies for breast cancer 
therapy aim to reduce the risk of distant metastasis prevent a recurrence of tumour and 
improve overall survival.  Clinically, a two-stage treatment strategy is commonly used to 
control the risk of local tumour recurrence.  The first stage is surgery to control the 
regional tumour and this is usually supplemented with radiotherapy.  Secondly, adjuvant 
hormonal therapy or chemotherapy is used to reduce risk of recurrence and improve long-
term survival among women with breast cancer (Goldhirsch et al. 2007). 
 
Guidelines for the use of adjuvant therapy in the management of early stage and metastases 
in breast cancer have developed over time.  Two categories were recommended for patients 
with node-positive breast cancer.  Adjuvant hormonal therapy (i.e. antioestrogen and 
aromatase inhibitors) is used for most patients who have ER-positive tumours but not 
recommended for women with ER-negative tumours.  Another category, adjuvant 
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chemotherapy is advised for women with oestrogen-independent tumours (Harlan et al. 
2006, Goldhirsch et al. 2007). 
 
In hormonal therapy, a better understanding of the role of the ER signalling pathway and 
the action of oestrogen in breast carcinogenesis is allowing the development of therapeutic 
inventions, particularly in hormonal therapy which has been used to treat advanced and 
localised breast cancer in patients with ER-positive tumours.  Antioestrogen therapy (e.g. 
tamoxifen and raloxifene) is commonly used as first-line therapy in pre-menopausal 
women.  They exhibit antagonist properties by competitively inhibiting the interaction 
between oestrogens and ER blocking oestrogen action at the ER and reducing ER levels 
(Moulder and Hortobagyi 2008).  However, Vogel and co-workers reported that the use of 
tamoxifen has been associated with a high risk of thromboembolism and ovarian cancer 
due to the similarity of its clinical efficacy to ovarian ablation.  Raloxifene is as effective 
as tamoxifen in the prevention of invasive breast cancer and has a lower risk of 
tamoxifen’s serious adverse effects (Vogel et al. 2006).   
 
Aromatase (CYP19A1) is the key enzyme that converts androgen to oestrogen.  Many 
aromatase inhibitors have been developed for the treatment of breast cancer and details of 
these are provided in Section 1.8.  They are an important approach for reducing growth-
stimulatory effects of oestrogen in post-menopausal oestrogen-dependent early stage breast 
cancer patients (Brueggemeier et al. 2005, Perez 2007).  Long-term treatment of aromatase 
inhibitors in breast tumours have, however, resulted in resistance to tamoxifen, which may 
be due to hypersensitivity of ER to oestrogen, mutations in ER or alteration of ER 
expression.  Cross-resistance between tamoxifen and aromatase inhibitor has also been 
reported in some breast cancer patients (Shao and Brown 2004). 
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In adjuvant chemotherapy, anthracycline based treatment such as the regimens of docetaxel 
and doxorubicin plus cyclophosphamide (TAC) are widely used as first-line therapy for 
node-positive breast cancer with ER-negative tumours.  These regimens have been shown 
to have better antitumour activity than the classical CMF regimen (cyclophosphamide plus 
methotrexate and 5-fluorouracil) as adjuvant chemotherapy with TAC significantly 
improves the overall survival of breast cancer patients (Ahluwalia et al. 2005).   
 
Doxorubicin (Adriamycin®) is an anthracycline antibiotic that interacts with DNA by 
intercalation and is widely used in the treatment of various types of cancers such as breast 
and ovary (O'Shaughnessy 2005).  Cyclophosphamide (Cytoxan®, Neosar®) is an 
alkylating agent from oxazaphosphorine prodrug which is used against a wide range of 
human tumours such as breast and ovary (Moulder and Hortobagyi 2008).  Docetaxel 
(Taxotere®) is a widely used taxane and the most active microtubule-interfering agents for 
breast cancer.  It is not cross-resistant with anthracycline and does not interfere with the 
action of doxurubicin (Ahluwalia et al. 2005).   
 
In addition, advances in adjuvant chemotherapy in patients who have ER-negative and 
node-positive breast cancer have been reported where biweekly doxorubicin and 
cyclophophamide combined with paclitaxel results in a lower rate of recurrence and 
improved survival compared to low dose of the CAF regimen (cyclophosphamide and 
doxorubicin plus 5-fluorouracil) (Berry et al. 2006).  However, these anticancer drugs used 
in the management of breast cancer have been shown to be associated with acute and long-
term cardiovascular complications (Jones et al. 2007). 
 
Indeed, these anticancer drugs offer an advantage of presenting a lethal threat to the 
tumour cell by killing rapidly proliferating cells.  At the same time, they also have a 
disadvantage to the body as they affect normal cells undergoing rapid proliferation, for 
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example buccal mucosa, bone marrow, gastrointestinal mucosa and hair cells, contributing 
to the toxic effects, thus limiting the dose of cytotoxic drugs (O'Shaughnessy 2005).   
 
Resistance to chemotherapeutics in breast cancer patients is another common phenomenon 
and a serious clinical problem, leading to reductions in the overall survival period.  Drug 
resistance can be generated via a number of mechanisms, none of which are fully 
understood.  However, tumour-specific physiological changes such as very low oxygen 
concentrations (tumour hypoxia) may facilitate the development of drugs that target the 
local gene expression responsible for malignant cells (McKeown et al. 2007).  Tumour 
hypoxia in solid tumours has been demonstrated to be involved in tumour progression as 
well as resistance to chemotherapy and radiotherapy (Denny 2004).  In addition, the 
presence of hypoxia is associated with aggressive phenotype and poor prognosis.  This has 
led to the development of tumour-selective therapy such as hypoxia-activated prodrugs, 
hypoxia-activated gene therapy and treatments targeting the hypoxia-inducible factor-1 
alpha (HIF-1α) (Nagasawa et al. 2006, Brown 2007). 
 
Due to problems with high drug toxicity and incidence of chemotherapeutic resistance, 
selective therapies that target the clinical and/or molecular characteristics of tumour cells 
are urgently required.  Anticancer drugs are usually biotransformed to active and/or 
inactive form by certain drug metabolising enzymes.  It is well recognised that cytochrome 
P450 enzymes (P450s) play a crucial role in the metabolism of various anticancer drugs 
(Section 1.8).  Many cytochrome P450s have been found in extrahepatic tissues and certain 
cytochrome P450 genes have been defined as having tumour-specific expression.  
Therefore, expression of individual cytochrome P450’s in breast cancer cells is of interest 
as it may help identify a new target for cancer therapy resulting in more effective and less 
toxic treatments for breast cancer patients. 
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1.3 The use of breast cancer cell lines as models 
In vitro systems such as cell culture have been widely established from several diseases 
including tumours, and have been characterised as models to represent the pathogenesis 
process in vivo (Weigelt et al. 2005).  Tumour-derived cell lines have been shown to 
closely resemble patient tumour characteristics and reflect breast cancer cells in vivo 
(Burdall et al. 2003, Lacroix and Leclercq 2004).  There are currently a limited number of 
breast cancer cell lines and only a few of these models (i.e. MCF7, T47D and MDA-MB-
231) have been extensively used to investigate cell signalling pathways and genes involved 
in cancer progression (Burdall et al. 2003).  Distinct features of available breast cancer cell 
lines have been previously detailed and classified by the origin of the cells, ethnic origin of 
patient, type of epithelial cells, oestrogen receptor status and in vitro invasive property.  
However, questions have been raised as to whether they are truly representative of the 
tissue of origin and cancer biology in vivo.  The same type of breast cancer cell lines 
distributed to different environments (laboratories), grown under various culture conditions 
and after numerous passages could generate both genetic and phenotypic alterations in 
subsequent sub-populations.  Serious consideration must be given to these factors when 
designing experiments, interpreting results and comparing findings with other studies 
(Lacroix and Leclercq 2004). 
 
Table 1.1 shows a database of seven breast cancer cell lines MCF7, T47D, ZR-75-1, ZR-
75-30, MDA-MB-157, MDA-MB-231 and MDA-MB-468 which were used in the present 
study.  Of the available cell lines, most originated from pleural effusions, containing 
human breast adenocarcinoma cells from metastatic tumours.  The advantages of using 
cells of this type are that they dissociate into single cells and generate viable tumour cells 
with low or no contamination by fibroblasts and tumour stroma cells (Lacroix and Leclercq 
2004).   
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Table 1.1: Database of human normal breast and breast cancer cell lines used in this study (Combined and adapted from Lacroix and Leclercq 2004 and the Breast Cancer Cell 
Line Database at The University of Texas MD Anderson Cancer Centre website http://www.mdanderson.org/). 
 
 
Cell line name 
 
Age  
(years) 
 
Site of origin 
 
Pathology 
 
Epithelial-mesenchymal 
transition (EMT) 
 
ER protein 
status 
 
In vitro invasive properties 
Caucasian 
 
      
  MCF7 
 
69 Pleural effusion Adenocarcinoma Luminal-epithelial like + Low 
  T47D 
 
54 Pleural effusion Ductal carcinoma Luminal-epithelial like + Low 
  ZR-75-1 
 
63 Ascitic effusion Infiltration ductal carcinoma Luminal-epithelial like + Low 
  MDA-MB-231 
 
51 Pleural effusion Adenocarcinoma Mesenchymal-epithelial like - High 
Afro-Caribbean       
  ZR-75-30 
 
47 Ascitic effusion Infiltration ductal carcinoma Luminal-epithelial like + Low 
  MDA-MB-157  
 
44 Pleural effusion Medulla carcinoma Mesenchymal-epithelial like - High 
  MDA-MB-468 
 
51 Pleural effusion Adenocarcinoma Weakly luminal-epithelial like - Low 
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Molecular classification of breast cancer cell lines using epithelial-mesenchymal transition 
(EMT) is very important as EMT is associated with increased aggressiveness, and the 
invasive and metastatic potential of cancer cells (Sarrio et al. 2008).  EMT is essential for 
the cell developmental process; it is an important component of tumour transformation and 
it can be characterised by cell adhesion, cell mobility and expression of E-cadherin.  
Specific characteristics of the initiation of invasive/metastatic cells are lack of cell 
adhesion, enhanced cell mobility and decreased E-cadherin expression.  The cell lines are 
classified by their invasive properties, which are tested using the chemo-invasion assay 
that detects the migratory activity associated with matrix degradation (Matrigel in a 
Boyden chamber).   
 
The cell lines can be divided into three phenotypes (Lacroix and Leclercq 2004).  The first 
group, luminal epithelial-like cells highly express the epitheliod markers (e.g. ER and E-
cadherin) and they have weak in vitro invasiveness.  This group consists of MCF7, T47D, 
ZR-75-1 and ZR-75-30 cell lines.  The second phenotype is weakly luminal epithelial-like 
cells which is very similar to the first group as they are poorly invasive cells (i.e. MDA-
MB-468).  The last group, mesenchymal epithelial-like cells express high amount of 
vimentin but do not express the ER/E-cadherin gene.  There are highly invasive breast 
cancer cell lines, such as MDA-MB-231 and MDA-MB-157 (Sommers et al. 1994, 
Pishvaian et al. 1999).   
 
Breast cancer classification is based on standard histopathology which describes both the 
morphology and pathogenesis of the tumour.  Normal breast is a bilayered structure that is 
composed of two types of epithelial cells, inner luminal secretory cells and outer 
contractile myoepithelial cells, and these cells are surrounded with basement membrane 
(Adriance et al. 2005).  In breast tumour, it has been demonstrated that disruption of 
myoepithelial layer and degradation of basement membrane are required for tumour 
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invasion.  In addition, tumour myoepithelial cells are associated with the loss of ER 
expression, a higher expression of invasion-related genes and a more aggressive cancer 
(Man and Sang 2005).  Gordon and colleagues investigated myoepithelial markers (i.e. 
CK14 and α6β4 integrin) in breast cancer cell lines, and demonstrated that MDA-MB-231 
and MDA-MB-468 cells are defined as myoepithelial phenotype whereas MCF7, T47D 
and ZR-75 cells are represented as luminal phenotype (Gordon et al. 2003). 
 
1.4 Cytochrome P450 enzymes (P450s) 
1.4.1 Introduction to cytochrome P450s 
Cytochrome P450 enzymes (P450s) have only been discovered and characterised in the last 
50 years.  The name cytochrome P450 was derived from the presence of a carbon 
monoxide binding pigment in rat liver microsomes which was first detected by 
Klingenberg (Klingenberg 1958).  Six years later, this enzyme was found to have an 
unusual spectrum which has a very strong optical absorption peak at 450 nm (Omura and 
Sato 1964).  The inactive form of cytochrome P450 has an absorbance maximum of 420 
nm, known as cytochrome P420 (Tian et al. 1995). 
 
Cytochrome P450s constitute a large superfamily of haem-containing proteins and are 
widely distributed among many organisms (e.g. bacteria, fungi, plants and animals).  To 
date, 57 functional genes and 58 pseudogenes have been discovered and identified in 
humans (Nelson et al. 2004).  These enzymes play a key role in several important 
biosynthesis and catalysis pathways (e.g. cholesterol, steroid hormones, bile acids, 
vitamins and arachidonic acids) as well as in the metabolism of various xenobiotic 
substrates including carcinogens and anticancer drugs (Guengerich et al. 2005, Nebert and 
Nelson 2005).  The major cytochrome P450 enzymes with physiological roles in the 
metabolism of endogenous and xenobiotic compounds are summarised in Figure 1.1.  
Details of cytochrome P450 expression and functions are described in Section 1.5. 
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Figure1.1: Cytochrome P450 enzymes implicated in the metabolism of endogenous and xenobiotic substrates. 
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1.4.2 Nomenclature  
According to the standardised cytochrome P450 nomenclature, individual cytochrome 
P450s within a family are defined as having at least 40% amino acid sequence homology 
and the family can be further subdivided into subfamilies which generally have at least 
55% amino acid sequence similarity.  This is followed by an Arabic numeral designating 
the family, a capital letter for the subfamily and a sequential Arabic number for the 
individual gene (Nebert et al. 1991).  CYP1A1, for example, has been categorised as 
belonging to the cytochrome P450 family 1 subfamily A and being the first individual gene 
identified in this subfamily (Figure 1.2). 
 
 
 
1.4.3 Biochemical characteristic features 
In eukaryotic cells, cytochrome P450 enzymes are primarily located in the endoplasmic 
reticulum or inner mitochondrial membrane.  These enzymes act as the terminal oxidase in 
the mix-function oxidase system and are therefore also known as mono-oxygenases 
(Nelson et al. 1996).  In a simplified form, cytochrome P450 function can be summarised 
as shown below (Montellano 1995). 
RH (substrate) + O2 + NADPH + H+ → ROH (product) + NAD+ + H2O 
The catalytic cycle of microsomal cytochrome P450 is shown in a schematic view in 
Figure 1.3.  A functional cytochrome P450 system includes the active site of the catalytic 
reaction which is a haem moiety containing the iron ion (Fe3+).  The reaction begins when 
the substrate binds to the ferric form of cytochrome P450 in the active site (1).  The 
 
Figure 1.2: An example of human cytochrome P450 enzyme nomenclature. 
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cytochrome P450-substrate complex is then reduced to the ferrous state (Fe2+) by 
nicotinamide adenine dinucleotide phosphate-oxidase (NADPH)-cytochrome P450 
reductase which serves as an electron donor protein (2).  This production binds to 
molecular oxygen (O2) (3) to generate asuperoxide complex which is unstable and easily 
auto-oxidised releasing O=2 (4, 5).  However, if the final step (the second reduction 
process) occurs this reaction can continue.  This form converts to an activated oxygen atom 
which reacts with the substrate molecule (6), resulting in the hydroxylation of the substrate 
(7) (Coon 2003, Guengerich 2004). 
 
 
 
 
 
 
 
 
1.5 Cytochrome P450 expression and function 
The 57 active cytochrome P450 genes are classified into 18 families and further subdivided 
into 43 subfamilies and they are located on 16 different chromosomes in the human 
genome which are summarised in Table 1.2.  Enzymes belonging to families 1, 2, 3 and 
some enzymes of family 4 are responsible for the deactivation and/or activation of 
xenobiotic compounds, while the members of families 4 to 51 play a central role in the 
biosynthesis and catabolism of endogenous substrates.  In the following sections, the 
importance and current knowledge of the cytochrome P450 genes are briefly described in 
terms of their expression and physiological roles in humans.  
 
Figure 1.3: The catalytic reaction of cytochrome P450 enzymes (adapted from Coon 2003). 
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Table 1.2: Chromosomal location of the cytochrome P450 genes (Adapted from Nebert and Nelson 2005). 
 
Chromosome No. Cytochrome P450s 
 
1 
 
CYP2J2, CYP4A11/22, CYP4B1, CYP4X1, CYP4Z1 
2 CYP1B1, CYP20A1, CYP26B1, CYP27A1 
3 CYP8B1 
4 CYP2U1, CYP4V2 
6 CYP21A2, CYP39A1 
7 CYP2W1, CYP3A4/5/7/43, CYP5A1, CYP51A1 
8 CYP7A1, CYP7B1, CYP11B1/2 
10 CYP2C8/9/18/19, CYP2E1, CYP26A1, CYP26C1 
11 CYP2R1 
12 CYP27B1 
14 CYP46A1 
15 CYP1A1/2, CYP11A1, CYP19A1 
17 CYP17A1 
19 CYP2A6/13, CYP2B6, CYP2F1, CYP2S1, CYP4F2/3/8/11/12/22 
20 CYP8A1, CYP24A1 
22 CYP2D6 
 
 
1.5.1 CYP1 family 
Three members CYP1A1, CYP1A2 and CYP1B1 are categorised in the cytochrome P450 
family 1 (Nebert and Jones 1989, Nelson et al. 1996).  The CYP1A1 (Jaiswal et al. 1986) 
and CYP1A2 (Ikeya et al. 1989) genes are located on chromosome 15q22-q24 and contain 
seven exons whereas the CYP1B1 gene is located on 2p21 and contains three exons (Tang 
et al. 1996).   
 
CYP1A1 mRNA is mainly expressed in extrahepatic tissues including the breast (Huang et 
al. 1996, Hellmold et al. 1998, Iscan et al. 2001, Modugno et al. 2003).  CYP1A1 catalyses 
the 2-hydroxylation of oestradiol and is induced by several procarcinogens, especially 
polycyclic aromatic hydrocarbons (PAHs) into reactive carcinogens which lead to the 
formation of DNA adducts (Tsuchiya et al. 2003, Shimada 2006).  The induction of 
CYP1A1 by PAHs (e.g. 2,3,7,8-tetrachlorodibenzo-p-dioxin, benzo(a)pyrene and 3-
methylcholanthrene) is mediated via the pathway of ligand-activated aryl hydrocarbon 
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receptor (AhR) complex (Kim and Guengerich 2005) which is described in Section 1.7.2.  
Previous studies demonstrated that CYP1A1 mRNA appears to be expressed in both breast 
cancer tissues (Huang et al. 1996, Iscan et al. 2001, Modugno et al. 2003) and cell lines 
(Spink et al. 1998, McFadyen et al. 2003).  These findings suggest that CYP1A1 may be 
involved in breast cancer initiation and progression because it has an important role in the 
metabolism of oestrogen and procarcinogens.  The cancer chemotherapeutic prodrug 
ellipticine (an intercalative alkaloid) is activated by CYP1A1/1A2 to form DNA adducts 
and is currently in clinical trials (Aimova et al. 2007). 
 
CYP1A2 is predominantly expressed in the liver but also at lower levels in extrahepatic 
tissues (Sterling and Cutroneo 2004).  CYP1A2 mRNA has been detected in both normal 
human breast or breast tumours (Hellmold et al. 1998, Modugno et al. 2003).  CYP1A2 
can be induced by carcinogenic heterocyclic amines such as 2-amino-3,8 dimethylimi-
dazo(4,5-f )quinoxaline (MeIQx) and 2-amino-1-methyl-6-phenylimidazo(4,5-b) pyridine 
(PhIP), which are produced in meat and fish during cooking (Guengerich and Shimada 
1991, Kim and Guengerich 2005).  It catalyses the 2-hydroxylation of oestrogen and this 
metabolite is believed to be associated with a reduced risk of breast cancer (Yager and 
Leihr 1996).  Takata and colleagues investigated an association between genetic 
polymorphisms in enzymes involved in oestrogen metabolism and mammographic density 
in both breast cancer and healthy members of the Hawaiian population.  Results showed an 
association between the CYP1A2 genotype and high levels of breast density, suggesting 
that CYP1A2 may be involved in the development of breast cancer (Takata et al. 2007).  In 
addition, CYP1A2 is involved in metabolism of the anticancer drug flutamide (Chimax®, 
Drogenil®), which is commonly used for the treatment of advanced prostate cancer (Goda 
et al. 2006). 
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CYP1B1 metabolises a wide range of procarcinogens (e.g. PAHs) and oestrogen (Shimada 
et al. 1996).  Like CYP1A1, the induction of CYP1B1 by PAHs is mediated through the 
AhR/ARNT complex (Section 1.7.2).  In addition, Hanna and co-workers demonstrated 
that inter-individual differences in breast cancer risk associated with oestrogen-mediated 
carcinogenicity may be related to CYP1B1 polymorphisms (Hanna et al. 2000).  Recently, 
Yang and co-workers showed that high levels of CYP1B1 expression are associated with 
constitutive expression of AhR in human breast cancer but not with CYP1A1, suggesting 
interactions between CYP1B1 and AhR may be important in breast cancer initiation and 
progression (Yang et al. 2007). 
 
CYP1B1 mRNA is expressed in several normal tissues but its protein expression has been 
detected primarily in tumours (i.e. breast, colon, lung, oesophagus, skin, lymph node, brain 
and testes) (Murray et al. 1997).  In addition, Gibson and co-workers  confirmed that 
overexpression of CYP1B1 protein was found in human colorectal tumours but lower 
levels were also found in normal colon cells (Gibson et al. 2003).  Most importantly, 
CYP1B1 protein was not detected in human liver (Edwards et al. 1998).  CYP1B1 
overexpression in tumour cells is now recognised as a biomarker of the malignant 
phenotype (McKay et al. 1995, Murray et al. 1997, McFadyen et al. 2001, Roos and Bolt 
2005, Barnett et al. 2007, Yang et al. 2007).  Therefore, CYP1B1 is considered to be a 
potential novel cancer therapeutic target in a therapeutic setting, and details of how this 
enzyme is being targeted are provided in Section 1.8.   
 
1.5.2 CYP2 family 
CYP2 is the largest cytochrome P450 family in humans containing 13 subfamilies and 16 
individual genes (Table 1.3).  There are three members in the CYP2A subfamily (i.e. 
CYP2A6, CYP2A7 and CYP2A13) but one of these CYP2A7, has been proven to be a 
pseudogene (Ding et al. 1995).  These genes are located on chromosome 19q13.2 and 
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contain nine exons (Fernandez-Salguero et al. 1995).  CYP2A6 is mainly expressed in the 
liver but lower levels are also expressed in extrahepatic tissues including the breast 
(Hellmold et al. 1998).  CYP2A6 plays a role in the oxidation of nicotine, coumarin (Yun 
et al. 1991) and anticancer drugs (i.e. tegafur and letrozole) (Rodriguez-Antona and 
Ingelman-Sundberg 2006).  In addition, this enzyme is involved in the metabolic activation 
of procarcinogens, such as a tobacco-specific carcinogen 4-(methylnitrosamino)-1(3-
pyridyl)-1-butanone (NNK) and the food mutagen aflatoxin B1 (Gonzalez and Gelboin 
1994).  CYP2A6 mRNA and protein have been shown to be induced in human liver cells 
by dexamethasone and the induction by this compound is suppressed by the antagonist of 
glucocorticoid receptor (RU468), suggesting that the glucocorticoid receptor may play a 
role in the regulation of CYP2A6 (Onica et al. 2008). 
 
Table 1.3: List of human CYP2 genes. 
 
Subfamily of CYP2 
 
Number of genes 
 
Members 
 
 
A 
 
3 
 
CYP2A6/7/13 
B 1 CYP2B6 
C 4 CYP2C8/9/18/19 
D 1 CYP2D6 
E 1 CYP2E1 
F 1 CYP2F1 
J 1 CYP2J2 
R 1 CYP2R1 
S 1 CYP2S1 
U 1 CYP2U1 
W 1 CYP2W1 
 
 
In breast cancer, Bieche and co-workers investigated xenobiotic metabolising enzymes in 
breast tumours compared to normal breast.  Results showed that higher levels of CYP2A6 
mRNA were found in ER-positive tumours than ER-negative tumours or normal breast, 
suggesting that CYP2A6 could be used as a biomarker to predict an antioestrogen 
responsiveness (Bièche et al. 2004).  It is important to note that CYP2A6 plays a role in the 
metabolism of a third-generation aromatase inhibitor letrozole which is widely used in 
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postmenopausal patients with oestrogen-dependent tumours (Ingelman-Sundberg et al. 
2007).  In addition, a recent study examined the regulation of CYP2A6 in the ER-positive 
breast cancer MCF7 cells and found that CYP2A6 is induced by oestrogen through ER.  
These results suggest that an interaction between CYP2A6 and oestrogen/ER may play a 
role in breast cancer initiation and progression (Higashi et al. 2007). 
 
CYP2A7 is also expressed in the liver and shares 94% amino acid sequence homology 
with CYP2A6.  However, CYP2A7 is a pseudogene as it has lost the haem-binding site 
(Wang et al. 2006).  CYP2A13 is predominantly expressed in the respiratory tract (i.e. lung 
and trachea) (Su et al. 2000).  This gene shares 93% amino acid sequence identity to 
CYP2A6 (Su et al. 2000) and their substrate-specificity is overlapping (He et al. 2004).  
However, the procarcinogen NNK is activated much more efficiently by CYP2A13 than 
CYP2A6, suggesting that CYP2A13 could be the primary enzyme in the human respiratory 
tract responsible for local metabolic activation of NNK and susceptibility to lung cancer 
(Su et al. 2000).  A study by Zhang and colleagues (Zhang et al. 2007) demonstrated that a 
high level of CYP2A13 expression is associated with an increased risk of lung cancer 
particularly in smokers. 
 
The CYP2B6 gene is located on chromosome 19q13.2 and contains nine exons (Miles et 
al. 1988).  CYP2B6 constitutes 1-2% of the total cytochrome P450 expression in the liver 
(Mimura et al. 1993) and can be found in extrahepatic tissues such as lung, kidney (Nelson 
et al. 1996), heart (Thum and Borlak 2000) and breast (Hellmold et al. 1998, Iscan et al. 
2001).  CYP2B6 is highly inducible by phenobarbital, and its induction is regulated by the 
nuclear receptors constitutively active receptor (CAR) (Honkakoski and Negishi 2000) as 
described in Section 1.7.3.  Extensive interindividual variability of CYP2B6 expression has 
been observed and polymorphisms cause functional alterations (Lamba et al. 2003), which 
have been shown to influence the pharmacokinetics of several drugs.  CYP2B6 activates 
Introduction 
 22 
anticancer prodrugs cyclophosphamide and ifosphamide into an active toxic form 
(phosphoramide mustard and acrolein), so polymorphisms of this gene may impact on the 
activation of cyclophosphamide and the outcome of treatment (Zanger et al. 2007).   
 
The human CYP2C subfamily contains four highly homologous genes CYP2C8, CYP2C9, 
CYP2C18 and CYP2C19 which are predominantly expressed in the liver (Shimada et al. 
1994).  These genes are located on chromosome 10q24.1-24.3 and contain nine exons 
(Gray et al. 1995).  CYP2C8 plays a role in the metabolism of endogenous compounds 
such as arachidonic acids and retinoic acids (Zhao and Imig 2003).  CYP2C8 is a major 
enzyme responsible for the inactivation of the anticancer drug paclitaxel which is an 
effective agent against a wide range of human cancers including breast cancer (Totah and 
Rettie 2005, Ingelman-Sundberg et al. 2007).  Several research groups have investigated 
CYP2C mRNA in normal human breast and breast tumours but their results seem to be 
inconsistent.  For example, Modugno and colleagues demonstrated that no CYP2C mRNA 
was detected in normal breast or breast cancer (Modugno et al. 2003) while two separate 
research groups found CYP2C mRNA in normal breast as well as breast tumour samples 
(Huang et al. 1996, Iscan et al. 2001).  Such inconsistencies may be due to the use of 
matched samples, low number of samples or inter-individual variations of this enzyme. 
 
CYP2C9, the major CYP2C form in human liver (~20%) metabolises several therapeutic 
drugs including the hypoglycemic agent tolbutamide, anticonvulsant phenytoin, 
anticoagulant warfarin, a number of nonsteroidal anti-inflammatory drugs flurbiprofen, 
diclofenac (Totah and Rettie 2005) and endogenous compounds arachidonic acids 
(Goldstein 2001).  It has been shown to participate in the metabolism of anticancer 
prodrugs tamoxifen (Boruban et al. 2006) and ifosfamide (Schmidt et al. 2004).  The 
genetic polymorphisms of the CYP2C9 gene have been demonstrated to have functional 
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consequences for clinical drug response and adverse drug effects (Ingelman-Sundberg et 
al. 2007).  
 
CYP2C18 mRNA is expressed in human liver at very low levels (Furuya et al. 1991) but is 
also found in extrahepatic tissues (i.e. trachea, small intestine, ovary and testes) (Bièche et 
al. 2007).  CYP2C18 shares 89%, 93% and 93% amino acid sequence identity to CYP2C8, 
CYP2C9 and CYP2C19 respectively (Goldstein and de Morais 1994).  Zhu and Yu  
reported that a variant allele of the CYP2C18 gene, which is associated with decreased 
enzyme activity, affects anticancer ifosfamide efficacy in human hepatoma HepG2 cells 
(Zhu-Ge and Yu 2004). 
 
CYP2C19 is a clinically important enzyme that metabolises a wide range of therapeutic 
drugs including the anticancer drugs tamoxifen and cyclophosphamide (Rodriguez-Antona 
and Ingelman-Sundberg 2006).  Polymorphisms in the CYP2C19 gene cause poor 
metabolism of these drugs, resulting in drug toxicity or a severe adverse drug response to 
specific drugs.  Approximately 3-5% of Caucasians and 12-23% of Asians have been 
shown to have a poor metaboliser phenotype (Mathijssen and van Schaik 2006).   
 
Recently, Wu and colleagues investigated CYP2C19 mRNA and protein in a wide range of 
tumours (i.e. breast, liver, colon, stomach, esophagus, lung, uterus, brain, pancreas, ovary 
and kidney) derived from the Chinese population using semi-quantitative RT-PCR and 
Western blotting methods respectively.  Results showed that the highest level of CYP2C19 
mRNA was detected in hepatocarcinoma tissues and their adjacent normal tissue.  
CYP2C19 protein was found only in hepatocarcinoma samples and their adjacent normal 
tissues, with no protein expression being detected in other types of tumour (Wu et al. 
2006). These findings suggest that CYP2C19 may be a tumour-specific expression in 
human liver. 
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The CYP2D subfamily contains one functional gene CYP2D6 which is of great importance 
in the metabolism of several clinically used drugs (e.g. anti-arrhythmic, antidepressants 
and antipsychotic drugs) (Pelkonen et al. 1998).  The CYP2D6 gene is located on 
chromosome 22q13.1 and contains nine exons (Gough et al. 1993).  CYP2D6 primarily 
catalyses the 4-hydroxylation of tamoxifen which has potent antioestrogenic effects.  
Tamoxifen is commonly used to treat patients with oestrogen-dependent breast cancer 
(Ingelman-Sundberg 2005a).  CYP2D6 mRNA and protein have been detected in the 
breast (Hellmold et al. 1998) and lung (Guidice et al. 1997).  Furthermore, a study by Iscan 
and colleagues showed that CYP2D6 mRNA expression in breast tumour was equivalent to 
tumour-free breast tissue (Iscan et al. 2001). 
 
Currently, more than eighty variant alleles of CYP2D6 have been identified.  The CYP2D6 
activity is extremely variable and interethnic variations in drug metabolism are well 
documented.  Poor metabolisers (PMs) display low or absence of CYP2D6 activity and 
have been found in 7% of Caucasians, whereas ultra-rapid metabolisers (UMs) exhibit 
dramatically high CYP2D6 activity and have been observed in 29% of the population in 
North Africa (Ethiopians) and the Middle East (Saudi Arabians) (de Leon et al. 2006a).  
Recently, Schroth and colleagues investigated an association between breast cancer 
treatment outcome with adjuvant tamoxifen and genotypes of enzymes involved in 
tamoxifen metabolism.  Findings demonstrated that CYP2D6 with low-activity alleles are 
unlikely to benefit from adjuvant tamoxifen treatment (Schroth et al. 2007).  In light of this 
evidence, new clinical tools such as the AmpliChip CYP450 genotyping test are being used 
to analyse psychiatric patient genotypes for CYP2D6 prior to initiating treatment with 
tricyclic antidepressants and antipsychotics (de Leon et al. 2006b).  This may be helpful for 
patients who take other CYP2D6 substrates including tamoxifen.  
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The CYP2E1 gene is located on chromosome 10q24.3-qter and contains nine exons 
(Kölble 1993).  CYP2E1 is responsible for the oxidative metabolism of many drugs (e.g. 
acetaminophen, halothane and chlorzoxazone) as well as the activation of several low-
molecular-weight toxicants and cancer suspect agents (e.g. ethanol, benzene, toluene and 
nitrosamines) (Tanaka et al. 2000).  CYP2E1 is inducible by ethanol as well as 
pathophysiological conditions (e.g. obesity, starvation and diabetes) (Johnsrud et al. 2003).  
It is widely recognised that CYP2E1 produces free radicals causing tissue damage 
particularly the hepatotoxicity of acetaminophen (Lee et al. 1996).  In addition, Reszka and 
colleagues examined a relationship between variant alleles of key enzymes implicated in 
dietary components and cancer susceptibility.  Results showed that CYP2E1 high-activity 
alleles appear to be associated with colorectal cancer risk (Reszka et al. 2006). 
 
The CYP2F1 gene is located on chromosome 19q13.1-13.2 and contains nine exons (Trask 
et al. 1993).  CYP2F1 is highly expressed in the lung but at very low levels or not at all in 
the liver (Ding and Kaminsky 2003).  A study by Thomas and co-workers showed a low 
level of CYP2F1 mRNA expression in sub-confluent cultured MCF10A cells but not in 
confluent cultures (Thomas et al. 2006).  This enzyme is responsible for metabolism of the 
prototypical pneumotoxicants 3-methyllindole and 1,1-dichloroethylene as well as the 
activation of carcinogens styrene, naphthalene and benzene which can produce 
carcinogenic epoxide in the lung tissues (Kartha and Yost 2008).  In primary ovarian 
cancer, CYP2F1 protein has been found at higher levels than in adjacent normal ovary 
tissues (Downie et al. 2005).   
 
The CYP2J2 gene is located on chromosome 1p31.2-p31.3 and contains nine exons (Ma et 
al. 1998).  CYP2J2 is highly expressed in the coronary endothelial cells and cardiac 
myocytes but at lower levels in the liver, small intestine, colon and kidney (Wu et al. 
1996).  This enzyme is involved in the epoxidation of arachidonic acid in cardiac tissue, 
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forming epoxyeicosatrienoic acids (EETs) (Wu et al. 1996) which are potent endogenous 
vasodilators and inhibitors of vascular inflammation (Node et al. 1999, Scarborough et al. 
1999).  A study by Jiang and colleagues demonstrated that higher levels of CYP2J2 mRNA 
and protein were found in a variety of tumours (i.e breast, oesophagus, lung, stomach, liver 
and colon) than in their corresponding normal tissues (Jiang et al. 2005).  Like CYP1B1, 
CYP2J2 is a tumour-associated cytochrome P450 enzyme which could be a new target for 
designing cancer therapeutic prodrugs activated by CYP2J2. 
 
The CYP2R1 gene is located on chromosome 11p15.2 and contains four exons (Cheng et 
al. 2003).  CYP2R1 (vitamin D3 25-hydroxylase) has been shown to play a crucial role in 
the synthesis of bioactive vitamin D3.  It has been long known that vitamin D3 has potent 
anticancer properties because it can inhibit cell proliferation and induce cell apoptosis.  
Therefore, enzymes involved in vitamin D3 signalling pathways have been developed and 
used as potential targets for anticancer therapeutics (Deeb et al. 2007).  CYP2R1 is 
predominantly expressed in the testes, kidney and pancreas (Ingelman-Sundberg 2005b, 
Karlgren et al. 2005).  Higher levels of CYP2R1 expression were detected in primary 
ovarian tumours than in their corresponding normal tissues (Downie et al. 2005).  Like the 
oncogene CYP24A1 (Section 1.5.13), CYP2R1 may be of particular interest to maximise 
vitamin D3 levels in tumour sites and could be used in cancer therapy. 
 
The CYP2S1 gene is located on chromosome 19q13.1-13.2 and contains nine exons 
(Rylander-Rudqvist et al. 2003).  CYP2S1 is highly expressed in human lung (Rivera et al. 
2002, Smith et al. 2003) but at lower levels in the liver (Rylander et al. 2001).  The 
expression of CYP2S1 mRNA and protein in human skin is induced by ultraviolet 
radiation, coal tar and all-trans retinoic acid (Smith et al. 2003).  CYP2S1 is also inducible 
by dioxin and this induction is mediated by AhR/ARNT which is similar to a manner 
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typical of members of the CYP1 family, suggesting that CYP2S1 may be involved in the 
metabolism of carcinogens (i.e. PAHs and naphthalene) (Saarikoski et al. 2005).   
 
In mouse models, the CYP2S1 gene is induced by hypoxia which is mediated via the HIF-
1α/ARNT heterodimer.  A recent study demonstrated that induction of CYP2S1 by both 
dioxin and hypoxia is mediated in a large part by multiple overlapping xenobiotic and 
hypoxia response elements.  In theory, AhR and HIF-1α requires ARNT for dimerisation 
prior to binding with the DNA response element of their target genes.  Therefore, an 
interaction between the AhR/ARNT and HIF-1α/ARNT heterodimerisation may affect the 
transcriptional activity of CYP2S1 (Rivera et al. 2007).  Higher levels of CYP2S1 protein 
expression was detected in ovarian cancer metastasis than in primary tumour cells (Downie 
et al. 2005).  CYP2S1 protein has been shown to be associated with poor prognosis in 
primary colorectal cancer (Kumarakulasingham et al. 2005).   
 
The CYP2U1 gene is located on chromosome 4q25 and contains five exons (Chuang et al. 
2004).  The human CYP2U1 mRNA and protein are predominantly expressed in the 
thymus and brain (Chuang et al. 2004, Karlgen et al. 2004).  CYP2U1 converts arachidonic 
acid into 19- and 20-hydroxyeicosatetraenoic acid (HETE) which serves as an endogenous 
vasoconstrictor and plays a biologically important role in the modulation of blood flow in 
the brain (Chuang et al. 2004, Karlgren et al. 2005).  The role of CYP2U1 in the 
metabolism of xenobiotic compounds has not been reported.  In primary ovarian cancer, a 
markedly higher level of CYP2U1 protein was found compared with normal ovary samples 
(Downie et al. 2005). 
 
The CYP2W1 gene is located on chromosome 7q22.3 and contains 9 exons (Nebert and 
Nelson 2005).  CYP2W1 has been detected at very low levels or not at all in foetal and 
adult human normal tissues but with higher CYP2W1 mRNA levels occuring in human 
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tumours particularly in colon and adrenal tumours (Karlgren et al. 2006).  This may 
suggest that CYP2W1 is specifically expressed in tumours and that it could potentially be 
targeted by a novel anticancer drug (Karlgren and Ingelman-Sundberg 2007).  A study by 
Thomas and co-workers showed a low level of CYP2W1 mRNA in the human normal 
breast MCF10A cell line (Thomas et al. 2006) but no information on CYP2W1 expression 
in breast cancer.  To date, little is known about the physiological function of CYP2W1 in 
humans.  
 
1.5.3 CYP3 family 
The human CYP3 family has a single subfamily CYP3A and four individual genes which 
account for approximately 30% of total liver cytochrome P450 content (Shimada et al. 
1994).  This family is the most important group of drug metabolising enzymes in humans, 
therefore, intra- and inter-individual variations of these enzymes may influence the 
efficacy of drug treatment.  CYP3A4 (Inoue et al. 1992), CYP3A5 (Gellner et al. 2001), 
CYP3A7 (Gellner et al. 2001) and CYP3A43 (Gellner et al. 2001) genes are all located on 
chromosome 7q22.1 and contain thirteen exons. 
 
CYP3A4 is the most abundant cytochrome P450s in human adult liver (Wrighton and 
Stevens 1992) and is also found in the small intestine (Kolars et al. 1992).  CYP3A4 is 
responsible for the oxidative metabolism of a wide range of xenobiotic compounds 
including approximately 60% of all therapeutic drugs such as anticancer drugs paclitaxel, 
mitoxantrone, tamoxifen, cyclophosphamide and ifosphamide (Guengerich 1999).  In 
addition, CYP3A4 is involved in the metabolism of several steroid hormones (i.e. 
oestrogen, progesterone and testosterone) (Wrighton and Stevens 1992) and activation of 
procarcinogens (e.g. aflatoxin B1) to carcinogens (Forrester et al. 1990).  The induction of 
CYP3A4 by these compounds is mainly mediated by pregnane X receptor (PXR, Section 
1.7.4).  Studies on CYP3A mRNA expression in normal human breast and breast tumour 
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samples appear to be generating inconsistent results.  For example, Iscan and colleagues 
demonstrated that CYP3A mRNA was not detected in normal breast or breast tumours 
(Iscan et al. 2001), whereas Huang and co-workers reported that CYP3A mRNA was 
higher in non-tumour breast tissues than in breast tumour samples (Huang et al. 1996).  In 
addition, Hass and colleagues reported that strong CYP3A4 protein expression was 
significantly associated with poor tumour differentiation (Haas et al. 2006). 
 
CYP3A5 shares 84% amino acid sequence identity to CYP3A4 and its substrates are 
similar to those of CYP3A4.  CYP3A5 is primarily expressed in the liver and extrahepatic 
tissues (e.g. kidney and intestine) (Blake et al. 2005).  High levels of CYP3A5 protein 
appear to be associated with primary colorectal cancer (Kumarakulasingham et al. 2005) 
and ovarian cancer (Downie et al. 2005) compared with their corresponding normal tissue.  
Large inter-individual and ethnic differences exist in the expression of CYP3A5 (Gervasini 
et al. 2007).  A recent study reported that no association between CYP3A5 polymorphisms, 
and cancer risk was observed in Caucasian patients with liver, gastric or colorectal cancer 
(Gervasini et al. 2007). 
 
CYP3A7 is predominantly expressed in human foetal liver.  CYP3A7 has similar catalytic 
properties to CYP3A4, and catalyses the 6β-hydroxytestosterone and 16α-hydroxylation of 
oestriol but not of oestradiol.  This enzyme is involved in oestriol biosynthesis which it is 
an important enzyme for foetal growth and development (Blake et al. 2005).  However, 
CYP3A7 has been shown to be involved in  the formation of the procarcinogenic 16α-
hydroxyestrone in women (Lee et al. 2003).  In addition, higher levels of CYP3A7 protein 
are found in primary ovarian cancer than in normal ovary tissue (Downie et al. 2005). 
 
CYP3A43 is a novel cytochrome P450 belonging to subfamily CYP3A.  CYP3A43 shares 
76%, 76%, and 72% amino acid homology with CYP3A4, CYP3A5, and CYP3A7 
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respectively (Westlind et al. 2001).  It is mainly expressed in the prostate (Domanski et al. 
2001) but also at very low level in the liver which differs from other CYP3A subfamily 
enzymes (Westlind et al. 2001).  Moreover, Zeigler-Johnson and colleagues examined an 
association between genotype of enzymes involved in testosterone metabolism and prostate 
cancer risk.  Findings showed that a CYP3A43 variant seems to be associated with prostate 
cancer susceptibility (Zeigler-Johnson et al. 2004).  In addition, CYP3A43 protein in 
primary ovarian cancer has been found to be higher than in normal ovary tissue (Downie et 
al. 2005).   
 
1.5.4 CYP4 family 
The CYP4 family consists of six subfamilies and twelve members (Table 1.4).  The 
CYP4A11 (Bell et al. 1993) and CYP4A22 (Nebert and Nelson 2005) genes are located in 
a cluster of other cytochrome P450 genes (i.e. CYP4B1, CYP4Z1 and CYP4X1) on 
chromosome 1p33 (Bellamine et al. 2003) and contain twelve exons.  CYP4A11 is 
predominantly expressed in the kidney and liver (Savas et al. 2003, Ito et al. 2007).  It 
catalyses the ω-hydroxylation of fatty acids (i.e. lauric acid, palmitic acid and arachadonic 
acid) (Sharma et al. 1989, Palmer et al. 1993).  CYP4A mRNA expression is induced by 
the synthetic glucocorticoid dexamethasone (Savas et al. 2003) and several peroxisome 
proliferators including hypolipidemic drugs clofibrate ciprofibrate and Wy14643 (or 
pirinixic acid) through a nuclear receptor called the peroxisome proliferator activated 
receptor alpha (PPARα) (Okita and Okita 2001, Hsu et al. 2007) as detailed in Section 
1.7.6.   
 
CYP4A22 shares 96% amino acid sequence identity to CYP4A11.  CYP4A22 mRNA is 
found to be expressed in the liver and kidney; however, the levels of CYP4A22 mRNA 
expression in human liver were lower than CYP4A11.  Unlike CYP4A11, CYP4A22 
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mRNA is not induced by glucocorticoids and peroxisome proliferators (Savas et al. 2003).  
The physiological role of human CYP4A22 is being investigated (Hsu et al. 2007).   
 
Table 1.4: List of human CYP4 genes. 
 
Subfamily of CYP4 
 
Number of genes 
 
Members 
 
 
A 
 
2 
 
CYP4A11/22 
B 1 CYP4B1 
F 6 CYP4F2/3/8/11/12/22 
V 1 CYP4V2 
X 1 CYP4X1 
Z 1 CYP4Z1 
 
 
The CYP4B1 gene is located on chromosome 1p34-12 and contains twelve exons 
(Nhamburo et al. 1989).  CYP4B1 is selectively expressed in human lung but at lower 
levels in the liver and gastrointestinal tissues (Poch et al. 2005).  CYP4B1 is involved in 
the activation of the pulmonary toxicant 4-ipomeanol and the metabolism of various 
arylamaines such as 2-aminofluorene, to more reactive intermediates which can cause 
bladder cancer (Baer and Rettie 2007), suggesting that CYP4B1 may be of interest for 
designing an anticancer prodrug activated by CYP4B1.  Unlike other CYP4 enzymes, the 
role of CYP4B1 in the metabolism of endogenous compounds has not been reported.   
 
There are six enzymes in the human CYP4F subfamily (Table 1.4) which are located on 
chromosome 19p13 (Nebert and Nelson 2005).  CYP4F2 encodes for a leukotriene B4 
(LTB4) ω-hydroxylase which inactivates LTB4 by ω-hydroxylation (Hsu et al. 2007).  A 
study by Zhang and Hardwick demonstrated that this enzyme is highly expressed in human 
hepatoma HepG2 cells and the CYP4F2 gene is modulated by all-trans retinoic acid 
(Zhang and Hardwick 2000). 
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CYP4F3 consists of two forms, CYP4F3A and CYP4F3B, which arise from different 
promoters (Christmas et al. 1999).  CYP4F3A preferentially catalyses the ω-hydroxylation 
of LTB4 and is mainly expressed in human polymorphonuclear leukocytes whereas 
CYP4F3B mainly catalyses fatty acids especially long chain fatty acid (Hsu et al. 2007).  
CYP4F3B shares 92% amino acid identity with CYP4F2 and they are predominantly 
expressed in the liver and kidney (Christmas et al. 2001). 
 
CYP4F8 (prostaglandin 19-hydroxylase) shares 81.2% and 76.7% amino acid similarity to 
CYP4F2 and CYP4F3 respectively (Bylund et al. 1999).  CYP4F8 mRNA and protein are 
detected in various normal tissues (i.e. seminal vesicle epithelium, epidermis, corneal 
epithelium and proximal renal tubules) (Stark et al. 2003).  CYP4F8 is closely related to 
CYP4F12 as they exhibit an overlapping catalytic profile.  They convert arachidonic acid 
to 18-HETE, and metabolise prostaglandin H1 and H2 to 19-hydroxyl compounds (Stark et 
al. 2005, Hsu et al. 2007). 
 
CYP4F11 and CYP4F12 mRNA are mainly expressed in human liver but also at lower 
levels in the kidney (Kalsotra et al. 2004).  These two enzymes have different catalytic 
profiles.  CYP4F11 efficiently metabolises xenobiotic compounds such as erythromycin 
but does not efficiently catalyse endogenous compounds particularly eicosanoids.  In 
contrast, CYP4F12 efficiently hydroxylates arachdonic acids to 18-HETE (Bylund et al. 
2001, Hsu et al. 2007).  Their physiological roles have not been characterised. 
 
CYP4F22 mRNA has been demonstrated to be expressed in human keratinocytes, testes, 
liver, kidney, small intestine and brain cell lines.  Little is known about human CYP4F22. 
A recent study showed that mutations of the CYP4F22 gene are associated with lamellar 
ichthyosis type 3, suggesting that this enzyme may play a role in the pathway of 12R-
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lipoxygenase which is implicated in the regulation of barrier production in skin (Lefevre et 
al. 2006).   
 
CYP4V2 is located on chromosome 4p35.1 and contains eleven exons (Li et al. 2004).  
CYP4V2 mRNA is highly expressed in the retina but also found in a wide range of human 
tissues (i.e. heart, brain, placenta, lung, liver, skeletal muscle, kidney, pancreas and 
lymphocytes) (Li et al. 2004).  In human normal breast MCF10A cells, CYP4V2 mRNA 
was also detected (Thomas et al. 2006).  In addition, CYP4V1 protein has been shown in 
colorectal cancer compared with adjacent normal colon samples.  Results showed that 
higher levels of CYP4V1 were detected in colon cancer with lymph node metastasis than 
in their corresponding primary tumour cells (Kumarakulasingham et al. 2005).  To date the 
catalytic properties and physiological function of CYP4V2 remain unknown. 
 
The CYP4X1 gene is located on chromosome 1p33 and contains twelve exons (Nelson 
2003).  CYP4X1 mRNA is highly expressed in human trachea and aorta but at lower levels 
in the breast, ovary, uterus, liver and kidney (Savas et al. 2005).  Recently, CYP4X1 
protein has been shown to be specifically expressed in mouse brain (Al-Anizy et al. 2006).  
A study by Savas and co-workers indicated that CYP4X1 mRNA in human hepatoma 
HepG2 cells is regulated by PPARα (Savas et al. 2005).  A physiological role of CYP4X1 
is currently unknown.  
 
CYP4Z1 is located on chromosome 1p33 and contains twelve exons (Rieger et al. 2004).  
CYP4Z1 mRNA is preferentially expressed in human mammary gland but lower levels in 
the liver, kidney, heart, brain, lung, prostate, testes and ovary.  CYP4Z1 mRNA and 
protein are overexpressed in breast tumour compared to their corresponding normal tissue 
(Rieger et al. 2004).  Higher levels of CYP4Z1 protein were found in primary ovarian 
cancer than in normal ovary tissue and its expression in primary ovarian cancer appears to 
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be an independent marker of prognosis (Downie et al. 2005).  A study by Savas and 
colleagues demonstrated conditional regulation of the human CYP4Z1 gene in breast 
cancer cell lines T47D and MCF7 using quantitative RT-PCR.  Results suggested that 
CYP4Z1 mRNA is induced by the glucocorticoid and progesterone receptor agonists but 
not by PPARα agonist Wy14643 (Savas et al. 2005). 
 
1.5.5 CYP5 family 
The CYP5A1 gene is located on chomosome 7q34-q35 and contains thirteen exons (Chase 
et al. 1993).  CYP5A1 (thromboxane A2 synthase) has a role to play in the conversion of 
the prostaglandin endoperoxide into thromboxane A2.  Thromboxane A2 is a potent 
vasoconstrictor and inducer of platelet aggregation which is important in the hemodynamic 
status in humans (Schuster and Bernhardt 2007).  In addition, Nie and co-workers reported 
finding higher levels of CYP5A1 expression in prostate cancer cells than in normal 
prostate epithelial cells (Nie et al. 2004). 
 
1.5.6 CYP7 family 
Currently, the CYP7 family consists of two subfamilies, CYP7A1 and CYP7B1.  CYP7A1 
shares 40% amino acid sequence homology to CYP7B1.  Both genes are located on 
chromosome 8q21.13.  The CYP7A1 and CYP7B1 genes contain six and five exons 
respectively (Setchell et al. 1998).  CYP7A1 (cholesterol 7α-hydroxylase) directly 
converts cholesterol into 7α-hydroxycholesterol, resulting in the production of deoxycholic 
acid (Beigneux et al. 2002).  CYP7A1 has been found to be expressed only in the liver 
(Wu et al. 1999).  The down-regulation and up-regulation of CYP7A1 are mediated by 
farnesoid X receptor (FXR, Section 1.7.8) and liver X receptor alpha (LXRα) respectively.  
A previous study showed that high levels of the deoxycholic acid in plasma are found in 
postmenopausal women with breast cancer.  In addition, FXR has been found to be highly 
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expressed in breast tumours and involved in the induction of apoptosis (Swales et al. 
2006). 
 
CYP7B1 mRNA is found in the liver and extrahepatic tissues (i.e. brain, testes, prostate, 
ovary and kidney).  CYP7B1 mainly catalyses 7α-hydroxylation of oxysterol (25- and 27-
hydroxycholesterol) and neurosteroids [dehydroepiandrosterone (DHEA) and 
pregnenolone] (Wu et al. 1999).  CYP7B1 expression is sexually dimorphic (male > 
female).  A study by Martin and co-workers demonstrated that CYP7B1 generates 7α-
hydroxy-DHEA to selectively activate oestrogen receptor beta in human prostate 
epithelium.  This suggests that CYP7B1 may have a role in the regulation of androgen 
and/or oestrogen in prostrate tissue (Martin et al. 2004).   
 
1.5.7 CYP8 family 
The human CYP8 family encodes two subfamilies, CYP8A and CYP8B (Nelson et al. 
1996).  The CYP8A1 gene resides on chromosome 20q13.11-13.13 and contains ten exons 
(Yokoyama et al. 1996).  CYP8A1 (prostacyclin synthase) is widely expressed in human 
tissues (i.e. ovaries, heart, skeletal muscle, lung and prostate) (Miyata et al. 1994).  It 
converts prostaglandin H2 to prostacyclin (prostaglandin I2) whose function is opposite to 
that of CYP5 (thromboxane A2 synthase).  Prostacyclin is a potent vasodilator and inhibitor 
of platelet aggregation.  In addition, a stable prostacyclin analogue, cicaprost has been 
demonstrated to play a key role in the prevention of metastasis and reduce growth of breast 
tumours in rodent models (Schirner and Schneider 1997).  Previous study showed that the 
levels of prostacyclin were reduced in colon cancer samples as compared with matched 
adjacent normal colon samples (Miyata et al. 1994).  Recently, variants of CYP8A1 have 
been demonstrated to be associated with colorectal polyps risk (Poole et al. 2006). 
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The CYP8B1 gene is located on chromosome 3p21.3-22 and contains only one exon 
(Gafvels et al. 1999).  CYP8B1 (sterol 12α-hydroxylase) is found in the liver.  It plays an 
important role in bile acid biosynthesis which is closely related to the CYP7 family 
(Eggertsen et al. 1996, Gafvels et al. 1999).  CYP8B1 activity can be altered by fasting, 
cholestyramine, streptozotocin-induced diabetes mellitus and clofibrate (Eggertsen et al. 
1996).  It has been long known that soy isoflavones are promising agents for breast cancer 
prevention.  Recently, Li and colleagues demonstrated that human hepatic CYP8B1 
expression can be up-regulated by soy isoflavones, suggesting that these agents can 
modulate cholesterol metabolism through CYP8B1 (Li et al. 2007).   
 
1.5.8 CYP11 family 
The CYP11 family consists of two subfamilies containing three enzymes; CYP11A, 
CYP11B1 and CYP11B2 which are localised to the inner mitochondrial membrane.   
The CYP11A1 gene is located on chromosome 15q23-q24 and contains nine exons (Chung 
et al. 1986).  This gene encodes the cholesterol side chain cleavage enzyme that catalyses 
the initial and rate-limiting step of steroid biosynthesis (Payne and Hales 2004).  CYP11A1 
is predominantly expressed in steroidogenic tissues such as adrenal cortex, ovary, testes, 
placenta and central/peripheral nervous systems (Compagnone et al. 1995). Yaspan and 
colleagues investigated the relationship between variation of genes involved in oestrogen 
biosynthesis and metabolism, in particular CYP11A1, and breast cancer susceptibility in a 
study of case-control from the Chinese population.  Findings showed that the CYP11A1 
polymorphisms may have a role in breast cancer (Yaspan et al. 2007). 
 
The CYP11B1 gene shares 95% amino acid sequence homology with the CYP11B2 gene 
(Mornet et al. 1989) and these genes are mainly expressed in the adrenal cortex (Curnow et 
al. 1991).  Both CYP11B1 and CYP11B2 genes reside on chromosome 8q21-q22 and 
contain nine exons (Mornet et al. 1989).  CYP11B1 (11β-hydroxylase) catalyses the last 
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steps in cortisol and corticosterone biosynthesis.  CYP11B2 (aldosterone synthase) 
specifically catalyse aldosterone biosynthesis (Hakki and Bernhardt 2006).  Inhibition of 
steroid biosynthesis by members of the CYP11 family is one of the therapy options for 
patients with inoperable adrenocoticoid cancer and hypercortisolism.  However, CYP11B1 
and CYP11B2 deficiencies can cause severe side effects such as Cushing’s syndrome 
which leads to chronic glucocorticoid excess.  Further development of selective inhibitors 
for distinct enzymes in this family is required (Schuster and Bernhardt 2007). 
 
1.5.9 CYP17 family 
The CYP17A1 gene is located on chromosome 10q24.3 which consists of eight exons (Fan 
et al. 1992).  CYP17 (17α-hydroxylase or 17,20-lyase) catalyses both 17α-hydroxylation 
and 17,20-lyase conversion of C21 steroids (progesterone or pregnolone) to C19 precursors 
of sex steroids (dehydroepiandrosterone or androstenedione) (Payne and Hales 2004).  
CYP17A1 is closely related to CYP21 and it shares almost 30% amino acid sequence 
identical to CYP21, however; CYP17A1 has lost two exons which are present in CYP21 
(Picado-Leonard and Miller 1987).  CYP17A1 is predominantly expressed in steroidogenic 
tissues such as the adrenal cortex and ovary (Nagamani and Urban 2003, Olson et al. 
2007). 
 
CYP17A1 is a key enzyme in the androgen biosynthesis.  Androgen is an important 
hormone in the development and maintenance of sexual characteristics in human males; 
however, it is believed to play a role in androgen-dependent diseases, in particular prostate 
cancer (Bruno and Njar 2007, Schuster and Bernhardt 2007).  Thus the use of potent 
CYP17A1 inhibitors such as ketoconazole have been introduced to treat androgen-
dependent prostate cancer patients (Bruno and Njar 2007, Moreira et al. 2007) and details 
of this treatment are provided in Section 1.8.  Recently, the interactions between gene-gene 
and gene-environment which are involved in hormone biosynthesis and metabolism 
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pathways have been investigated by several research groups.  One of these studies 
demonstrated that CYP17A1 polymorphism in combination with long-term hormone-
replacement therapy use and high body mass index in postmenopausal women may 
contribute to breast cancer susceptibility (Chen et al. 2008). 
 
1.5.10 CYP19 family 
The CYP19A1 gene resides on chromosome 15q21.1 which contains eleven exons (Chen 
et al. 1988).  CYP19A1 (aromatase or oestrogen synthase) has important physiological 
functions both in sex steroid hormone biosynthesis and growth/ differentiation in humans.  
It converts the C19 androgens, testosterone and 16α-hydroxyandrostenedione into the C18 
oestrogens, oestradiol and oestrone respectively.  This enzyme is widely expressed in 
several tissues (i.e. ovary, Leydig cells, placenta, adipose tissue and bone), however; 
tissue- and sex-specific expression in cellular metabolism have been demonstrated in these 
tissues as reviewed by Payne and Hales (Payne and Hales 2004).  CYP19A1 activity 
appears to be increased in breast cancer tissues, thus several potent CYP19A1 inhibitors 
have become a powerful tool in the treatment of oestrogen-dependent diseases, in 
particular breast cancer (Brueggemeier et al. 2005, Gibson et al. 2007, Jonat et al. 2007, 
Perez 2007).  Details of CYP19 inhibitors in cancer therapy are provided in Section 1.8. 
 
1.5.11 CYP20 family 
The CYP20A1 gene is located on chromosome 2q33 which contains thirteen exons.  Only 
one member has been found in this family and human CYP20A1 has been shown to be 
homologous in mouse, cow and fish but not in Drosophila or Caenorhabditis elegans 
(Nebert and Nelson 2005).  A recent study suggests that a high level of CYP20A1 
expression is found in immune system cell types (Thomas 2007) but its physiological 
function in humans is still unknown. 
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1.5.12 CYP21 family 
The CYP21A2 is found on chromosome 6p21.3 which contains ten exons (Higashi et al. 
1986).  CYP21A2 (steroid 21-hydroxylase) is mainly expressed in the adrenal cortex 
(Wijesuriya et al. 1999) and converts the C21 of progesterone and 17α-hydroxyproges-
terone into 11-deoxycorticosterone and 11-deoxycortisol respectively in the zona 
fasciculata of the adrenal cortex.  CYP21A2 plays an important role in the biosynthesis of 
sex hormones, glucocorticoids and mineralocorticoids, and is closely related to CYP17A1 
(Payne and Hales 2004, Dragan et al. 2006).  Dragan and colleagues determined the effect 
of IC50 values of various known CYP17A1 inhibitors (i.e. ketoconazole, Sa40, YZ5ay and 
BW33) on CYP21A2 expression in a fission yeast strain expressing mammalian 
cytochrome P450 steroid hydroxylases.  Results showed that CYP17A1 inhibitors appear 
to be moderate CYP21A2 inhibitors (Dragan et al. 2006). 
 
1.5.13 CYP24 family 
The CYP24A1 gene resides on chromosome 20q13.2-13.3 and contains twelve exons 
(Hahn et al. 1993).  The mitochondrial enzyme CYP24A1 (1, 25-(OH)2D3-24-hydroxylase) 
plays a crucial role in the degradation of vitamin D3 (1, 25-(OH)2D3) (Masuda et al. 2006).  
CYP24A1 mRNA is regulated either by calcium ions or excess amounts of vitamin D3 and 
is mediated through it nuclear receptor vitamin D receptor (VDR).  CYP24A1 is expressed 
in several normal tissues such as kidney, liver and gastrointestinal tract (Jones et al. 1998).  
However, Anderson and colleagues detected overexpression of CYP24A1 in a wide range 
of tumour cells (i.e. breast, colon, ovary and lung) compared with their matched adjacent 
normal cells, suggesting that CYP24A1 may be an oncogene (Anderson et al. 2006).  
Inhibition of CYP24A1 has been developed as a new strategy for cancer therapy as it has 
an antiproliferative effect (Sundaram et al. 2006) (Section 1.8). 
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1.5.14 CYP26 family 
Three CYP26 isoforms have been identified in humans, CYP26A1, CYP26B1 and 
CYP26C1 (Ray et al. 1997, Nelson 1999, Taimi et al. 2004).  CYP26 is induced by all-
trans-retinoic acid (ATRA) through its nuclear receptor (retinoic acid receptor, RAR) and 
retinoid X receptor (RXR), which then interacts with retinoic acid response elements 
within the promoter of CYP26 (Bastien and Rochette-Egly 2004).  ATRA is an active 
metabolite of vitamin A or retinoid which play an important role in the cell differentiation 
and proliferation of epithelial cells, vision and reproduction (White et al. 2000).  ATRA 
has been shown to induce apoptosis in various cancer cell lines, suggesting that it can be 
used as a chemopreventive agent (Osanai and Petkovich 2005) 
 
The CYP26A1 gene is found on chromosome 10q23-q24 and contains seven exons (White 
et al. 1998).  CYP26A1 is mainly expressed in the brain, liver and placenta (Ray et al. 
1997).  The metabolism of ATRA by CYP26A1 can produce two main metabolites, 4-
hydroxy-ATRA and 4-oxo-ATRA which can bind to RAR but with low affinity, resulting 
in the inactivation of ATRA (Villani et al. 2004).  This indicates that high levels of 
CYP26A1 decrease the effects of ATRA in target cells.  A higher level of CYP26A1 
protein was detected in primary ovarian cancer than in normal ovary tissues (Downie et al. 
2005).  In addition, overexpression of CYP26A1 has been shown to be associated with 
human breast and colon cancer cells (Sonneveld et al. 1998), suggesting that inhibition of 
CYP26A1 may be a new strategy to increase local ATRA and inhibit the catabolism of 
ATRA.  CYP26A1 inhibitors (e.g. liarozole, R116010 and R115866) have entered clinical 
trials for the treatment of cancer patients (Schuster and Bernhardt 2007) and these are 
described in Section 1.8. 
 
The CYP26B1 gene carries six exons located on chromosome 2p12 (Nebert and Nelson 
2005).  CYP26B1 is mainly expressed in the adult brain several regions (i.e. cerebellum 
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and pons) (White et al. 2000) and embryonic tissues (MacLean et al. 2007).  CYP26B1 is 
involved in the metabolism of ATRA which is similar to CYP26A1.  In animal models, it 
appears to have an essential role in the development of the embryo (MacLean et al. 2001).  
 
The CYP26C1 is the newest member of the CYP26 family to be identified in humans.  
CYP26C1 expression is found in human keratinocyte cell lines.  It can be induced by 
ATRA and 9-cis-retinoic acid which differs from CYP26A1 and CYP26B1 (Taimi et al. 
2004, Njar et al. 2006).  However, the physiological function of CYP26C1 relevant to 
diseases in humans remains unknown.  
 
1.5.15 CYP27 family 
The three subfamilies CYP27A1, CYP27B1 and CYP27C1 have been identified in the 
human CYP27 family.  The CYP27A1 gene is located on chromosome 2q33-qter and 
contains eleven exons (Cali and Russell 1991).  CYP27A1 is a multifunctional 
mitochondrial enzyme, sterol 27-hydroxylase, that is predominantly expressed in the liver 
and catalyses several oxidative reactions in the biosynthesis of bile acids and the 
bioactivation of vitamin D3 (Gottfried et al. 2006).  This enzyme is an initial enzyme in the 
pathway of bile acid biosynthesis which is related to CYP7A and CYP8B.  Tang and co-
workers demonstrated the regulation of CYP27A1 mRNA and activity in human hepatoma 
HepG2 and prostate cancer LNCaP cells.  Results showed that CYP27A1 is regulated by 
hormones especially oestrogen and androgen compounds (Tang et al. 2007).  
 
The CYP27B1 gene is located on chromosome 12q13.1-q13.3 and contains nine exons (St-
Arnaud et al. 1997).  CYP27B1 converts the vitamin D3 precursor into the most active 
form of vitamin D3 (1,25-(OH)2D3) in the kidney and is also called 25-OH-D3-1α-
hydroxylase.  This enzyme has a crucial role in physiological function such as cell 
differentiation and proliferation (Takeyama et al. 1997).  In the proximal tubules, 
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CYP27B1 mRNA and protein have been shown to be repressed in the presence of (1,25-
(OH)2D3).  CYP27B1 was found in non-renal tissues (i.e. skin, lymph nodes, colon, 
pancreas and brain) (Zehnder et al. 2001) including human mammary epithelial cells 
(Kemmis et al. 2006).  In addition, several cancer cell lines have shown CYP27B1 
expression (Diesel et al. 2005, Becker et al. 2007, Cordes et al. 2007, Turunen et al. 2007).  
A study by de Lyra and colleagues showed that decreased levels of 1,25-(OH)2D3 are 
associated with breast cancer (de Lyra et al. 2006).  In addition, maximising 1,25-(OH)2D3 
by using the combination of a CYP24A1 inhibitor (genetein) and a CYP27B1 inducer 
(trichotatin A) has been demonstrated to increase the antiproliferative effect of 1,25-
(OH)2D3 in prostate cancer cells (Farhan et al. 2003, Khorchide et al. 2005).  Currently, the 
CYP27C1 gene has been sequenced and identified in humans but it was not detected in 
rodent (Nelson et al. 2004).  The physiological function of CYP27C1 remains unknown. 
 
1.5.16 CYP39 family 
The CYP39A1 gene is located on chromosome 6p21-p11.2 and carries twelve exons (Li-
Hawkins et al. 2000).  CYP39A1 is predominantly found in the liver and its expression in 
females is higher than in males, which is opposite to that of CYP7B1 expression.  In the 
liver, 7α-hydroxylation of cholesterol is the rate-limiting step of bile acid synthesis and 
metabolic elimination, and this is mediated by CYP7A1 and CYP39A1.  CYP39A1 is 
specific for 24S-hydroxycholesterol as a substrate.  Dietary cholesterol, bile acids or a bile 
acid-binding resin does not affect hepatic CYP39A1 mRNA level (Li-Hawkins et al. 
2000).  Higher levels of CYP39A1 protein were found in colorectal cancer patients with 
lymph node metastasis than in their corresponding primary tumours (Kumarakulasingham 
et al. 2005). 
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1.5.17 CYP46 family 
The CYP46A1 gene resides on chromosome 14q32.1 and contains fifteen exons (Lund et 
al. 1999, Nebert and Nelson 2005).  This gene encodes cholesterol 24S hydroxylase which 
is a rate-limiting enzyme for cholesterol removal from the brain.  CYP46 mRNA and 
protein are selectively expressed in human brain particularly in neurons and some 
astrocytes.  It modulates the turnover of cholesterol in the brain by converting excess 
cholesterol into 24S-hydroxycholesterol (Bjorkhem et al. 1998).  High levels of CYP46A1 
have been shown to be associated with degenerating neuritic plaques in Alzheimer’s 
disease.  These observations suggest that CYP46 expression may lead to cholesterol being 
abundant in plasma, resulting in greater loss of synapses in the brain and the development 
of Alzheimer’s disease (Bogdanovic et al. 2001, Desai et al. 2002, Brown et al. 2004).  
Recently, Bretillon and colleagues examined CYP46A1 expression in mammalian neural 
retina using RT-PCR and immunohistochemical analysis.  Results showed that CYP46A1 
mRNA and protein were specifically expressed in bovine and rat samples (Bretillon et al. 
2007). 
 
1.5.18 CYP51 family 
The CYP51A1 gene is located on chromosome 7q21.2-21.3 and contains ten exons (Nebert 
and Nelson 2005).  CYP51A1 (lanosterol 14α-demethylase) is found in both prokaryotes 
and eukaryotes (Aoyama et al. 1996, Waterman and Lepesheva 2005).  CYP51A1 mRNA 
is expressed in most tissues in humans but the highest expression has been detected in 
Leydig cells in the testes (Stromstedt et al. 1998).  CYP51A1 plays an important role in the 
key step of cholesterol biosynthesis as it catalyses the oxidative removal of the 14α-methyl 
group from lanosterol (Rozman et al. 1996).  Inhibitors of human CYP51A1 have been 
attracting interest in antimicrobial and anticholesterolemic drug research (Waterman and 
Lepesheva 2005, Schuster and Bernhardt 2007).  A high expression of CYP51 protein has 
been shown to be associated with poor prognosis and is an independent marker of 
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prognosis in colorectal cancer (Kumarakulasingham et al. 2005).  In addition, a higher 
level of CYP51A1 protein was detected in primary ovarian cancer than in normal ovary 
tissues (Downie et al. 2005). 
 
1.6 Expression of cytochrome P450s in breast cancer cell lines 
As mentioned in Section 1.3, in vitro cell culture models in breast cancer cells have been 
extensively studied in preclinical models with respect to the investigation of molecular 
mechanisms involved in breast carcinogenesis, mechanisms of drug resistance/sensitivity 
in tumour cells and the identification of novel targets for cancer therapeutics (Lacroix and 
Leclercq 2004).  Knowledge of cytochrome P450 enzymes derived from preclinical 
models, including their expression profile can be representative of the malignant cells in 
relation to clinical findings.  MCF7 is the most popular of the oestrogen-dependent breast 
cancer cells and this cell line has been shown to stably express cytochrome P450s (i.e. 
CYP1A1) in a similar manner to their tissue of origin (Rekha and Sladek 1997, Michael 
and Doherty 2005).   
 
However, there remains controversy regarding mRNA/protein expression profile in breast 
cancer tissues and cell lines.  For instance, expression of CYP1B1 mRNA and protein 
appeared to be high in human breast cancer tissues (McKay et al. 1995, Murray et al. 1997, 
McFadyen et al. 1999), but MCF7 cells expressed CYP1B1 mRNA but not protein 
(McFadyen et al. 2003).  This may be due to the expression alteration of key transcription 
factors involved in the translation of cytochrome P450.  It reflects individual variation in 
the expression profiles.  Nevertheless, cell line models are useful tools, especially in 
human breast cancer research where animal models may not truly represent cytochrome 
P450 expression found in humans as species and strain differences in expression of these 
enzymes are well recognised (Miles et al. 1990, Michael and Doherty 2005).  No model is 
perfect and it is important to keep these limitations in mind. 
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Previous studies have demonstrated the presence of cytochrome P450 mRNA in breast 
cancer cell lines.  However, a very few of these models (i.e. MCF7, T47D and MDA-MB-
231) have been widely used and only a limited number of individual cytochrome P450 
enzymes are currently available in these models.  Also, there appears to be a lack of data 
on the association between cytochrome P450 expression and breast tumour characteristics 
(i.e. oestrogen receptor status, invasiveness and ethnicity).   
 
1.7 Nuclear receptors involved in regulation of cytochrome P450s 
1.7.1 Introduction 
Members of the nuclear receptor superfamily fundamentally function as ligand-regulated 
transcription factors by transforming the extracellular and intracellular signals, and 
controlling the transcription of their target genes.  Nuclear receptors can be found within 
the nucleus and they are responsible for sensing the presence of certain ligands such as 
lipophilic hormones, vitamins, dietary lipids and other xenobiotic compounds  
(Zhang et al. 2004).  These receptors are highly conserved across species and play a role in 
the growth and development of organisms.  They are also important in several signalling 
pathways (i.e. cell differentiation, reproduction, metabolism of lipids, drugs and energy) 
(Sonoda et al. 2008).  Currently, 48 nuclear receptors have been identified in the human 
genome (Zhang et al. 2004).   
 
In principle, nuclear receptors share a common structural domain (Figure 1.4).  The N-
terminal regulatory domain contains the activation function-1 (AF-1) whose action is 
independent on the presence of bound ligand, and this domain is highly variable in 
sequence between various nuclear receptors.  The DNA-binding domain (DBD) is the most 
conserved region which comprises of two zinc finger (ZF-1 and ZF-2) complexes and is 
involved in dimerisation (homo- or heterodimerisation) of nuclear receptors.  The hinge 
region is responsible for connecting the DBD and ligand binding domain (LBD), and this 
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is a flexible domain containing the nuclear localisation signal.  LBD, which is the largest 
domain, contributes to the dimerisation interface of the receptor and binds to coactivator/ 
corepressor protein.  The LBD contains the activation function-2 (AF-2) (Sonoda et al. 
2008).  Nuclear receptors bind to each other by either homo- or heterodimerisation, 
resulting in transcriptional activation or repression of the target genes, which mediates 
physiological significances (Figure 1.5). 
 
 
 
 
 
As mentioned above, nuclear receptors are usually activated by ligand binding, and many 
cytochrome P450 enzymes are involved in the metabolism of these ligands (Akiyama and 
Gonzalez 2003).  The molecular mechanism of cytochrome P450 induction by its ligands 
was discovered almost 50 years ago, and this knowledge is essential for both the study of 
drug metabolism and the carcinogenic process in humans (Meyer 2007).  Many ligand-
activated nuclear receptors have been demonstrated to be key mediators in the induction of 
 
Figure 1.4: Schematic view of structural organisation of nuclear receptors (Adapted from Sonoda et al. 2008). 
 
Figure 1.5: Schematic view of general mechanism for nuclear receptor activation and/or repression 
(Adapted from Xie and Evans 2001). 
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cytochrome P450s.  The transcriptional activation of some members of the cytochrome 
P450 family (i.e. families 1, 2, 3, 4, 7, 24 and 26) that are involved in the metabolism of 
endogenous and xenobiotic compounds have been identified (Honkakoski and Negishi 
2000).  The review in this section summarises the roles of cytochrome P450-associated 
nuclear receptors such as aryl hydrocarbon receptor (AhR), pregnane X receptor (PXR), 
constitutive androstane receptor (CAR), PPARα, vitamin D receptor (VDR), retinoic acid 
receptor (RAR) and farnesoid X receptor (FXR) including crosstalk in the regulation of 
cytochrome P450 expression.  The regulation of cytochrome P450 genes by nuclear 
receptors and their heterodimerisation with a partner is shown in Figure 1.6. 
 
 
 
 
 
 
Figure 1.6: Schematic diagrams for activated-ligand nuclear receptors involved in the regulation of cytochrome 
P450s and their heterodimerisation with a partner. 
Abbreviations: DRE; DNA response element, AhR; aryl hydrocarbon receptor, ARNT; AhR nuclear 
translocator, CAR; constitutive androstane receptor, RXR; retinoid X receptor, PXR; pregnane X receptor, 
PPARα;peroxisome proliferator-activated receptor alpha, FXR; farnesoid X receptor, LXRα; liver X receptor, 
VDR; vitamin D receptor, RAR; retinoic acid receptor. 
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1.7.2 Aryl hydrocarbon receptor (AhR)  
Aryl hydrocarbon receptor (AhR) is a member of the basic helix-loop-helix (bHLH) 
protein which belongs to the Per-Arnt-Sim (PAS) family of transcription factors.  AhR 
plays a role in xenobiotic metabolism and in mediating the carcinogenic effects of dioxin-
like compounds.  A number of studies have demonstrated that the induction of CYP1 
family member expression is controlled by AhR signalling pathway.  AhR ligands include 
polycyclic aromatic hydrocarbons (PAHs, e.g. 3-methylcholanthrene) and 2,3,7,8-
tetrachlorodibenzo-p-dioxin (TCDD) (Kim et al. 2005).  In the absence of ligand, AhR is a 
cytoplasmic protein complex consisting of chaperone proteins such as heat shock protein 
90 (Hsp90), p23 and ARA9.  In the presence of ligand, AhR ligand-bound is dissociated 
from the chaperone proteins in the cytoplasm and is translocated into the nucleus where it 
dimerises with AhR nulcear translocator (ARNT, also called hypoxia inducible factor-1 
beta; HIF-1β) protein. This complex then binds to DNA response elements (DRE) in 
regulatory regions of AhR responsive genes (AhREs), leading to the induction of CYP1 
genes in tissue-specific targets (Kawajiri and Fujii-Kuriyama 2007).  In addition, Kim and 
co-workers demonstrated a significant positive correlation between hepatic AhR and 
CYP1A1 expression levels (Kim et al. 2005). 
 
Another key protein in the PAS family is the AhR repressor (AhRR), which is 
constitutively expressed in the nucleus and is inducible in an AhR-dependent manner.  
AhRR needs to form a dimer with ARNT and the AhRR/ARNT complex binds to DREs.  
It was believed that AhRR can inhibit the AhR signalling pathway by inhibition of the 
AhR/ARNT complex and binding to DREs (Kawajiri and Fujii-Kuriyama 2007).  
However, Evans and colleagues have recently shown that repression of AhR activity by 
AhRR is through protein-protein interactions rather than the previously proposed 
mechanism (Evans et al. 2008).  In addition to the induction of CYP1 genes by AhR, 
hypoxia-inducible factor-1alpha (HIF-1α) requires dimerisation with ARNT to begin 
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transcription of its target genes which is similar to either AhR or AhRR expression.  In the 
breast cancer ZR-75-1 cells grown under hypoxic conditions for 24 hours, AhR-mediated 
transactivation was significantly decreased and this contributed to loss of Ah-
responsiveness, possibly due to decreased expression of AhR or competetion for ARNT or 
their bindings with CYP1A1 promoter (Khan et al. 2007).  These observations suggest that 
expression of AhR, ARNT, AhRR or HIF-1α affects the regulation of CYP1 genes. 
 
A novel chemotherapeutic prodrug aminoflavone (an AhR ligand) leads to a translocation 
of AhR from the cytoplasm to the nucleus, resulting in the interaction between AhR and 
DRE, and CYP1A1 transcription.  This was observed in the aminoflavone-sensitive MCF7 
cells but not in the resistant MDA-MB-435 cells, suggesting that the toxicity of 
aminoflavone prodrug was selectively activated through the engagement of AhR-mediated 
signal transduction only in a sensitive breast tumour cell line (Loaiza-Perez et al. 2004).  
This is an essential consideration for the use of aminoflavone in breast cancer patients in 
clinical studies. 
 
1.7.3 Constitutive androstane receptor (CAR) 
Constitutive androstane receptor (CAR), also called constitutive active receptor, is the 
most closely related to PXR.  CAR is highly expressed in the liver and at lower levels in 
the intestine.  It is called a ‘constitutive’ receptor because of its ability to transactivate in 
the absence of ligand-binding (Akiyama and Gonzalez 2003).  CAR plays an important 
role in the transcription of CYP2B6, CYP3A4 and CYP2C (Pascussi et al. 2003), and its 
role in xenobiotic regulation of CYP2B6 genes has been widely studied in humans.  The 
CYP2B6 gene is inducible by phenobarbital-like inducers (e.g. phynetoin) through CAR, 
which bind to the phenobarbital-response element (PBRE) sites as a heterodimer with 
retinoid X receptor (RXR) in the nucleus.  The CAR/RXR heterodimer results in the 
transcriptional activation of CYP2B6 mRNA (Wang et al. 2004).  Chang and co-workers  
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showed a significant positive relationship between CYP2B6 and CAR expression in human 
liver (Chang et al. 2003).   
 
In addition to CAR ligands, the PXR activator clotrimazole can bind to CAR and 
subsequently suppresses CYP2B6 transcription.  The antifungal antibiotic clotrimazole and 
steroid hormone androstanol are classified as potent deactivators of CAR and inverse 
agonists, suggesting that CAR and PXR might share xenobiotic and steroid ligands (Moore 
et al. 2000).  However, CAR has also been shown to be involved in the detoxification of 
some endogenous ligands (i.e. bile acids and bilirubin) (Moore et al. 2006) and 
biosynthesis of sterols and steroids in human liver (Meyer 2007) which alter the induction 
of CYP2B6 gene. 
 
1.7.4 Pregnane X receptor (PXR) 
Pregnane X receptor (PXR) also termed steroid X receptor (SXR) is predominantly 
expressed in the liver and small intestine (Moore et al. 2006) and mediates induction of 
CYP3A4, CYP2B6, CYP2C8 and CYP2C9 (Pascussi et al. 2003).  PXR functions as a 
sensor for steroids (e.g. oestrogen, progesterone and corticosteroid) and xenobiotics (e.g. 
phenobarbital, clotrimazole, rifampicin and nifedipine).  PXR mainly activates CYP3A4, 
which is a primary target gene of PXR.  Therefore, compounds that activate PXR also 
induce transcriptional activity of CYP3A4.  The ligand-activated PXR forms a heterodimer 
with RXR, and the heterodimer PXR/RXR binds with an everted repeat separated by six 
base pairs (ER6) from the CYP3A4 proximal promoter, resulting in an increase in 
CYP3A4 induction (Vyhlidal et al. 2004).  PXR and CAR are closely related nuclear 
receptors, sharing ligands and sharing a heterodimer partner (RXR).  In addition, CAR and 
PXR are also involved in biosynthesis and catabolism of steroid hormones, lipid 
metabolism, glucose homeostasis and inflammation.  This could explain crosstalk between 
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these receptors (Section 1.7.9), which may affect cytochrome P450 expression and 
physiological functions (Moreau et al. 2007b). 
 
Miki and colleagues investigated the expression of PXR mRNA and protein using real-
time RT-PCR and immunohistochemical methods in 60 human breast cancer tissues.  They 
reported that PXR was detected in breast tumours but not in matched adjacent normal 
breast cells.  Positive correlations between PXR and both the histological grade and lymph 
node status of the tumours were noted in this study (Miki et al. 2006), suggesting that PXR 
may be involved in human breast carcinogenesis.  These findings are in disagreement with 
a study by Dotzlaw and co-workers (Dotzlaw et al. 1999) though, who demonstrated PXR 
mRNA in both breast tumour and their corresponding normal breast tissues.  Higher levels 
of PXR mRNA were detected in ER-negative tumours than in ER-positive tumours.  They 
showed that PXR is expressed in breast cancer cell lines T47D, MCF7 and MDA-MB-231. 
 
1.7.5 Vitamin D receptor (VDR) 
1,25-(OH)2D3 and its analogues have been shown to inhibit proliferation, induce apoptosis 
and immunomodulation of human cancer cells mediated by vitamin D receptor (VDR).  
Ligand-activated VDR forms a heterodimer with RXR and binds to vitamin D-response 
elements (VDREs) on the target genes, causing either activation or repression of target 
gene expression (Moreau et al. 2007a).  VDR is mainly expressed in the kidney, intestine 
and thyroid (Moore et al. 2006).  CYP24A1 is one of the VDR target genes which is 
directly regulated by VDR, and plays a role in the inactivation of vitamin D in the kidney 
(Zhou et al. 2006).  Anderson and colleagues demonstrated overexpression of CYP24A1 
and down-regulation of VDR mRNA in various cancer cell lines including breast cancer 
MCF7 cells (Anderson et al. 2006), suggesting that the inverse relationship between 
CYP24A1 and VDR is associated with carcinogenesis.  In addition, Yee and co-workers 
showed that a combination of ketoconazole and tetralone inhibits CYP24A1 mRNA and 
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enhances VDR signalling in androgen-independent prostate cancer DU-145cells (Yee et al. 
2006).   
 
1.7.6 Peroxisome proliferator-activated receptor alpha (PPARα) 
Peroxisome proliferators (e.g. fibrate class of hypolipidemic drugs including WY-14643 or 
pirinic acid) are a group of chemicals that lead to an increase in size and number of hepatic 
peroxisomes when administered to rodents.  PPARα is highly expressed in the liver, 
kidney and vascular wall and is activated by a variety of fatty acids.  PPARα plays a role 
in the transcriptional regulation of enzymes involved in the ω- or β-fatty acid oxidative 
pathway (Bishop-Bailey and Wray 2003).  In the presence of peroxisome proliferators, 
PPARα can heterodimerise with RXR, and the PPARα/RXR heterodimer complex binds 
to peroxisome proliferator-response elements (PPREs), leading to the transcriptional 
activity of target genes such as CYP4A (Ito et al. 2007).  High levels of PPARα mRNA 
have been demonstrated in MCF7 breast cancer cells, and this may suggest a crucial role 
for PPARα  in human breast carcinogenesis (Suchanek et al. 2002) 
 
1.7.7 Retinoic acid receptor (RAR) 
All-trans-retinoic acid (ATRA), the most active metabolite of retinoids (vitamin A) plays 
an important role in cell differentiation and proliferation of epithelial cells mediated by 
retinoic acid receptor alpha (RARα) (Njar et al. 2006).  The binding of ligand to RARα 
results in a heterodimer with RXR, and the RARα/RXR heterodimer binds to retinoic acid 
response elements (RAREs) or retinoid X response elements (RXREs), causing 
transcriptional suppression or activation of target genes such as CYP26A1.  In human 
breast cancer, a positive relationship was found between the retinoid growth-inhibitory 
effects and RARα expression (Fitzgerald et al. 1997).  Expression of RAR and RXR has 
been demonstrated in breast cancer cells (Titcomb et al. 1994).  In addition, Mu and 
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colleagues investigated the effects of various nuclear receptor ligands on CYP19A1 
activity in the breast cancer MCF7 cells.  Findings showed that RAR and RXR selective 
ligands increased CYP19A1 activity, suggesting that these compounds may be involved in 
the regulation of oestrogen production in breast cancer cells (Mu et al. 2000). 
 
1.7.8 Farnesoid X receptor (FXR) 
Bile acids are the main product of cholesterol metabolism in the liver and are important for 
lipid absorption in the intestine.  Farnesoid X receptor (FXR) has been characterised as a 
bile acid receptor.  In the presence of the most potent bile acid (chenodeoxycholic acid; 
CDCA), FXR forms a heterodimer with RXR and the FXR/RXR heterodimer binds to the 
bile acid response elements (BAREs), resulting in the suppressive effects of bile acid and a 
transcriptional repression of target genes such as CYP7A1 (Akiyama and Gonzalez 2003).  
FXR is found to be expressed in breast cancer tissue, suggesting that FXR expression in 
association with high levels of bile acid may play a role in breast carcinogenesis.  This 
raised the possibility that FXR inhibitors could be used for breast cancer treatment (Swales 
et al. 2006).   
 
1.7.9 Crosstalk between nuclear receptors 
Crosstalk is defined as a functional interaction between two (or more) signalling pathways 
of members of the nuclear receptor superfamily.  Crosstalk between nuclear receptors has 
been extensively studied (Keller et al. 1995, Zhou et al. 2006, Meyer 2007, Moreau et al. 
2007b, Roth et al. 2008) and their interactions have been demonstrated to be involved in 
several intracellular signalling pathways (i.e. growth factors, hormones and cytokines) and 
xenobiotic metabolism (Figure 1.7).  Regulation of target gene expression by nuclear 
receptors is complex.  A better understanding of the associated molecular mechanism is 
likely to explain biological phenomena in the body. 
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As shown in Figure 1.5, transcriptional activation of nuclear receptors’ target genes 
requires a number of different steps (i.e. ligand binding, coactivator/corepressor protein, 
dimerisation with a partner and DNA binding within their target genes) and each signalling 
pathway is usually connected with other pathways (Reményi et al. 2004).  Crosstalk may 
lead to alterations in other genes’ target gene expression or activity (Waxman 1999, 
Honkakoski and Negishi 2000).  This section provides some examples of crosstalk 
between nuclear receptors which have been shown to affect cytochrome P450 expression. 
 
 
 
The negative crosstalk between ER and AhR signalling pathways has been well 
documented by several research groups using breast tumour tissue and cell lines (Safe et al. 
1998, Safe et al. 2000, Safe and Wormke 2003, Matthews et al. 2005, Matthews and 
Gustafsson 2006).  ER and AhR are ligand-activated transcription factors.  As mentioned 
in Section 1.7.2, AhR mediates the toxic effects of dioxin-like compounds (e.g. TCDD) 
and is involved in the induction of CYP1 genes.  However, the AhR signalling pathway 
can be linked to the ER signalling pathway as CYP1 genes play a key role in oestrogen 
metabolism.  Recently, mechanisms of inhibitory cross talk between ER and AhR have 
been proposed by Matthews and Gustafsson (Matthews and Gustafsson 2006).  There are 
at least five mechanisms that are involved in the role of AhR inhibiting ER activity (1) 
 
Figure 1.7: Crosstalk interactions between the regulation of xenobiotic and endogenous compounds. 
Abbreviations: AhR; arylhydrocarbon receptor, PXR; pregnane X receptor, CAR; constitutive androstane 
receptor, PPARα; peroxisome proliferator-activated receptor alpha VDR; vitamin D receptor, RAR; retinoic 
acid receptor, ER; oestrogen receptor, P450; cytochrome P450, cpds; compounds, met; metabolism. 
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direct inhibition via inhibitory xenobiotic response elements (iXREs), (2) squelching 
shared coactivators (i.e. ARNT), (3) synthesis of an inhibitory factor (unknown), (4) 
increased ER degradation and (5) increased expression of enzymes involved in oestrogen 
synthesis (i.e. CYP19) and metabolism (i.e. CYP1A1 and CYP1B1).  In addition, these 
cytochrome P450s play an important role in the metabolism of anticancer drugs (Section 
1.8), and this knowledge could improve the clinical approach to particular cancer therapies 
 
Transcriptional crosstalk between ER and RAR has been demonstrated in human breast 
cancer cells (Rousseau et al. 2003).  Retinoic acid has been shown to be associated with 
down-regulation of ER mRNA and inhibition of cell growth in oestrogen-dependent breast 
cancer MCF7 cells.  By contrast, this was not observed in ER-negative breast cancer 
MDA-MB-231 cells.  Higher levels of RAR were found in ER-positive breast cancer than 
in ER-negative breast cancer cell lines (Rubin et al. 1994), suggesting that expression of 
RAR and ER is essential for retinoid responsiveness.  Furthermore, oestrogen has been 
shown to elevate RAR expression, whereas antioestrogen seems to be associated with 
down-regulation of RAR (Lu et al. 2005). 
 
CAR and PXR are mediated by induction of CYP2B and CYP3A genes respectively, and 
share a common heterodimerisation partner i.e. RXRα, ligands and DNA response 
elements within their target genes (Handschin and Meyer 2003).  The CAR and PXR genes 
are closely related members of the nuclear receptor family and have overlapping 
substrates.  These nuclear receptors are involved in the regulation of various endogenous 
compounds such as steroid hormones, bile acids, eicosanoids and cholesterol (Echchgadda 
et al. 2007).   
 
A recent study investigated CAR- and VDR-binding to specific response elements in 
human hepatocyte cells using electromobility shift assay, and determined CYP24 
Introduction 
 56 
expression (Moreau et al. 2007a).  Results showed that the CAR/RXR heterodimerisation 
binds to the promoter of CYP24, which is the same region as VDR/RXR, resulting in 
decreased CYP24 expression and response to vitamin D3, suggesting that CAR ligands 
interfere with VDR target genes.  These findings are similar to a previous study that 
investigated crosstalk between PXR and VDR and showed that the PXR/RXR heterodimer 
binds to the promoter of CYP24 and competes with VDR (Pascussi et al. 2005).  This 
suggests that PXR, CAR and VDR share DNA response elements in the promoter of their 
target genes, leading to altered expression of CYP24A1, CYP2B6 and CYP3A4.   
 
It is important to note that RXR is a common heterodimerisation partner for several nuclear 
receptors (i.e. PXR, VDR, RAR, PPARα, FXR and LXRα, Figure 1.6) and this may also 
cause crosstalk between other signalling pathways, not only vitamin D3 metabolism.  
Crosstalk between PPARα/RXR and ER has been reported by Keller and colleagues 
(Keller et al. 1995).  A PPARα/RXR heterodimer inhibits ER activity through competition 
for binding to oestrogen response elements. 
 
1.8 Cancer treatment approaches based on cytochrome P450s  
The role and importance of cytochrome P450s in cancer formation and progression has led 
to the development of cancer therapeutics-based on cytochrome P450 expression and 
metabolic pathways.  Knowledge in the area of these enzymes’ substrate and mechanism of 
action in tumour cells has become very useful in the design of new chemotherapeutics 
and/or development of more effective existing anticancer drugs.  It can help reduce 
systemic toxicity and enhance specificity to tumour cells.  To date, applications of 
cytochrome P450s in cancer therapy consist of (1) inhibiting enzymes involved in 
hormone-dependent cancer and vitamin metabolism, (2) designing prodrugs activated by 
the enzymes and (3) immunotherapy targeted at tumour-specific enzymes (McFadyen et al. 
2004, Bruno and Njar 2007, Purnapatre et al. 2008) (Figure 1.8).
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In steroid hormone biosynthesis pathways, CYP17 and CYP19 are key enzymes that 
regulate the biosynthesis of oestrogen.  CYP17 plays an important role in the conversion of 
pregnenolone and progesterone to androgen and oestrogen precursors, whereas CYP19 or  
 
 
 
aromatase is involved in the conversion of testosterone and androstenedione to oestradiol 
and oestrone.  Several inhibitors of CYP19 such as letrozole, anastrazole and exemestane 
have been developed as anticancer agents for the management of breast cancer patients 
who have oestrogen-dependent tumours.  These agents inhibit the production of oestrogen 
in target tissues and improve survival in patients with metastatic breast cancer (Gibson et 
al. 2007, Perez 2007a).  Inhibitors of CYP17 such as ketoconazole and abriaterone are also 
used as anticancer drugs for the treatment of androgen-dependent cancers particularly 
prostate cancer, and these compounds inhibit androgen production and are more effective 
in advanced prostate cancer treatment (Moreira et al. 2007). 
 
Vitamins A and D are believed to have a crucial role in cancer prevention and treatment.  
All-trans-retinoic acid (ATRA) is the most active metabolite of vitamin A, it plays a role in 
cell differentiation and proliferation of epithelial cells, and has been shown to be associated 
 
Figure 1.8: Implications of cytochrome P450s in cancer therapy. 
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with tumour growth inhibition in various solid tumours (Njar 2002).  CYP26A1 is involved 
in the metabolic inactivation of ATRA and it is related to the rapid ATRA metabolism in 
cancer patients.  Inhibitors of CYP26A1 (e.g. liarozole, R115866 and R116010) inhibit 
both ATRA metabolism and CYP19 activity.  However, liarozole lacks specificity, and has 
a relatively weak potency for CYP26A1, and is no longer being developed as an anticancer 
agent.  R116010 is more potent and a selective inhibitor of CYP26A1 (Njar et al. 2006) 
which is currently in preclinical trial for patients with hormone-independent prostate and 
breast tumours (Njar 2002, Njar et al. 2006). 
 
The biologically active metabolite of vitamin D3 has been shown to play a role in the 
inhibition of cell proliferation, promotion of differentiation and induction of apoptosis and 
it has potential as a cancer therapeutic (González-Sancho et al. 2006, Deeb et al. 2007).  
CYP24A1 is the key enzyme involved in the catabolism of 1,25-(OH)2D3 to the less active 
vitamin D3 metabolite.  Overexpression of CYP24A1 has been shown in a wide range of 
tumours (Mimori et al. 2004, Anderson et al. 2006, González-Sancho et al. 2006) and is 
known as an oncogene (Mimori et al. 2004).  In addition, Townsend and colleagues 
demonstrated that higher levels of CYP24A1 were detected in breast tumour compared to 
normal breast tissue (Townsend et al. 2005).  Inhibitors of CYP24 such as genestein, QW-
1624F2-2 and EB1089 are vitamin D3 analogues and have ability to inhibit CYP24A1 
expression (Bruno and Njar 2007).  Recently, Sundaram and co-workers showed that QW-
1624F2-2 inhibits cell proliferation and invasion of breast tumour and has been proposed 
for preclinical studies as an effective chemotherapeutic agent in breast cancer treatment 
(Sundaram et al. 2006).  
 
As mentioned previously (Section 1.2.2), hypoxic conditions existing in the tumour 
microenvironment are associated with resistance to chemotherapy and radiotherapy in 
malignant cells.  However, tumour hypoxia appears to be a specific property of cells in 
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many solid tumours, and it is a potential target for tumour-specific prodrugs activated by 
oxygen-sensitive reductase (bioreductive drugs) including cytochrome P450s (Denny 
2004).  The topoisomerase II inhibitor prodrug AQ4N (Banoxantrone) is designed to have 
anti-tumour activity following activation by CYP1A1, CYP1B1 and CYP3A4.  Under 
hypoxic conditions, AQ4N is metabolised to the potent topoisomerase II inhibitor AQ4 this 
process is inhibited by oxygen..  AQ4N is currently in phase Ib/IIa clinical trials, and it has 
been reported that it is well tolerated and less toxic than another bioreductive prodrug 
tirapazamine (McKeown et al. 2007).   
 
Recently, Albertella and colleagues demonstrated clinical results derived from a phase I 
study of AQ4N in thirty-two patients with advanced solid tumours (i.e. breast, cervix, 
glioblastoma, bladder, and head and neck).  These patients received a single dose of AQ4N 
prior to surgery and results showed that AQ4N penetrated well within tumour cells, as high 
concentrations of the activated form AQ4 were detected in tumour samples (Albertella et 
al. 2008).  This data indicates that the effect AQ4N has on solid tumours is hypoxia-
selective and further evaluation in clinical trials is required. 
 
A number of cytochrome P450 enzymes are involved in the activation and/or inactivation 
of several anticancer drugs.  Paclitaxel which is widely used in cancer chemotherapy is 
inactivated in human liver by CYP2C8 forming a 6α-hydroxylation derivative with 30-fold 
less than the parent drug (Taniguchi et al. 2005).  Another example of a taxane anticancer 
drug or stabilising-microtubule agent that is inactivated in the liver by CYP3A is docetaxel 
(Scripture et al. 2005).  In addition, the tumour response to docetaxel in human breast 
tumours can be predicted by CYP3A4 (Miyoshi et al. 2005).  Patients with CYP3A4 
negative tumours showed a higher response rate to docetaxel than those with CYP3A4 
positive tumours.  However, a previous study reported that the coadminstration of 
CYP3A4 inhibitors (e.g. ketoconazole and midazolam) with docetaxel may cause a 
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significant drug interaction, resulting in toxic effects such as febrile neutropenia (Engels et 
al. 2004).  These findings are in agreement with a study by Alexandre and colleagues 
(Alexandre et al. 2007) who investigated the relationship between CYP3A activity, 
inflammatory status and risk of docetaxel-induced febrile neutropenia in patients with 
advanced cancer. 
 
The anticancer prodrugs cyclophosphamide, doxorubicin and tamoxifen are bioactivated to 
active agents mainly by cytochrome P450s.  Cyclophosphamide is an alkylating agent 
derived from the produrg oxazaphosphorine which is primarily activated in the liver by 
CYP2B6 to generate a cytotoxic activity of phosphoramide mustard and acrolein, then 
delivered to tumour cells via blood circulation (Stoff-Khalili et al. 2006).  To prevent 
deleterious secondary effects and minimise damage to normal tissue, cytochrome P450 
mediated gene-directed enzyme and prodrug therapy (GDEPT) have recently been 
developed with CYP2B6 for the treatment of cyclophophamide by delivery of exogenous 
cytochrome P450s to the target site (Roy and Waxman 2006).  MetXia encodes human 
CYP2B6, it activates cyclophosphamide in tumour cells is designed to sensitise malignant 
cells and can be directly injected into tumours prior to cyclophosphamide treatment.  
MetXia is currently in phase I/II clinical trials for advanced breast cancer patients 
(Braybrooke et al. 2005). 
 
The anthracycline antibiotic prodrug doxorubicin is one of the most widely used anticancer 
drugs.  Doxorubicin is activated in human liver by CYP3A4 to form a potent active 
metabolite methoxymorpholinyl doxorubicin (MMDX) which interacts with DNA by 
intercalation and inhibition of topoisomerase II (Mathijssen and van Schaik 2006).  In 
addition, a study by Lu and colleagues investigated anti-tumour activity of MMDX in 
various tumour cell lines (i.e. breast, lung, brain and colon).  Results showed that very low 
levels of CYP3A4 expression and low anti-tumour activity of MMDX were found in these 
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cell lines (Lu and Waxman 2005), suggesting that increasing the content of CYP3A4 in the 
tumour site using gene-therapy vectors may be helpful when treating patients with 
doxorubicin.   
 
Tamoxifen is currently used for the treatment of oestrogen-dependent breast cancer 
patients and is activated in the liver by several cytochrome P450s (i.e. CYP2D6, CYP3A, 
CYP2C9, CYP2C19 and CYP2B6).  It is mainly activated by CYP2D6, forming 4-
hydroxytamoxifen which has 50-100-fold more potent antioestrogenic effects than 
tamoxifen (Dehal and Kupfer 1997).  CYP2D6 is a highly polymorphic gene and this may 
contribute to variability of treatment outcome between individuals and/or ethnicities 
(Zanger et al. 2007).  Other cytochrome P450s appear to have less important roles in the 
metabolism of tamoxifen (Scripture et al. 2005). 
 
Novel synthetic prodrugs selectively designed to be activated by cytochrome P450s, 
especially CYP1A1 and CYP1B1, have been developed and show promise as new options 
for cancer therapeutics.  The phytoestrogen resveratrol (3,5,4’-trihydroxy-trans-stilbene) is 
derived from natural sources (i.e. red grape skin).  Resveratrol is mainly metabolised by 
CYP1B1 within tumour cells to form the anticancer agent piceatannol (Piver et al. 2004) 
which has antioestrogen effects.  It has antioxidant and anti-inflammatory effects which 
may induce apoptosis and modulate the function of ER in breast cancer cells (Athar et al. 
2007).  Phase I and pharmacokinetic evaluations of oral resveratrol in healthy volunteers 
have recently been demonstrated through investigation of six metabolites of resveratrol in 
urine (Boocock et al. 2007).  Results suggested that the highest dose of resveratrol did not 
cause severe adverse drug reaction and cancer chemopreventive effects of resveratrol 
metabolites in this study warrant further investigation by clinical studies. 
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Another novel synthetic prodrug involving cytochrome P450s is a water-soluble 
fluorinated benzothiazole prodrug phortress that is a potent AhR agonist and can induce 
CYP1A1 expression.  CYP1A1 converts phortress prodrug into an electrophilic reactive 
intermediate, that induces formation of DNA adducts resulting in DNA damage and cell 
death.  Phortress is rapidly hydrolysed in the presence of cells to its lipophilic parent drug, 
which is then selectively taken up into sensitive cells, followed by AhR binding and 
translocation into the nucleus, leading to induction of CYP1A1 (Leong et al. 2003).  
Phortress has recently entered phase I clinical studies with breast cancer patients in the UK 
(Bradshaw and Westwell 2004).  However, Brockdorff and colleagues demonstrated that 
increased expression of CYP1A1 and CYP1B1 is associated with antioestrogen resistance 
in breast cancer cell lines (Brockdorff et al. 2000), and further clinical studies are required 
to investigate CYP1A1 and CYP1B1 expression in tumour cells and avoid this problem in 
patients. 
 
Gene expression of tumour-specific cytochrome P450s has introduced the concept of 
cancer immunotherapy using a DNA vaccine.  CYP1B1 has been shown to be a tumour-
associated antigen that is overexpressed in a wide range of tumour tissues and cell lines 
(e.g. breast, uterus and ovary) and therefore represents an attractive target for immune-
based therapy.  The CYP1B1-based DNA vaccine Zyc300 is designed to induce the 
immune system anti-CYP1B1-specific CD8+ T-cell against CYP1B1-expressing tumour 
cells.  Zyc300 is currently in phase I evaluation (Maecker et al. 2003) and has been shown 
to improve survival in cancer patients who have developed immunity to CYP1B1.  In 
addition, a study by Gribben and co-workers has shown that increased anti-CYP1B1 
immunity in patients with metastatic tumours (i.e. ovarian, colorectal, renal, prostate and 
breast cancer) dramatically improved their response to next salvage therapy (Gribben et al. 
2005).  Though unexpected, it was associated with a good clinical outcome and low 
toxicity.   
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A CYP3A4-based therapeutic antisense phosphorodiamidate morpholino oligomer AVI-
4457 has been developed as CYP3A4 plays an important role in the deactivation of 
paclitaxel and cyclophosphamide which are important chemotherapeutic agents, but it is 
not a tumour-specific expression enzyme (McFadyen et al. 2004).  A previous study 
demonstrated that inhibition of CYP3A4 expression was observed in primary human 
hepatocytes after 24 hours exposure to AVI-4557.  Findings showed that the cytocidal 
activity of cyclophosphamide and paclitaxel are inhibited and induced with AVI-4557 
treatment in these cells respectively, but no effect on the cytocidal activity of cisplatin 
(Arora et al. 2002).  However, further information on clinical trials of this agent has not 
been reported. 
 
1.9 Aims 
Cytochrome P450 enzymes are involved in the carcinogenic process as well as cancer 
treatment.  The current study aimed to detect the presence of these enzymes and their 
regulatory nuclear receptors in breast cancer cell lines as models, and to identify potential 
novel targets for breast cancer treatment based upon the expression profiles obtained.  This 
study selected 24 cytochrome P450 genes and 10 P450-regulatory nuclear receptors for 
investigation (Table 1.5).  Characterisation and regulation of CYP4Z1 expression were of 
particular interest.   
Table 1.5: List of candidate genes in this study. 
Cytochrome P450 enzymes Cytochrome P450-regulatory nuclear 
receptors 
Family 1:  CYP1A1, CYP1A2 and CYP1B1 
Family 2:  CYP2A6, CYP2B6, CYP2C8, CYP2C9,  
CYP2C18, CYP2C19, CYP2D6, CYP2F1, 
CYP2J2, CYP2R1, CYP2S1 and CYP2U1 
Family 3:  CYP3A4, CYP3A5, CYP3A7, CYP3A43 
Family 4:  CYP4X1 and CYP4Z1 
Family 24: CYP24A1 
Family 26: CYP26A1 and CYP26B1 
AhR, ARNT, AhRR, HIF-1α, CAR, PXR, 
VDR, RAR, RXR and ER 
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Chapter 2 
Materials and Methods 
 
2.1 Introduction 
As previously detailed (Section 1.3), the use of cell culture as an in vitro model system has 
become increasingly important in several aspects of biomedical sciences at the molecular 
and cellular levels in order to provide a better understanding of cell biology in vivo 
particularly in disease stages.  Established human breast cancer cell lines representing 
characteristics of the primary breast tumours (e.g. ethnicity, ERα status, epithelial-
mesenchymal transition (EMT) and invasive phenotype) have been extensively used to 
determine target gene expression (Burdall et al. 2003). 
 
Microbial contamination in cell culture is one of the most common problems that can lead 
to incorrect interpretation of gene expression as it may result in serious effects (i.e. 
alteration of cell growth pattern, cell morphology, and synthesis of DNA or RNA or 
protein).  To minimise contamination, all cell culture procedures (e.g. maintenance of cell 
lines, resuscitation of frozen cells, trypsinisation and freezing cell cultures) in this study 
were carried out in a Class II safety cabinet (BioAir Instruments S.r.l., Siziano, Italy).  
Pipette tips and glass containers were autoclaved at 121oC and 15 lbs/in2 for 15 minutes, 
and glassware was heated at 160oC for 2 hours.  Penicillin/streptomycin solution is the 
most widely used combination of antibiotics in mammalian cell culture to prevent bacterial 
growth.  In this study, a final concentration of 100 U/ml of penicillin and 100 µg/ml of 
streptomycin was used in growth media (Freshney 2005). 
 
In addition, all cell lines, growth media and sterile solutions of reagent were tested for 
microbial contamination prior to use.  Brain heart infusion (BHI) broth was used to test for 
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bacterial contamination by incubating at 37oC for 1-2 days.  Sabouraud (SAB) broth was 
used to detect fungal and yeast contamination by incubating at 32oC for 7-10 days 
(Freshney 2005).   
 
Over the last 50 years, molecular biologists have made advances in the isolation, 
manipulation, and characterisation of the genetic material in cells.  The genetic material is 
transcribed into RNA and then translated into protein.  Total RNA is isolated from the cell 
of interest, and a complementary DNA (cDNA) library is synthesised from messenger 
RNA (mRNA) using an oligonucleotide deoxythymidylic acid (oligo dT) primer which is 
annealed onto the polyadenylated (poly A) tail of the mRNA template.  Thus, single 
stranded mRNA is converted into a cDNA copy of the message using a reverse 
transcriptase enzyme and deoxynucleotide triphosphates (dNTPs).  The reverse 
transcription-polymerase chain reaction (RT-PCR) is commonly used in the determination 
of the abundance of mRNA within a cell as a measure of gene expression.  RT-PCR is used 
to amplify specific regions of the cDNA template using sequence specific primers.  The 
molecular weight size of the DNA fragment is estimated by semi-logarithmic plotting and 
compared to size prediction from known sequence.  Restriction digestion and DNA 
sequencing are widely used to identify the gene products.   
 
Figure 2.1 represents a flowchart of the process used in this thesis for the detection of 
gene-specific expression.  The following sections in this chapter provide information on 
molecular biology techniques.  A list of chemicals and reagents including their suppliers 
are presented in Appendix A. 
 
2.2 Cell culture and cell lines  
The growth media, cell lines and culture techniques employed in starting growth and 
maintaining cell lines, resuscitation of frozen cells, trypsinisation, freezing cell cultures 
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and cell viability determination are described below.  All working steps in cell culture 
procedure were performed in a Class II safety cabinet. 
 
 
 
 
2.2.1 Growth media 
2.2.1.1 GlutaMaxTMI 
L-glutamine is an unstable essential amino acid required in most cell culture media 
formulations.  It is used for energy production, protein synthesis and nucleic acid synthesis.  
However, L-glutamine spontaneously degrades in cell culture media or aqueous solution to 
the ammonium product.  High ammonia concentrations are toxic to cells, lowering cell 
viability and protein production.  Therefore, several cell culture media which can be 
purchased are now supplemented with L-glutamine in dipeptide forms, such as alanyl-l-
glutamine and glycyl-l-glutamine.   
 
Figure 2.1: Flowchart of procedure for the detection of gene-specific expression. 
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GlutaMaxTMI formulation is a dipeptide which is cleaved by aminopeptidase releasing, L-
glutamine and L-alanine.  GlutaMaxTMI contains a stabilized form of L-glutamine, in equal 
molar concentrations as glutamine-containing media.  Therefore, GlutaMaxTMI-containing 
cell culture media can increase media stability, minimise toxic ammonia build-up and 
maximize cell performance (Christie and Butler 1994).  Media formulations RPMI 1640, 
L15, DMEM and DMEM/F12 supplemented with GlutaMaxTMI were employed for all cell 
culture experiments. 
 
2.2.1.2 Roswell Park Memorial Institute medium (RPMI1640) 
This was developed by Moore et al. (Moore et al. 1967) at Roswell Park Memorial 
Institute (RPMI).  The formulation utilizes a biocarbonate buffering system, and is based 
on the RPMI1630 series with alterations in the amounts of amino acids and vitamins.  
RPMI1640 medium has extensive applications for culturing growth of several types of 
cells, such as human normal and neoplastic leukocyte cell lines. 
 
2.2.1.3 Leibovitz’s medium (L15) 
This medium was developed by Leibovitz (Leibovitz 1963) in 1963 and was originally 
formulated for use in the culture of tumour cell lines in the absence of carbon dioxide 
(CO2) and without a sodium bicarbonate buffer system.  L15 medium is buffered by a 
particularly high concentration of free base amino acids (L-arginine primarily, but also L-
histidine and L-cysteine) and sodium pyruvate.  The sodium pyruvate can be utilized as a 
more readily accessible energy source for cell metabolism and can produce endogenous 
carbon dioxide.  Production of acidic metabolites is reduced by replacing glucose with 
galactose in order to maintain physiological pH (Barngrover et al. 1985). 
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2.2.1.4 Dulbecco’s Modified Eagle’s Medium (DMEM) 
DMEM is one of the most commonly used variations of Basal Medium Eagle (BSE).  This 
medium contains twice the amino acid concentrations of MEM and four times the vitamin 
concentrations, as well as additional components to facilitate better buffering (e.g. hydro-
gencarbonate and carbon dioxide concentrations).  High and low glucose forms are 
available containing 4.5 g/L and 1 g/L of glucose respectively.  This formulation is well 
suited for culturing a wide range of mammalian cell lines (Dulbecco and Freeman 1959).  
 
2.2.1.5 DMEM/Ham’s F12 medium 
Ham’s F12 media was developed to clone Chinese Hamster Ovary (CHO) cells in low 
serum concentrations (Ham 1965) and is now extensively used to culture different kinds of 
mammalian cells.  The mixture of DMEM and Ham’s F12 (1:1 v/v) is suitable for some 
epithelial, endothelial, and granulose cell types.   
 
2.2.2 Cell lines 
A database of the seven breast cancer cell lines used in this study is shown in Table 1.1.  
MDA-MB-157, MDA-MB-231, T47D, ZR-75-1 and ZR-75-30 cells were obtained from 
the European Collection of Cell Cultures (ECACC; Salisbury, Wiltshire, UK).  MDA-MB-
468 cells were a generous gift from Professor Andreas Gescher (Department of Cancer 
Studies and Molecular Medicine, Leicester Medical School, University of Leicester, UK).  
MCF7 cells were an established cell line within the School of Pharmacy and Life Sciences, 
The Robert Gordon University, Aberdeen, UK.   
 
MCF10A, a non-transformed human breast epithelial cell line is derived from breast tissue 
of a 36 year old patient with fibrocystic disease (Soule and McGrath 1986).  A previous 
study demonstrated that MCF10A contains a number of features of normal breast 
epithelium, for example, lack of carcinogenicity in nude mice, and dependence on 
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hormones and growth factors for cell proliferation (Soule et al. 1990).  In the present study, 
MCF10A was obtained from the American Type Culture Collection (ATCC; LGC 
Promochem, Middlesex, UK). 
 
2.2.3 Growth and maintenance of human normal breast and breast cancer cells 
All the media used (i.e. DMEM, RPMI1640, L15 and DMEM/Ham’s F12) were 
supplemented with GlutaMaxTMI and all cell lines were cultured under the recommended 
conditions.  Stock cultures of MCF7, T47D and MDA-MB-157 cells were grown in 
DMEM.  Cell stocks of ZR-75-30 and MDA-MB-468 cells were propagated in RPMI1640.  
Stock cultures of ZR-75-1 cells were grown in RPMI1640 containing 1 mM sodium 
pyruvate.  The media above were supplemented with 10% (v/v) foetal bovine serum (FBS).  
Stock cultures of MDA-MB-231 cells were cultured in L15 supplemented with 15% (v/v) 
FBS.  Cell stocks of MCF10A cells were grown in DMEM: Ham's F12 medium (1:1) 
supplemented with 20 ng/mL epidermal growth factor, 0.01 mg/mL insulin, 500 ng/mL 
hydrocortisone and 5% (v/v) horse serum (Thomas et al. 2006).  All growth media were 
prepared containing penicillin (100 U/mL) and streptomycin (100 µg/mL) in order to 
reduce the risk of microbial contamination.  Cells were seeded at 2-5x104 cells/cm2 and 
grown as a monolayer at 37oC in 5% CO2 and 95% air.  The cell culture media was 
changed regularly every 2-3 days to prevent a build-up of waste products as the cells grew 
and divided.  Cells reached 70-80% confluence within 5-7 days.   
 
As mentioned above, L15 medium (Section 2.2.1.3) must be used without carbon dioxide, 
therefore, MDA-MB-231 cells were cultured in flasks without vented filter caps and the 
flask caps were opened in the cell culture cabinet for 30 minutes daily to allow gaseous 
exchange to occur with atmospheric air and the replenishment of oxygen content as 
recommended by ECACC.   
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MDA-MB-157 cells were grown in L15 with GlutaMaxTMI supplemented with 15% (v/v) 
FBS as recommended (ECACC), but they were extremely slow growing.  Subsequently, 
ECACC’s technical support suggested changing their growth media to DMEM with 
GlutaMaxTMI supplemented with 10% (v/v) FBS.  The MDA-MB-157 cells clearly grew 
better in DMEM medium than L15 medium.  However, there was no difference in the 
morphological appearance between the cells cultured in L15 and in DMEM growth 
medium.  The morphological appearance of all cell lines in this study is shown in Figures 
2.2 and 2.3.  All cells were photographed as a living monolayer (at high and low density) 
using an inverted microscope Leica AF6000 system (Germany) with Leica DFC300FX 
camera (20x magnification). 
 
2.2.4 Resuscitation of frozen cells 
Gentle handling and immediate removal of cryopreservative medium was required for the 
recovery of cells, as cryopreserved cells are extremely fragile.  A cryovial containing 
frozen cells was transferred from liquid nitrogen storage to a Class II safety cabinet.  The 
outside of the cryovial was wiped with 70% (v/v) ethanol to avoid microbial 
contamination, and the screw top was opened slightly for 2 seconds to reduce the pressure 
within the vial.  The bottom half of the vial was then immediately immersed in a 37oC 
water bath until thawed.  The cell suspension was gently transferred to a sterile universal 
tube containing 10 mL of an appropriate pre-warmed growth medium in order to remove or 
dilute residual dimethyl sulphoxide (DMSO), prior to centrifugation at 500 x g (Heraeus 
Biofuge Primo centrifuge, USA) for 5 minutes at room temperature.  Increased speed and 
prolonged spin time has been suggested as decreasing viability of cells (Freshney 2005).  
The cell pellet was then re-suspended in 10 mL growth medium and the resulting 
suspension was transferred into a 25 cm2 flask, before being placed in the incubator at 
37oC in an atmosphere of 5% CO2 and 95% air. 
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Figure 2.2: Morphology of oestrogen positive receptor breast cancer cell lines.  Living monolayer, low 
and high density of MCF7 (A, B), T47D (C, D), ZR-75-1 (E, F) and ZR-75-30 (G, H) cells.  Scale bar = 
200 µm. 
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Figure 2.3: Morphology of oestrogen negative receptor breast cancer cell lines.  Living monolayer, low 
and high density of MDA-MB-231 (A, B), MDA-MB-157 (C, D), MDA-MB-468 (E, F), and normal breast 
cell line MCF10A (G, H) cells.  Scale bar = 200 µm. 
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2.2.5 Trypsinisation 
Trypsin is a proteolytic enzyme that cleaves proteins at the carboxyl side of the basic 
amino acids lysine and arginine.  In a cell culture laboratory, trypsin solutions are 
commonly used to dissociate adherent cell monolayers during the process of harvesting 
cells.  In this study, cells were harvested using trypsin-ethylenediaminetetraacetic acid 
(EDTA) (0.05% w/v trypsin with 0.53 mM EDTA.4Na) which had been derived from 
porcine pancreas.  This solution was prepared in Hanks' Balanced Salt Solution (HBSS) 
without calcium and magnesium.  EDTA promotes disaggregation of cells and is a chelator 
that binds divalent cations such as calcium and magnesium. 
 
Cells were harvested at 70-80% confluence.  Spent culture medium was aspirated from the 
flask, and cells were washed twice with 10 mL of calcium-magnesium free-phosphate 
buffered saline (pH 7.4) to remove residual medium containing foetal bovine serum, which 
is a rich source of trypsin inhibitors.  Calcium and magnesium also inhibit trypsinisation, 
as these two cations play a critical role in cell-to-cell and cell-to-substrate attachment.  
Depending on the size of flask either 2 mL (for a 25 cm2 flask) or 3 mL (for a 75 cm2 
flask) of trypsin-EDTA was added, and incubated at 37oC in 5% CO2 and 95% air.  The 
progress of cell detachment was checked briefly under the inverted microscope every 5 
minutes.  When the cells were completely detached, trypsin was inactivated and EDTA 
removed by adding 10 mL of growth medium containing foetal bovine serum.  The 
resulting cell suspension was collected and centrifuged at 500 x g for 5 minutes at room 
temperature.  The cell pellet was re-suspended in 10 mL growth medium, and cell density 
and viability were determined using the trypan blue stain (Section 2.2.7).  Cells were 
seeded at 2-5x104 cells/cm2 into a new flask.  A total volume of 10 mL and 15 mL growth 
medium was used for 25 cm2 and 75 cm2 flasks respectively.  The cell cultures were 
incubated at 37oC in an atmosphere of 5% CO2 and 95% air. 
Materials and Methods 
 74 
2.2.6 Freezing cell cultures 
Freezing cells or cryopreservation is a technique where cells are stored at very low 
temperatures.  Cells become metabolically inert and genetically stable and ice crystal 
formation is minimised.  DMSO solution is the most commonly used cryoprotectant for the 
protection of cells from mechanical and physical stress, and reduction of water content 
within cells.  The reagents are made into a solution with media or serum; cells are 
suspended in this solution, and are stored in liquid nitrogen at -196oC (Greene et al. 1967, 
Freshney 2005).   
 
As indicated earlier, cells cultured following a high passage are more likely to change in 
cell characteristics (i.e. morphology, growth pattern and genetic stability) than cells 
derived from a low passage (Davis 2002).  The procedure of freezing cells allows cells to 
be stored for long periods without alterations in viability or other characteristics (Freshney 
2005).  For this reason, the present study kept a stock of cells at a low passage level in 
liquid nitrogen with freezing medium.  Cells that had been passaged between 5 and 15 
times were used for experiments. 
 
After trypsinisation (Section 2.2.5), the cell pellet was re-suspended in 10 mL growth 
medium, cell samples were counted and viability determined using trypan blue (Section 
2.2.7).  The suspended cells were centrifuged at 500 x g for 5 minutes at room temperature.  
The cell pellet was re-suspended in an appropriate volume of freezing medium containing 
10% (v/v) DMSO and 90% (v/v) FBS (ECACC recommended) to achieve a cell density of 
1x106 cells/mL and placed in cryovials.  These cells were frozen by a controlled rate 
freezing device (isopropanol bath at -80oC) to slow the freezing process to ~ -1°C/minute.  
A slow cooling rate is important as it provides adequate time for proper adjustment of cells 
to the frozen environment and this limits cell death.  Cells were placed in a -80oC freezer 
for 24 hours, prior to transfer to liquid nitrogen for storage.  
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2.2.7 Cell viability determination by trypan blue stain  
Trypan blue stain which is used to determine the viability of cells does not pass across the 
plasma membrane unless the cell is damaged or dead.  Therefore, viable cells with intact 
cell membranes are unstained and non-viable cells are stained blue.  Cells were counted 
using a haemocytometer and an inverted microscope (Freshney 2005).   
 
After trypsinisation (Section 2.2.5), the cell pellet was re-suspended in 10 mL growth 
medium, and 20 µL of the cell suspension was mixed with 20 µL 0.4% (w/v) trypan blue 
stain in a sterile 1.5 mL microcentrifuge tube (giving a dilution factor of 2).  This mixture 
was placed on a haemocytometer for cell counting.  The hemacytometer has 2 chambers 
(Figure 2.4A) and there are 9 large squares with grid in each chamber (Figure 2.4B).  Each 
outer quadrant is divided into 16 smaller squares and Figure 2.4B shows one chamber of a 
haemocytometer slide under 10x magnification.  Only cells that overlap the top and left 
borders of squares should be counted to avoid overestimating the cell concentration (Davis 
2002). 
 
The four outer quadrants in the grid were used in both chambers to count the non-viable 
and viable cells at 10x magnification.  The total count was divided by eight to determine 
the average number of cells in one quadrant, and this number was multiplied by 2 (the 
dilution factor) and then 104 in order to calculate the number of cells in one millilitre of 
suspension (the number 104 is derived from the total volume of each quadrant; 0.1 mm3 or 
1x10-4 mL).  The percentage of viable cells was determined by dividing the number of 
unstained cells by the total number of cells and multiplying by 100. 
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2.3 Purification of total RNA 
Monolayer cells were washed twice with 10 mL sterile phosphate buffered saline.  Total 
RNA was isolated from the cells using a Qiagen RNeasy Plus Mini kit according to the 
manufacturer’s instructions as follows (Figure 2.5).  In brief, lysis buffer which contained 
guanidine thiocyanate and 1% (v/v) beta-mercaptoethanol as a reducing reagent was added 
to the cells in order to disrupt the cell walls, and release the RNA contained in the sample.  
The lysed cells were manually scraped and transferred to a new 1.5 mL microcentrifuge 
tube.  Cell lysate was passed though a 23-gauge needle attached to a sterile plastic syringe 
20 times manually to reduce the viscosity of the cell lysates, and shear the high-molecular 
weight genomic DNA.  The lysate was then transferred to a genomic DNA Eliminator spin 
column and centrifuged at 14,500 x g for 30 seconds (Eppendorf microcentrifuge 5415D, 
Germany). The column was discarded, and one volume of 70% (v/v) ethanol was added to 
 
 
Figure 2.4: Cell counting using a haemocytometer.  (A) A haemocytometer slide.  (B) Improved 
Neubauer pattern ruled haemocytometer (Davis 2002). 
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the flow-through and mixed well.  The cell lysate was then placed in an RNeasy mini 
column and centrifuged at 14,500 x g for 15 seconds.  The flow-through was discarded and 
this process repeated.  An aliquot (700 µL) of RW1 Buffer (provided in the Kit) was added 
to the RNeasy column and centrifuged at 14,500 x g for 15 seconds; the flow-through was 
then discarded.  The RNeasy column was washed with 500 µL RPE Buffer (provided in 
the Kit) and centrifuged at 14,500 x g for 15 seconds; again the flow-through was 
discarded.  The RNeasy silica-gel membrane was dried by adding an additional 500 µL of 
RPE Buffer prior to centrifugation at 14,500 x g for 2 minutes, the resulting flow-through 
was discarded and the tube recentrifuged once more at 25,000 x g for 1 minute.  The 
RNeasy column was then placed on a new sterile 1.5 mL microcentrifuge collection tube.  
Total RNA was eluted from the column by the addition of 2 x 50 µL RNase-free water, 
and the column was then centrifuged twice at 14,500 x g for 1 minute, using the same 
collection tube.  All centrifugation steps were performed at room temperature.  The RNA 
isolation procedures were performed in a Class II safety cabinet. 
  
 
 
Figure 2.5: Flowchart of isolation of RNA using RNeasy Plus procedure. 
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The total RNA was precipitated by the addition of 0.1x volume of 3.0 M sodium acetate 
(pH 5.2) and 3x volume of ice cold ethanol.  The RNA sample was subsequently mixed 
gently and stored at -20oC overnight.  RNA was recovered by centrifugation at 15,000 x g 
(Heraeus Biofuge 28RS centrifuge, Germany) for 5 minutes at 4oC.  The pellet was washed 
with 0.5 mL of 70% (v/v) ethanol and then centrifuged at 15,000 x g for 5 minutes at 4oC 
and this process repeated in order to remove residual salt.  Evaporation of residual ethanol 
from the RNA pellet was performed by leaving the open tube on the lab bench at room 
temperature for 20 minutes.  Care was taken not to overdry the RNA pellet, as this makes it 
more difficult to solubilise the pellet.  The RNA pellet was re-suspended in 20 µL 0.1% 
(v/v) diethyl pyrocarbonate (DEPC)-treated water (Appendix B) and stored at -80oC until 
required (Sambrook and Russell 2001).  RNA samples solubilised in RNase-free water can 
be stored at -80oC without degradation for more than one year (Chomczynski 1992). 
 
RNA concentration and purity were determined by spectrophotometry (Thermo Electron 
Spectrometry Biomate 5TM, UK).  Ten µL of the total RNA was diluted with 490 µL of 
0.1% (v/v) DEPC-treated water (a dilution factor of 50).  The RNA concentration of a 
diluted sample was determined by absorbance at 260 nm (A260), with one absorbance unit 
of A260 corresponding to 40 µg of RNA per mL.  The A260/ A280 ratio was calculated to 
give an indication of sample purity, with ranges between 1.8 and 2.1 considered acceptable 
for good quality RNA (Sambrook and Russell 2001).  
 
Agarose gel electrophoresis is commonly used to judge the quality of the isolated total 
RNA sample by inspection of the 28S and 18S ribosomal RNA (rRNA) bands.  A sample 
loading of 1 µg RNA was verified visually by electrophoresis on a 1.0% (w/v) agarose gel 
dissolved in Tris-Borate-EDTA (TBE) buffer and containing a final concentration of 0.5 
µg/mL ethidium bromide.  Electrophoresis was carried out for 60 minutes at 100 V in a 
Minicell EC370M (EC Apparatus Corporation, USA).  With intact total RNA, the upper 
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rRNA (28S, Mw 5.0 kb) band should be approximately twice as intense as the lower (18S, 
Mw 1.9 kb) rRNA band, indicating non-degraded high quality RNA (Jones et al. 1994).  
Additional information on agarose gel electrophoresis is provided in Section 2.8. 
 
2.4 Reverse transcription and first strand cDNA synthesis 
Since RNA does not serve as a template for DNA polymerase, a total RNA sample must 
firstly be reverse-transcribed into complementary DNA (cDNA) using a reverse 
transcriptase (RT) reaction.  The subsequent cDNA can then be amplified by the 
polymerase chain reaction (PCR) method to detect the expression of target genes.  The RT 
reaction consists of RNA template, reverse transcriptase (e.g. moloney murine leukemia 
virus; M-MLV or avian myeloblastosis virus; AMV), specific primers (e.g. oligo(dT)n, 
anchored oligo(dT)n, random hexamers, sequence-specific) and deoxynucleotide 
triphosphates (dATP, dCTP, dGTP and dTTP) (Figure 2.6).   
 
 
 
M-MLV reverse transcriptase is most commonly used to synthesise full-length copies of 
RNA molecules which can generate high copies of cDNA in samples containing low 
amounts of RNA (Newton and Graham 1997).  At the 3′ end of mRNA, there is a long 
sequence of adenine nucleotides known as ‘the 3′ poly (A) tail’ which can be hybridised 
 
Figure 2.6: Synthesis of the first strand cDNA. 
Abbreviations: cDNA; complementary deoxyribonucleic acid, A+; adenine dT; deoxythymidylic acid 
dATP; deoxyadenosine triphosphate, dCTP; deoxycytidine triphosphate, dGTP; deoxyguanosine 
triphosphate, dTTP; deoxythymidine triphosphate, mRNA; messenger ribonucleic acid, M-MLV ; 
moloney murine leukemia virus; or AMV; avian myeloblastosis virus 
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with a short complementary synthetic oligo (dT) primer.  Oligo (dT)n  is an oligomer (n 
usually between 12 and 18 nucleotides) that is mainly used to synthesise full-length 
cDNAs from poly (A)n mRNA (Sambrook and Russell 2001). 
 
In this study, 5 µg of total RNA was added to a 5 µM suspension of oligo (dT)13 primers, 
and then made up to a reaction volume of 12 µL with 0.1% (v/v) DEPC-treated water, 
gently mixed, and followed by a brief centrifuge at 4000 x g for 2 seconds to bring all 
components to bottom of tube.  The reaction was incubated at 70oC for 10 minutes in the 
Biometra T3000 thermocycler (Thistle scientific Ltd., UK) to allow annealing of the oligo 
dT to the RNA template; the tubes were then placed on ice for 15 minutes to stop the 
reaction.  Eight µL of RT reaction mixture consisted of 2 µL 10x RT reaction buffer, 1 µL 
200 U M-MLV reverse transcriptase, 1 µL 10 mM dNTPs and 0.1% (v/v) DEPC-treated 
water to make up a total volume of 8 µL.  The RT reaction was prepared as presented in 
Table 2.1.  The reaction mixture was incubated at 42°C for 50 minutes, prior to terminating 
the reaction at 95oC for 5 minutes and chilling at 4°C for 30 minutes in the thermocycler.  
The thermal profile for the first strand synthesis was set as shown in Table 2.2.  Following 
the thermocycling reaction 80 µL 0.1% (v/v) DEPC-treated water was added to the 
samples.  In order to standardise all subsequent procedures, the concentration of this is then 
represented as an equivalent cDNA concentration of 50 ng cDNA/µL which was stored at -
80°C until further use. 
Table 2.1: Components of first strand (RT) reaction. 
 
Component 
 
Concentration in reaction 
 
Template RNA 
 
5 µg 
 
Oligo(dT)13 
 
5 µM 
 
10x RT reaction buffer 
 
1x (containing 50 mM Tris-HCl, pH 8.3, with 50 mM KCl, 
3 mM MgCl2, and 5 mM DTT) 
 
dNTPs (10 mM) 
 
0.5 mM each of dATP, dCTP, dGTP, dTTP 
 
M-MLV RT 
 
10 U 
 
0.1% (v/v) DEPC-treated water 
 
 
To make final volume 20 µL 
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Table 2.2: Thermocycling conditions for first strand (RT) cDNA synthesis. 
 
Phase 
 
Temperature 
 
Duration 
 
Oligo (dT) priming 
 
70oC 
 
10 minutes 
 
Reverse transcription (RT) 
 
42oC 
 
50 minutes 
 
RT inactivation 
 
 
95oC 
 
5 minutes 
 
2.5 Qualitative reverse transcription-polymerase chain reaction 
(RT-PCR) analysis 
Polymerase chain reaction (PCR), a technique originally invented by Kary Mullis in 1985, 
is an in vitro enzymatic reaction capable of amplifying the number of copies of a target 
DNA sequence.  This method can be used for a variety of analyses in biomedical research 
(Newton and Graham 1997).  Over two decades, PCR has been modified and developed for 
different applications.  Reverse transcription-polymerase chain reaction (RT-PCR) is a 
highly sensitive technique and widely used in the study of gene expression at the RNA 
level, as a low copy number of RNA molecule can be detected.  The first strand cDNA is 
synthesised (Section 2.4), followed by amplification of the specific parts of double-
stranded DNA within cells using the PCR.  PCR is carried out in a thin walled tube 
contained within a thermocycler using a specified programme that can control the precise 
temperature requirements for each step of the reaction.   
 
The PCR requires basic components containing Taq DNA polymerase, reaction buffer 
(including magnesium chloride; MgCl2), dNTPs, primers, template DNA and water in a 
single tube.  Determination of the optimal concentration of each component in a PCR 
reaction is important when DNA synthesis fidelity is critical.  Taq DNA polymerase is a 
thermostable polymerase originally isolated from the thermophilic bacterium Thermus 
aquaticus and is the most widely used in PCR as it allows application of high annealing 
and extension temperatures during the amplification process.  Under optimal conditions 
this enzyme can synthesise a new DNA strand at a rate of 35-100 nucleotides/second at 70-
80oC and is stable during incubation at 95oC, allowing denaturation steps in the 
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amplification cycling (Newton and Graham 1997).  The enzyme has exonuclease activity 
5’→3’ but not on the 3’→5’ direction.  The concentrations between 1.0 and 2.5 U of Taq 
DNA polymerase are usually used in 50 µL of PCR reaction mixture.  An optimal 
concentration of Taq DNA polymerase is necessary to obtain a better yield of PCR 
products as a higher concentration of enzyme may result in non-specific products and 
lower amounts of Taq DNA polymerase may result in low yield of the desired product 
(Toranzos 1997).   
 
The MgCl2 concentration in the reaction is one of the most important factors for successful 
amplification of cDNA as it functions as a cofactor for DNA polymerase.  However, Mg2+ 
ions can interact with dNTPs, primers and DNA templates to form complexes so the 
MgCl2 concentration has to be optimal for each experiment.  Excessive Mg2+ ions can lead 
to high levels of non-specific products, whereas inadequate Mg2+ ions will inhibit the 
reaction, resulting in low yield of PCR products.  The recommended range of MgCl2 
concentration in the final reaction mixture is between 0.5 and 5.0 mM for the standard 
reaction conditions (Newton and Graham 1997).  All four dNTPs (i.e. dATP, dCTP, dGTP 
and dTTP) are required for the synthesis of DNA.  Usually, the final concentration of each 
dNTP in the PCR reaction mixture is between 0.15 mM and 0.2 mM and these should be 
used at equal concentration to minimise misincorporation (Toranzos 1997).   
 
The design of good synthetic oligonucleotide primers to anneal to target DNA is essential 
for the specificity of amplification product in order to have a successful PCR.  Guidelines 
for primer selection in the current study are detailed in Section 2.6.  In the PCR reaction 
mixture, the final concentration of each primer is in the range of 0.1-0.5 µM and must be 
used in equal concentrations.  Higher concentrations of primer usually generate non-
specific products and form primer-dimers (Toranzos 1997). 
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The working concentration of template DNA should be between 100 and 500 ng in a total 
PCR reaction volume of 50 µL.  Insufficient template DNA can lead to low yield of 
products while excessive template DNA usually may generate non-specific products and 
reduce efficiency (John and Stirling 2003). 
 
Regarding the cycling conditions, a series of twenty-five to thirty-five cycles of PCR are 
usually carried out with each cycle of the PCR consisting of three steps (i.e. denaturation, 
annealing and extension of the DNA template, Figures 2.7A and 2.7B) (Newton and 
Graham 1997).  During repeated cycles of PCR, the copy of new synthesised DNA strands 
increases exponentially and the target DNA replicates several million-fold.  It is essential 
that the target DNA is analysed within the exponential phase of the PCR reaction, before 
the plateau phase when the reaction components are insufficient, leading to the low 
efficiency of amplification (Kainz 2000). 
 
Initially, the double-stranded DNA is heated to 94-96oC in order to break apart the 
hydrogen bonds between the two DNA strands.  The first denaturing step requires an 
extended time period to ensure that the template DNA is completely separated into single-
strands.  Denaturation for 0.5-2 minutes is usually sufficient.  Following denaturation, the 
temperature is lowered to allow the primers to anneal to specific sequences on the single-
stranded DNA in a step known as primer annealing.  Identifying the appropriate annealing 
temperature (Ta) for each primer pair is a critical factor in the PCR reaction and is based on 
the composition of the individual primer pairs (i.e. melting temperature; Tm) in order to 
minimise non-specific amplification products.  Ta should be set approximately 5oC below 
Tm  (Newton and Graham 1997).  Annealing of the oligonucleotides to the sequence of 
interest usually takes between 1 and 2 minutes.  In the final elongation step the temperature 
is raised to the optimal temperature for the thermostable enzyme Taq DNA polymerase 
(70-80oC) as mentioned above. 
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                                              (A)                                        (B) 
 
Housekeeping genes are constitutively expressed in all cells and can be used to ensure the 
efficiency of amplification reaction.  Several housekeeping genes have been used as 
control genes in different model systems such as glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH), β-actin and β2-microglobulin (Schmittgen and Zakrajsek 2000, 
Lupberger et al. 2002).  β2-microglobulin is commonly used as an internal standard gene in 
gene expression studies as it shows low variation between different cell origins (Lupberger 
et al. 2002).  This gene was used in the present study to verify the expression of target 
genes.   
 
In this study, the standard PCR was performed in 50 µL reaction mixtures.  The PCR 
reaction mixture contained 5 µL of 10x PCR reaction buffer, 1 µL of dNTP mixture, 0.5 
µL of Taq DNA polymerase (5 U/µL), 5 µL of the mixture of forward and reverse primers, 
template cDNA (50 ng/µL) and 0.1% (v/v) DEPC-treated water to make up a total volume 
of 50 µL.  A negative control (no template cDNA) was included in each PCR reaction.  
Initially, the standard PCR reaction was prepared as shown in Table 2.3.  All components 
were mixed gently and followed by a brief centrifuge at 4000 x g for 2 seconds to collect 
them at the bottom of the microfuge tube.  The reaction mixture was incubated in a 
 
Figure 2.7: The polymerase chain reaction (PCR).  (A) The PCR temperature cycling profile (B) The cycling 
reaction (Adapted from Newton and Graham 1997). 
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Biometra T3000 thermocycler (Germany) which was set as shown in Table 2.4.  
Optimisation of the PCR procedure involved identification of the appropriate annealing 
temperature, the concentration of template cDNA and the appropriate primer sets in the 
PCR reaction as described in Chapter 3. 
 
Table 2.3: Components of second strand (PCR) reaction. 
 
Component 
 
Concentration in reaction 
 
10x reaction buffer 
 
1x (containing 10 mM Tris-HCl, 1.5 mM, MgCl2,  
50 mM KCl, pH 8.3) 
 
Template cDNA 
 
100 ng 
 
Mixture of forward and reverse primers  
 
0.5 µM each of forward and reverse primers 
 
dNTPs (10 mM) 
 
0.2 mM each of dATP, dCTP, dGTP, dTTP 
 
Taq DNA polymerase  
 
2.5 U 
 
0.1% (v/v) DEPC-treated water 
 
To make final volume 50 µL 
 
 
Table 2.4: Thermocycling conditions for second strand (PCR) cDNA synthesis. 
 
Phase 
 
Temperature 
 
Duration 
 
Number of cycle 
 
Initial denaturation 
 
94oC 
 
2 minutes 
 
1 
 
Template denaturation 
 
94oC 
 
50 seconds 
 
Primer annealing 
 
5oC below Tm of primers 
 
1 minute 
 
DNA synthesis 
 
72oC 
 
1 minute 
 
 
30  
 
Elongation 
 
 
72oC 
 
5 minutes 
 
1  
 
2.6 Design of synthesis of oligonucleotide primers 
A primer is a short synthetic oligonucleotide which is used to determine the DNA fragment 
to be amplified in applications of PCR or DNA sequencing.  The primers are designed to 
be complementary to the target sequence of template DNA, which serves as a starting point 
for synthesising a new DNA strand or DNA replication by a DNA polymerase.  Primer 
design is a critical issue in PCR-based detection methods as an inappropriate primer may 
produce internal secondary structures and primer-dimers.  Internal secondary structure and 
primer-dimer formation occurs, if the forward and reverse primer can anneal to each other 
or have internal hybridisation.  This reduces the available amount of primers, resulting in 
low effective amplification.  Poor primer design may also cause non-specific products 
which appear as an incorrect product (Newton and Graham 1997, Lodge et al. 2007). 
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Selection of efficient and specific primers remains empirical.  There is no firm rule for the 
synthesis of effective or specific primer pairs for an amplification reaction but the primer 
should be designed according to some general guidelines.  Usually, a suitable primer for 
the PCR process should be between 20 and 30 nucleotides in length with a melting 
temperature (Tm) between 55°C and 65°C, and the PCR reaction works well if primer pairs 
have similar Tm in order to set the same annealing temperature.  Primers that are too short 
may lead to non-specific copies as they can anneal at many points on a DNA template.  
However, if primers are too long they are limited by high annealing temperature (Newton 
and Graham 1997).  Currently, there are several free and commercially available web-
based services or software provided for primer design, with Primer3 being the most widely 
used.  The web-based application Primer3 programme is hosted by the Whitehead Institute 
for Biomedical Research (Rozen and Skaletsky 2000).  Initially, primers in this study were 
designed to cross an exon-exon boundary in order to prevent co-amplification of genomic 
DNA.  The designation was performed using design criteria as shown in Table 2.5. 
 
Table 2.5: Criteria for primer picking conditions using the web-based Primer3 programme. 
 
Primer condition 
 
Minimum 
 
Optimum 
 
Maximum 
 
Primer size (bp) 
 
18 
 
20 
 
27 
 
Primer Tm (oC) 
 
57 
 
60 
 
63 
 
Primer GC content (%) 
 
 
20 
 
50 
 
80 
 
Resulting primer sequences were then analysed for any cross-matching with the non-
redundant database of GenBank using the standard nucleotide-nucleotide BLAST (The 
Basic Local Alignment Search Tool) search of the National Centre for Biotechnology 
Information (NCBI) available at http://www.ncbi.nlm.nih.gov/blast/.  The Genbank 
accession number of each P450 and P450-NR genes used fro primer design is shown in 
Tables 2.6 and 2.7.Table 2.6 lists the primers for the candidate genes which were designed 
using programme Primer3.  Table 2.7 shows the list of published primers which were 
considered for PCR experiments depending on particular objectives, and details will be 
provided in the subsequent chapters. 
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Table 2.6(1): List of designed primers. 
 
Gene name 
 
Accession No 
 
Primer 
 
Sequence (5’ to 3’) 
 
Length  
 
Tm  (oC) 
 
Ta (oC) 
 
Product size (bp) 
 
β2-microglobulin 
 
NM_004048 
 
Forward 
Reverse 
 
24CCTTGAGGCTATCCAGCGTACTCCAAA50 
342TGATGCTGCTTACATGTCTC323 
 
27 
20 
 
60.7 
55.2 
 
58 
 
319 
CYP1A1 K03191 
 
Forward 
Reverse 
1019CTTGGACCTCTTTGGAGCTG1038 
1230CGAAGGAAGAGTGTCGGAAG1211 
20 
20 
63.8 
63.8 
58 212 
CYP1A2 Z00036 Forward 
Reverse 
575CAATCAGGTGGTGGTGTCAG594 
819GCTCCTGGACTGTTTTCTGC800 
20 
20 
64.2 
63.9 
58 245 
CYP1B1 U03688 Forward 
Reverse 
1132GCAGCTCAACCGCAACTTCA1151 
1528AAAGCTGGAGAAGCGCATGG1509 
20 
20 
68.8 
68.6 
60 397 
CYP2A6 X13930 Forward 
Reverse 
1001TTGACAGAGTGATCGGCAAG1120 
1186GGTACACTTCGGTGCCCTTA1167 
20 
20 
64.1 
63.7 
58 186 
CYP2B6 M29874 Forward 
Reverse 
2402CCCCATACCCCATTCTCTTT2421 
2595GCAGAGGTTGCAGTGAACAA2576 
20 
20 
63.6 
64.1 
58 194 
CYP2C8 Y00498 Forward 
Reverse 
964TATGGACTCCTGCTCCTGCT983 
1193CCCTTGGGGATGAGGTAGTT1174 
20 
20 
63.9 
63.9 
58 230 
CYP2C9 M61855 Forward 
Reverse 
905GGACAGAGACGACAAGCACA924 
1060CATCTGTGTAGGGCATGTGG1041 
20 
20 
64.2 
64.1 
58 156 
CYP2C18 M61856 Forward 
Reverse 
1522CCGCATGGAGCTGTTTTTAT1541 
1720GAGAATTGCAGGTGACAGCA1701 
20 
20 
63.7 
64.1 
58 199 
CYP2C19 M61854 Forward 
Reverse 
887ACTTGGAGCTGGGACAGAGA906 
1053CATCTGTGTAGGGCATGTGG1034 
20 
20 
64.0 
64.1 
58 167 
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Table 2.6(2): List of designed primers. 
 
Gene name 
 
Accession No 
 
Primer 
 
Sequence (5’ to 3’) 
 
Length  
 
Tm  (oC) 
 
Ta (oC) 
 
Product size (bp) 
 
CYP2D6 
 
X08006 
 
Forward 
Reverse 
 
830CAGAGATGGAGAAGGCCAAG849 
1020CCCTATCACGTCGTCGATCT1001 
 
20 
20 
 
63.8 
64.0 
 
58 
 
191 
CYP2S1 AK027605 Forward 
Reverse 
331AGGTCAGGCTGAGGAGTTCA350 
546TCTGTCCCCTGGAATGTCTC527 
20 
20 
64.0 
64.1 
58 216 
CYP3A4 J04449 Forward 
Reverse 
666CAAGACCCCTTTGTGGAAAA685 
849CGAGGCGACTTTCTTTCATC830 
20 
20 
63.7 
63.7 
58 184 
CYP3A5 J04813 Forward 
Reverse 
856AAGAAAAGTCGCCTCAACGA875 
1082TGCAGTTTCTGCTGGACATC1063 
20 
20 
63.7 
64.1 
58 227 
CYP3A7 D00408 Forward 
Reverse 
776AAGGTCGCCTCAAAGAGACA795 
998TGCACTTTCTGCTGGACATC979 
20 
20 
63.9 
64.1 
58 223 
CYP3A43 AA417369 Forward 
Reverse 
97AGGGAAAGTCAGGGTCCACT116 
286GCATGAGGTTTGCTCTCACA267 
20 
20 
63.8 
64.1 
58 190 
CYP4Z1 AY262056 Forward 
Reverse 
575TCATGAAGTGTGCCTTCAGC594 
733GGCCTTGAGAGCTGAATTTG714 
20 
20 
64.1 
63.7 
58 159 
CYP24A1 L13286 Forward 
Reverse 
1590GGCAACAGTTCTGGGTGAAT1609 
1838TATTTGCGGACAATCCAACA1819 
20 
20 
63.9 
63.8 
58 249 
CYP26A1 AF005418 Forward 
Reverse 
1159TTCGGGTTGCTCTGAAGACT1178 
1349TCCTCCAAATGGAATGAAGC1330 
20 
20 
63.9 
63.8 
58 191 
CYP26B1 AF252297 Forward 
Reverse 
383ACACGGTGTCCAATTCCATT402 
554GCCTCCTGGTACACGTTGAT535 
20 
20 
64.0 
63.9 
58 172 
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Table 2.6(3): List of designed primers. 
 
Gene name 
 
Accession No 
 
Primer 
 
Sequence (5’ to 3’) 
 
Length  
 
Tm  (oC) 
 
Ta (oC) 
 
Product size (bp) 
 
HIF-1α 
 
U29165 
 
Forward 
Reverse 
 
2035GAAAGCGCAAGTCCTCAAAG2054 
2201TGGGTAGGAGATGGAGATGC2182 
 
20 
20 
 
63.8 
64.0 
 
58 
 
167 
AhR NM_001621 Forward 
Reverse 
1117GGACAGAAAAAGAAAGGGAAAG1138 
1378CGGCACAATAAAGCATATCAG1358 
22 
21 
61.8 
61.9 
55 262 
ARNT NM_178427 Forward 
Reverse 
2075ATCCTCCTTCAGCTCCATGTCC2096 
2461TTTCTCCCCCACCCCTTATC2442 
22 
20 
67.6 
65.9 
60 387 
AhRR BM682431 Forward 
Reverse 
120TTCAGGATAGGCTCCTGCAT139 
290AGTGACCACCATCCAAGCTC271 
20 
20 
63.6 
64.1 
58 171 
CAR*  Z30425 Forward 
Reverse 
861GCAGCTGTGGAAATCTGTCA880 
1092CAGGTCGGTCAGGAGAGAAG1073 
20 
20 
64.1 
64.0 
58 232 
PXR AJ009936 Forward 
Reverse 
3958CTGTGTGGATGCTGAGCTGT3977 
4171TGATTGTCAGCGTAGCCTTG4152 
20 
20 
64.3 
63.9 
58 214 
VDR J03258 Forward 
Reverse 
1597GAGACCTCAGCCATGAGGAG1616 
1846CGTGAGTAAGGCAGGAGAGG1827 
20 
20 
64.0 
63.8 
58 250 
ER X03635 Forward 
Reverse 
1625TGGAGATCTTCGACATGCTG1644 
1832GCCATCAGGTGGATCAAAGT1813 
 
20 
20 
64.1 
63.9 
58 208 
Note: *; This primer set was also used as nested primer for the published CAR. 
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Table 2.7(1): List of published primers. 
 
Name 
 
Accession No 
 
Primer 
 
Sequence (5’ to 3’) 
 
Length 
 
Tm (oC) 
 
Ta (oC) 
 
Product size (bp) 
 
Reference 
 
CYP1A1 
 
K03091 
 
Forward 
Reverse 
 
967TGGATGAGAACGCCAATGTC986 
1358TGGGTTGACCCATAGCTTCT1339 
 
20 
20 
 
66.0 
63.3 
 
58 
 
394 
 
Huang et al. 1996 
 
CYP2D6 M20403 Forward 
Reverse 
1033CCAGAGATGGGTGACCAG 1050  
1293CTCCGGCTTCACAAAGTG1276 
18 
18 
61.8 
62.1 
55 261 Thomas et al. 2006 
CYP2F1 NM_000774 Forward 
Reverse 
646CCATTATCCGCCTTATCAAT665   
950GCCAAAGAGCAGGTTATGT932 
20 
19 
60.1 
59.3 
55 305 Thomas et al. 2006 
CYP2J2 NM_000775 
 
Forward 
Reverse 
466GCTTAGAGGAACGCATTCA484 
1179CAGCCAAAGTGGTATCAACT1160 
19 
20 
60.5 
59.2 
55 714 Thomas et al. 2006 
CYP2R1 NM_024514 Forward 
Reverse 
260TGGTTCTAAATGGCTATGATG280 
567GTTTGAAACAGCATTCGTTA548 
21 
20 
59.0 
57.8  
52 308 Thomas et al. 2006 
CYP2U1 NM_183075 Forward 
Reverse 
545GCTCATCTCCATCGTGAC562 
864TTTCTAGGCCTCGTGACATA845 
18 
20 
59.2 
59.8 
55 320 Thomas et al. 2006 
CYP3A4 M14096 Forward 
Reverse 
782CTGTGTGTTTCCAAGAGAAGTTAC805 
1523TGGTTGAAGAAGTCCTCCTAAG1502 
24 
22 
60.6 
61.2 
55 742 Huang et al. 1996 
CYP3A5 J04813 Forward 
Reverse 
799GTCTCTCTGTTTCCAAAAGATACC822 
1536TGAAGAAGTCCTTGCGTGTC1516 
24 
20 
60.9 
63.0 
55 737 Huang et al. 1996 
CYP4X1 NM_178033 Forward 
Reverse 
655GCATCGTCGCCTACTAACTC674  
1018CTGATTCAACACTCGGCTTA999 
20 
20 
61.4 
60.4 
55 364 Thomas et al. 2006 
CYP4Z1 NM_178134 Forward 
Reverse 
 
1147ATATCCCGGTTACTCGACAA1166 
1403GCCACTGCCACTTTACACT1385 
20 
19 
60.7 
60.3 
55 257 
 
Thomas et al. 2006 
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Table 2.7(2): List of published primers. 
 
Name 
 
Accession No 
 
Primer 
 
Sequence (5’ to 3’) 
 
Length 
 
Tm (oC) 
 
Ta (oC) 
 
Product 
size (bp) 
 
Reference 
 
CAR 
 
Z30425 
 
 
Forward 
Reverse 
 
684CCAGCTCATCTGTTCATCCA703 
1110GGTAACTCCAGGTCGGTCAG1081 
 
20 
20 
 
63.9 
63.5 
 
58 
 
417 
 
Chang et al. 2003 
 
PXR AF061056 
 
Forward 
Reverse 
678CAAGCGGAAGAAAAGTGAACG698 
923CACAGATCTTTCCGGACCTG904 
21 
20 
65.7 
64.6 
60 246 Chang et al. 2003 
 
PGR M15716 Forward 
Reverse 
1817GATTCAGAAGCCAGCCAGAG1836  
2349TGCCTCTCGCCTAGTTGATT2330 
20 
20 
64.0 
63.7 
58 533 Lau et al. 1999 
GCR X03225 Forward 
Reverse 
2038CTACCCTGCATGTACGACC2056 
2396TCAGCTAACATCTCGGGG2378 
19 
18 
60.6 
61.4 
55 360 Gupta and Wagner 2003 
PPARα L02932 Forward 
Reverse 
913GCCAGTAACAATCCACCTTTT933 
1647AAGGTGTGGCTGATCTGAAGG1627 
21 
21 
61.7 
65.4 
55 735 Saidi et al. 2006 
RXR NM_002957 
 
Forward 
Reverse 
490GCTCCTCAGGCAAGCACTATGGAGTGTA517 
1010GGAGAAGGAGGCGATGAGCAGCTCATT984 
28 
27 
73.1 
75.9 
68 521 Wang and Yen 2004 
RAR 
 
NM_000964 
 
Forward 
Reverse 
 
908GGGCATGTCCAAGGAGTCTGTGAGAA933 
1663GGGATCTCCATCTTCAGCGTGATCA1638 
26 
25 
73.8 
73.0 
68 756 Wang and Yen 2004 
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Oligonucleotide primers were synthesised by Sigma-Genosys Ltd.  Lyophilised primers 
were diluted to a stock concentration of 100 µM by adding 0.1% (v/v) DEPC-treated water 
according to the manufacturers supplied OD readings, then adjusting this to a working 
concentration of 5 µM.  
 
2.7 Nested PCR  
Nested PCR is used to enhance sensitivity and specificity of amplification as it can 
eliminate the occurrence of non-specific products generated from unexpected primer 
binding sites.  Nested PCR technique is performed with two sets of primers one internal to 
the other.  The primary amplification product is used as template in the nested PCR 
reaction with another primer set (Figure 2.8).  The components for this reaction are listed 
in Table 2.8. 
 
 
 
Table 2.8: Components of the nested PCR. 
 
Components 
 
Concentration in reaction 
 
10x reaction buffer 
 
1x (1.5 mM MgCl2) 
 
RT-PCR product from the primary amplification 
used as a template 
 
 
5 µL 
 
Mixture of forward and reverse nested primers  
 
0.5 µM each of forward and reverse nested primers 
 
dNTPs (10 mM) 
 
0.2 mM each of dATP, dCTP, dGTP, dTTP 
 
Taq DNA polymerase  
 
0.025 U 
 
0.1% (v/v) DEPC-treated water 
 
 
To make final volume 50 µL 
 
 
Figure 2.8: Illustration of nested PCR.   
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2.8 Agarose gel electrophoresis of DNA 
Electrophoresis is a technique used to separate DNA, RNA or protein molecule by size.  
Nucleic acids (DNA and RNA) have a negative charge and when an electric current is 
applied they move through the agarose matrix migrating towards the positive electrode.  
Larger DNA fragments move at a slower rate than smaller fragments.  Ethidium bromide is 
a fluorescent dye that intercalates between bases of nucleic acids.  On exposure to UV 
light, ethidium bromide transmits the energy as visible orange light and allows detection of 
DNA fragments.  A final concentration of 0.5 µg/mL ethidium bromide is usually used and 
this can be added into the gel either before or after electrophoresis.  The gel is prepared by 
dissolving the agarose in an appropriate volume of buffer following heating in a 
microwave oven.  The dissolved agarose solution is then placed into a horizontal gel 
manifold and allowed to cool.  Once the gel is set (approximately 30 minutes to 1 hour) it 
is then placed into the electrophoresis tank.  The same buffer used to prepare the gel is then 
used to fill the tank.  Samples (PCR products) are prepared as follows.  Gel loading buffer 
must always be added to the samples prior to loading to increase the density of the samples 
and ensure that they sink into the well, and to add colour to the samples so they can be 
easily seen when loading.  The gel is generally run at 1-10 V/cm until the dyes have 
migrated an appropriate distance which depends on the size of DNA to be analysed.  Each 
gel electrophoresis must include at least one lane of molecular weight markers to enable 
analysis of DNA fragment size in the samples.  The most commonly used buffers for DNA 
are TAE (Tris-acetate-EDTA) and TBE (Tris-borate-EDTA).  TBE buffer is recommended 
for analysing fragments less than 1 kb as it gives better resolution and sharper bands.  The 
concentration of agarose used is dependent on the size of product being determined and is 
varied accordingly for different fragment ranges (Table 2.9) in order to achieve good 
separation (Martin 1996, Sambrook and Russell 2001). 
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Table 2.9: Agarose concentration used for separating different DNA fragment sizes (Sambrook and Russell 
2001). 
 
 
Agarose concentration [% (w/v)] 
 
 
DNA fragment ranges (kb) 
 
0.3 
 
5-60 
 
0.6 
 
1-20 
 
0.7 
 
0.8-10 
 
0.9 
 
0.5-7 
 
1.2 
 
0.4-6 
 
1.5 
 
0.2-3 
 
2.0 
 
 
0.1-2 
 
For analysing the PCR product in this study, a 2.5 µL aliquot of 6x loading dye (10mM 
Tris-HCl (pH 7.6), 0.03% bromophenol blue, 0.03% xylene cyanol FF and 60% glycerol, 
60mM EDTA) was added to 10 µL of the PCR product and mixed well.  A 1 µL aliquot of 
6x loading dye was added to 5 µL of PCR markers (1000, 750, 500, 300, 150 and 50 bp) 
and this mixture was loaded beside the samples as a reference for relative qualification of 
PCR products.  The PCR marker and sample mixture were separated by gel electrophoresis 
using a 1.5% (w/v) agarose gel dissolved in TBE buffer (89 mM Tris-HCl pH 7.8, 89 mM 
Boric acid and 2 mM EDTA) containing ethidium bromide.  Electrophoresis was carried 
out for 70 minutes at 150 V in a Sub-Cell GT system (BioRad, USA) at room temperature.  
The UV visualised photographs of gels were taken using a Polaroid camera (Hoya, Japan) 
in the roof of the transilluminator (UVI tech, Cambridge, England).  To photograph a gel, 
the aperture (F-stop) at 5.6 was set with an exposure time (shutter speed) of 2 seconds.   
 
Following visualisation of a band in a PCR product, the size of DNA fragments was 
determined using semi-logarithmic plotting to estimate molecular weight.  To predict an 
unknown fragment, a logarithmic scale on the vertical (y axis) was plotted for all the 
molecular weight marker sizes in base pairs against the distance each of those bands had 
migrated from the wells in millimetres (horizontal; x-axis).  The log-linear relationship 
between migration on the gel and fragment size of the markers provided a standard curve 
to determine the size of unknown fragments by measuring distance migrated.  Figure 2.9 
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shows how DNA fragment size was estimated by semi-logarithm plotting using an 
example from an experiment in the current study.  The semi-logarithm plot of distance 
migration based on the DNA markers used allows the size of an unknown fragment that 
migrated 43 mm to be estimated as approximately 275 bp in size. 
 
2.9 Restriction digestion  
Restriction digestion is the method of cutting double-stranded DNA molecules at specific 
sequences (known as recognition sites) into smaller fragments using restriction enzymes.  
This process is useful in molecular biology applications as it provides high sequence 
specificity and precision cutting.  Figure 2.10 shows an example of the DNA nucleotide 
sequences recognised by the restriction enzyme known as EcoRI.   
 
 
 
The expression of an individual gene can be identified by restriction digestion.  In this 
study, an appropriate restriction enzyme for each individual (presence) candidate gene was 
 
 
Figure 2.10: Recognition sequence of the restriction endonuclease EcoRI (Adapted from Albert et al 
2002). 
 
Figure 2.9: Example of semi-logarithm plot of distance migrate the DNA markers used (scanned from one of 
the results in this study). 
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selected and information on these enzymes is presented in Table 2.10.  Table 2.11 
highlights the conditions used for restriction digests in this research.  All components were 
mixed gently by pipetting and followed by a brief centrifuge at 4000 x g for 2 seconds to 
collect them at the bottom of the tube.  This mixture was kept on ice prior to the reaction.  
Restriction digests were performed in a thermocycler at 37oC for 1 hour to complete 
digestion, and then incubated at 70oC for 10 minutes to inactivate the restriction enzyme.  
The digested and undigested products were further analysed by 2% (w/v) agarose gel 
electrophoresis to separate the fragments by size or alternatively stored at -20oC until 
required. 
 
2.10 Purification of DNA and DNA sequencing 
DNA sequencing is used to determine nucleotide sequences of a specific DNA molecule in 
order to identify the gene product and predict its physiological functions.  This requires the 
purification of DNA fragments from agarose gels or amplification reactions.  Purification 
of DNA from low-melting point (LMP) agarose gel is commonly used as it is a quick 
procedure and produces high purity DNA.  LMP agarose gel can be melted at 65-75oC and 
this will not dissociate the double-stranded nature of duplex DNA, whereas a standard 
agarose gel can only be melted at 80-90oC and this will disrupt duplex DNA molecules 
(Martin 1996). 
 
A high Pure PCR product purification kit (Roche Diagnostics Ltd., Lewes, UK) was used 
for isolation of DNA, according to the manufacturer’s instructions (Figure 2.11).  In brief, 
PCR product was loaded on a 1.8% (w/v) low melting point (LMP) agarose gel containing 
a final concentration of 0.5 µg/mL ethidium bromide and TAE (40 mM Tris acetate, 2 mM 
EDTA; pH 8.5) was used as running buffer.  Electrophoresis was carried out for 60 
minutes in a Minicell EC370M (EC Apparatus Corporation) at 100 V.  To handle LMP  
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Table 2.10: Recognition sequences for the restriction endonucleases used. 
 
Name 
 
Restriction enzyme 
 
Recognition site 
 
Size of fragment (bp) 
 
Buffer** 
 
β2-microglobulin 
 
EcoRI 
 
G/AATTC 
 
215, 104 
 
SH 
CYP1B1 RsaI GT/AC 174, 223 SL 
CYP2A6 HaeIII GG/CC 48, 72, 66 SM 
CYP2B6 HaeIII GG/CC 30, 164 SM 
CYP2C8 MspI C/CGG 170, 60 SL 
CYP2C18 RsaI GT/AC 125, 74 SL 
CYP2S1 AluI AG/CT 103, 63, 50 SA 
CYP3A7 EcoRI G/AATTC 65, 158 SH 
CYP4Z1 RsaI GT/AC 47, 112 SL 
CYP24A1 BamHI G/GATCC 68, 181 SB 
CYP26A1 AluI AG/CT 172, 19 SA 
CYP26B1 AluI AG/CT 104, 68 SA 
HIF-1α SspI AAT/ATT 140, 27 SH 
AhR MspI  C/CGG 99, 163 SL 
ARNT PstI CTGCA/G 118, 269 SH 
AhRR HaeIII GG/CC 92, 79 SM 
VDR PstI CTGCA/G 198, 52 SH 
ER RsaI GT/AC 111, 97 SL 
Nested CAR  PstI CTGCA/G 170, 62 SH 
CYP1A1* HaeIII GG/CC 188, 40, 164 SM 
CYP2D6* RsaI GT/AC 119, 142 SL 
CYP2F1* MspI C/CGG 195, 110 SL 
CYP2J2* AluI AG/CT 331,170,159,54 SA 
CYP2R1* HaeIII GG/CC 130, 118, 60 SM 
CYP2U1* HaeIII GG/CC 252, 60, 8 SM 
CYP4X1* RsaI GT/AC 278, 86 SL 
CYP4Z1* AluI AG/CT 196, 61 SA 
PXR* MspI  C/CGG 142, 90, 14 SL 
PGR* AluI AG/CT 32, 84, 417 SA 
GCR* AluI AG/CT 148, 36, 172, 4 SA 
PPARα* RsaI GT/AC 518, 188, 29 SL 
RXR* BamHI G/GATCC 280,153,88 SB 
RAR* 
 
HaeIII GG/CC 456, 193, 107 SM 
Note: *; Previously published primers, ** ; The digestion buffer was varied according to the enzyme of 
choice and was supplied along with the restriction enzyme from supplier.  Composition of the 1x buffer is 
shown in Appendix C.  
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Table 2.11: Components of the restriction digest. 
 
Stock solution 
 
Undigested sample (µL) 
 
Digested sample (µL) 
 
Re-amplified RT-PCR product 
 
2 
 
2 
 
10x digestion buffer 
 
2 
 
2 
 
Restriction enzyme (10 U/µL) 
 
0 
 
1 
 
0.1% (v/v) DEPC-treated water 
 
 
16 
 
15 
 
agarose gel, these procedures were performed on ice due to the fragile nature of gels at 
higher temperatures (Martin 1996). 
 
 
 
The desired DNA band was excised from the gel using a sterile scalpel blade and the DNA 
gel slice dissected into small fragments under UV light.  A 100 mg portion of the agarose 
gel slice was then placed into a pre-weighed 1.5 mL microcentrifuge tube containing 300 
µL Binding Buffer provided by the manufacturer (3 M guanidine-thiocyanate, 10 mM Tris-
HCl, 5% ethanol (v/v), pH 6.6) and vortexed for 30 seconds.  To release the DNA, the 
agarose gel slice was dissolved in the binding buffer, incubated at 65oC for 10 minutes and 
vortexed for 15 seconds every 2 minutes during incubation.  Isopropanol (150 µL) was 
added to the dissolved gel and vortexed for 15 seconds prior to transfer to a High Pure 
 
Figure 2.11: Flowchart of purification of DNA using Roche High Pure PCR product Purification 
procedure. 
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Filter Tube.  The tube was centrifuged at 25,000 x g for 1 minute at room temperature and 
the flow-through was discarded.  A 500 µL aliquot of Washing Buffer (20 mM NaCl, 2 
mM Tris-HCl, pH 7.5) was added to the filter tube and centrifuged at 25,000 x g for 1 
minute with flow-through again being discarded.  To ensure optimal purity of the sample, 
an additional wash with 200 µL of Wash buffer provided by the manufacturer centrifuged 
at 25,000 x g for 1 minute was carried out.  The filter tube was then placed into a new 
sterile 1.5 mL microcentrifuge tube and a 50 µL aliquot of Elution Buffer provided by the 
manufacturer (10 mM Tris-HCl, pH 8.5) was added to the tube and centrifuged at 25,000 x 
g for 1 minute.   
 
The purified DNA was precipitated by the addition of 0.1x volume of 3 M sodium acetate 
(pH 5.2) and 2x volume of ice cold ethanol to the DNA sample which was gently mixed, 
before storing at -20oC overnight.  The DNA was recovered by centrifugation at 15,000 x g 
(Heraeus Biofuge 28RS centrifuge, Germany) for 5 minutes at 4oC.  The pellet was washed 
with 0.5 mL of 70% (v/v) ethanol and then centrifuged twice at 15,000 x g for 5 minutes at 
4oC to remove residual salt.  Evaporation of residual ethanol from the DNA pellet was 
performed by leaving the open tube on the lab bench for 20 minutes.  The DNA pellet was 
re-suspended in 20 µL 0.1% (v/v) DEPC-treated water and stored at -80oC until required.   
 
DNA amount and purity was determined by spectrophotometry (Thermo Electron 
Spectrometry Biomate 5TM, UK).  Ten microlitres of the purified DNA was diluted with 
490 µL of 0.1% (v/v) DEPC-treated water.  Absorbance at 260 nm was measured to 
determine DNA concentration, with each unit of A260 corresponding to 50 µg/mL double 
stranded DNA.  The A260 /A280 ratio provided an estimate of the DNA purity.  Pure 
preparations of DNA should have a value of 1.8 and 2.1.  All purified DNA of interest was 
sent to the Rowett Research Institute (Bucksburn, Aberdeen UK) to identify the sequences 
of DNA.  The method used was automated dideoxy DNA sequencing.  The results of 
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sequencing were analysed using the standard nucleotide-nucleotide BLAST search and 
comparing with the non-redundant database of GenBank. 
 
2.11 Summary  
This chapter encompasses the methodological approach used in this thesis.  Section 2.2 
covers cell biology techniques, while molecular biology techniques are described in 
Sections 2.3 to 2.10.  In Chapters 3, 4, 5 and 6, the techniques are described in more 
detailed terms and in relation to the particular objectives of the thesis.  Chapter 3 describes 
validation of RT-PCR analysis.  In Chapter 4, the conditions for RT-PCR analysis were 
optimised for MCF7 and MDA-MB-468 cell lines and these conditions were used to 
profile P450s in a panel of breast cancer cell lines compared to a normal breast cell line.  
Chapter 5 is concerned with characterisation of CYP4Z1 in PCR products, while Chapter 6 
identifies the receptors that regulate the expression of the CYP4Z1 gene and evaluates 
whether the transcription or translation process regulates CYP4Z1 expression. 
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Chapter 3 
Validation of RT-PCR analysis in breast cancer cell lines 
 
3.1 Introduction 
RT-PCR is a highly sensitive method so the risk of contamination and false-positive results 
is of concern.  To reduce the risk of RT-PCR contamination, the preparation of total RNA 
including pre-PCR work was performed in a Class II safety cabinet and away from the 
PCR area which was set up in a separate designated laboratory.  The PCR workstation was 
always cleaned with 70% (v/v) ethanol before use.  Pipette tips and pipettors used in the 
amplification procedures were pre-treated with UV crosslinker for 15 minutes, and water 
used for the PCR reactions was treated with diethylpyrocar-bonate (DEPC) prior to use in 
order to inactivate RNase (Appendix B, Sambrook and Russell 2001).  A set of dedicated 
pipettes was used for each separate laboratory procedure (i.e. pre-PCR, PCR and post-PCR 
work) and storage of all PCR reagents isolated from samples.   
 
To detect DNA carryover contamination and false-positive products, the use of negative 
controls (no DNA template) is important and these must be routinely used when 
conducting PCR.  No product formation should be seen (Hamadeh and Afshari 2004).  In 
addition, a known housekeeping gene such as β2-microglobulin which is expressed in most 
cells should be employed to verify the expression of DNA template (Section 2.5).   
 
The validation process identifies aspects of a procedure that are critical and must be 
carefully controlled.  To validate an RT-PCR assay, a demonstration of the accuracy, 
reliability and reproducibility of PCR-based technologies is required and realisation of the 
limitations of the method.  As detailed in Sections 2.4 and 2.5, there are a number of 
considerations involved in amplifying a specific region of cDNA such as the quality of 
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RNA sample and the PCR reaction conditions which are detailed in the following sections.  
Quality of total RNA obtained is essential for the successful amplification of the gene of 
interest and this can be checked on a gel by examination of the 28S and 18S rRNA bands 
(Section 2.3).   
 
As described in Section 2.8, agarose gel electrophoresis of DNA is most commonly used to 
determine the size of products obtained from PCR reaction.  The appearance of desired 
DNA fragments under UV light is vital for identification of the PCR products which can be 
further confirmed by restriction digestion or purified for various purposes such as DNA 
sequencing.  In the current study, both restriction digestion and DNA sequencing were 
used to identify the sequence specificity of PCR products.  However, if PCR products 
appear as multiple fragments or non-specific products, nested PCR can be used to improve 
specificity of the PCR reaction. 
 
The main aim of this chapter was to optimise the conditions for RT-PCR analysis for the 
target cytochrome P450 and P450-regulartory nuclear receptor genes using MCF7 and 
MDA-MB-468 cells as representative oestrogen receptor (ER) protein positive and 
negative breast cancer cell lines respectively. 
 
3.2 Materials and Methods 
3.2.1 RNA isolation 
As discussed in Section 2.3, total RNA was isolated with the Qiagen RNeasy Plus Mini kit.  
The absorbance at 260 nm (A260) of a diluted RNA sample was used to assess RNA 
concentration and the A260/A280 ratio was employed to determine RNA purity.  Quality of 
the purified RNA was determined by 1% (w/v) agarose gel electrophoresis.  Total RNA 
was precipitated by ethanol and sodium acetate to ensure stable and concentrated storage 
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of the starting material.  The resulting pellet was washed and re-centrifuged prior to 
storage or use. 
 
3.2.2 Reverse transcription (RT) and cDNA synthesis 
As described in Section 2.4, first strand cDNA was synthesised from 5 µg of purified RNA 
samples using M-MLV reverse transcriptase.  The components of the RT-reaction are 
summarised in Table 2.1.  All reagents were thawed on ice prior to centrifugation.  The 
reverse transcriptase assay was initiated by addition of M-MLV reverse transcriptase.  The 
reaction conditions were as previously described in Table 2.2.  Following first strand 
synthesis the RT product was placed on ice to inactivate the reaction before it was diluted 
to a concentration of 50 ng of template cDNA per mL and stored at -80oC until use. 
 
3.2.3 Optimisation of PCR analysis 
3.2.3.1 Initial PCR amplification 
Optimisation of each component (i.e. concentration of primer, amount of template cDNA, 
dNTPs, Taq DNA polymerase, MgCl2 and thermocycling parameters) including 
thermocycling conditions in a PCR reaction is important to obtain a better yield of 
amplification products (Section 2.5).  Using cDNA template derived from the MCF7 and 
MDA-MB-468 cells as representative of the test cell lines, it was possible to detect the 
presence/absence and optimise the RT-PCR conditions for the determination of the PCR 
products of 19 cytochrome P450 and 8 P450-regulatory nuclear receptor genes (Table 2.6).  
The routine amplification was developed as shown in Tables 2.3 and 2.4.  In each PCR 
reaction in this investigation, negative controls and β2-microglobulin were always 
included.  Where a visible PCR product is evident, this is subsequently referred to as 
mRNA by extrapolation from the method described. 
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3.2.3.2 Optimisation of template cDNA and primer concentrations 
In this research, when the routine amplification resulted in no product formation the 
concentration of template cDNA was first varied (i.e. 150, 200 and 250 ng) and the 
concentration of primers was kept constant at 0.5 µM (Figure 3.1, stage 2A).  If PCR 
product was still not seen, a high range of primer concentrations (i.e. 1.0 and 1.5 µM) was 
then used (Figure 3.1, stage 2B).  A low range of primer concentrations (i.e. 0.1, 0.2, 0.3 
and 0.4 µM) was employed when the presence of a desired band as well as non-specific 
products were detected (Figure 3.1, stage 2C).  Optimisation of primer concentration, both 
low and high ranges, was performed with a fixed quantity of 100 ng template DNA.  In 
addition, the recommended concentrations of Taq DNA polymerase, MgCl2 and dNTPs 
were used for the RT-PCR assay (Table 2.3). 
 
3.2.3.3 Oligonucleotide primer design 
All designed primers (Table 2.6) were optimised using the procedures described in 
Sections 3.2.3.1 and 3.2.3.2.  However, there were twelve primer sets used that failed to 
detect mRNA expression in the MCF7 and MDA-MB-468 cells.  This may be because 
mRNA expression was below the limit of detection, and details will be provided in the 
result section.  Five out of the twelve undetectable genes (i.e. CYP1A1, CYP3A4, 
CYP3A5, CAR and PXR) were considered for PCR experiments using previously 
published primer sequences (Table 2.7) as previous studies have provided evidence of 
these genes in breast cancer research.  These primers were checked for specificity by 
BLAST analysis. 
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Figure 3.1: General guidelines used for optimisation of template cDNA and primer concentration. 
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3.2.4 Nested PCR  
As mentioned in Section 2.7, nested PCR is a simple technique which can be employed to 
improve specificity of multiple fragment products using the first PCR product as a 
template for the second PCR reaction.  In this research, design of the internal primer 
sequences for the CAR used in the nested PCR was performed by importing the known 
sequence of the primary PCR product (417 bp in size) into the Primer3 programme.  
BLAST analysis confirmed the specificity of the primer used.  Information on these 
primers is shown in Table 2.6 and the nested PCR reaction was performed under the 
conditions described in Table 2.8. 
 
3.2.5 Restriction enzyme digestion of DNA 
As previously described (Section 2.9), digestion of PCR products was carried out with 
specific restriction enzymes for each individual PCR product (Table 2.10).  All restriction 
digests were performed in the same manner as the example presented in Table 2.11. 
 
3.2.6 DNA purification and sequencing 
The desired DNA fragment was purified with the High Pure PCR product purification kit 
as detailed in Section 2.10.  DNA concentration and purity were assessed by 
spectrophotometry and the acceptable A260/A280 ratio was between 1.8 and 2.1.  The 
purified DNA was sequenced by the method of automated dideoxy DNA sequencing. 
 
3.3 Results  
3.3.1 RNA isolation 
Initial purity of total RNA in this study was poor with a calculated RNA A260/A280 ratio of 
between 1.3 and 1.6.  On investigation, the number of lysed cells loaded onto the RNeasy 
spin column was shown to play a major role in determining the purity of RNA collected.  
The number of cells loaded onto individual columns was reduced from > 2x106 cells per 
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purification to an optimal loading of between 5x105 and 2x106 cells.  Additional measures 
were also employed to increase purity and recovery as explained in Section 2.3.  Following 
these measures the recovery of total RNA was between 25 and 60 µg per purification.  In 
addition, the ratio of RNA obtained (A260/A280) was between 1.8 and 2.1.  The quality of 
the purified RNA was confirmed by inspecting the rRNA bands on a 1% (w/v) agarose gel 
containing ethidium bromide.  No smear or band below the lower 18S rRNA band, a 
common indication of degraded low-quality RNA, was found in any sample (Figure 3.2). 
 
 
3.3.2  β2-microglobulin RT-PCR 
3.3.2 β2-microglobulin RT-PCR 
β2-microglobulin was identified as a band of 319 bp corresponding to the β2-microglobulin 
cDNA product size.  The intensity of β2-microglobulin amplification product increased 
between 15 and 30 cycles.  The optimal cycle number for β2-microglobulin amplification 
was identified as 20 cycles because under these conditions the product appeared as a sharp 
band (Figure 3.3).  This cycle number was used for all β2-microglobulin RT-PCR 
experiments. 
 
Little variation was observed between β2-microglobulin mRNA in the MCF7 and MDA-
MB-468 cells.  Figure 3.4 highlights the level of reproducibility found in β2-microglobulin 
expression in replicate studies of this research.  Restriction digestion using EcoRI 
 
Figure 3.2: Quality of RNA isolated from four independent RNA preparations. Lanes 1-2: RNA isolated 
from the MCF, Lanes 3-4: RNA isolated from the MDA-MB-468. 
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confirmed the specificity of β2-microglobulin with a total digest of the PCR product 
resulting in fragments of the expected sizes 215 bp and 104 bp (Figure 3.5). 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4: β2-microglobulin RT-PCR.  Lane 1: 1000 bp PCR markers, Lane 2: negative control,  
Lanes 3&4: cDNA samples from the MCF7, Lanes 5&6: cDNA samples from the MDA-MB-468. 
 
Figure 3.5: Restriction digestion of β2-microglobulin RT-PCR using EcoRI.  Lane 1: 1000 bp PCR 
markers, Lane 2: undigested product, Lane 3: digested product. 
Figure 3.3: Determination of the optimal cycle number for amplification of β2-microglobulin.  Lane 1: 
1000 bp PCR markers, Lane 2: negative control, Lane 3: 15 cycles, Lane 4: 20 cycles, Lane 5: 25 
cycles, Lane 6: 30 cycles. 
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3.3.3 Cytochrome P450 enzyme RT-PCR 
3.3.3.1 CYP1 family RT-PCR 
Initially, the primer sequence designed for CYP1A1 by Primer3 (Table 2.6) failed to detect 
expression of CYP1A1 mRNA in either the MCF7 or MDA-MB-468 cells.  These results 
did not correlate with the findings of earlier investigations which showed CYP1A1 mRNA 
to be present in MCF7 cells (Spink et al. 1998, Brockdorff et al. 2000, McFadyen et al. 
2003).  To further confirm the expression of CYP1A1 mRNA in the MCF7 cells, a 
published CYP1A1 primer set (Table 2.7) was used in this experiment.  A band of 392 bp 
was observed for CYP1A1 mRNA expression.  The amount of template cDNA derived 
from the MCF7 cells was varied (i.e. 100, 150, 200 and 250 ng) with 0.5 µM of CYP1A1 
primer (Figure 3.6).  One hundred and fifty ng of template cDNA was selected for 
CYP1A1 amplification in subsequent experiments as this was the minimum concentration 
of cDNA that generated a sharp and clear band.  Expression of CYP1A1 mRNA in the 
MCF7 cells was confirmed following observation of 188 bp and 164 bp fragments in 
restriction enzyme HaeIII digested samples (Figure 3.7).  However, no CYP1A1 mRNA 
was detected in the MDA-MB-468 cells using these methods. 
 
The CYP1A2 primer sequence designed by Primer3 (Table 2.6) showed the expected 
amplified product (245 bp) with bands representing non-specific amplification in either the 
MCF7 or MDA-MB-468 cells (Figure 3.8) and the images were inverted from positive to 
negative images for better visualisation.  As detailed in section 3.2.3.2, optimisation of 
primer concentration in a low range (Figure 3.1, stage 2C) was performed but no PCR 
product of the correct size was seen.  This experiment failed to confirm the specificity of 
CYP1A2.  However, further experiments screening for the presence/absence of CYP1A2 
mRNA in the remaining cell lines were performed and results are presented in Chapter 4. 
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The routine amplification by RT-PCR using CYP1B1 primers did not show a 397 bp 
cDNA product corresponding to CYP1B1 mRNA.  To further optimise the PCR 
 
 
 
Figure 3.8: CYP1A2 RT-PCR (negative image).  Lane 1: 1000 bp PCR markers, Lane 2: negative 
control, Lane 3: MCF7, Lane 4: MDA-MB-468. 
Figure 3.6: CYP1A1 RT-PCR optimisation of template cDNA in MCF7.  Lane 1: 1000 bp PCR 
markers, Lane 2: negative control, Lane 3: 100 ng, Lane 4: 150 ng, Lane 5: 200 ng, Lane 6: 250 ng. 
Figure 3.7: Restriction digestion of CYP1A1 RT-PCR with HaeIII.  Lane 1: 1000 bp PCR markers,       
Lane 2: undigested product, Lane 3: digested product. 
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conditions, the primer concentration was set at 0.5 µM and the amount of template cDNA 
varied (i.e. 100, 150, 200 and 250 ng).  The optimal concentration of template cDNA was 
identified as 150 ng because this was the minimum concentration that appeared as a sharp 
band (Figure 3.9).  CYP1B1 mRNA was found in both the MCF7 and MDA-MB-468 cells.  
The presence of CYP1B1 mRNA was confirmed by restriction digest with RsaI, which 
generated a digested fragment of the correct size (174 bp and 223 bp) as shown in Figure 
3.10. 
 
3.3.3.2 CYP2 family RT-PCR 
Initial studies failed to demonstrate the presence of CYP2A6 or CYP2D6 mRNA in either 
the MCF7 or MDA-MB-468 cell lines.  Further experiments to verify the presence or 
absence of the CYP2A6 and CYP2D6 PCR product were performed.  Figure 3.1 (stage 2A 
and 2B) indicates the primer and cDNA template concentrations used.  CYP2A6 and 
CYP2D6 mRNA were below the levels of detection in both the MCF7 and MDA-MB-468 
cells under the conditions used. 
 
A faint amplification product of 194 bp was correctly determined for CYP2B6 RT-PCR in 
the MDA-MB-468 cells, though no corresponding product was observed in the MCF7 cells 
when analysis was performed using 250 ng of template cDNA (Figure 3.11).  CYP2B6 
mRNA expression in the MDA-MB-468 cells was confirmed by restriction digestion with 
HaeIII which generated a fragment of 164 bp (Figure 3.12). 
 
Differential expression of the CYP2C subfamily mRNA was observed in the MCF7 and 
MDA-MB-468 cell lines.  CYP2C9 and CYP2C19 mRNA were below detectable limits in 
both cell lines under the conditions used although template cDNA and primer (a high 
range) concentrations have been optimised (Figure 3.1, stages 2A and 2B).
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Figure 3.9: CYP1B1 RT-PCR optimisation of template cDNA in MCF7.  Lane 1: 1000 bp PCR 
markers, Lane 2: negative control, Lane 3: 100 ng, Lane 4: 150 ng, Lane 5: 200 ng, Lane 6: 250 ng. 
Figure 3.10: Restriction digestion of CYP1B1 RT-PCR using RsaI.  Lane 1: 1000 bp PCR markers,    
Lane 2: undigested product, Lane 3: digested product. 
Figure 3.11: CYP2B6 RT-PCR.  Lane 1: 1000 bp PCR markers, Lane 2: negative control, Lane 3: 
MCF7, Lane 4: MDA-MB-468. 
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Expression of CYP2C8 mRNA was only detectable in the MCF7 cells as a faint product at 
the correct size of 230 bp and a negative image of gel is presented in Figure 3.13 in order 
to improve the visualisation.  To confirm CYP2C8 mRNA expression, the PCR product 
was digested with MspI and the predicted digested fragments of 170 bp and 60 bp were 
observed (Figure 3.14). 
 
CYP2C18 mRNA was detected in both cell lines at the correct cDNA product size of 199 
bp.  Similar levels of expression were observed in both the MCF7 and MDA-MB-468 cells 
(Figure 3.15).  Restriction digestion of CYP2C18 mRNA by the enzyme RsaI generated 
fragments (125 bp and 74 bp) of the correct size, though a partial digest product was seen 
(Figure 3.16) and this will be discussed in Section 3.4. 
 
A band of 216 bp was observed at the correct size for CYP2S1 mRNA in both the MCF7 
and MDA-MB-468 cells.  It was noticed that a slightly higher level of CYP2S1 mRNA 
expression occurred in the MDA-MB-468 cells compared to the MCF7cells (Figure 3.17).  
To confirm the CYP2S1 mRNA expression, the PCR product was digested with restriction 
enzyme AluI and the correct fragments were found at 103 bp and 63 bp (Figure 3.18).  The 
purified DNA from the 216 bp fragment was confirmed by DNA sequencing (Section 
 
Figure 3.12: Restriction digestion of CYP2B6 RT-PCR using HaeIII.  Lane 1: 1000 bp PCR markers, 
Lane 2: undigested product, Lane 3: digested product. 
  
Validation of RT-PCR analysis  
114 
2.10).  The results of sequencing were analysed using the standard nucleotide-nucleotide 
BLAST search and compared with the non-redundant GenBank database.  The findings 
were 100% matched (183/183) to Homo sapiens CYP2S1 mRNA (GenBank accession 
number: NM_030622) (Appendix D, Figure D.1). 
 
 
 
 
 
 
 
 
 
Figure 3.13: CYP2C8 RT-PCR (negative image).  Lane 1: 1000 bp PCR markers, Lane 2: negative 
control, Lane 3: MCF7, Lane 4: MDA-MB-468. 
Figure 3.14: Restriction digestion of CYP2C8 RT-PCR using MspI.  Lane 1: 1000 bp PCR markers, 
Lane 2: undigested product, Lane 3: digested product. 
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Figure 3.15: CYP2C18 RT-PCR.  Lane 1: 1000 bp PCR markers, Lane 2: negative control, Lane 3: 
MCF7, Lane 4: MDA-MB-468. 
Figure 3.16: Restriction digestion of CYP2C18 RT-PCR using RsaI.  Lane 1: 1000 bp PCR markers, 
Lane 2: undigested product, Lane 3: digested product. 
 
Figure 3.17: CYP2S1 RT-PCR.  Lane 1: 1000 bp PCR markers, Lane 2: negative control, Lane 3: 
MCF7, Lane 4: MDA-MB-468. 
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3.3.3.3 CYP3A subfamily RT-PCR 
Initially, the primer sequence designed for CYP3A4/5/7/43 by Primer3 (Table 2.6) failed 
to detect the presence of any of the four candidate genes in either the MCF7 or MDA-MB-
468 cells.  From the literature, it appears that many research groups have demonstrated the 
expression of CYP3A in human breast tumours, but these results are inconsistent (Albin et 
al. 1993, Huang et al. 1996, Iscan et al. 2001, Modugno et al. 2003, Miki et al. 2006).  
These inconsistencies could have arisen in several ways, for example the use of samples 
from non-matched individuals and method choices.  However, CYP3A expression has not 
been previously reported in breast cancer cell lines.  Furthermore, CYP3A plays a major 
role in the metabolism of oestrogen and several anticancer drugs such as tamoxifen, 
ifosphamide, taxol and vinblastine (Scripture and Figg 2006).  In the present study, 
CYP3A4 and CYP3A5 mRNA expression were therefore examined using published primer 
sets (Table 2.7) which were analysed by the BLAST search.  Optimisation of template 
cDNA and primer concentration was performed as described in Section 3.2.3 (Figure 3.1), 
but the expression of CYP3A4 mRNA and CYP3A5 mRNA were below detectable limits 
under the conditions used.  In addition neither CYP3A7 nor CYP3A43 mRNA was 
detected in this study. 
 
Figure 3.18: Restriction digestion of CYP2S1 RT-PCR using AluI.  Lane 1: 1000 bp PCR markers, 
Lane 2: undigested product, Lane 3: digested product. 
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3.3.3.4 CYP4 family RT-PCR 
Expression of CYP4Z1 mRNA was detectable in the MDA-MB-468 cells as a product at 
the correct size of 159 bp but no corresponding product was observed in the MCF7 cells.  
Analysis was performed using 100 ng of template cDNA with 0.5 µM of CYP4Z1 primer 
set.  The result obtained from the MCF7 cells was compared with data from previous 
studies (Rieger et al. 2004, Savas et al. 2005) which detected CYP4Z1 mRNA in the 
MCF7 cells.  Template cDNA and primer concentrations were therefore optimised (Figure 
3.1, stages 2A and 2B) but these studies failed to demonstrate the expression of CYP4Z1 
mRNA in the MCF7 cells.  Regarding the presence of CYP4Z1 mRNA in a cDNA product 
of MDA-MB-468 cells, it should be noted that an additional band of approximately 250 bp 
(~250 bp) was observed (Figure 3.19).   
 
Template cDNA samples from the MDA-MB-468 cells were amplified at different 
annealing temperatures (i.e. 55, 56, 57, 58, 59, 60, 61, 62 and 63oC) under the same PCR 
conditions.  The purpose of this was to investigate the effect of annealing temperature on 
the specificity of primers and the yield of PCR product of CYP4Z1 mRNA, and to 
understand the presence of the additional band.  After varied annealing temperature, 
products of 159 bp and ~250 bp were still visualised though DNA bands appeared sharp 
and clear at annealing temperatures of 58 and 59oC (Figure 3.20).  Therefore, an annealing 
temperature of 58oC was selected for CYP4Z1 amplification in all subsequent experiments. 
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The 159 bp DNA fragments and the additional band of ~250 bp obtained from the MDA-
MB-468 cells were purified by the method explained in Section 2.10, and the resulting 
DNA products were digested with RsaI.  Restriction digestion of the purified DNA product 
of the 159 bp fragment generated a fragment of the 112 bp (Figure 3.21A).  By 
comparison, the purified DNA product of the ~250 bp band generated a fragment of 112 bp 
and an additional band at 120 bp (Figure 3.21B).   
 
 
Figure 3.19: CYP4Z1 RT-PCR.  Lane 1: 1000 bp PCR markers, Lane 2: negative control, Lane 3: 
MCF7, Lane 4: MDA-MB-468. 
Figure 3.20: Illustration of the effect of annealing temperature on CYP4Z1 RT-PCR products .  Lane 1: 1000 
bp PCR markers, Lane 2: negative control, Lane 3: 55oC, Lane 4: 56oC, Lane 5: 57oC, Lane 6: 58oC, Lane 7: 
59oC, Lane 8: 60oC, Lane 9: 61oC, Lane 10: 62oC, Lane 11: 63oC. 
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The purified DNA products from the 159 bp and ~250 bp fragments were further 
investigated by DNA sequencing.  The standard nucleotide-nucleotide BLAST was used to 
analyse the results of DNA sequencing and compared with the non-redundant GenBank 
database.  This indicated that purified DNA of the 159 bp and ~250 bp fragments were 
94% (118/125) (Appendix D, Figure D.2) and 98% (77/78) (Appendix D, Figure D.3) 
identical to Homo sapiens CYP4Z1 mRNA (GenBank accession number: NM_178134) 
respectively.  The expression of CYP4Z1 mRNA in breast cancer cell lines will be further 
investigated in Chapter 4 and characterised in Chapter 5. 
 
 
 
 
3.3.3.5 CYP24 family RT-PCR 
A band of the correct size at 249 bp was not observed for CYP24A1 mRNA expression 
after routine amplification.  When the amount of template cDNA was varied (i.e. 100, 150, 
200 and 250) with 0.5 µM of CYP24A1 primer, expression of CYP24A1 mRNA was 
found in the MCF7 cells but no amplification product was detected in the MDA-MB-468 
cells.  The optimal amount of template cDNA was identified as 150 ng for CYP24A1 
amplification because this was the lowest amount that produced a sharp DNA band (Figure 
3.22).  This amount would be utilised in subsequent experiments.  Expression of CYP24A1 
 
Figure 3.21: Restriction digestion of purified DNA products from CYP4Z1 RT-PCR using RsaI (negative 
images). (A) Purified DNA product of 159 bp fragment.  (B) Purified DNA product of 250 bp fragment.  
Lane 1: 1000 bp PCR markers, Lane 2: undigested product, Lane 3: digested product. 
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mRNA in the MCF7 cells was confirmed by restriction digestion with BamHI and 
observation of the correct digested fragments of 68 bp and 181 bp (Figure 3.23). 
 
 
 
 
3.3.3.6 CYP26 family RT-PCR 
The expression of CYP26A1 and CYP26B1 mRNA was detected in both the MCF7 and 
MDA-MB-468 cells as 191 bp and 172 bp cDNA products respectively (Figures 3.24A and 
3.24B).  It was noted that a slightly higher level of CYP26A1 mRNA expression was 
found in the MCF7 compared to the MDA-MB-468 cells, while a higher level of 
CYP26B1 mRNA expression was observed in the MDA-MB-468 cells compared to the 
MCF7 cell line.  To confirm CYP26A1 mRNA expression, the PCR product was digested 
with AluI and the correct digested fragment of 172 bp was observed (Figure 3.25A).  The 
 
 
Figure 3.22: CYP24A1 RT-PCR optimisation of template cDNA in MCF7.  Lane 1: 1000 bp PCR 
markers, Lane 2: negative control, Lane 3: 100 ng, Lane 4: 150 ng, Lane 5: 200 ng, Lane 6: 250 ng. 
 
Figure 3.23: Restriction digestion of CYP24A1 RT-PCR using BamHI.  Lane 1: 1000 bp PCR markers, 
Lane 2: undigested product, Lane 3: digested product. 
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presence of CYP26B1 mRNA was also confirmed by restriction digestion with AluI and 
observation of digested fragments of the correct size (104 bp and 68 bp); as shown in 
Figure 3.25B).  Partial digest products, observed in Figures 3.25A and 3.25B, will be 
discussed in Section 3.4. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.3.4 Cytochrome P450-regulatory nuclear receptors RT-PCR 
The presence of hypoxia-inducible factor-1 alpha (HIF-1α), aryl hydrocarbon receptor 
(AhR), aryl hydrocarbon receptor nuclear translocator (ARNT) and aryl hydrocarbon 
receptor repressor (AhRR) mRNA was detected in both the MCF7 and MDA-MB-468 
cells as 167 bp, 262 bp, 387 bp and 171 bp cDNA products respectively.  A product of 250 
bp was correctly determined for vitamin D receptor (VDR) in the MCF7 cells although no 
 
Figure 3.24: CYP26A1 and CYP26B1 RT-PCR.  (A) CYP26A1.  (B) CYP26B1.  Lane 1: 1000 bp PCR 
markers, Lane 2: negative control, Lane 3: MCF7, Lane 4: MDA-MB-468.  
 
Figure 3.25: Restriction digestion of CYP26A1 and CYP26B1 RT-PCR using AluI.  (A) CYP26A1.  (B) 
CYP26B1.  Lane 1: 1000 bp PCR markers, Lane 2: undigested product, Lane 3: digested product.  
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corresponding product was observed in the MDA-MB-468 cells (Figure 3.26).  All 
experiments were performed using 100 ng of template cDNA with 0.5 µM of each primer 
set. 
 
Stronger intensity of PCR product of HIF-1α mRNA expression was clearly observed in 
the MCF7 compared to the MDA-MB-468 cells, whereas slightly higher levels of AhR and 
ARNT mRNA expression were found in the MDA-MB-468 compared to the MCF7 cells.  
Similar levels of AhRR mRNA expression were detected in both the MCF7 and MDA-
MB-468 cells. 
 
Restriction digestion of HIF-1α mRNA by the enzyme SspI generated a fragment of 142 
bp (Figure 3.27).  To confirm the AhR mRNA expression, the PCR product was restricted 
with the enzyme MspI and the correct fragments of 163 bp and 99 bp were detected (Figure 
3.28).  The presence of ARNT and VDR mRNA was confirmed by restriction digestion 
with PstI which generated digested fragments of 269 bp and 118 bp for ARNT mRNA 
(Figure 3.29) and a fragment of 198 bp for VDR mRNA (Figure 3.31).  To confirm AhRR 
mRNA expression, the PCR product was digested with HaeIII and the correct digested 
fragments of 92 bp and 79 bp were observed (Figure 3.30). 
 
 
 
Figure 3.26: RT-PCR products of HIF-1α, AhR, ARNT, AhRR and VDR.  Lane 1: 1000 bp PCR 
markers, Lanes 2-3: HIF-1α, Lanes 4-5: AhR, Lanes 6-7: ARNT, Lanes 8-9: AhRR, Lanes 10-11: VDR 
Lanes number 2, 4, 6, 8, 10 represent MCF7 and lanes number 3, 5, 7, 9, 11 indicate MDA-MB-468. 
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Figure 3.27: Restriction digestion of HIF-1α RT-PCR using SspI.  Lane 1: 1000 bp PCR markers,  
Lane 2: undigested product, Lane 3: digested product. 
 
Figure 3.29: Restriction digestion of ARNT RT-PCR using PstI.  Lane 1: 1000 bp PCR markers,  
Lane 2: undigested product, Lane 3: digested product. 
 
Figure 3.28: Restriction digestion of AhR RT-PCR using MspI.  Lane 1: 1000 bp PCR markers,  
Lane 2: undigested product, Lane 3: digested product. 
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3.3.4.1 Oestrogen receptor (ER) RT-PCR 
A band of the correct size at 208 bp was observed for ER mRNA expression in both the 
MCF7 and MDA-MB-468 cells.  However, an additional fainter band at 450 bp was also 
detected in this experiment (Figure 3.32).  The DNA products of 208 bp and 450 bp were 
purified by the method described in Section 2.10, and the purified DNA products were 
digested with the restriction enzyme RsaI.  The correct fragments of 111 bp and 97 bp 
were observed only in the purified 208 bp DNA fragment (Figure 3.33), not in the purified 
450 bp DNA product. 
 
Figure 3.30: Restriction digestion of AhRR RT-PCR using HaeIII.  Lane 1: 1000 bp PCR markers, 
Lane 2: undigested product, Lane 3: digested product. 
 
 
Figure 3.31: Restriction digestion of VDR RT-PCR using PstI.  Lane 1: 1000 bp PCR markers, Lane 2: 
undigested product, Lane 3: digested product. 
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The purified DNA products of 208 bp and 450 bp fragments were further analysed by 
DNA sequencing.  The product of 208 bp fragment was sequenced and found to be a 92% 
match (69/75) to Homo sapiens ER mRNA (GenBank accession number: NM_000125) 
(Appendix D.4), whereas the product of the 450 bp fragment was sequenced and found to 
consist of unrelated ER sequences.  This will be discussed in Section 3.4. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.3.4.2 Constitutive androstane receptor (CAR) RT-PCR 
An initial experiment using the primer sequence designed for CAR by Primer3 (Table 2.6) 
failed to detect CAR mRNA in either the MCF7 or MDA-MB-468 cells.  As mentioned in 
Section 1.7.3, CAR plays an important role in the transcriptional regulation of certain 
P450s (e.g. CYP2B6) and a study by Chang and co-workers (Chang et al. 2003) 
 
 
Figure 3.32: ER RT-PCR.  Lane 1: 1000 bp PCR markers, Lane 2: negative control, Lane 3: MCF7, 
Lane 4: MDA-MB-468. 
 
Figure 3.33: Restriction digestion of ER RT-PCR using RsaI.  Lane 1: 1000 bp PCR markers, Lane 2: 
undigested product, Lane 3: digested product. 
 
  
Validation of RT-PCR analysis  
126 
demonstrated a positive correlation between CAR and CYP2B6 mRNA level in human 
liver tissues.  In this study, the expression of CYP2B6 mRNA was detected and confirmed 
in the MDA-MB-468 cells (Figures 3.11 and 3.12); therefore, CAR mRNA was considered 
for investigation in this experiment using the published CAR primer set (Table 2.7).  
Results showed the expected PCR product (417 bp) for both MCF7 and MDA-MB-468 
cells, though non-specific products were detected in the MCF7 cells (Figure 3.34). 
 
Following the non-specificity of the published primer above, the nested CAR primer set 
(Table 2.6) was employed to enhance specificity of the first round PCR product under the 
conditions shown in Table 2.8.  To obtain optimal conditions for this experiment, the 
volume of the first PCR product was varied (i.e. 1, 2, 3, 4 and 5 µL) with 0.5 µM of the 
nested CAR primer (Figure 3.35A), and the nested CAR primer concentration was varied 
(i.e. 0.1, 0.2, 0.3, 0.4 and 0.5 µM) with 5 µL of the first PCR product (Figure 3.35B).  The 
optimal conditions were found to be 0.2 µM of the nested primers with 5 µL of the first 
PCR product and this was used for the remainder of this study.  Expression of CAR mRNA 
was found in both the MCF7 and MDA-MB-468 cells which was confirmed by restriction 
digestion with PstI and observation of the correct fragments of 170 bp and 62 bp (Figure 
3.36). 
 
 
 
 
 
Figure 3.34: Nested CAR RT-PCR.  Lane 1: 1000 bp PCR markers, Lane 2: negative control,  
Lane 3: MCF7, Lane 4: MDA-MB-468. 
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Figure 3.35: Nested CAR RT-PCR optimisation of the volume of the first PCR product and concentration 
of nested CAR primers in the MCF7.  Lane 1: 1000 bp PCR markers, Lane 2: negative control (A) Varied 
the volume of the first PCR products.  Lane 3: 1 µL, Lane 4: 2 µL, Lane 5: 3 µL, Lane 6: 4 µL, Lane 7: 5 
µL.  (B) Varied the concentration of nested CAR primers.  Lane 3: 0.1 µM, Lane 4: 0.2 µM, Lane 5: 0.3 
µM, Lane 6: 0.4 µM, Lane 7: 0.5 µM. 
Figure 3.36: Restriction digestion of nested CAR RT-PCR using PstI.  Lane 1: 1000 bp PCR markers, 
Lane 2: undigested product, Lane 3: digested product.   
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3.3.4.3 Pregnane X receptor (PXR) RT-PCR 
Initially, the primer sequence designed for PXR by Primer3 (Table 2.6) failed to 
demonstrate PXR mRNA expression in either the MCF7 or MDA-MB-468 cells.   
However, the expression of PXR mRNA in MCF7 cells has been demonstrated in previous 
studies (Miki et al. 2006, Sakai et al. 2006).  In this research, the published PXR primer set 
(Table 2.7) was therefore used to determine the expression of PXR mRNA.  No PCR 
product was detected after routine amplification so the optimisation of PCR analysis was 
performed.  Amount of template cDNA was varied (i.e. 100, 150, 200 and 250 ng) with 0.5 
µM of PXR primer (Figure 3.37), and 250 ng of template cDNA was chosen for PXR 
amplification because the product appeared as an intense DNA band when compared to 
either 150 ng or 200 ng.  The expression of PXR mRNA was found in only the MCF7 
cells, not in the MDA-MB-468 cells.  The presence of PXR mRNA in the MCF7 cells was 
confirmed by digestion with restriction enzyme MspI, which generated fragments of the 
correct size (142 bp and 90 bp; Figure 3.38). 
 
 
 
 
 
 
 
 
 
Figure 3.37: PXR RT-PCR optimisation of template cDNA in MCF7.  Lane 1: 1000 bp PCR markers as 
indicated, Lane 2: negative control, Lane 3: 100 ng, Lane 4: 150 ng, Lane 5: 200 ng, Lane 6: 250 ng. 
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3.4 Discussion 
This chapter describes an RT-PCR protocol to optimise the detection of cytochrome P450 
and P450-regulatory nuclear receptor mRNA.  The advantages of using end-point PCR in 
this study are that it is a simple and rapid method for screening and detecting amplification 
products of high numbers of candidate genes in cell lines.  This study assessed a number of 
variables affecting RT-PCR analysis including the methods of RNA isolation, cDNA 
verification, PCR and restriction digest reaction conditions, and DNA purification and 
sequencing.  
 
Isolating total RNA of high purity was critical for validation of the PCR system as cellular 
contaminants such as genomic DNA (gDNA) can interfere with reaction efficiency and 
complicate interpretation of results.  Initially the RNA purity in this study was low with an 
A260/A280 ratio between 1.3 and 1.6 (instead of 1.8-2.1) and this seriously affected the 
specificity of the RT-PCR reactions.  To overcome this problem several technical measures 
were implemented, in particular it was felt that there had been overloading of cells onto the 
RNeasy spin column and that the method of disrupting the cells was critical.  The use of a 
cell number between 5x105 and 2x106 per purification, and an increased efficiency in the 
homogenisation process resulted in higher RNA purity, non-degraded RNA (Figure 3.2) 
 
Figure 3.38: Restriction digestion of PXR RT-PCR using MspI.  Lane 1: 1000 bp PCR markers,      
Lane 2: undigested product, Lane 3: digested product.   
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and less gDNA contamination in downstream applications.  Upon successful validation, 
this methodology was utilised for the remainder of the study. 
 
In this investigation, β2-microglobulin was used as an internal control to detect false 
negative results by comparing mRNA expression with the gene of interest in different cell 
lines.  Low variation in β2-microglobulin mRNA between the MCF7 and MDA-MB-468 
cells was observed (Figure 3.4), suggesting that this gene was an appropriate reference 
gene in this study.  As mentioned in Section 3.1, the use of negative controls (no DNA 
template) is critical for conducting PCR as it can monitor false-positive results in the PCR 
assay.  No product was detected in the negative controls in any of the experiments in this 
chapter, indicating that PCR reaction mixtures were free from DNA carryover 
contamination. 
 
Specificity in primer sequences is one of the most important keys to success in the PCR 
assay.  In this research, the candidate sequences designed by Primer3 programme were 
assessed via a direct BLAST search.  Ten out of the nineteen cytochrome P450 enzymes 
(i.e. CYP1A1, CYP1A2, CYP2A6, CYP2C9, CYP2C19, CYP2D6, CYP3A4, CYP3A5, 
CYP3A7 and CYP3A43), and two out of the eight P450-regulartory nuclear receptors (i.e. 
CAR and PXR) primers designed by Primer3 programme failed to demonstrate their 
mRNA expression in either the MCF7 or MDA-MB-468 cells, although sufficient 
validation following general guidelines used in this research was performed.   
 
However, five out of the twelve undetectable genes (i.e. CYP1A1, CYP3A4, CYP3A5, 
CAR and PXR) were considered for further investigation using the published primers 
(Table 2.7) because evidence regarding the presence or the relevance of them has been 
demonstrated in breast cancer cells and they are involved in the metabolism of oestrogen 
and anticancer drugs.  A single specific PCR product of CYP1A1 and PXR mRNA was 
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successfully detected after varying the concentration of cDNA template (Figures 3.6 and 
3.37).  The published CAR primer set was performed under routine amplification, but it 
generated non-specific PCR product (Figure 3.34).  Therefore, nested PCR was used to 
improve specificity of the primer, a specific product was detected and its sequence identity 
confirmed by restriction digestion.  The observation of non-specific bands in the first round 
PCR may be due to the fact published PCR conditions were not used in this experiment.  In 
an attempt to generate high quality data, experiments were performed using the procedure 
described in Section 3.2.3 as standard.  Unfortunately, the published primers of CYP3A4 
and CYP3A5 fail to demonstrate mRNA expression in the cell lines used despite their 
validation.   
 
It is well-known that CYP2D6 catalyses the N-demesthylation and 4-hydroxylation of 
tamoxifen which have potent anti-oestrogen effects.  Tamoxifen is widely used in the 
treatment of breast cancer (Schroth et al. 2007).  Previous studies demonstrated that 
CYP2D6 mRNA was expressed in normal breast as well as in breast tumour samples 
(Huang et al. 1996, Hellmold et al. 1998, Iscan et al. 2001, Bièche et al. 2007).  In 
addition, Hellmond and colleagues (Hellmold et al. 1998) demonstrated CYP2D6 protein 
expression in normal breast.  These findings were in disagreement with those of Modugno 
and co-workers (Modugno et al. 2003), who investigated CYP2D6 mRNA expression in 
breast tumour and normal adjacent breast tissues using quantitative RT-PCR.  The present 
study is the first to examine the expression of CYP2D6 mRNA in breast cancer MCF7 and 
MDA-MB-468 cell lines, but no CYP2D6 mRNA was observed.  As mentioned above, the 
importance of CYP2D6 in the metabolism of tamoxifen has been emphasised in the 
treatment of breast cancer.  For this reason, the current project sought to ascertain whether 
CYP2D6 is present or absent in the test cells using the published primers.  Preliminary 
work with previously published CYP2D6 mRNA in normal breast and seven breast cancer 
cell lines will be discussed in the next chapter.
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According to the general guidelines for the optimisation of PCR analysis in this study 
(Figure 3.1), the findings indicated that optimal cDNA template amount for the genes of 
interest was between 100 and 250 ng in a PCR reaction.  The optimal primer concentration 
for each individual gene was generally 0.5 µM because non-specific PCR products were 
seen at higher primer concentration of 1.0 µM to 1.5 µM.  Regarding the thermocycling 
conditions, twenty-five to thirty-five cycles is generally standard for a PCR reaction.  In 
the current investigation, thirty amplification cycles were selected and performed for all 
candidate genes, but not for β2-microglobulin.  Twenty cycles were sufficient for β2-
microglobulin amplification as the product generated a clear and sharp band (Figure 3.3). 
 
This research aimed to detect the expression of a number of target mRNAs in a series of 
cell lines.  Due to time constraints, a single repetition was performed in individual genes.  
However, in experiments where genes were undetectable after routine amplification, the 
procedure was repeated with varying amounts of cDNA template and/or primer and any 
detectable products were then confirmed by restriction digestion and/or DNA sequencing. 
 
PCR products of detectable genes were confirmed by restriction digestion and observation 
of digested fragments of the correct size on gels.  It should be noted that partial restriction 
digestion was observed for products of CYP2C18 (Figures 3.16), CYP26A1 (Figures 
3.25A), CYP26B1 (Figures 3.25B), and AhR (Figures 3.28).  These results may be due to 
excessive amounts of starting material being used, insufficient incubation time for 
reactions and/or low activity of restriction enzymes.  This problem could be investigated 
by repeating experiments with lower DNA template concentrations, an increased 
incubation time and a new batch/fresh supply of restriction enzymes for further study. 
 
In section 3.3.3.4, it was shown that MDA-MB-468 cells express CYP4Z1 mRNA (159 
bp) with the presence of an additional band of ~250 bp.  To ensure specificity of primers, 
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annealing temperature of PCR analysis was varied between 55oC and 63oC.  However, two 
bands were still visualised on the gel, and this experiment showed that an annealing 
temperature of 58oC was optimal (Figure 3.20).  Purified DNA of the two fragments was 
digested using restriction enzyme RsaI and a restricted fragment size of 112 bp was found 
in both purified fragments.  This finding suggested that these fragments may contain 
similar DNA and they were therefore sequenced.  The results of DNA sequencing were 
accessed directly by a BLAST search, and this predicted that both fragments were human 
CYP4Z1 mRNA (Appendix D).  However, more than fifty percent of CYP4Z1 (~250bp) 
sequences were unreadable, possibly due to poor quality of the purified DNA samples or 
an unknown factor involved in the expression of CYP4Z1 mRNA.  Prior to further 
characterisation of the CYP4Z1 mRNA (Chapter 5), the previously published primers 
which have been demonstrated a single PCR product were used to confirm the presence of 
CYP4Z1 mRNA in the cDNA samples employed in this study.  Results will be shown and 
discussed in Chapter 4. 
 
Several novel extrahepatic P450 enzymes may be of particular interest in breast cancer 
cells in terms of potential targets for cancer therapy as they are preferentially expressed in 
extrahepatic tissues, and overexpression of some cytochrome P450s have been identified in 
certain types of tumours.  A preliminary investigation demonstrated the expression of 
CYP2F1, CYP2J2, CYP2R1, CYP2U1 and CYP4X1 in a panel of breast cancer cell lines 
and compared to a normal breast cell line performed by the Honours students within the 
School of Pharmacy who employed the same cDNA samples and established methods used 
in the current investigation.  This preliminary work also investigated the expression of 
retinoic acid receptor (RAR) and retinoid X receptor (RXR), because their physiological 
roles have been shown to be involved in the development of various types of cancer 
(Germain et al. 2003, Altucci et al. 2007) and the regulation of some cytochrome P450 
enzymes (Meyer 2007).  These results will be shown in Chapter 4.  
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Table 3.1 summarises the presence of cytochrome P450 and cytochrome P450-regulatory 
nuclear receptor mRNA in the MCF7 and MDA-MB-468 cells after optimisation and 
confirmation of their expression.  In summary, this chapter provides information on 
validation of PCR conditions derived from the model cell lines, MCF7 and MDA-MB-468.  
These conditions will be used for the remaining breast cancer cell lines and compared to a 
normal breast cell line in the next chapter. 
Table 3.1: The presence of cytochrome P450 and P450-regulatory nuclear receptor mRNA in the MCF7 and 
MDA-MB-468 cells 
 
 
P450 
 
MCF7 
 
MDA-MB-468 
 
NR 
 
MCF7 
 
MDA-MB-468 
 
CYP1A1 
 
+ 
 
- 
 
HIF-1α 
 
+ 
 
+ 
 
CYP 1A2 
 
NS 
 
NS 
 
AhR 
 
+ 
 
+ 
 
CYP1B1 
 
+ 
 
+ 
 
ARNT 
 
+ 
 
+ 
 
CYP2A6 
 
- 
 
- 
 
AhRR 
 
+ 
 
+ 
 
CYP2B6 
 
- 
 
+ 
 
CAR 
 
+ 
 
+ 
 
CYP2C8 
 
+ 
 
- 
 
PXR 
 
+ 
 
- 
 
CYP2C18 
 
+ 
 
+ 
 
VDR 
 
+ 
 
- 
 
CYP2C9 
 
- 
 
- 
 
ER 
 
+ 
 
+ 
 
CYP2C19 
 
- 
 
- 
   
 
CYP2D6 
 
- 
 
- 
   
 
CYP2S1 
 
+ 
 
+    
 
CYP3A4 
 
- 
 
- 
   
 
CYP3A5 
 
- 
 
- 
   
 
CYP3A7 
 
- 
 
- 
   
 
CYP3A43 
 
- 
 
- 
   
 
CYP4Z1 
 
- 
 
+    
 
CYP24A1 
 
+ 
 
- 
   
 
CYP26A1 
 
+ 
 
+    
 
CYP26B1 
 
 
+ 
 
+    
Abbreviations: P450; cytochrome P450 enzyme, NR; P450-regulatory nuclear receptor, NS; non-specific 
product by RT-PCR analysis, +; PCR product detected at predicted size and sequence specificity, -; not 
detected by visual inspection. 
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Chapter 4 
Cytochrome P450 expression in breast cancer cell lines 
 
4.1 Introduction 
Clinically, the majority of breast tumours express oestrogen receptor (ER) and it is well 
established that local production of oestrogen is particularly high in breast tumours (Suzuki 
et al. 2005).  Oestrogen is involved in the development and progression of breast cancer 
(Yager and Davidson 2006).  Women with ER-positive breast tumours are more likely to 
benefit from endocrine therapy than patients with ER-negative tumours.  Approximately 
60-65% of patients with ER-positive tumours respond to anti-oestrogen therapy (i.e. 
tamoxifen) whereas in women with ER-negative tumours, only low levels of response are 
achieved.  Moreover, ER-negative women have a poorer survival and prognosis than 
patients who have node positive and ER-positive tumours (Putti et al. 2005).   
 
However, the overall cytochrome P450 profile in breast cancer and the role of these 
enzymes in breast carcinogenesis is yet to be defined.  A better understanding of the 
differential expression of these enzymes in different oestrogen receptor status, invasive 
phenotypes and racial groups could potentially be of enormous value in the development of 
novel cancer therapeutics (targeted at these enzymes) and the design of more effective drug 
regimens.  Therefore, this chapter was designed to identify the cytochrome P450 and P450-
regulatory nuclear receptor mRNA profile in a panel of breast cancer cell lines derived 
from different ethnic backgrounds (i.e. Caucasians and Afro-Caribbeans) and including 
different breast tumour characteristics (i.e. oestrogen receptor status and invasive 
phenotype).  A normal breast cell line was also examined for comparative purposes.  
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4.2 Materials and Methods 
4.2.1 Cell lines and cell culture 
The eight cell lines used were obtained from different sources (Section 2.2.2) and a 
summary of their characteristics is presented in Table 1.1.  All cells were maintained under 
the growth conditions described in Section 2.2.3.  All experiments were conducted using 
cells cultured for no more than 15 passages after resuscitation of the first cell stock.  All 
culture techniques were performed as explained previously (Sections 2.2.4 to 2.2.7). 
 
4.2.2 RNA isolation and cDNA sysnthesis 
Total RNA was isolated from all cell lines using the RNeasy Plus Mini kit from Qiagen as 
detailed in Section 2.3.  Approximately 5x105 to 2x106 cells were extracted per purification 
as discussed in Section 3.3.1.  The quantity and quality of total RNA in each preparation 
were determined by A260/A280 ratios and inspection of the 28S and 18S rRNA bands in 1% 
(w/v) agarose gels.  As described in Section 2.4, reverse transcription (RT) reactions were 
conducted in a final volume of 20 µL (Table 2.1) using the reaction conditions summarised 
in Table 2.2. 
 
4.2.3 Qualitative PCR amplification 
PCR was performed under optimal conditions (Section 3.3) in order to profile P450 and 
P450-regulatory nuclear receptor mRNA expression in the test cell lines.  The PCR 
products obtained from the housekeeping gene β2-microglobulin and the target genes from 
each cell line were visualised on 1.5% agarose gels containing ethidium bromide.  
Following visualisation of bands in the PCR products, the band intensity of photographed 
gel (positive) images was subjected to densitometric scanning using UVI-BandMap 
software (UVItec, Cambridge, UK).  Densitometry is the quantitative measurement of 
optical density which can be expressed as the number of dark spots in a given volume of 
intensity.  The sensitivity (maximum spot size) was set at 5 mm for all samples to measure 
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the volume density of the amplified products.  To demonstrate a relative expression of 
candidate genes’ mRNA in each cell line tested, mRNA expression of each gene was 
normalised against β2-microglobulin mRNA expression.  In the result section, some gel 
images were inverted from positive to negative images for better visualisation. 
 
In this chapter, the PCR assay was used qualitatively i.e. it was used to determine whether 
mRNA was present or absent in all individuals from the test cell lines.  To facilitate 
comparisons between the cell lines, the volume density of the β2-microglobulin RT-PCR 
and the relative intensities of target genes normalised against β2-microglobulin were 
determined. 
 
4.2.4 Oligonucleotide primer design  
Prior to further elucidation of the CYP4Z1 sequence the present investigation confirmed 
the expression of CYP4Z1 mRNA in the eight cDNA samples using the previously 
published primers (Table 2.7, Thomas et al. 2006) which had been designed to cross 
between exon 7 and exon 8 boundaries (Figure 5.2).  Thomas and colleagues found that 
this primer set generated a single band of the CYP4Z1 amplification product.  
 
During the course of the current study, the expression of CYP2D6, CYP2F1, CYP2J2, 
CYP2R1, CYP2U1, CYP4X1, RAR and RXR was investigated using cDNA samples as 
mentioned in Section 3.4.  These were subjected to routine amplification (Tables 2.3 and 
2.4) with the previously published primers (Table 2.7) and the products obtained were 
digested with restriction enzymes (Table 2.10) under the conditions described in Table 
2.11 to confirm the mRNA expression of candidate genes. 
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4.3 Results 
4.3.1 RNA isolation 
Total RNA isolated from the cell lines had A260/A280 ratios between 1.8 and 2.1.  One 
microgram of total RNA isolated from the eight cell lines was loaded onto a 1% (w/v) 
agarose gel to confirm RNA quality (Figure 4.1). 
 
 
 
 
 
4.3.2 β2-microglobulin RT-PCR 
A band of 319 bp corresponding to the cDNA product size for β2-microglobulin was 
detected for all cell lines.  There was no visible difference in the housekeeping gene 
β2-microglobulin mRNA expression between the breast cancer cells and the normal breast 
cell line used.  No band was detected in the negative controls (no template cDNA, Figure 
4.2).  This data was used for each subsequent analysis in this chapter. 
 
4.3.3 CYP1 family RT-PCR 
CYP1A1 mRNA was detected in five out of the seven breast cancer cell lines as the correct 
band at 392 bp and it was expressed at a very low level in the normal breast MCF10A cell 
line.  No CYP1A1 mRNA expression was detected in the ZR-75-30 and MDA-MB-468 
cells (Figure 4.3). 
 
Figure 4.1: Quality of total RNA isolated.  Lane 1: MCF10A, Lane 2: MCF7, Lane 3: T47D, Lane 4: 
ZR-75-1, Lane 5: ZR-75-30, Lane 6: MDA-MB-231, Lane 7: MDA-MB-157, Lane 8: MDA-MB-468. 
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Figure 4.3: CYP1A1 RT-PCR.  (A) Visualisation of the CYP1A1 amplified products.  Lane 1: 1000 bp 
PCR markers, Lane 2: negative control, Lane 3: MCF10A, Lane 4: MCF7, Lane 5: T47D, Lane 6: ZR-
75-1, Lane 7: ZR-75-30, Lane 8: MDA-MB-231, Lane 9: MDA-MB-157, Lane 10: MDA-MB-468.  (B) 
Relative intensities of CYP1A1 normalised against β2-microglobulin.   
Figure 4.2: β2-microglobulin RT-PCR.  (A) Visualisation of the β2-microglobulin amplified products.  
Lane 1: 1000 bp PCR markers, Lane 2: negative control, Lane 3: MCF10A , Lane 4: MCF7, Lane 5: 
T47D, Lane 6: ZR-75-1, Lane 7: ZR-75-30, Lane 8: MDA-MB-231, Lane 9: MDA-MB-157, Lane 10: 
MDA-MB-468.  (B) Volume density of the β2-microglobulin amplified products (pixels). 
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As mentioned in Section 3.3.3.1, the CYP1A2 primer sequence designed by Primer3 failed 
to detect the presence of CYP1A2 mRNA in either the MCF7 or MDA-MB-468 cells.  
This primer set was also used for the remaining cell lines, but unfortunately the results still 
showed non-specific amplification in all cases. 
 
A band of 397 bp was observed for CYP1B1 mRNA in both the normal breast (MCF10A) 
and breast cancer cell lines.  MCF7, T47D, ZR-75-1, MDA-MB-231 and MDA-MB-157 
demonstrated higher levels of expression than the ZR-75-30 cells.  Only very weak 
expression was detected in the MDA-MB-468 cells (Figures 4.4). 
 
 
 
 
4.3.4 CYP2 family RT-PCR 
As mentioned in Section 3.3.3.2, both the MCF7 and MDA-MB-468 cell lines failed to 
show the presence of CYP2A6 mRNA during PCR validation.  However, a band of 186 bp 
corresponding to the cDNA product size for CYP2A6 mRNA was detected in three of the 
cell lines.  CYP2A6 mRNA was expressed in the ZR-75-1 and T47D cells at higher levels 
 
Figure 4.4: CYP1B1 RT-PCR.  (A) Visualisation of CYP1B1 amplified products.  Lane 1: 1000 bp PCR 
markers, Lane 2: negative control, Lane 3: MCF10A, Lane 4: MCF7, Lane 5: T47D, Lane 6: ZR-75-1, 
Lane 7: ZR-75-30, Lane 8: MDA-MB-231, Lane 9: MDA-MB-157, Lane 10: MDA-MB-468. (B) Relative 
intensities of CYP1B1 normalised against β2-microglobulin.   
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than the MDA-MB-157 cells (Figures 4.5).  The expression of CYP2A6 mRNA was 
confirmed by restriction digestion with HaeIII, which generated digested fragments of the 
correct size (72 bp and 66 bp, Figure 4.6). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.6: Restriction digestion of CYP2A6 RT-PCR with HaeIII.  Lane 1: 1000 bp PCR markers, 
Lane 2: undigested product, Lane 3: digested product. 
 
Figure 4.5: CYP2A6 RT-PCR.  (A) Visualisation of CYP2A6 amplified products (negative image).  Lane 
1: 1000 bp PCR markers, Lane 2: negative control, Lane 3: MCF10A, Lane 4: MCF7, Lane 5: T47D, 
Lane 6: ZR-75-1, Lane 7: ZR-75-30, Lane 8: MDA-MB-231, Lane 9: MDA-MB-157, Lane 10: MDA-MB-
468.  (B) Relative intensities of CYP2A6 normalised against β2-microglobulin.   
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A band of 194 bp corresponding to the cDNA product size for CYP2B6 mRNA was found 
in five out of the seven breast cancer cell lines but no product was visible in the normal 
breast cells.  A high level of expression was observed in the T47D, ZR-75-1 and MDA-
MB-157 cells, while very low levels were detected in the ZR-75-30 and MDA-MB-468 
cells.  CYP2B6 mRNA expression was not detected in the MCF7 and MDA-MB-231 cells 
(Figure 4.7).   
 
CYP2C8 mRNA was detected in three out of the seven breast cancer cell lines as a cDNA 
product at 230 bp but no mRNA was observed in the normal breast cell line.  A higher 
level of CYP2C8 expression was found in the MDA-MB-157 cells compared to the MCF7 
and ZR-75-1 cells (Figure 4.8). 
 
A band of 199 bp was observed for the presence of CYP2C18 mRNA in four out of seven 
breast cancer and the normal breast cell lines.  It was expressed in the T47D cells at a high 
level, whereas very weak levels were detected in the normal breast cell line, and the breast 
cancer cell lines MCF7, MDA-MB-157 and MDA-MB-468 (Figure 4.9). 
 
During PCR validation (Section 3.3.3.2) both the MCF7 and MDA-MB-468 cells failed to 
demonstrate expression of CYP2C9/19 and CYP2D6 mRNA.  Similarly, no amplification 
product was detected in the cell lines investigated.  However CYP2D6, an enzyme which 
plays a crucial role in the metabolism of antioestrogen tamoxifen and is associated with 
breast cancer was considered for PCR experiments using previously published sequences 
(Table 2.7, Thomas et al. 2006).  Preliminary results are shown in Figures 4.27 and 4.28. 
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Figure 4.7: CYP2B6 RT-PCR.  (A) Visualisation of CYP2B6 amplified products (negative image).  Lane 
1: 1000 bp PCR markers, Lane 2: negative control, Lane 3: MCF10A, Lane 4: MCF7, Lane 5: T47D, 
Lane 6: ZR-75-1, Lane 7: ZR-75-30, Lane 8: MDA-MB-231, Lane 9: MDA-MB-157, Lane 10: MDA-MB-
468.  (B) Relative intensities of CYP2B6 normalised against β2-microglobulin.   
Figure 4.8: CYP2C8 RT-PCR.  (A) Visualisation of CYP2C8 amplified products (negative image).  Lane 
1: 1000 bp PCR markers, Lane 2: negative control, Lane 3: MCF10A, Lane 4: MCF7, Lane 5: T47D, 
Lane 6: ZR-75-1, Lane 7: ZR-75-30, Lane 8: MDA-MB-231, Lane 9: MDA-MB-157, Lane 10: MDA-MB-
468.  (B) Relative intensities of CYP2C8 normalised against β2-microglobulin.   
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A band of 216 bp corresponding to the cDNA product size for CYP2S1 mRNA was highly 
expressed in all of the cell lines except MCF10A and ZR-75-30.  The highest level of 
expression was found in the T47D cells.  Moderate expression was detected in the MCF7, 
ZR-75-1, MDA-MB-231, MDA-MB-157 and MDA-MB-468 cells (Figure 4.10). 
 
4.3.5 CYP3 family RT-PCR 
In the CYP3A subfamily, the primer sequences designed for CYP3A4/5/7/43 by Primer3 
(Table 2.6) failed to detect CYP3A mRNA expression in the MCF7 and MDA-MB-468 
cells during PCR validation (Section 3.3.3.3).  When profiling these genes against a series 
of cell lines, only a very weak level of CYP3A7 mRNA expression was detected in the 
normal breast cell line MCF10A as a cDNA product of 223 bp (Figure 4.11).  The 
expression of CYP3A7 mRNA was confirmed by restriction digestion with EcoRI which 
generated fragments of the correct size (158 bp and 65 bp) (Figure 4.12).  However, no 
 
Figure 4.9: CYP2C18 RT-PCR.  (A) Visualisation of CYP2C18 amplified products (negative image).  
Lane 1: 1000 bp PCR markers, Lane 2: negative control, Lane 3: MCF10A, Lane 4: MCF7, Lane 5: 
T47D, Lane 6: ZR-75-1, Lane 7: ZR-75-30, Lane 8: MDA-MB-231, Lane 9: MDA-MB-157, Lane 10: 
MDA-MB-468.  (B) Relative intensities of CYP2C18 normalised against β2-microglobulin.   
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CYP3A4/5/43 mRNA expression was detected in either the normal breast or breast cancer 
cell lines under the conditions used in this study. 
 
 
 
 
 
 
 
 
Figure 4.10: CYP2S1 RT-PCR.  (A) Visualisation of CYP2S1 amplified products.  Lane 1: 1000 bp PCR 
markers, Lane 2: negative control, Lane 3: MCF10A, Lane 4: MCF7, Lane 5: T47D, Lane 6: ZR-75-1, 
Lane 7: ZR-75-30, Lane 8: MDA-MB-231, Lane 9: MDA-MB-157, Lane 10: MDA-MB-468.  (B) Relative 
intensities of CYP2S1 normalised against β2-microglobulin.   
Figure 4.11: CYP3A7 RT-PCR.  (A) Visualisation of CYP3A7 amplified products (negative image).  
Lane 1: 1000 bp PCR markers, Lane 2: negative control, Lane 3: MCF10A, Lane 4: MCF7, Lane 5: 
T47D, Lane 6: ZR-75-1, Lane 7: ZR-75-30, Lane 8: MDA-MB-231, Lane 9: MDA-MB-157, Lane 10: 
MDA-MB-468.  (B) Relative intensities of CYP3A7 normalised against β2-microglobulin.   
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4.3.6 CYP4 family RT-PCR 
A cDNA product at 159 bp indicated CYP4Z1 mRNA was found in three out of the seven 
breast cancer cell lines and the normal breast cell line.  CYP4Z1 was expressed in the 
MDA-MB-468 and T47D cells at higher levels than in the MCF10A and ZR-75-1 cells.  
An additional band of ~250 bp was observed with the presence of CYP4Z1 mRNA in all 
four cell lines (Figure 4.13).  
 
A single band of 257 bp corresponding to the cDNA product size for the published 
CYP4Z1 mRNA was detected in four of the seven breast cancer cell lines and the normal 
breast cell line (Figure 4.14).  There was no additional band in this primer set.  The 
CYP4Z1 mRNA in the MDA-MB-468 cells seemed to be overexpressed compared with 
the MCF10A, T47D and ZR-75-1 cells.  CYP4Z1 mRNA was expressed in the ZR-75-30 
cells at a very low level.  Expression of CYP4Z1 mRNA in the MDA-MB-468 cells was 
confirmed by restriction digest with AluI, and the correct fragments of 196 bp and 61 bp 
were observed (Figure 4.15). 
 Figure 4.12: Restriction digestion of CYP3A7 RT-PCR with EcoRI.  Lane 1: 1000 bp PCR markers, 
Lane 2: undigested product, Lane 3: digested product. 
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Figure 4.13: CYP4Z1 RT-PCR.  (A) Visualisation of CYP4Z1 amplified products (negative image).  Lane 
1: 1000 bp PCR markers, Lane 2: negative control, Lane 3: MCF10A, Lane 4: MCF7, Lane 5: T47D, 
Lane 6: ZR-75-1, Lane 7: ZR-75-30, Lane 8: MDA-MB-231, Lane 9: MDA-MB-157, Lane 10: MDA-MB-
468.  (B) Relative intensities of CYP4Z1 (159 bp) normalised against β2-microglobulin.   
 
Figure 4.14: CYP4Z1 RT-PCR using the previously published primer set.  Lane 1: 1000 bp PCR 
markers, Lane 2: negative control, Lane 3: MCF10A, Lane 4: MCF7, Lane 5: T47D, Lane 6: ZR-75-1, 
Lane 7: ZR-75-30, Lane 8: MDA-MB-231, Lane 9: MDA-MB-157, Lane 10: MDA-MB-468.   
Figure 4.15: Restriction digestion of CYP4Z1 RT-PCR (using the published primers) with AluI.  Lane 1: 
1000 bp PCR markers, Lane 2: undigested product, Lane 3: digested product. 
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4.3.7 CYP24 family RT-PCR 
A band at 249 bp was observed for CYP24A1 mRNA expression and it was detected in 
almost all the cell lines tested with the exception of ZR-75-30 and MDA-MB-468.  Very 
low levels of CYP24A1 were observed in the MCF10A and MDA-MB-231 cells, whereas 
moderate expression was found in the MCF7, T47D, ZR-75-1 and MDA-MB-157 cells 
(Figure 4.16). 
 
4.3.8 CYP26 family RT-PCR 
CYP26A1 mRNA, at 191 bp, was detected in all cell lines except ZR-75-1 and the normal 
breast cell line.  CYP26A1 was expressed in MDA-MB-231 and MDA-MB-468 at very 
low levels, while a higher level of expression was observed in the MDA-MB-157 cells 
(Figure 4.17). 
 
A band indicating the presence of CYP26B1 mRNA at 172 bp was detected in the normal 
breast cell line and six out of the seven breast cancer cell lines.  No CYP26B1 mRNA was 
expressed in the ZR-75-30 cells.  Very weak levels of CYP26B1 mRNA were found in the 
MCF7, T47D and ZR-75-1 cells, whereas higher levels were detected in both the normal 
breast and the breast cancer cell lines (MDA-MB231, MDA-MB-157 and MDA-MB-468; 
Figure 4.18).  
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Figure 4.16: CYP24A1 RT-PCR.  (A) Visualisation of CYP24A1 amplified products.  Lane 1: 1000 bp 
PCR markers, Lane 2: negative control, Lane 3: MCF10A, Lane 4: MCF7, Lane 5: T47D, Lane 6: ZR-
75-1, Lane 7: ZR-75-30, Lane 8: MDA-MB-231, Lane 9: MDA-MB-157, Lane 10: MDA-MB-468.  (B) 
Relative intensities of CYP24A1 normalised against β2-microglobulin.   
 
Figure 4.17: CYP26A1 RT-PCR.  (A) Visualisation of CYP26A1 amplified products.  Lane 1: 1000 bp 
PCR markers, Lane 2: negative control, Lane 3: MCF10A, Lane 4: MCF7, Lane 5: T47D, Lane 6: ZR-
75-1, Lane 7: ZR-75-30, Lane 8: MDA-MB-231, Lane 9: MDA-MB-157, Lane 10: MDA-MB-468.  (B) 
Relative intensities of CYP26A1 normalised against β2-microglobulin.   
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4.3.9 Cytochrome P450-regulatory nuclear receptor RT-PCR 
The expression of HIF-1α, AhR and ARNT mRNA was detected in both the normal breast 
and breast cancer cell lines at the correct band size of 167 bp, 262 bp and 387 bp 
respectively (Figures 4.19, 4.20 and 4.21).  HIF-1α mRNA was expressed at high levels in 
the normal breast cells MCF10A, and the breast cancer cell lines T47D and MDA-MB-
231.  It was detected at lower levels in the ZR-75-1, ZR-75-30 and MDA-MB-468 cells.  
AhR and ARNT mRNA were expressed at similar levels in the cell lines used, and low 
levels of both AhR and ARNT mRNA expression were observed in the ZR-75-30 cells.   
 
A band for the expression of AhRR mRNA at 171 bp was detected in six out of the seven 
breast cancer cell lines and in the normal breast cell line.  Very weak levels of AhRR 
mRNA were found in the normal breast cells and ZR-75-30.  AhRR mRNA expression 
was not detected in the ZR-75-1 cells (Figure 4.22).   
 
 
Figure 4.18: CYP26B1 RT-PCR.  (A) Visualisation of CYP26B1 amplified products (negative image).  
Lane 1: 1000 bp PCR markers, Lane 2: negative control, Lane 3: MCF10A, Lane 4: MCF7, Lane 5: 
T47D, Lane 6: ZR-75-1, Lane 7: ZR-75-30, Lane 8: MDA-MB-231, Lane 9: MDA-MB-157, Lane 10: 
MDA-MB-468.  (B) Relative intensities of CYP26B1 normalised against β2-microglobulin.   
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A band of 250 bp corresponding to the cDNA product size for VDR mRNA was found in 
five out of the seven breast cancer cell lines and in the normal breast cell line but no 
product was detected in the ZR-75-30 and MDA-MB-468 cells (Figure 4.23).   
 
ER mRNA was found in six out of the seven breast cancer cell lines as a correct band at 
208 bp but it was not detected in the normal breast cell line or the breast cancer cell line 
MDA-MB-231.  ER was expressed in the T47D, ZR-75-1, ZR-75-30 and MDA-MB-157 
cells at higher levels than in the MCF7 and MDA-MB-468 cells.  An additional fainter 
band at 450 bp was only observed in the MCF7 and MDA-MB-468 cells as mentioned in 
Section 3.3.4.1 (Figure4.24). 
 
 
 
 
 
Figure 4.19: HIF-1α RT-PCR.  (A) Visualisation of HIF-1α amplified products.  Lane 1: 1000 bp PCR 
markers, Lane 2: negative control, Lane 3: MCF10A, Lane 4: MCF7, Lane 5: T47D, Lane 6: ZR-75-1, 
Lane 7: ZR-75-30, Lane 8: MDA-MB-231, Lane 9: MDA-MB-157, Lane 10: MDA-MB-468.  (B) Relative 
intensities of HIF-1α normalised against β2-microglobulin.   
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Figure 4.21: ARNT RT-PCR.  (A) Visualisation of ARNT amplified products.  Lane 1: 1000 bp PCR 
markers, Lane 2: negative control, Lane 3: MCF10A, Lane 4: MCF7, Lane 5: T47D, Lane 6: ZR-75-1, 
Lane 7: ZR-75-30, Lane 8: MDA-MB-231, Lane 9: MDA-MB-157, Lane 10: MDA-MB-468.  (B) Relative 
intensities of ARNT normalised against β2-microglobulin. 
Figure 4.20: AhR RT-PCR.  (A) Visualisation of AhR amplified products.  Lane 1: 1000 bp PCR 
markers, Lane 2: negative control, Lane 3: MCF10A, Lane 4: MCF7, Lane 5: T47D, Lane 6: ZR-75-1, 
Lane 7: ZR-75-30, Lane 8: MDA-MB-231, Lane 9: MDA-MB-157, Lane 10: MDA-MB-468.  (B) Relative 
intensities of AhR normalised against β2-microglobulin.   
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Figure 4.22: AhRR RT-PCR.  (A) Visualisation of AhRR amplified products (negative image).  Lane 1: 
1000 bp PCR markers, Lane 2: negative control, Lane 3: MCF10A, Lane 4: MCF7, Lane 5: T47D, Lane 
6: ZR-75-1, Lane 7: ZR-75-30, Lane 8: MDA-MB-231, Lane 9: MDA-MB-157, Lane 10: MDA-MB-468.  
(B) Relative intensities of AhRR normalised against β2-microglobulin. 
Figure 4.23: VDR RT-PCR.  (A) Visualisation of VDR amplified products.  Lane 1: 1000 bp PCR 
markers, Lane 2: negative control, Lane 3: MCF10A, Lane 4: MCF7, Lane 5: T47D, Lane 6: ZR-75-1, 
Lane 7: ZR-75-30, Lane 8: MDA-MB-231, Lane 9: MDA-MB-157, Lane 10: MDA-MB-468.  (B) Relative 
intensities of VDR normalised against β2-microglobulin. 
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A band of 232 bp was observed for the CAR mRNA using nested PCR in the breast cancer 
cell lines but it was not detected in the normal breast cell line.  CAR mRNA (nested) was 
expressed at lower levels in the ZR-75-1 and MDA-MB-468 cells than in the MCF7, 
T47D, ZR-75-1, MDA-MB-231 and MDA-MB-157 cells.  It was noticed that there were 
multiple bands of nested CAR RT-PCR product in the T47D, ZR-75-30, MDA-MB-231 
and MDA-MB-468 cells (Figure 4.25). 
 
A band of 246 bp was observed at the correct size for PXR mRNA in four out of the seven 
breast cancer cell lines but it was not expressed in the normal breast cell lines.  PXR 
mRNA was expressed at similar levels in the ZR-75-1 and MDA-MB-157 cells and at very 
low levels in the MCF7 and T47D cells (Figure 4.26). 
 
 
Figure 4.24: ER RT-PCR.  (A) Visualisation of ER amplified products.  Lane 1: 1000 bp PCR markers, 
Lane 2: negative control, Lane 3: MCF10A, Lane 4: MCF7, Lane 5: T47D, Lane 6: ZR-75-1, Lane 7: 
ZR-75-30, Lane 8: MDA-MB-231, Lane 9: MDA-MB-157, Lane 10: MDA-MB-468.  (B) Relative 
intensities of ERα normalised against β2-microglobulin. 
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Figure 4.25: Nested CAR RT-PCR.  (A) Visualisation of Nested CAR amplified products.  Lane 1: 1000 
bp PCR markers, Lane 2: negative control, Lane 3: MCF10A, Lane 4: MCF7, Lane 5: T47D, Lane 6: 
ZR-75-1, Lane 7: ZR-75-30, Lane 8: MDA-MB-231, Lane 9: MDA-MB-157, Lane 10: MDA-MB-468.  
(B) Relative intensities of Nested CAR normalised against β2-microglobulin. 
Figure 4.26: PXR RT-PCR.  (A) Visualisation of PXR amplified products (negative image).  Lane 1: 
1000 bp PCR markers, Lane 2: negative control, Lane 3: MCF10A, Lane 4: MCF7, Lane 5: T47D, Lane 
6: ZR-75-1, Lane 7: ZR-75-30, Lane 8: MDA-MB-231, Lane 9: MDA-MB-157, Lane 10: MDA-MB-468.  
(B) Relative intensities of PXR normalised against β2-microglobulin. 
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4.3.10 Preliminary work 
A band of 261 bp indicated the cDNA product size for the published CYP2D6 mRNA was 
detected in both the normal breast and breast cancer cell lines (Figure 4.27).  CYP2D6 
mRNA was expressed at a lower level in the MDA-MB-231 cells than in the MCF7, T47D, 
ZR-75-1 and MDA-MB-157 cells.  It should be noted that the presence of a cDNA product 
at 261 bp in MCF10A (Lane 2), MDA-MB-468 (Lane 6) and ZR-75-30 (Lane 9) shows up 
as visible smear in the background between ~250 bp and ~800 bp.  However, the 
expression of CYP2D6 mRNA in the T47D cells was confirmed by restriction digestion 
with RsaI, which generated digested fragments of the correct size (142 bp and 119 bp, 
Figure 4.28). 
 
The expression of CYP2F1 mRNA was detected in two out of the seven breast cancer cell 
lines (i.e. ZR-75-1 and MDA-MB-468) at the expected band size of 305 bp but it was not 
detected in the normal breast cell line (Figure 4.29).  CYP2F1 was expressed in the MDA-
MB-468 cells at a higher level than in the ZR-75-1 cells.  An additional fainter band at 
~900 bp was only observed in the ZR-75-1 cells.  Expression of CYP2F1 mRNA in the 
MDA-MB-468 cells was confirmed by restriction digestion with MspI and observation of 
the correct fragments of 195 bp and 110 bp (Figure 4.30). 
 
A single band of 714 bp corresponding to the cDNA product size for the CYP2J2 mRNA 
was found in both the normal breast and breast cancer cell lines (Figure 4.31).  CYP2J2 
mRNA was expressed in the MCF10A and MDA-MB-231 cells at very low levels while 
high levels of CYP2F1 mRNA were observed in almost breast cancer cell lines.  To 
confirm CYP2J2 mRNA expression, the PCR product fromMDA-MB-468 cells was 
restricted with the enzyme AluI and the correct fragments of 330 bp and 170 bp were 
detected (Figure 4.32).
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Figure 4.29: Visualisation of CYP2F1 RT-PCR. Lane 1: 1000 bp PCR markers, Lane 2: MCF10A, Lane 
3: MCF7, Lane 4: MDA-MB-157, Lane 5: MDA-MB-231, Lane 6: MDA-MB-468, Lane 7: T47D, Lane 8: 
ZR-75-1, Lane 9: ZR-75-30, Lane 10: negative control. 
 
 
Figure 4.27: Visualisation of CYP2D6 RT-PCR. Lane 1: 1000 bp PCR markers, Lane 2: MCF10A, Lane 
3: MCF7, Lane 4: MDA-MB-157, Lane 5: MDA-MB-231, Lane 6: MDA-MB-468, Lane 7: T47D, Lane 8: 
ZR-75-1, Lane 9: ZR-75-30, Lane 10: negative control. 
 
Figure 4.28: Restriction digestion of CYP2D6 RT-PCR with RsaI.  Lane 1: 1000 bp PCR markers,  
Lane 2: undigested product, Lane 3: digested product. 
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Figure 4.31: Visualisation of CYP2J2 RT-PCR. Lane 1: 1000 bp PCR markers, Lane 2: MCF10A,  
Lane 3: MCF7, Lane 4: MDA-MB-157, Lane 5: MDA-MB-231, Lane 6: MDA-MB-468, Lane 7: T47D, 
Lane 8: ZR-75-1, Lane 9: ZR-75-30, Lane 10: negative control. 
 
Figure 4.30: Restriction digestion of CYP2F1 RT-PCR with MspI.  Lane 1: 1000 bp PCR markers,  
Lane 2: undigested product, Lane 3: digested product. 
 
Figure 4.32: Restriction digestion of CYP2J2 RT-PCR with AluI.  Lane 1: 1000 bp PCR markers,  
Lane 2: undigested product, Lane 3: digested product. 
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During the validation procedure of CYP2R1 RT-PCR analysis, a primer concentration of 
0.2 µM was used for RT-PCR experiments as a higher concentration of primer (from 0.3 to 
0.5 µM) generated non-specific amplification products.  A band of 308 bp was observed 
for the CYP2R1 mRNA in both the normal breast and breast cancer cell lines (Figure 
4.33).  CYP2R1 mRNA was expressed at very low levels in the ZR-75-30 and MDA-MB-
468 cells whereas higher levels of CYP2R1 mRNA were observed in the normal breast 
MCF10A cells and the breast cancer MCF7, T47D, MDA-MB-157, MDA-MB-231 and 
ZR-75-1 cells.  Restriction digestion using HaeIII confirmed the expression of CYP2R1 
mRNA in the ZR-75-1 cells, and the correct fragment of 130 bp was observed but not a 
restricted band of 118 bp (Figure 4.34).  It is possible that there was an overlapping band 
of the two fragments as they are close in size. 
 
A cDNA product at 320 bp indicated CYP2U1mRNA was found in both the normal breast 
and breast cancer cells (Figure 4.35).  CYP2U1 was expressed in the breast cancer cell 
lines (except in the ZR-75-30 cells) at higher levels than in the normal breast MCF10A 
cells.  Expression of CYP2U1 mRNA in the ZR-75-1 cells was confirmed by restriction 
digestion HaeIII, and the correct fragments of 252 bp and 60 bp were detected (Figure 
4.36). 
 
CYP4X1 mRNA was detected in both the normal breast and breast cancer cell lines at the 
correct cDNA product size of 364 bp (Figure 4.37).  Very weak levels of CYP4X1 mRNA 
were observed in the MCF7, MDA-MB-157 and MDA-MB-231 ells.  High levels of 
expression were found in the normal breast MCF10A and the breast cancer MDA-MB-468 
and T47D cells.  Restriction digestion of CYP4X1 mRNA by the enzyme RsaI generated 
fragments (278 bp and 86 bp) of the correct size (Figure 4.38). 
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Figure 4.33: Visualisation of CYP2R1 RT-PCR. Lane 1: 1000 bp PCR markers, Lane 2: MCF10A,  
Lane 3: MCF7, Lane 4: MDA-MB-157, Lane 5: MDA-MB-231, Lane 6: MDA-MB-468, Lane 7: T47D, Lane 
8: ZR-75-1, Lane 9: ZR-75-30, Lane 10: negative control. 
Figure 4.35: Visualisation of CYP2U1 RT-PCR. Lane 1: 1000 bp PCR markers, Lane 2: MCF10A,  
Lane 3: MCF7, Lane 4: MDA-MB-157, Lane 5: MDA-MB-231, Lane 6: MDA-MB-468, Lane 7: T47D, Lane 
8: ZR-75-1, Lane 9: ZR-75-30, Lane 10: negative control. 
 
Figure 4.34: Restriction digestion of CYP2R1 RT-PCR with HaeIII.  Lane 1: 1000 bp PCR markers, 
Lane 2: undigested product, Lane 3: digested product. 
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Figure 4.36: Restriction digestion of CYP2U1 RT-PCR with HaeIII.  Lane 1: 1000 bp PCR markers, 
Lane 2: undigested product, Lane 3: digested product. 
 
Figure 4.37: Visualisation of CYP4X1 RT-PCR. Lane 1: 1000 bp PCR markers, Lane 2: MCF10A,  
Lane 3: MCF7, Lane 4: MDA-MB-157, Lane 5: MDA-MB-231, Lane 6: MDA-MB-468, Lane 7: T47D, 
Lane 8: ZR-75-1, Lane 9: ZR-75-30, Lane 10: negative control. 
Figure 4.38: Restriction digestion of CYP4X1 RT-PCR with RsaI.  Lane 1: 1000 bp PCR markers, Lane 
2: undigested product, Lane 3: digested product. 
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RAR mRNA was detected in both the normal breast and breast cancer cell lines at the 
expected cDNA product size of 756 bp (Figure 4.39).  Higher levels of RAR mRNA were 
observed in the T47D, ZR-75-1, MDA-MB-157 and MDA-MB-468 cells than in the 
MCF10A, MCF7, ZR-75-30 and MDA-MB-231 cells.  To confirm the RAR mRNA 
expression, the PCR product was digested with restriction enzyme HaeIII and the correct 
fragments were found at 456 bp, 193 bp and 107 bp (Figure 4.40). 
 
A band of 521 bp corresponding to the cDNA product size for RXR mRNA was found in 
both the normal breast and breast cancer cell lines.  The highest expression was detected in 
the ZR-75-1 cells, and RXR mRNA was detected at weak to moderate levels in the 
MCF10A, T47D and MDA-MB-157 cells.  Very low mRNA levels were detected in the 
MCF7, ZR-75-30 MDA-MB-231 and MDA-MB-468 cells (Figure 4.41).  To confirm the 
RXR mRNA expression, the PCR product was digested with restriction enzyme BamHI 
and the correct fragments were found at 280 bp, 153 bp and 88 bp (Figure 4.42). 
 
 
 
 
 
 
 
Figure 4.39: Visualisation of RAR RT-PCR. Lane 1: 1000 bp PCR markers, Lane 2: MCF10A, Lane 3: ZR-
75-30, Lane 4: ZR-75-1, Lane 5: T47D, Lane 6: MCF7, Lane 7: MDA-MB-468, Lane 8: MDA-MB-231, Lane 
9: MDA-MB-157, Lane 10: negative control.  
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Figure 4.41: RXR RT-PCR.  Lane 1: 1000 bp PCR markers, Lane 2: negative control, Lane 3: 
MCF10A, Lane 4: MCF7, Lane 5: T47D, Lane 6: ZR-75-1, Lane 7: ZR-75-30, Lane 8: MDA-MB-231, 
Lane 9: MDA-MB-157, Lane 10: MDA-MB-468.   
Figure 4.42: Restriction digestion of RXR RT-PCR using BamHI.  Lane 1: 1000 bp PCR markers, Lane 2: 
undigested product, Lane 3: digested product. 
 
Figure 4.40: Restriction digestion of RAR RT-PCR with HaeIII.  Lane 1: 1000 bp PCR markers,  
Lane 2: undigested product, Lane 3: digested product. 
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4.4 Discussion 
Results presented in this chapter provide a comprehensive profile of cytochrome P450 
mRNA expression in a series of seven breast cancer cell lines as compared with the 
expression profile in a normal breast cell line using RT-PCR.  Cytochrome P450-
regulatory nuclear receptors were also investigated to explore the relationship between 
expression of cytochrome P450 mRNA and corresponding receptors.  In research presented 
here, the qualitative comparative analysis of target gene expression between human normal 
breast and breast cancer cell lines was determined.  The expression of CYP1A1, CYP1B1, 
CYP2C18, CYP2D6, CYP2R1, CYP2U1, CYP4X1, CYP4Z1 CYP24A1 and CYP26B1 
mRNA was detected in both the normal breast and individual breast cancer cell lines.  
CYP3A7 mRNA was expressed only in the normal breast cell line, while CYP2A6, 
CYP2B6, CYP2C8, CYP2F1, CYP2J2, CYP2S1 and CYP26A1 mRNA were found only 
in individual breast cancer cell lines.  The findings demonstrate differential mRNA 
expression of individual cytochrome P450s between normal breast and breast cancer cells, 
and some cell line-specific expression of individual cytochrome P450s.  The findings 
showed seven out of the ten cytochrome P450 corresponding receptors (i.e. HIF-1α, AhR, 
ARNT, AhRR, VDR, RAR and RXR) were expressed in both the normal breast and breast 
cancer cells while the expression of CAR, PXR and ER mRNA was detected only in 
individual breast cancer cell lines (Table 4.1). 
 
The relationship between candidate mRNA profile and breast cancer cell lines from 
different ethnic groups (i.e. Caucasian and Afro-Caribbean) with oestrogen status (i.e. ER-
positive and ER-negative) was also explored.  CYP1B1, CYP2D6, CYP2J2, CYP2R1, 
CYP2U1, CYP4X1 and CYP26A1 mRNA were found in all cell lines.  The expression of 
CYP1A1, CYP2S1, CYP24A1 and CYP26B1 mRNA was not detected in the ER-positive 
Afro-Caribbean breast cancer cell line (ZR-75-30) and no CYP2B6 expression was 
observed in the ER-negative Caucasian breast cancer cell line (MDA-MB-231).  CYP2A6 
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(T47D, ZR-75-1 and MDA-MB-157), CYP2C8 (MCF7, ZR-75-1 and MDA-MB-157), 
CYP2C18 (MCF7, T47D, MDA-MB-468 and MDA-MB-157), CYP2F1 (ZR-75-1 and 
MDA-MB-468) and CYP4Z1 (T47D, ZR-75-1 and MDA-MB-468) mRNA were expressed 
in the ER-positive Caucasian and ER-negative Afro-Caribbean breast cancer cell lines.  
Although no differences in cytochrome P450 mRNA expression were observed between 
the different ethnic groups, these preliminary results suggest potential similarities in the 
ER-positive Caucasian and ER-negative Afro-Caribbean breast cancer cells which warrant 
further investigation. 
 
In addition to comparing cytochrome P450 expression with ethnicity (i.e. Caucasian and 
Afro-Caribbean) and ER status, the relationship between ethnic difference and invasive 
phenotype was also examined.  CYP1B1, CYP2D6, CYP2J2, CYP2S1, CYP2R1, 
CYP2U1, CYP4X1 mRNA were found in all cell lines.  CYP1A1, CYP2A6, CYP2C8 and 
CYP24A1 mRNA were not detected in the non-invasive Afro-Caribbean breast cancer cell 
lines.  CYP26A1 mRNA was below the levels of detectability in only the normal breast 
MCF10A and ZR-75-1 ER-positive breast cancer cell lines.  CYP26B1 mRNA was below 
limits of detectability only in the ER-positive ZR-75-30 breast cancer cell line.  No 
cytochrome P450 mRNA was specific for the invasive phenotype, but the expression of 
CYP4Z1 mRNA appears to be specific for the non-invasive phenotype.  CYP2F1 was 
observed in only two out of the eight cell lines both of the non invasive phenotype.  No 
CYP2B6 or CYP2C18 expression was observed in the invasive Caucasian breast cancer 
cells.  Although of a preliminary nature these results suggest an inverse relationship of 
cytochrome P450 expression (i.e. CYP2A6 and CYP2C8 mRNA) between ethnic group 
and invasive phenotype, particularly the non-invasive Caucasian and invasive Afro-
Caribbean breast cancer cell lines.  These preliminary findings warrant further 
investigation potentially in relation to patient samples. 
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Table 4.1: The presence of cytochrome P450 and cytochrome P450-regulatory nuclear receptor mRNA in 
breast cancer cell lines compared to the normal breast cell line. 
 
ER status ER-positive ER-negative 
Ethnicity Cau Cau Cau Cau Afro Cau Afro Afro 
Invasive 
phenotype 
NBC Non-inv Non-inv Non-inv Non-inv Inv Inv Non-inv 
Cell lines MC10A MCF7 T47D ZR-75-1 ZR-75-30 MDA-MB-
231 
MDA-MB-
157 
MDA-MB-
468 
Cytochrome P450 mRNA 
CYP1A1* + + + + - + + - 
CYP 1A2 NS NS NS NS NS NS NS NS 
CYP1B1 + + + + + + + + 
CYP2A6 - - + + - - + - 
CYP2B6 - - + + + - + + 
CYP2C8 - + - + - - + - 
CYP2C18 + + + - - - + + 
CYP2C9 - - - - - - - - 
CYP2C19 - - - - - - - - 
CYP2D6* + + + + + + + + 
CYP2F1* - - - + - - - + 
CYP2J2* + + + + + + + + 
CYP2R1* + + + + + + + + 
CYP2S1 - + + + - + + + 
CYP2U1* + + + + + + + + 
CYP3A4* - - - - - - - - 
CYP3A5* - - - - - - - - 
CYP3A43 - - - - - - - - 
CYP3A7 + - - - - - - - 
CYP4X1* + + + + + + + + 
CYP4Z1 + - + + - - - + 
CYP24A1 + + + + - + + - 
CYP26A1 - + + - + + + + 
CYP26B1 + + + + - + + + 
Cytochrome P450-regulatory nuclear receptor mRNA 
HIF-1α + + + + + + + + 
AhR + + + + + + + + 
ARNT + + + + + + + + 
AhRR + + + - + + + + 
CAR* - + + + + + + + 
PXR* - + + + - - + - 
VDR + + + + - + + - 
ER - + + + + - + + 
RAR* + + + + + + + + 
RXR* + + + + + + + + 
 
Note: Blue and yellow labelled indicate the detected and undetected mRNA in all cell lines respectively.  
Abbreviations: ER; oestrogen receptor, Cau; Caucasian, Afro; Afro-Caribbean, NS; non-specific product, *; published primers, NBC; 
normal breast cell line, Inv; invasive phenotype
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The CYP1 family comprises three enzymes, CYP1A1, CYP1A2 and CYP1B1, and they 
are involved in the metabolism of oestrogen as well as procarcinogens (e.g. PAHs).  
Research conducted by several groups, with both tissues and cell lines, suggests an 
association between the roles of these enzymes in oestrogen metabolism and breast 
carcinogenesis (Singh et al. 2005, Tsuchiya et al. 2005, Cavalieri et al. 2006, Fernandez et 
al. 2006, Yager and Davidson 2006).   
 
The expression of CYP1A1 mRNA has been detected in normal breast tissue (Huang et al. 
1996, Hellmold et al. 1998, Iscan et al. 2001, Modugno et al. 2003) and breast tumours 
(Huang et al. 1996, Iscan et al. 2001, Modugno et al. 2003).  Hellmold and co-workers 
showed CYP1A1 protein to be present in (5/15) normal breast (Hellmold et al. 1998).  El-
Rayes and colleagues reported that CYP1A1 protein was significantly higher (P < 0.05) in 
normal adjacent breast tissues than in breast tumours by immunoblotting (El-Rayes et al. 
2003).  However, these findings are in disagreement with those of Albin and colleagues 
who did not detect CYP1A1 protein in breast tumours and normal adjacent breast tissues 
using the same method (Albin et al. 1993).   
 
In the present study, CYP1A1 mRNA was found in the normal breast MCF10A cells 
which is in agreement with previous studies (Spink et al. 1998, Thomas et al. 2006).  The 
expression of CYP1A1 mRNA was detected in all breast cancer cell lines except for the 
ER-positive Afro-Caribbean ZR-75-30 and ER-negative Afro-Caribbean MDA-MB-468 
breast cancer cells.  The finding that CYP1A1 mRNA is present in the MCF7, ZR-75-1, 
T47D and MDA-MB-231 cells correlates well with results from a study by Spink and 
colleagues who investigated CYP1A1 mRNA using Northern hybridisation (Spink et al. 
1998).  The present investigation also found CYP1A1 mRNA in the MDA-MB-157 cells, 
though this was not detected in the previous study (Spink et al. 1998).  The lack of 
CYP1A1 expression in the MDA-MB-468 cells is in agreement with an earlier 
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investigation (Wang et al. 1997).  However, the expression of CYP1A1 mRNA in the ZR-
75-30 cells has not been previously reported.  In addition, McFadyen and co-workers 
reported that that the MCF7 cells express CYP1A1 mRNA but did not express the protein 
(McFadyen et al. 2003).  These observations suggest that CYP1A1 protein expression in 
these cell lines warrants further investigation to clarify the functional significance of the 
CYP1A1 expression. 
 
The association between the CYP1A1 polymorphisms and cancer susceptibility, lung 
cancer in particular, have been demonstrated to be dependent upon ethnicity of population.  
However, investigation into a possible relationship between the CYP1A1 alleles and breast 
cancer risk has generated inconsistent results and this remains unclear (Masson et al. 
2005).  Preliminary findings from the present study suggest that CYP1A1 is expressed in 
the majority of cell lines apart from Afro-Caribbean cell lines of the non-invasive 
phenotype. 
 
Several breast cancer research groups have demonstrated the expression of CYP1B1 
mRNA in normal breast (Huang et al. 1996, Hellmold et al. 1998, Iscan et al. 2001) and 
breast tumour tissues (Huang et al. 1996, Iscan et al. 2001).  A higher level of CYP1B1 
mRNA was found in breast tumours than in normal breast tissue (Modugno et al. 2003).  In 
addition, previous studies demonstrated that CYP1B1 protein was overexpressed in breast 
tumour samples and undetectable in normal breast tissue (Murray et al. 1997, McFadyen et 
al. 1999).  On this basis, tumour-specific CYP1B1 expression appears to be a potential 
target for the development of new anticancer treatments and a CYP1B1 inhibitor and 
CYP1B1 vaccine are currently in clinical trials (Section 1.8).  In this research, CYP1B1 
mRNA was detected in the normal breast MCF10A cells and the seven breast cancer cell 
lines.  No difference in CYP1B1 mRNA expression was observed between the different 
ER status, ethnic groups or invasive phenotype.  However, it is essential to confirm 
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CYP1B1 protein expression in these cell lines before it can be verified as a target for the 
development of new anticancer drugs. 
 
The CYP1A1 and CYP1B1 genes are regulated by the aryl hydrocarbon receptor (AhR) 
and induced by AhR agonists such as TCDD and benzo(a)pyrene (Iwanari et al. 2002).  
The AhR belongs to the basic helix-loop-helix/Per-ARNT-Sim (bHLH-PAS) family which 
consists of the AhR dimerisation partners such as AhR nuclear translocator (ARNT), 
hypoxia inducible factor-1 alpha (HIF-1α) (Semenza 2000) and AhR repressor (AhRR) 
(Tsuchiya et al. 2003).  These findings suggest that the AhR-mediated pathway may 
interact with other nuclear receptor signalling pathways which are associated with the 
expression of CYP1A1 and CYP1B1. 
 
It is well known that CYP1A1 and CYP1B1 are involved in oestrogen metabolism and 
Angus and colleagues demonstrated that oestradiol can also induce the transcriptional 
expression of CYP1A1 and CYP1B1 (Angus et al. 1999).  The induction of CYP1B1 by 
oestradiol has been demonstrated in breast cancer oestrogen-dependent (i.e. MCF7) and 
oestrogen-independent (i.e. MDA-MB-435) cells.  An increased CYP1B1 mRNA level 
was found in the MCF7 cells but not in the MDA-MB-435 cells, indicating that the 
induction of CYP1B1 by oestradiol may be transcriptionally regulated by oestrogen 
receptor as previously demonstrated (Tsuchiya et al. 2004, Tsuchiya et al. 2005).  In 
addition, Beischlag and colleagues (Beischlag and Perdew 2005) demonstrated that AhR 
agonist TCDD can increase the expression of CYP1A1 and that it activates inhibitory 
crosstalk between ER and the AhR-ARNT complex.   
 
In the current project, expression of AhR, ARNT and HIF-1α mRNA was found in all the 
test cells, which is similar to CYP1B1 mRNA but not CYP1A1 mRNA expression.  Allan 
and co-workers found that decreased CYP1A1 expression under hypoxic conditions.  
 Profile P450s in breast cancer cell lines 
 170 
These findings may have been caused by competition for dimerisation with ARNT, leading 
to inhibition of target genes of AhR (i.e. CYP1A1), as dimerisation of AhR/ARNT and 
HIF-1α/ARNT is required for transcription initiation in their target genes including 
CYP1A1 and CYP1B1 (Allen et al. 2005).  These cell lines could be useful models to 
clarify their relationship in breast cancer cells. 
 
Previous studies have failed to detect CYP1A2 mRNA expression in normal human breast 
or breast tumour tissues (Hellmold et al. 1998, Modugno et al. 2003).  However, a recent 
study using immunohistochemistry detected CYP1A2 protein expression in 51 out of the 
393 breast tumours tested (Haas et al. 2006).  Although multiple bands were observed in 
the present study, no specific product at the correct size was identified for CYP1A2 mRNA 
in either the normal breast or breast cancer cell lines.  The lack of CYP1A2 mRNA 
expression in the normal breast MCF10A cell line is in agreement with the recent study by 
Thomas and colleagues (Thomas et al. 2006).  The lack of CYP1A2 mRNA expression is 
surprising as CYP1A2 is involved in the metabolism of oestradiol (Tsuchiya et al. 2005, 
Yager and Davidson 2006) and the catalysis of a wide range of procarcinogens e.g. 
heterocyclic amines, nitrosamine, aflatoxin B1 and arylamine (Kim and Guengerich 2005).  
It should be noted that CYP1A2 mainly catalyses flutamide (a nonsteroidal antiandrogenic 
anticancer drug) which is commonly used for prostate cancer treatment (Goda et al. 2006). 
 
CYP2A6 mRNA expression was detected in (10/15) normal breast tissues (Hellmold et al. 
1998) whereas Iscan and co-workers reported no mRNA expression of CYP2A6 in normal 
breast tissues or breast tumour tissues (Iscan et al. 2001).  Using real-time quantitative RT-
PCR analysis, Bieche and colleagues (Bièche et al. 2004) demonstrated that the CYP2A6 
mRNA level in ER-positive breast tumours is higher than in either ER-negative breast 
tumours or normal breast tissue.  As was observed in present investigation, the expression 
level of CYP2A6 was higher in the breast cancer ER-positive Caucasian ZR-75-1 and 
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T47D than in the ER-negative Afro-Caribbean MDA-MB-157.  However, it is important to 
note that CYP2A6 expression was not observed in the invasive Caucasian MDA-MB-231 
or the non-invasive Afro-Caribbean MDA-MB-468 breast cancer cells.  No CYP2A6 
mRNA was found in the normal breast MCF10A cells either, which correlates well with 
results from a study by Thomas and colleagues (Thomas et al. 2006).   
 
The importance of CYP2A6 in the metabolism of anticancer drugs (i.e. letrozole) and 
procarcinogens (i.e. nitrosamine and food mutagens) has been emphasised, and it has been 
reported that this cytochrome P450 enzyme may play a role in the development of breast 
cancer (von Weymarn et al. 2006).  CYP2A6 metabolises a third-generation aromatase 
inhibitor, letrozole, which is superior to tamoxifen for first-line treatment in breast cancer 
(Simpson et al. 2004).  Therefore, the findings in the present study suggest that expression 
of CYP2A6 mRNA in the opposite oestrogen receptor status/invasive phenotype of 
Caucasian and Afro-Caribbean breast cancer cell lines could be of benefit in the design of 
more effective drug regimens in cancer patients.   
 
The expression of CYP2B6 mRNA was found in (12/14) breast tumours and (13/14) 
normal breast tissues (Iscan et al. 2001), and Hellmond and co-workers detected CYP2B6 
mRNA expression in (9/15) normal breast tissues (Hellmold et al. 1998).  In the present 
study, CYP2B6 mRNA was observed in five out of the seven breast cancer cell lines but 
not in the normal breast MCF10A cells.  The lack of CYP2B6 mRNA expression in the 
MCF7 and MCF10A cells is in agreement with the studies of Soulez and Parker (Soulez 
and Parker 2001), and Thomas and colleagues (Thomas et al. 2006) respectively.  The 
presence of CYP2B6 mRNA in the ZR-75-1 cells is in agreement with the research of 
Soulez and Parker (Soulez and Parker 2001).  The absence of CYP2B6 mRNA in the 
MDA-MB-231 cells, classified as invasive and ER-negative Caucasian breast cancer cells, 
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is important to note as CYP2B6 converts the prodrug cyclophosphamide to an active 
phospharamide mustard and acrolein (Zanger et al. 2007).   
 
Targeting drugs at CYP2B6 is an attractive concept for cancer research as this would lead 
to local activation of the prodrug and higher concentrations of the active metabolites at the 
tumour site.  MetXia is a recombinant retroviral vector encoding human CYP2B6 which is 
designed to activate cyclophosphamide.  MetXia is currently in Phase I trial and being 
investigated in advanced breast cancer patients (Braybrooke et al. 2005).   
 
The CYP2B6 gene is regulated by CAR (Honkakoski and Negishi 2000) and a positive 
correlation between CYP2B6 and CAR mRNA expression has been demonstrated in 
human liver (Chang et al. 2003).  A study by Lamba and colleagues showed that ethnic and 
gender differences influence the expression of CYP2B6 and CAR (Lamba et al. 2003).  
The expression level of CYP2B6 mRNA was significantly higher in females than in males 
(p<0.001) and CYP2B6 activity in Hispanic females higher than in Caucasian (p<0.022) or 
African-American (p<0.038) females.  These findings can be related to female hormones 
including oestrogen.  However, Min and colleagues (Min et al. 2002) demonstrated 
inhibitory crosstalk between ER and CAR in human hepatoma HepG2 cell line and that 
CAR inhibits ER-mediated transactivation of endogenous and exogenous oestrogen.  
Recent research by the same group found that ER-mediated transactivation can be 
regulated by CAR which is dependent on the oestrogen response elements (EREs) and 
oestrogen receptor status of target cells (Min 2006).   
 
In research presented here, a direct correlation between CYP2B6 and CAR mRNA was 
observed in the ER-positive Caucasian T47D and the ER-negative Afro-Caribbean MDA-
MB-157 and MDA-MB-468 breast cancer cells.  Further investigation of the expression of 
CYP2B6 protein in these cell lines is warranted prior to determination in clinical samples. 
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The expected product size of CAR is 232 bp following nested PCR, but multiple bands are 
seen in lanes 5, 7, 8 and 10 (Figure 4.25).  The presence of non-specific products may be 
due to too much template (first round PCR product) and/or insufficient primer.  This 
problem can be resolved by diluting the concentration of template.  However, during the 
validation of CAR in this research, the PCR product was confirmed by restriction digestion 
and the expected products were clearly seen (Figure 3.36). 
 
There are four members of the CYP2C subfamily CYP2C8, CYP2C9, CYP2C18 and 
CYP2C19.  They are highly homologous genes and are clinically relevant in anticancer 
drug treatments.  In cancer chemotherapy, CYP2C8 catalyses the metabolism of paclitaxel 
(Taniguchi et al. 2005) whereas CYP2C9 and CYP2C19 catalyse the bioactivation of 
cyclophophamide and ifosfamide (Goldstein 2001, Schmidt et al. 2004) as well as the 
metabolism of tamoxifen.  CYP2C18 is involved in the activation of ifosfamide (Zhu-Ge 
and Yu 2004).  Modugno and colleagues reported that the expression of CYP2C mRNA 
was not detected in normal breast tissues or breast tumours (Modugno et al. 2003).  In 
contrast, previous studies showed that CYP2C mRNA expression was found in normal 
breast as well as breast tumour tissues (Huang et al. 1996, Iscan et al. 2001).  In addition, 
CYP2C protein was expressed in normal breast tissues (Hellmold et al. 1998).  These 
findings disagreed with those of Albin and colleagues who did not detect CYP2C in 
normal breast or breast tumours (Albin et al. 1993).  All four CYP2C isoforms were 
investigated in the current study.  Unfortunately, no CYP2C9 or CYP2C19 mRNA was 
detected in the eight cell lines, while the expression of CYP2C8 and CYP2C18 mRNA was 
detected in the ER-positive Caucasian and ER-negative Afro-Caribbean breast cancer cell 
lines.  These preliminary findings suggest potential ethnic differences in the relationship 
between the expression of CYP2C8/18 mRNA and ER status should be taken into 
consideration in the development of novel cancer therapeutics.  CYP2C18 mRNA 
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expression was also observed in the normal breast MCF10A cells, a result which differs 
from the finding of Thomas and colleagues (Thomas et al. 2006).   
 
CYP2D6 catalyses the N-demesthylation and 4-hydroxylation of tamoxifen which have 
potent antioestrogen effects.  Tamoxifen is widely used in the treatment of breast cancer 
(Coller et al. 2002).  Previous studies demonstrated that CYP2D6 mRNA was expressed in 
normal breast as well as breast tumour samples (Huang et al. 1996, Hellmold et al. 1998, 
Iscan et al. 2001, Bièche et al. 2007).  In addition, Hellmond and colleagues demonstrated 
CYP2D6 protein expression in normal breast (Hellmold et al. 1998).  These findings are in 
disagreement with those of Modugno and co-workers, who did not detect CYP2D6 mRNA 
expression in breast tumour and normal adjacent breast tissue using quantitative RT-PCR 
(Modugno et al. 2003).  The present study is the first to examine the expression of 
CYP2D6 mRNA in breast cancer cell lines.  An initial experiment using the primer 
sequence designed for CYP2D6 by Primer3 (Table 2.6) failed to detect CYP2D6 mRNA in 
the test cell lines.  However, the previously published CYP2D6 primer set (Table 2.7) was 
employed to confirm the expression of CYP2D6 mRNA and this primer set successfully 
demonstrates a cDNA product of CYP2D6 mRNA in the eight cell lines.   
 
In the preliminary work, CYP2D6 mRNA was detected in all four ER-positive breast 
cancer MCF7, T47D, ZR-75-1 and ZR-75-30 cells, suggesting that a local tamoxifen 
metabolism mediated by CYP2D6 in these cells may be of particular interest in the 
development of hormonal therapy for breast cancer.  It is known that approximately 35% 
of ER-positive breast cancer patients do not respond to tamoxifen therapy and some 
patients who do respond to tamoxifen eventually become resistant to this treatment 
(Osborne 1998, Jin et al. 2005). 
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In addition, preliminary results showed that the presence of CYP2D6 mRNA is detected 
with the appearance of smearing bands in the two Afro-Caribbean breast cancer cells lines 
MDA-MB-468 and ZR-75-30 (Figure 4.27, lanes 2 and 9).  This is likely to be related to 
the presence of a splice variant of this gene as currently more than eighty alleles have been 
identified for the CYP2D6 gene.  Variant alleles of the CYP2D6 gene may lead to 
increased, decreased or absent functionality of the CYP2D6 gene (Klein et al. 2007).  The 
activity of CYP2D6 is extremely variable, and inter-ethnic variations in drug metabolisms 
are well recognised.  Poor metabolisers (PMs) lacking CYP2D6 activity have been found 
in 7% of Caucasians and 1-3% of other ethnic groups, whereas ultra-rapid metabolisers 
(UMs) displaying unusually high activity of CYP2D6 have been observed in 29% of 
people from North Africa and the Middle East (de Leon et al. 2006a).  Unfortunately, 
information on the specific country of origin of the breast cancer cells used in the current 
study is not available.  However, these findings suggest that the breast cancer cell line 
models may be of particular relevance in the development of cancer therapy for Afro-
Caribbean breast cancer patients.   
 
Unlike the MDA-MB-468 and ZR-75-30 cells, CYP2D6 mRNA was observed with 
smearing in the normal breast MCF10A cells derived from a Caucasian woman.  This data 
is in agreement with the original study (Thomas et al. 2006) using the same primers but 
Thomas and co-workers detected a fainter expression.  This difference may be due to the 
use of an annealing temperature and concentration of MgCl2.  The current project used a 
lower annealing temperature (55oC) and 1.5 mM MgCl2 whereas Thomas and co-workers 
employed an annealing temperature at 60oC and 5 mM MgCl2.   
 
CYP2F1 is predominantly expressed in human lung, with low level or no expression being 
detected in the liver or other extrahepatic tissues (Carr et al. 2003, Tournel et al. 2007a).  
CYP2F1 is involved in the activation of some pneumotoxicants including naphthalene and 
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3-methylindole (Kartha and Yost 2008).  The current project is the first to examine 
expression of CYP2F1 mRNA in a series of breast cancer cell lines.  No CYP2F1 mRNA 
was observed in the normal breast MCF10A cells whereas the original study demonstrated 
weak expression of CYP2F1 in sub-confluent but not confluent MCF10A cells (Thomas et 
al. 2006).  This finding is in disagreement with preliminary work from the present 
investigation (see discussion in following section; CYP2S1).   
 
CYP2F1 was detected only in the ER-positive Caucasian ZR-75-1 cells and the ER-
negative Afro-Caribbean MDA-MB-468 cells.  Recently, Tournel and colleagues (Tournel 
et al. 2007b) demonstrated inter-ethnic variations in CYP2F1 genetic polymorphism, and 
results from their studies suggest that a higher frequency of poor metabolisers occur in 
Afro-Caribbean populations (i.e. Gabonese and Senegalese) compared to French 
Caucasians and Tunisians.  Although this association was derived from healthy volunteers, 
it may be of interest to assess inter-ethnic variation in cancer patients including those with 
breast cancer.   
 
CYP2J2 is expressed in various normal tissues (i.e. liver, small intestine, colon and kidney) 
but higher levels occur in the coronary endothelial cells and cardiac myocytes (Wu et al. 
1996).  CYP2J2 is involved in the metabolism of arachidonic acids to form 
epoxyeicosatrienoic acids (EETs) which are which are potent endogenous vasodilators and 
inhibitors of vascular inflammation (Node et al. 1999, Scarborough et al. 1999).  The 
physiological function of CYP2J2 in xenobiotic metabolism remains unknown.   
 
Preliminary work showed high expression of CYP2J2 mRNA in all breast cancer cell lines 
but at a very low level in the invasive Caucasian breast cancer MDA-MB-231 cells.  Weak 
expression of CYP2J2 mRNA was detected in the normal breast MCF10A cells which is in 
agreement with the original investigation (Thomas et al. 2006) using this primer set.  
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CYP2J2 mRNA in breast cancer cell lines has not been previously reported, but Jiang and 
co-workers detected higher levels of CYP2J2 mRNA and protein in breast cancer than in 
their corresponding normal tissues (Jiang et al. 2005).  These findings suggest that CYP2J2 
mRNA is specifically expressed in breast cancer cells and may be involved in breast 
carcinogenesis.  It is important to further investigate the function of CYP2J2 in these cell 
lines prior to using them as models in breast cancer research.  
 
Many research groups reported the expression of CYP2S1 mRNA and protein in several 
extrahepatic tissues (Choudhary et al. 2005, Karlgren et al. 2005, Saarikoski et al. 2005, 
Rivera et al. 2007), but it has not been previously reported in normal breast tissues or 
breast tumour samples.  One previous study has demonstrated CYP2S1 mRNA in sub-
confluent normal breast MCF10A cells but not in confluent cultures (Thomas et al. 2006), 
and this finding is in disagreement with the present study.  The MCF10A cells used in this 
project were grown under the same conditions as the previous study (Thomas et al. 2006), 
and approximately 70-80% confluent MCF10A culture was employed to determine 
CYP2S1 mRNA.  The observed differences in CYP2S1 mRNA expression in MCF10A 
between the two research groups could be attributable to differences in PCR conditions 
(i.e. RNA isolation method, primer sequences and MgCl2 concentration) and primer 
sequences used.  The present study is the first to report expression of CYP2S1 mRNA in a 
series of breast cancer cell lines, and it was detected in all cancer cell lines except for the 
ER-positive Afro-Caribbean ZR-75-30 cells. 
 
CYP2S1 has several characteristics similar to members of the CYP1 family (i.e. CYP1A1 
and CYP1B1).  A recent study has reported that induction of CYP2S1 mRNA by dioxin 
and hypoxia is mediated by AhR/ARNT and HIF-1α/ARNT complex pathway respectively 
(Rivera et al. 2007).  In addition, CYP2S1 is known to be induced by retinoic acid (Smith 
et al. 2003), naphthalene (Karlgren et al. 2005) and PAHs (Rivera et al. 2002).  There is no 
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information available on crosstalk between these receptors and CYP2S1 expression in 
breast cancer cells.  However, the current study demonstrated the presence of AhR, ARNT, 
HIF-1α mRNA in all the test cell lines and this could facilitate a better understanding of 
the role of CYP2S1 in cancer development and cancer treatment, following confirmation 
of CYP2S1 protein expression in these cell lines. 
 
Previous studies demonstrated that CYP2S1 protein was associated with poor prognosis of 
colorectal tumours (Kumarakulasingham et al. 2005), and an increased expression of 
CYP2S1 protein was found in metastasis disease compared with primary ovarian cancer 
(Downie et al. 2005).  In the present study, CYP2S1 mRNA was detected in the ER-
positive/negative and the non-invasive/invasive phenotype. 
 
When detecting CYP2S1 by RT-PCR, a faint band was observed above 216 bp in lane 5 
(Figure 4.10).  The presence of this non-specific amplification product may have been 
caused by excessive template cDNA.  Importantly though, the expected product size of 216 
bp representing CYP2S1 mRNA was seen as a clear band, and this was confirmed by 
restriction digest (Figure 3.18) and DNA sequencing (Figure D.1) during the validation 
step in this study. 
 
Another novel exptrahepatic cytochrome P450, CYP2U1, is highly expressed in human 
thymus and brain (Karlgen et al. 2004).  Chuang and colleagues demonstrated that 
CYP2U1 plays a role in the metabolism of arachidonic acid and other long chain fatty 
acids (Chuang et al. 2004).  CYP2U1 converts arachidonic acid into 19- and 20-
hydroxyeicosatetraenoic acids (HETEs).  The 20-HETE is potent vasoconstrictor in the 
cerebral circulation, and this indicates that CYP2U1 may control the brain blood flow 
(Karlgren et al. 2005).  In addition, an association between the expression of CYP2U1 and 
tumour tissues has been shown by two studies and the findings suggest the same trend.  
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Currently, the role of CYP2U1 in the metabolism of xenobiotic compounds remains 
unknown.  CYP2U1 protein in ovarian and colorectal tumours was higher than in normal 
ovary (Downie et al. 2005) and colon tissues (Kumarakulasingham et al. 2005) 
respectively.  This may indicate that CYP2U1 plays a role in the carcinogenic process in 
certain types of tumour.   
 
To date, CYP2U1 expression in breast cancer cells has not been demonstrated.  
Preliminary results from the current study showed that CYP2U1 mRNA was detected in 
both the normal breast and breast cancer cell lines.  CYP2U1 mRNA in the MCF10A cells 
confirmed the findings of a previous study (Thomas et al. 2006).  With the exception of the 
ZR-75-30 cells, this enzyme was expressed at a lower level in MCF10A than in breast 
cancer cell lines.  Preliminary results suggest that CYP2U1 mRNA in the breast cancer 
cells relative to the normal breast cells shows a similar trend in ovarian and colorectal 
cancer as mentioned above.  The breast cancer cell line models could potentially be 
exploited in the development of novel cancer therapeutics and CYP2U1 could be used as a 
prognostic biomarker for breast cancer.  This warrants further investigation. 
 
The human CYP3A subfamily comprises four enzymes, CYP3A4, CYP3A5, CYP3A7 and 
CYP3A43.  CYP3A4 plays an important role in the metabolism of steroid hormones (i.e. 
oestrogen and glucocorticoid) (Guengerich 1999) as well as xenobiotic compounds (i.e. 
paclitaxel, cyclophosphamide and doxorubicin) (McFadyen et al. 2004, Michael and 
Doherty 2005).  The CYP3A genes are induced by glucocorticoids, phenobarbital and 
vitamin D (Pascussi et al. 2003).  They are regulated by pregnane X receptor (PXR) which 
binds DNA as heterodimer with retinoid X receptor (RXR) and activates gene 
transcription.  However, Pascussi and colleagues report that CYP2B6, CYP2C8 and 
CYP2C9 are also regulated by PXR.  These observations suggest that the interaction 
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among PXR, CAR and VDR may occur after heterodimerisation with RXR as they share 
DNA response elements, partners and target genes (Pascussi et al. 2003). 
 
Many research groups have investigated the expression of CYP3A in breast tumour tissues, 
but their findings seem to be inconsistent.  For example, Iscan and colleagues found no 
CYP3A4 or CYP3A5 or CYP3A7 mRNA in normal breast or breast tumours (Iscan et al. 
2001), whereas Huang and co-workers reported that CYP3A4 or CYP3A5 mRNA was 
higher in non-tumour breast tissues than in breast tumour samples (Huang et al. 1996).  
Hellmond and colleagues demonstrated the presence of CYP3A mRNA in normal breast 
too but they did not detect CYP3A protein in these tissues (Hellmold et al. 1998).  These 
finding correlate well with those of Albin and co-workers who detected no CYP3A4 
protein in breast tumours or normal adjacent breast tissues (Albin et al. 1993).  Modugno 
and colleagues demonstrated CYP3A4 mRNA in normal breast as well as in breast tumour 
tissues, but they did not detect CYP3A5 mRNA in normal breast or breast tumour tissues 
(Modugno et al. 2003).  The CYP3A43 gene is the most recently discovered in the CYP3A 
subfamily (Domanski et al. 2001) and the expression of CYP3A43 in breast cells has not 
been previously reported.  
 
The present study failed to detect any members of the CYP3A subfamily in the panel of 
breast cancer cell lines.  The lack of CYP3A mRNA expression is surprising as the CYP3A 
enzymes are involved in the metabolism of oestradiol and the activation of procarcinogens 
(e.g. aflatoxin B1, PAHs and NNK), CYP3A4 in particular (Guengerich 1999).  However, 
a weak expression of CYP3A7 mRNA was found in the normal breast MCF10A cells, a 
finding which is in accordance with the results of  Thomas and co-workers who 
investigated CYP3A mRNA in the MCF10A cells (Thomas et al. 2006). 
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CYP3A7 is a human foetal liver P450 isoform which plays a role in the hydroxylation of 
retinoic acid and the 16α-hydroxylation of steroids, suggesting it may be relevant to 
human normal development and hormone dependent cancer (Daly 2006).  However, a 
previous study showed that a high level of mRNA expression was detected in well 
differentiated hepatocellular carcinoma (Tsunedomi et al. 2005) and its protein expression 
was found to be associated with primary ovarian cancer when compared to normal ovary 
tissues (Downie et al. 2005).   
 
Transcriptional expression of the CYP3A genes is regulated by PXR.  The induction of 
CYP3A4 by PXR has been shown to play a crucial role in endometrial cancer.  PXR 
ligands induce PXR expression, resulting in altered regulation of PXR target genes 
including CYP3A4 (Masuyama et al. 2003, Masuyama et al. 2005).  In addition, a recent 
report claimed that down-regulation of PXR in the presence of the anticancer drug 
paclitaxel increased the inhibition of cell growth and apoptosis, leading to a higher 
sensitivity to anticancer drugs and the overcoming of drug resistance in the treatment of 
endometrial cancer (Masuyama et al. 2007).  Although the present study did not detect 
CYP3A mRNA in the breast cancer cell lines used, it should be noted that PXR mRNA 
was found in the MCF7, T47D, ZR-75-1 and MDA-MB-157 cells.  These findings suggest 
that the regulation of CYP3A genes in breast cancer cells may be involved in other 
signalling pathways rather than the PXR signalling pathway. 
 
CYP24A1 (1,25-(OH)2D3-24-hydroxylase) is involved in the inactivation of vitamin D3 
and is regulated by vitamin D receptor (VDR).  Recently, overexpression of CYP24A1 
mRNA has been demonstrated in a variety of tumour tissues such as breast, prostate and 
lung (Cross et al. 2003).  In addition, CYP24A1 mRNA has been shown to be associated 
with poor prognosis of oesophageal cancer by Mimori and co-workers (Mimori et al. 
2004).  These findings suggested that CYP24A1 expression plays a role in the carcinogenic 
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process and that CYP24A1 is a candidate oncogene (Anderson et al. 2006).  Consequently, 
an inhibitor of CYP24A1 (EB1089) which has been demonstrated to have an 
antiproliferative effect on breast cancer has been developed and is currently in clinical 
trials (Sundaram et al. 2006). 
 
Using real-time quantitative RT-PCR analysis, Fisher and co-workers detected the 
expression of CYP24A1 wild-type and splice variants in the normal breast MCF10A and 
breast cancer MCF7 cells; though an association between splice variants and CYP24A1 
activity was not clearly established (Fisher et al. 2007).  The detection of CYP24A1 
mRNA in the MCF10A and MCF7 cells correlates well with results from the present study.  
CYP24A1 mRNA was detected in all the test cell lines except for the ER-positive ZR-75-
30 and ER-negative MDA-MB-468 Afro-Caribbean breast cancer cell lines.  It is important 
to note that ER status differences in CYP24A1 expression may be of particular relevance 
to the use of an inhibitor of CYP24A1 in breast cancer treatment.  Regarding qualitative 
comparison, a correlation between CYP24A1 and VDR mRNA was observed in this 
research.  The absence of CYP24A1 mRNA (Figure 4.16) agrees with the lack of VDR 
mRNA (Figure 4.23) in the ZR-75-30 and MDA-MB-468 cells. 
 
In addition to metabolism of vitamin D3 by cytochrome P450 enzymes, the conversion of 
the vitamin D3 precursor into the active metabolite 1,25-(OH)2D3 is mediated by CYP2R1 
and CYP27A1 which are predominantly expressed in human liver, and by CYP27B1 
which is mainly expressed in the kidney (Cheng et al. 2003).  Vitamin D3 is believed to 
exhibit potent anticancer properties as it inhibits proliferation and stimulates apoptosis of 
cells.  For this reason, enzymes involved in the activation and inactivation of vitamin D3 
are of particular relevance to cancer therapy.  To date no information on the physiological 
role of CYP2R1 in xenobiotic metabolism has been reported.  CYP2R1 mRNA is highly 
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expressed in human liver and testis but lower levels are found in other tissues (Karlgren et 
al. 2005).  
 
The preliminary work presented in this chapter is the first evidence of CYP2R1 mRNA 
expression in a panel of breast cancer cell lines compared with the normal breast cells.  
CYP2R1 mRNA in the normal breast MCF10A cells was also observed in this work and is 
in agreement with the original study (Thomas et al. 2006) using these primers.  CYP2R1 
mRNA was highly expressed in almost all breast cancer cell lines but lower levels were 
observed in the Afro-Caribbean breast cancer MDA-MB-468 and ZR-75-30 cells.  
Regarding the breast cancer cells derived from Caucasian patients, CYP2R1 mRNA seems 
to be expressed at similar levels both in ER-positive and ER-negative phenotype, 
suggesting that CYP2R1 may be of interest as a potential target for chemotherapy in either 
an oestrogen-independent or an oestrogen-dependent breast tumour once protein 
expression is confirmed in these cell lines. 
 
Members of the CYP26 family (i.e. CYP26A1 and CYP26B1) specifically catalyse the 4-
hydroxylation of all trans-retinoic acid (ATRA) (Sonneveld et al. 1998).  CYP26A1 is 
overexpressed in various tumours including breast tumours (Mira-Y-Lopez et al. 2000) and 
these findings have led to the use of a CYP26A1 inhibitor (R116010) in oestrogen-
independent mouse breast tumours (Njar 2002).  Previous studies demonstrated CYP26A1 
mRNA in ER-positive T47D (Sonneveld et al. 1998) and MCF7 (van Heusden et al. 1998, 
Mira-Y-Lopez et al. 2000) and these findings are in agreement with the present study.  The 
current study also detected CYP26A1 in all the cancer cell lines except the ZR-75-1 cells, 
suggesting that CYP26A1 may be specifically expressed in breast cancer cells and that the 
test cell lines could be used as models to investigate novel anticancer drugs.   
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Earlier studies have shown that CYP26B1 is predominantly expressed in human adult 
brain, particularly the cerebellum and cephalic tissues (White et al. 2000, Trofimova-
Griffin and Juchau 2002).  However, there is no information on CYP26B1 mRNA in 
normal breast or breast tumour tissues.  The current investigation is the first to screen a 
panel of breast cancer cell lines and a normal breast cell line for the presence of CYP26B1 
mRNA.  The presence of CYP26B1 mRNA was detected in the normal breast MCF10A 
cells and all breast cancer cell lines except the ZR-75-30 cells.  It is important to note that 
CYP26B1 mRNA expression was elevated in the normal breast and ER-negative breast 
cancer cells compared to the ER-positive breast cancer cell lines, suggesting that oestrogen 
may affect the expression of CYP26B1 mRNA.   
 
The CYP26 genes are regulated by nuclear receptor retinoic acid receptor (RAR) and 
retinoid X receptor (RXR) which bind to RA response elements and regulate transcription 
of target genes (Nezzar et al. 2007).  RXR is a common heterodimeric partner for several 
nuclear receptors (i.e. CAR, PXR, PPARα and VDR) and crosstalk between these 
receptors leads to unexpected expression of cytochrome P450 enzymes (Section 1.7.9).  In 
the present study, the expression of RAR and RXR mRNA was detected in both the normal 
breast and breast cancer cell lines; however, no correlation between RAR and RXR mRNA 
was observed regarding ER status, invasive phenotype or ethnicity.  These findings suggest 
that any applications of the inhibition of CYP24 or CYP26 in cancer therapy must consider 
a significant function of their corresponding nuclear receptors and possible crosstalk 
between nuclear receptors in the same superfamily. 
 
Transcriptional expression of some cytochrome P450 genes is regulated by their 
corresponding nuclear receptors (Section 1.7).  However, the existence of intracellular 
crosstalk between these receptors appears to have important consequences on cytochrome 
P450 gene regulation as the receptors share heterodimeric partner, ligands, DNA response 
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elements and target genes.  A study of coexpression of cytochrome P450s and their 
corresponding nuclear receptors in breast cancer cells may lead to a better understanding of 
how the event alters the cancer biology. 
 
CYP4X1 mRNA is widely expressed in several human tissues (i.e. breast, ovary, uterus, 
liver and kidney, trachea and aorta).  Savas and colleagues demonstrated that peroxisome 
proliferator activated receptor-alpha (PPARα) is involved in the activation of human 
CYP4X1, as investigated through used of human hepatoma HepG2 cells that stably express 
a mouse PPARα mutant.  A physiological role of CYP4X1 is currently unknown but the 
consistently high levels of CYP4X1 in the aorta and trachea may suggest that CYP4X1 
plays a role in the generation of arachidonic acid metabolites, compounds with vasoactive 
properties (Savas et al. 2005).  Preliminary results showed that CYP4X1 mRNA was 
expressed in both the normal breast and breast cancer cell lines.  The detection of CYP4X1 
mRNA in the normal breast MCF10A cells is in agreement with a previous study (Thomas 
et al. 2006) using these primers, but it is more likely to be overexpressed compared with 
those of Thomas and co-workers.  The expression of CYP4X1 mRNA has not been 
previously investigated in breast cancer cells.  CYP4X1 mRNA was expressed in the seven 
breast cancer cell lines but at very high levels in the ER-positive Caucasian breast cancer 
T47D and the ER-negative Afro-Caribbean breast cancer MDA-MB-468 cells.  This 
finding warrants further investigation. 
 
Using real-time quantitative RT-PCR, Savas and co-workers reported that CYP4Z1 mRNA 
was higher in normal breast tissue than other human normal tissues (Savas et al. 2005).  
The study of Rieger et al. (2004) demonstrated that CYP4Z1 mRNA was overexpressed in 
breast tumours compared with the corresponding normal breast tissue.  In addition, a 
previous study demonstrated CYP4Z1 in the normal breast MCF10A cells and this is in 
agreement with results from the present study (Thomas et al. 2006).  In breast cancer cell 
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lines, CYP4Z1 mRNA was detected in the MCF7 (Rieger et al. 2004, Savas et al. 2005) 
and T47D cells (Savas et al. 2005).  The detection of CYP4Z1 mRNA in the T47D cells is 
in agreement with results from the present study, though this is not the case for the MCF7 
cells.  This discrepancy may be attributable to the different conditions used for cell culture 
and the sensitivity of the RT-PCR method.  However, results from studies examination the 
expression of CYP4Z1 protein in breast cancer cells generally appear to be inconsistent.  
Rieger and colleagues detected CYP4Z1 protein in MCF7 cells (Rieger et al. 2004) but 
Savas and co-workers reported no CYP4Z1 protein expression in MCF7 (Savas et al. 
2005). 
 
The present study also demonstrated CYP4Z1 mRNA in the ZR-75-1 and MDA-MB-468 
cells and this has not been previously reported.  These findings suggest that CYP4Z1 
mRNA is more likely to be specifically expressed in the non-invasive phenotype of breast 
cancer cells.  A higher level of CYP4Z1 expression was observed in the ER-negative Afro-
Caribbean MDA-MB-468 breast cancer cell line than in the ER-positive Caucasian T47D 
and ZR-75-1 breast cancer cells and this warrants further investigation. 
 
Prior to further elucidation of the sequence, the present investigation confirmed the 
expression of CYP4Z1 mRNA in all the cDNA samples, using previously published 
primers (Thomas et al. 2006) that had been designed to cross between exon 9 and exon 12 
boundaries (Figures 4.14 and 4.15).  This primer set successfully demonstrates a single 
product of CYP4Z1 mRNA in the test cells.  The presence of CYP4Z1 mRNA in the 
normal breast MCF10A cells is in agreement with the original study (Thomas et al. 2006) 
using this primer set.  The presence of CYP4Z1 mRNA in the MCF10A, T47D, ZR-75-1 
and MDA-MB-468 cells using primers designed by Primer3 is also in agreement with the 
original study (Figure 4.13).  In addition, CYP4Z1 mRNA was observed with a faint band 
in the ZR-75-30 cells (Figure 4.14).   
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In summary, Chapter 4 has examined the profile of cytochrome P450 mRNA expression in 
a panel of breast cancer cell lines compared to that of a normal breast cell line.  One of the 
target genes in this study, CYP4Z1, is a novel isoform of the CYP4 family and has been 
associated with metastatic disease and poor prognosis of specific types of tumours 
(Downie et al. 2005).  Overexpression of CYP4Z1 has also been found in breast cancer 
(Rieger et al. 2004), though the mechanism of gene regulation and substrate-specificity are 
still unclear.  The presence of two bands at 159 bp and ~250 bp in the CYP4Z1 RT-PCR 
warrants furthers investigation and this will be carried out in Chapter 5. 
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Chapter 5 
Characterisation of CYP4Z1 mRNA in Breast Cancer Cells 
 
5.1 Introduction 
The previous two chapters of this study (Sections 3.3.3.4 and 4.3.6) detected CYP4Z1 
amplification products by RT-PCR.  Results with these primers showed a band of ~250 bp 
in addition to a band of the correct product size (159 bp).  A similar pattern of two bands 
was found in four of the eight cell lines (i.e. MCF10A, T47D, ZR-75-1 and MDA-MB-
468).  Purified DNA of both fragments was further investigated by restriction digestion and 
DNA sequencing.  It is important to note that the results of the restricted fragment sizes 
(Figure 3.21) and the BLAST analysis of DNA sequences did not distinguish between the 
fragment of 159 bp and ~250 bp.  Further elucidation of the sequence is required to 
identify the source of the additional band.  The reproducibility of the presence of this PCR 
product ruled out a non-specific product, and raises the possibility that alternate splicing of 
the gene is producing variations in the size of the mRNA. 
 
Alternative splicing is one of the regulatory mechanisms that contribute to variation in the 
incorporation of coding regions (exons) into messenger RNA, leading to the production of 
protein.  It is well-known that alternative splicing is of great importance to genetics 
because a splicing error can disrupt the open reading frame of mRNA, and this will 
generate different mature RNA encoding distinct protein products from a single gene.  
There are four common types of gene splicing event (i.e. exon skipping, intron retention, 
alternative 5’ site and alternative 3’ site; Figure 5.1) and these can occur in the genes after 
the transcriptional process (Ferreira et al. 2007).  In human cells, alternative splicing has 
been estimated in 40-60% of all genes, and more than 70% of alternative splicing generates 
significant functional diversity (Modrek and Lee 2002, Stamm et al. 2005).  
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Splicing errors in human genes appear to be associated with genetic polymorphisms which 
result in the alteration of signalling/enzymatic activities in several key genes involved in 
drug metabolism including cytochrome P450 enzymes (Stamm et al. 2005).  CYP4F3 plays 
an important role in the metabolism of leukotriene B4 and arachidonic acid.  Christmas and 
colleagues (Christmas et al. 2001) reported that alternative splicing events of CYP4F3 
influence substrate-specificity, and tissue-specific alternative splicing of pre-mRNA has 
also been demonstrated.  There are two isoforms of alternative splice variants of human 
CYP4F3.  CYP4F3A was predominantly expressed in neutrophils, bone marrow and 
peripheral blood leukocytes while CYP4F3B was preferentially expressed in liver and 
kidney.  With regard to catalytic activity, higher activities for arachidonic acid or 
leukotriene B4 were found in CYP4F3B than in CYP4F3A, indicating that alternative 
splice variants of CYP4F3 generate functional diversity of enzymes. 
 
Figure 5.1: Patterns of alternative splicing.  Constitutive and alternative exons are indicated by blue 
and grey boxes respectively and introns are shown by straight lines (Adapted from Ferreira et al. 
2007). 
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An alternative splicing of the CYP1A1 gene that results in deletion of 87 bp of exon 6 
(exon 6 del CYP1A1) was detected in human brain but not in liver.  This splice variant 
does not metabolise polycyclic aromatic hydrocarbon to genotoxic metabolites that causes 
formation of DNA adducts in the human brain, and therefore differs from wild-type 
CYP1A1.  These observations suggest that splice variants play an important role in the 
metabolism of procarcinogens (Kommaddi et al. 2007).  This effect may contribute to 
other CYP1A1 substrates including anticancer drugs.   
 
Evidence of a link between alternative splice variants of some cytochrome P450 genes and 
a variety of cancers has emerged.  Leung and co-workers detected overexpression of 
CYP1A1 protein and its splice variant (CYP1A1v) in ovarian cancer cells and found they 
can metabolise procarcinogens such as 17β-oestradiol and benzo(a)pyrene.  This suggests 
that the splice variant of CYP1A1 may be involved in both the initiation and progression of 
ovarian cancer (Leung et al. 2005).  An alternative splicing of the CYP27B1 gene has been 
shown to be associated with breast cancer cells (Cordes et al. 2007) and endometrial cancer 
cells (Becker et al. 2007).  These findings suggest that splice variants may be involved in 
the initiation and progression of specific types of tumours. 
 
In the CYP4Z1 gene, no information on its alternative splicing has previously been 
reported although Rieger and colleagues found a truncated version of CYP4Z1 a 
pseudogene CYP4Z2P with 96% identity to CYP4Z1. Currently, there are two studies that 
have demonstrated a specific amplification product of CYP4Z1 mRNA using qualitative 
RT-PCR.  Figure 5.2 highlights the structure of the CYP4Z1 gene and shows the positions 
of the primers used in this study and previous studies using a physical mapping of the 
CYP4Z1 genome (GenBank accession number: NC_000001; Human Genome Sequencing 
Consortium International 2004).  Thomas and co-workers (Thomas et al. 2006) employed 
specific primers against CYP4Z1 mRNA, designed to cross between exon 9 and exon 12  
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Figure 5.2: Schematic view of the structure of the CYP4Z1 gene showing the positions of the primers in this study and previous studies. 
Abbreviations: E; exon, I; intron 
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boundaries, whereas Savas and colleagues (Savas et al. 2005) used primers located 
crossing the exon 7 to exon 8 boundaries of the CYP4Z1 gene.  These two separate studies 
detected CYP4Z1 mRNA in the normal breast MCF10A cells (Thomas et al. 2006), human 
normal tissues (i.e. breast, liver and kidney) and the breast cancer cell lines (i.e. MCF7 and 
T47D) (Savas et al. 2005).  Both found a single band of the CYP4Z1 amplification 
product.   
 
By contrast, the present study designed the CYP4Z1 primer set F1&R1 (Figure 5.3), 
crossing from exon 5 to exon 6 boundaries and detected the presence of two bands (159 bp 
and ~250 bp).  These observations would suggest an alternative splicing event particularly 
intron retention in CYP4Z1.  Prior to elucidation of the sequence, the previous chapter 
(Section 4.3.6) confirmed the expression of CYP4Z1 mRNA in all the cDNA samples 
using the previously published CYP4Z1 primer (Thomas et al. 2006).  The primer set 
successfully demonstrates a single PCR product of CYP4Z1 mRNA in the test cells.  The 
presence of CYP4Z1 mRNA in the normal breast MCF10A cells is in agreement with the 
original study (Thomas et al. 2006) using this primer set.  The aims of this chapter were to 
identify the mRNA sequences (exon 5-6) and further elucidate the two bands at 159 bp and 
~250 bp. 
 
5.2 Materials and Methods 
5.2.1 Qualitative and nested RT-PCR of CYP4Z1 mRNA 
To further elucidate the sequence between exon 5 and exon 6 boundaries, the purified 
DNA of 159 bp and ~250 bp fragments (i.e. T47D, ZR-75-1 and MDA-MB-468), cDNA 
samples (i.e. MCF10A, T47D, ZR-75-1 and MDA-MB-468) and the first PCR products 
were used as template DNA for PCR reactions.  It is important to note that the MCF10A 
cells were excluded from the experiments which required the use of purified DNA  
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Figure 5.3: The sequence of exon 5-intron 5-exon 6 boundaries of the CYP4Z1 gene showing the position of the primer set F1&R1 (Table 2.6).  Exon sequences are shown 
in upper cases and intron sequences in lower case letters.  The sequences in exon 5 and exon 6 are indicated in yellow and green respectively. 
Abbreviations: F1; forward primer 1, R1; reverse primer 1 
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fragments as templates because CYP4Z1 mRNA in this cell line was expressed at a very 
low level and it was very difficult to purify a DNA sample.  Templates were subjected to 
the PCR protocols with four different pairs of primers (Table 5.1).  The first protocol 
employed a set of primers F1&r2 that are located in the exon 5 (46 bp) and the intron-
retained (79 bp), and used the purified DNA (Figures 5.4 and 5.5) and cDNA samples as 
template (Figure 5.7).  To amplify the intron 6-retained, the second PCR protocol was a 
nested PCR, using a pair of primers Ff2&r2 covering the exon 5 (10 bp) and the intron-
retained (79 bp) and the first PCR product of the first protocol as template (Figure 5.6).  
The third protocol used primers F3&R3 that are located in the beginning of exon 5 (118 
bp) and the middle of exon 6 (123 bp), and employed the cDNA samples as template 
(Figure 5.8).  The final protocol was a nested PCR using primers F3&r2 that cover the 
beginning of exon 5 (118 bp) and the intron-retained (79 bp), and employing the first PCR 
product of the third PCR protocol as template DNA (Figure 5.9).  The specificity of the 
primer sequences used was confirmed by BLAST analysis.  The first PCR and nested PCR 
were performed under the conditions previously described (Tables 2.3, 2.4 and 2.8).   
 
5.2.2 Purified DNA and DNA sequencing 
PCR product was purified using the high pure PCR product purification kit, and the 
purified DNA samples were sent to the Rowett Research Institute for sequence analysis 
using automated dideoxy DNA sequencing (Section 2.10, Appendix D; Figure D.3).  The 
acceptable A260/A280 ratio of DNA extracted sample was between 1.8 and 2.1. 
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Table 5.1: Primer sequences for CYP4Z1 used to elucidate the sequence between exon 5 and exon 6. 
 
Protocol 
 
Name 
 
Primer 
 
Position 
 
Sequence (5’ to 3’) 
 
Length 
 
Tm (oC) 
 
Ta (oC) 
 
Product size (bp) 
 
1 
 
CYP4Z1 
(F1&r2) 
 
Forward (F1) 
Reverse (r2) 
 
Exon 5 
Intron 5 
 
TCATGAAGTGTGCCTTCAGC 
ctggaatagggaagatggaa 
20 
20 
 
64.1 
60.4 
 
55 
 
125 
2  
CYP4Z1 
(F/f2&r2) 
 
Forward (F/f2) 
Reverse (r2) 
 
Exon 5/Intron 5 
Intron 5 
 
AGTTGGACAGgtcagtgaca 
ctggaatagggaagatggaa 
20 
20 
 
60.8 
60.4 
 
55 
 
89 
 
3 
 
CYP4Z1 
(F3&R3) 
 
Forward (F3) 
Reverse (R3) 
 
Exon 5 
Exon 6 
 
GGGAGGAACACATTGCCCA 
GAAAAGATTTGGCCTTGAGAGC 
 
19 
22 
 
68.3 
64.9 
 
60 
 
241 
 
4 
 
CYP4Z1 
(F3&r2) 
 
 
Forward (F3) 
Reverse (r2) 
 
Exon 5 
Intron 5 
 
GGGAGGAACACATTGCCCA 
ctggaatagggaagatggaa 
 
 
19 
20 
 
68.3 
60.4 
 
55 
 
197 
Note: Exon sequences are shown in capital letters and intron sequences in lower case letters 
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5.3 Results 
5.3.1 Identification of CYP4Z1 splice variants in the cell lines 
Initial experiments were performed using the primer set CYP4Z1 F1&R1, and the results 
showed fragments of 159 bp and ~250 bp in the amplification product of CYP4Z1 RT-
PCR (Figures 3.20 and 4.13).  Restriction digestion and DNA sequencing confirmed both 
of these products as CYP4Z1.  Prediction of PCR products from whole genomic sequences 
(Figure 5.2) was a PCR product of 159 bp generated from an intron free mRNA (exon 5 
(46 bp)/exon 6 (113 bp)) and a product of ~250 bp obtained from a retained intron mRNA 
(exon 5 (46 bp)-intron 5 (79 bp)-exon 6 (113 bp)). 
 
The first PCR protocol (primer set CYP4Z1 F1&r2) was designed to investigate the exon 5 
and a retained intron using the purified 159 bp and ~250 bp DNA fragments.  First of all, 
purified 159 bp and ~250 bp DNA fragments from the T47D cells were amplified at 
different annealing temperatures (i.e. 55, 58 and 60oC) under the same PCR conditions.  
The purpose of this was to investigate the effect of annealing temperature on the specificity 
of primers.  After varied temperature annealing, a single product of retained intron (125 
bp) was detected in both purified fragments, and 55oC was selected as the optimum 
annealing temperature for CYP4Z1 F1&r2 amplification as DNA bands appeared sharp 
and clear (Figure 5.4).  This annealing temperaure would be employed for experiments 
with MDA-MB-468 and ZR-75-1 cells.  Similarly, the expected size of 125 bp was found 
in the purified DNA of 159 bp and ~250 bp from the MDA-MB-468 and ZR-75-1 cells 
(Figure 5.5).  However, the 125 bp product was expected only for the purified DNA of 
~250 bp to confirm intron retention event in the CYP4Z1 gene and not for the purified 
DNA of 159 bp.  These results were different to those expected (Figure 5.5A). 
 
To further identify the complete intron 5 sequences, the second PCR protocol was 
performed using the first PCR products (125 bp) obtained from T47D, MDA-MB-468 and 
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ZR-75-1 cells as templates, and the primer set CYP4Z1 F/f2&r2 used as nested primers.  A 
product size of 89 bp was expected for nested PCR obtained from the purified DNA of 
~250 bp fragment.  The results showed the presence of the expected product size (89 bp) 
but the product size of primary template (125 bp) was also detected in all PCR products.  It 
should be noted that a fragment of ~250 bp was detected in the purified 159 bp DNA 
fragment derived from the ZR-75-1 cells (Figure 5.6).  These observations suggest that 
there may have been too much template in the PCR reaction. 
 
(A) 
 
(B) 
 
 
 
 
 
 
Figure 5.4: The first protocol (a pair of primers F1&r2) used purified DNA as templates. (A) The 
position of the primers F1&r2 in the CYP4Z1 gene and the expected product size. (B) Illustration of the 
effect of annealing temperature on the primer F1&r2 RT-PCR product in the T47D cells .  Lane 1: 1000 
bp PCR markers, Lane 2: negative control, Lanes 3-5: purified DNA of 159 bp, Lanes 6-8: purified DNA 
of 250 bp, Lanes 3&6: 55oC, Lanes 4&7: 58oC, Lanes 5&8: 60oC   
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(B) 
 
 
 
 
 
 
 
Figure 5.5: The first protocol (a pair of primers F1&r2) used purified DNA as templates. (A) The 
position of the primers F1&r2 in the CYP4Z1 gene and the expected product size. (B) CYP4Z1 F1&r2 
RT-PCR in the ZR-75-1 and MDA-MB-468 cells .  Lane 1: 1000 bp PCR markers, Lane 2: negative 
control, Lanes 3-4: ZR-75-1, Lanes 5-6: MDA-MB-468, Lanes 3&5: purified DNA of 159 bp, Lanes 4&6: 
purified DNA of 250 bp. 
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(A) 
 
(B) 
 
 
 
 
 
In addition, the original cDNA samples isolated from the T47D, MDA-MB-468 and ZR-
75-1 cells were also used with the first PCR protocol (primer set CYP4Z1 F1&r2).  The 
expected product size of this protocol was 125 bp and this was detected, but there were 
also faint DNA fragments present at 159 bp, ~250 bp and ~450 bp in all cDNA used 
(Figure 5.7).  The occurrence of non-specific amplification products may be due to low 
specificity of primers, although the BLAST analysis showed that the primers were specific 
for the CYP4Z1 gene. 
 
 
Figure 5.6: The second protocol (a pair of primers F/f2&r2) used the first round PCR product of the first 
protocol as templates. (A) The position of the primers F/f2&r2 in the CYP4Z1 gene and the expected 
product size.  (B) Nested PCR CYP4Z1 F1&r2 RT-PCR using the primer set CYP4Z1 F/f2&r2.  Lane 1: 
1000 bp PCR markers, Lane 2: negative control, Lanes 3&6: MDA-MB-468, Lanes 4&7:T47D, Lanes 
5&8: ZR-75-1, Lanes 3-5: purified DNA of 159 bp, Lanes 6-8: purified DNA of 250 bp. 
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(A) 
 
(B) 
 
 
The third PCR protocol (a primer pair F3&R3) was designed to further identify the 
sequence between exon 5 and exon 6 boundaries which were at different positions to the 
original primers F1&R1.  This primer set was amplified with the cDNA isolated from 
MCF10A, T47D, MDA-MB-468 and ZR-75-1 cells.  The expected product sizes for intron 
free mRNA [exon 5 (118 bp)/exon 6 (123 bp)] and retained intron mRNA [exon 5 (118 
bp)-intron 5 (79 bp)-exon 6 (123 bp)] were 241 bp and 320 bp fragments.  However, the 
presence of 241 bp and 320 bp fragments was detected and an additional band of 520 bp 
band was also found in all cDNA samples (Figure 5.8).  It should be noted that a band of 
241 bp detected in the MCF10A cells was expressed at a very low level when compared to 
 
 
Figure 5.7: The first protocol (a pair of primers F1&r2) used cDNA samples as templates. (A) The 
position of the primers F1&r2 in the CYP4Z1 gene and the expected product size. (B) CYP4Z1 F1&r2 
RT-PCR.  Lane 1: 1000 bp PCR markers, Lane 2: negative control, Lane 3: T47D, Lane 4: ZR-75-1, Lane 
5: MDA-MB-468. 
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those of the T47D, MDA-MB-468 and ZR-75-1 cells.  Although the primer set failed to 
detect a single band of PCR product, it behaved in the same pattern as primer set F1&R1. 
 
(A) 
 
(B) 
 
 
 
 
To further elucidate the retained intron sequence, the fourth PCR protocol was performed 
using the primary PCR products obtained from the third protocol as templates and primers 
F3&r2.  The product size of 197 bp was expected for nested PCR but a band of 197 bp and 
the first PCR products used as templates (241 bp and 320 bp) were detected as well as a 
faint additional band of 520 bp (Figure 5.9). 
 
 
Figure 5.8: The third protocol (a pair of primers F3&R3) used cDNA samples as templates. (A) The 
position of the primers F3&R3 in the CYP4Z1 gene and the expected product size. (B) CYP4Z1 F3&R3 
RT-PCR.  Lane 1: 1000 bp PCR markers, Lane 2: negative control, Lane 3: MCF10A, Lane 4: MDA-MB-
468, Lane 5: T47D, Lane 6: ZR-75-1. 
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(A) 
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5.4 Discussion 
The investigation in this chapter provides the first evidence of alternative splicing pre-
mRNA by intron retention in the CYP4Z1 gene.  As mentioned in Section 5.1, alternative 
splicing events in cytochrome P450 enzymes, for example the CYP4F3 (Christmas et al. 
2001) and CYP1A1 (Kommaddi et al. 2007) genes, are associated with some aspects of 
enzymatic activity such as substrate-specificity, catalytic activity and functional protein 
diversity.  Tissue-specific alternative splice variants have also been shown.  In addition, 
 
 
Figure 5.9: The fourth protocol (a pair of primers F3&r2) used the first round PCR product of the third 
protocol as templates. (A) The position of the primers F3&r2 in the CYP4Z1 gene and the expected 
product size.  (B) Nested PCR CYP4Z1 F3&R3 RT-PCR using the primer set CYP4Z1 F3&r2.  Nested 
PCR CYP4Z1 F3&R3 RT-PCR using the primer set CYP4Z1 F3&r2 using different templates.  Lane 1: 
1000 bp PCR markers, Lane 2: negative control, Lane 3: MCF10A, Lane 4: MDA-MB-468, Lane 5: 
T47D, Lane 6: ZR-75-1. 
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alternative splicing events in cytochrome P450s such as CYP1A1 (Leung et al. 2005) and 
CYP27B1 (Becker et al. 2007, Cordes et al. 2007) have been demonstrated to play a key 
role in the carcinogenic process, suggesting that this could be a potential target for the 
development of cancer therapeutics.  Alternative splicing in the CYP4Z1 gene has not been 
previously documented.  The current study is the first to present the sequence between 
exon 5 and exon 6 boundaries and this does show potential alternative splicing intron 
retention in the normal breast MCF10A cells and the breast cancer T47D, MDA-MB-468 
and ZR-75-1 cells.   
 
The present study initially employed specific primers against CYP4Z1 mRNA designed to 
cross between the exon 5 and exon 6 boundaries that generated the fragments of 159 bp 
and ~250 bp in the amplification product of CYP4Z1 RT-PCR (Figures 3.20 and 4.13).  
These observations were required to further elucidate the sequence because restriction 
digestion and DNA sequencing confirmed that both of these products were indicated as 
Homo sapiens CYP4Z1 mRNA (GenBank accession number: NM_178134).  In addition, 
the result obtained from digestion of purified ~250 bp DNA fragment with RsaI i.e. 112 bp 
and 120 bp fragments (Figure 3.21B) was unexpected.  The recognition site for RsaI is 
GT//AC.  In the physical mapping of CYP4Z1 genome (Figure 5.3), G and g are located at 
the end of exon 5 and intron 5 respectively, and TAC is shown at the beginning of exon 6, 
which might explain the two restricted products [i.e. 126 bp (exon 5 (46 bp) + intron 5 (79 
bp) + exon 6 (1 bp)) + exon 6 (112 bp) = 238 bp fragment].  These findings suggested that 
the retained intron may be located at the junction of intron 5 and exon 6. 
 
In PCR reactions, the four different primer sets covering the exon 5 to exon 6 boundaries 
were used to further elucidate the sequences.  The primer sets F1&r2 (the first protocol) 
and F3&r2 (the fourth protocol) were designed to detect the sequence in exon 5 and intron 
5 whereas primer pairs F/f2&r2 (the second protocol) cover only the retained intron region.  
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The primers F3&R3 (the third protocol) are located in the beginning of exon 5 and the 
middle of exon 6. 
 
The primer set in the first protocol (F1&r2) was initially amplified with the purified DNA 
of 159 bp and ~250 bp fragments. A single band of 125 bp was detected in purified DNA 
of both fragments from the T47D, MDA-MB468 and ZR-75-1 cells (Figures 5.6 and 5.7).  
Originally, the 125 bp product was expected only for the purified fragment of ~250 bp as it 
could prove retained intron mRNA, but not in the purified fragment of 159 bp.  This may 
be due to unknown sequences in this splice variant, perhaps duplicated coding sequence in 
exon 5.  For clarification, further experiments were performed using the primer set in the 
second protocol (F/f2&r2) to detect the nucleotide sequences of intron 5.  The presence of 
the expected product size of 89 bp was detected as well as the first PCR product (125 bp) 
(Figure 5.6), suggesting that there may have been too much template DNA or non-
specificity of primers.  The pair of primers F1&r2 were also amplified with the original 
cDNA, but non-specific products were detected (Figure 5.7).  Varying annealing 
temperatures to confirm specificity of primers could be used to address this problem. 
 
The third PCR protocol with the primer set F3&R3 was use to amplify cDNA samples.   
Non-specific amplification of PCR products was detected (Figure 5.8) though nested PCR 
using the primer set F3&r2 was performed to increase primer specificity and detect 
retained intron (Figure 5.7).  It is essential to note that the primers used failed to detect a 
single band of expected product size, but the presence of predicted retained intron products 
was found in all experiments (Figures 5.4-5.9).   
 
Currently, there are two available databases to search full genomes of the CYP4Z1 genes; 
the NCBI (http://www.ncbi.nlm.nih.gov/sites/entrez) and Genatlas (http://www.genatlas. 
org).  The NCBI database (NC_000001) which was used to identify the intron 5 sequences 
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in the CYP4Z1 gene during this research was markedly different in sequences from those 
of the Genatlas database (Figure 5.10).  At a glance in the Genatlas database, there are two 
regions of the CYP4Z1 gene which demonstrate duplicate repeat sequences, one between 
exon 5 and intron 5 (101 nucleotides, Figure 5.11A) and the other between intron 5 and 
intron 5/exon 6 (180 nucleotides, Figure 5.11B).  This may help to explain the non-specific 
products obtained in this chapter because the duplicated sequences also cover the primer 
sequence used in this research.  The forward primer F1 is found in exon 5 and intron 5 
whereas the reverse primer r2 is located in two positions in intron 5.  The forward primer 
F/f2 is found in the junction at exon 5/intron 5 and intron 5, and eight nucleotides of the 
reverse primer R1 were found in intron 5 (Figure 5.12).  Obviously, the sequences in exon 
5-intron 5-exon 6 in the CYP4Z1 gene appear to be complicated.  Further analysis 
including advanced molecular analysis of genomic/proteomic data is required to achieve a 
better understanding of the alternative splicing event in the CYP4Z1 gene. 
 
Introns with a high GC content are associated with lower excision rates, increased 
susceptibility to transcription factor binding and higher transcriptional activity (Goodall 
and Filipowicz 1991, Galante et al. 2004).  The GC content within intron 5 of the CYP4Z1 
genome (the NCBI database) is approximately 42% (33 sequences of GC in a total 79 
sequences).  Moreover, average lengths of retained and non-retained introns are ~115 bp 
and 3.3 kb respectively, and several studies have confirmed that retained introns are 
usually shorter than non-retained introns (Stamm et al. 2000, Galante et al. 2004, Chen et 
al. 2006).  Intron 5 of the CYP4Z1 gene has only 79 nucleotide sequences (Figure 5.3).  
Therefore, the specific region of this gene is more likely to have retained intron. 
 
Data presented in this chapter provides the first evidence of CYP4Z1 mRNA expression in 
normal breast and breast cancer cell lines, and also of a retained intron 5.  Future work 
could identify the sequences of intron 5 by DNA sequencing and elucidate the distribution 
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of intron retention events on CYP4Z1 mRNA by cloning PCR products of interest in the 
cell lines used.  The biological significance of this event warrants further investigation.  
This chapter provides information on basal mRNA expression of the CYP4Z1 gene.  The 
next chapter will provide information on the regulation of CYP4Z1 mRNA by 
investigating the potential nuclear receptors that regulate CYP4Z1 expression in induced 
cells and determining if the proposed alternative spliced forms are differentially expressed. 
 
 
 
 
 
Figure 5.10:  Sequence comparison of the CYP4Z1 gene from the NCBI and Genatlas database.  Exon 
sequences are shown in upper cases and intron sequences in lower case letters.  The sequences in exon 5 
and exon 6 are indicated in yellow and green respectively. 
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Figure 5.11: Highly repeated DNA sequences found in the CYP4Z1 gene using the Genatlas database.  (A) 
Similar sequences between the exon 5 and intron 5 (101 nucleotides) defined by black box. (B) Similar 
sequences between the intron 5 and intron5/ exon 6 (180 nucleotides) defined by pink box.  Exon sequences 
are shown in upper cases and intron sequences in lower case letters.  The sequences in exon 5 and exon 6 
are indicated in yellow and green respectively. 
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Figure 5.12: Repeated DNA sequences in the CYP4Z1 gene using the Genatlas database associated with 
primer sequences used.  Exon sequences are shown in upper cases and intron sequences in lower case letters.  
The sequences in exon 5 and exon 6 are indicated in yellow and green respectively. 
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Chapter 6 
Regulation of CYP4Z1 expression in Breast Cancer Cell Lines 
 
6.1 Introduction 
In Chapter 5, evidence was found of alternative pre-mRNA splicing of the CYP4Z1 gene 
in the normal breast MCF10A cells and the breast cancer T47D, MDA-MB-468 and ZR-
75-1 cells.  Although experiments have not been successful in fully characterising the 
alternative splicing by intron retention, the expected product size of the retained intron 5 
(79 bp) was present in all the test cells.  Usually, the molecular basis of eukaryotic 
transcription is controlled by a complex regulatory system as gene expression can be 
regulated at a variety of steps in the pathway from DNA to RNA and RNA to protein.  
Transcription is the process by which a monocistronic mRNA is transcribed from DNA 
and it is controlled by the level of RNA polymerase.  The resulting pre-mRNA is capped at 
the 5’ end and the 3’ end is polyadenylated.  Introns are removed by splicing before the 
mature mRNA is released from the nucleus to be translated by ribosomes in the cytoplasm 
into cellular protein (Figure 6.1) (Turner 2005).   
 
Most members of cytochrome P450 family 4 catalyse the ω-hydroxylation of fatty acids, 
steroid hormones (i.e progesterone, testosterone and growth hormones) and arachidonic 
acids (i.e. leukotrienes and prostanoid) and these enzymes appear to be implicated in 
vascular tone and blood pressure regulation (Hsu et al. 2007).  Currently, the cytochrome 
P450 subfamilies 4A and 4F are the most widely characterised and they are mainly 
expressed in human liver and kidney.  Information on expression, function and genetic 
variation of these genes has been well established in animal models (i.e. rat, mouse and 
rabbit) (Hsu et al. 2007).  The expression of CYP4A genes is induced by peroxisome 
proliferators (i.e. hypolipidemic drug fibrates and Wy14643 or pirinixic acid).  The 
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induction of CYP4A expression by peroxisome proliferators is mediated by the 
peroxisome proliferator activated receptor alpha (PPARα) (Waxman 1999, Okita and 
Okita 2001), which requires heterodimerisation with the retinoid X receptor (RXR) for 
transcriptional regulation of CYP4A (Waxman 1999, Okita and Okita 2001).  PPARα is 
believed to play an important role in the regulation of lipid homeostasis as well as lipid 
metabolism.  However, crosstalk between PPARα and other nuclear receptors such as 
retinoic acid receptor (RAR), vitamin D receptor (VDR), constitutive androstane receptor 
(CAR) and pregnane X receptor (PXR) may occur as they share a dimmeric partner (RXR) 
and substrates (i.e. steroid hormones) (Honkakoski and Negishi 2000). 
 
 
 
 
The CYP4Z1 gene is a novel cytochrome P450 enzyme that belongs to family 4 and the 
physiological functions of the CYP4Z1 gene are yet to be clearly characterised.  The tissue 
localisation of CYP4Z1 has been studied in an attempt to identify its functions.  Reiger and 
co-workers reported that CYP4Z1 mRNA and protein are preferentially expressed in breast 
tumour tissues but low levels are seen in other tumour types (i.e. uterus, prostate, lung and 
kidney) (Rieger et al. 2004).  No significant difference in CYP4Z1 mRNA was found in 
 
Figure 6.1: A schematic view of eukaryotic gene expression (Adapted from Turner 2005). 
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the breast tumour types and progression stages.  In addition, Downie and colleagues 
demonstrated that overexpression of CYP4Z1 is associated with a poor prognosis of 
primary ovarian cancer (Downie et al. 2005).  These two research groups suggest that the 
expression of CYP4Z1 is involved in the carcinogenic process of human breast and ovary. 
 
A study by Savas and co-workers demonstrated that CYP4Z1 mRNA in the breast cancer 
T47D cells is markedly induced by progesterone or the synthetic glucocorticoid 
dexamethasone.  The induction of CYP4Z1 mRNA by these compounds was suppressed 
by the antagonist of progesterone and glucocorticoid receptor RU486.  In addition, 
CYP4Z1 mRNA in the breast cancer progesterone receptor negative MCF7 cells is 
elevated by dexamethasone but not progesterone.  However, there was no significant 
alteration of CYP4Z1 mRNA by the PPARα agonist pirinixic acid in either the T47D or 
MCF7 cells (Savas et al. 2005).  These findings suggest that the CYP4Z1 gene has cell-
type specificity for the induction of mRNA expression. 
 
The physiological role of the splicing variant in the CYP4Z1 gene found in this study is 
unknown, but it is likely to be involved in the carcinogenic property of the test cell lines.  
Therefore, the regulation of gene transcription and substrate-specificity of this gene with 
the occurrence of the alternative splice variant in CYP4Z1 are of interest for further 
investigation.  The main aims of this chapter were to (a) profile mRNA expression of the 
candidate nuclear receptors (i.e. progesterone receptor; PGR, glucocorticoid receptor; GCR 
and peroxisome proliferator-activated receptor alpha; PPARα) for the CYP4Z1 gene, (b) 
determine the inducibility of the two forms of CYP4Z1 mRNA, and (c) ascertain whether 
the induction of CYP4Z1 mRNA is regulated at the transcriptional or translational level.  
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6.2 Materials and Methods 
6.2.1 Cell culture and CYP4Z1 induction in cultured cells 
6.2.1.1 Induction of CYP4Z1 mRNA by the nuclear receptor agonists 
All four CYP4Z1-expressing cell lines (i.e MCF10A, T47D, MDA-MB-468 and ZR-75-1) 
and two representative non-CYP4Z1-expressing cell lines (i.e. MCF7 and MDA-MB-231) 
were used to determine the inducibility of CYP4Z1 mRNA by agonists of the progesterone 
receptor (PGR), glucocorticoid receptor (GCR) and peroxisome proliferator-activated 
receptor alpha (PPARα).  The cells were seeded at 5x105 cells in a 25 cm2 flask, and were 
grown under appropriate conditions (Section 2.2.3).  Cells at ~60% confluence were 
treated with growth medium containing one of the following nuclear receptor agonists for 
21 hours; either 2 µM progesterone, 1 µM dexamethasone or 50 µM PPARα agonist 
(pirinixic acid) as previously described (Savas et al. 2005) with the exception that 
chemicals were dissolved in ethanol instead of dimethysulphoxide (DMSO).  This 
amendment was made because a previous study had demonstrated that expression of 
certain cytochrome P450s, particularly members of the CYP1, CYP2 and CYP3 families 
can be inhibited or induced by DMSO in in vitro studies (Busby et al. 1999).  The final 
concentration of ethanol in the culture medium was 0.1% (v/v).  Vehicle control cells were 
exposed to 0.1% (v/v) ethanol and treated in the same manner as those treated with nuclear 
receptor agonists.  Untreated cells were used as an additional control against which to 
compare the solvent controls. 
 
6.2.1.2 Evaluation of transcriptional and translational regulation of CYP4Z1  
The breast cancer T47D and ZR-75-1 cell lines were used to ascertain whether CYP4Z1 
mRNA induction is through transcriptional or translational regulation.  This is because 
CYP4Z1 mRNA in the T47D or ZR-75-1 cells was highly inducible by the nuclear 
receptor agonists according to results obtained from the initial experiment (Section 
6.2.1.1).  Cells at 60% confluence were pre-treated with either 10 µg/mL of actinomycin D 
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or 10 µg/mL of cycloheximide for 30 minutes in order to block the transcriptional or 
translational regulation respectively.  Spent medium containing actinomycin D or 
cycloheximide was removed, and the cells were washed twice with warm (37oC) serum-
free medium to minimise the residue of actinomycin D or cycloheximide.  Growth media 
containing the same concentrations of progesterone, dexamethasone or pirinixic acid 
(Section 6.2.1.1) were used to treat the cells for 21 hours.  Untreated and vehicle control 
cells were included in each experiment.  Three independent experiments were performed in 
triplicate on cultures of the T47D and ZR-75-1 cells. 
 
6.2.2 RNA extraction and cDNA synthesis 
Following treatment of the cells with vehicle control, the nuclear receptor agonists or co-
exposure to actinomycin D/cycloheximide with the nuclear receptor agonists (Section 
6.2.1), total RNA was isolated using the RNeasy Plus Mini kit.  The RNA concentration 
and purity were quantified by A260/A280 ratios.  Integrity of the isolated total RNA sample 
was determined by examination of the 28S and 18S rRNA bands on 1% (w/v) agarose gel 
electrophoresis (Section 2.3).  Synthesis of cDNA was performed under the conditions 
described in Tables 2.2 and 2.3. 
 
6.2.3 Qualitative RT-PCR analysis  
To determine the appropriate receptor for mRNA expression in the test cell lines, the eight 
cDNA samples from the investigation of the target genes in Chapter 4 were employed.  
These samples were subjected to routine amplification (Tables 2.3 and 2.4) with previous 
PGR, GCR and PPARα published primers (Table 2.7).  Primer specificity was confirmed 
by BLAST analysis.  The PCR products were separated by 1.5% (w/v) agarose gels 
containing ethidium bromide and visualised by ultra-violet light (Section 2.8).  To confirm 
expression of the target genes, the PCR products were digested with specific restriction 
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enzymes as described previously (Section 2.9).  Table 2.10 illustrates the restriction 
enzymes used and the expected size of the products. 
 
To examine the inducibility of the two forms of CYP4Z1 mRNA by the nuclear receptor 
agonists in the six cell lines, expression of β2-microglobulin and CYP4Z1 mRNA was 
assessed in each cell line by the qualitative RT-PCR method (Sections 3.3.2 and 3.3.3.4).  
The PCR products were visualised on 1.5% (w/v) agarose gels containing ethidium 
bromide. 
 
6.2.4 Semi-quantitative PCR amplification 
In order to determine whether CYP4Z1 mRNA induction is through transcriptional or 
translational regulation, the PCR products obtained from β2-microglobulin and CYP4Z1 
mRNA in the T47D and ZR-75-1 cells were visualised on 1.5% (w/v) agarose gels 
containing ethidium bromide.  To normalise amplified RNA products and PCR variations, 
the band intensities of CYP4Z1 mRNA were corrected with the band intensities of β2-
microglobulin mRNA as the internal standard (Section 4.2.3). 
 
6.2.5 Statistical analysis 
Results of CYP4Z1/β2-microglobulin mRNA relative expression for each sample from 
three independent experiments in the T47D and ZR-75-1 cells were presented as mean ± 
standard error of the mean (SEM).  Statistical analysis was performed with one-way 
analysis of variance (ANOVA), followed by Tukey’s Honesty Significant Difference 
(HSD) to compare the results from the various experimental groups with their 
corresponding controls (vehicle control or untreated cells) and the nuclear receptor agonist 
alone.  The differences were considered statistically significant when the p value was less 
than 0.05, 0.01 or 0.001.  Data were analysed with SPSS version 13 (SPSS Corporation, 
Chicago, Illinois, USA).
 Regulation of CYP4Z1 gene 
 215 
6.3 Results 
6.3.1 Profile of constitutive mRNA of the candidate nuclear receptors 
As stated in Section 6.2.3, the eight cDNA samples used were the same set as those 
investigated for the target genes in Chapter 4.  All RNA samples derived from the eight 
cell lines were shown to have high integrity and purity (Figure 4.1).  Reverse transcription 
efficiency was verified by the presence of β2-microglobulin and no major difference in 
expression was observed (Figure 4.2). 
 
6.3.1.1 Progesterone receptor (PGR) RT-PCR 
PGR mRNA was detected in four out of the seven breast cancer cell lines as the correct 
band at 533 bp but no product was found in the normal breast MCF10A cell line.  A higher 
level of expression was observed in the T47D cells than in the MCF7, ZR-75-1 and MDA-
MB-157 cells (Figure 6.2).  The expression of PGR mRNA was confirmed by restriction 
digestion with AluI which generated restricted product of the correct size (417 bp and 84 
bp, Figure 6.3).  
 
 
 
 
 
 
Figure 6.2: PGR RT-PCR.  Lane 1: 1000 bp PCR markers, Lane 2: negative control, Lane 3: MCF10A, 
Lane 4: MCF7, Lane 5: T47D, Lane 6: ZR-75-1, Lane 7: ZR-75-30, Lane 8: MDA-MB-231, Lane 9: 
MDA-MB-157, Lane 10: MDA-MB-468.   
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6.3.1.2 Glucocorticoid receptor (GCR) RT-PCR 
A band of 360 bp corresponding to the cDNA product size for GCR mRNA was found in 
three out of the seven breast cancer cell lines and the normal breast cell line.  A higher 
mRNA level was detected in the ZR-75-1 cells than in the MCF10A cells.  Very low levels 
of expression were observed in both the MDA-MB-157 and MDA-MB-468 cells.  
However, there is a faint band below 360 bp in the presence of GCR mRNA expression 
(Figure 6.4).  To confirm the GCR mRNA expression, the PCR product was digested with 
restriction enzyme AluI and the correct fragments were found at 172 bp and 148 bp (Figure 
6.5). 
 
 
 
 
 
 
 
Figure 6.4: GCR RT-PCR.  Lane 1: 1000 bp PCR markers, Lane 2: negative control, Lane 3: MCF10A, 
Lane 4: MCF7, Lane 5: T47D, Lane 6: ZR-75-1, Lane 7: ZR-75-30, Lane 8: MDA-MB-231, Lane 9: 
MDA-MB-157, Lane 10: MDA-MB-468.   
Figure 6.3: Restriction digestion of PGR RT-PCR using AluI.  Lane 1: 1000 bp PCR markers, Lane 2: 
undigested product, Lane 3: digested product. 
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6.3.1.3 Peroxisome proliferator-activated receptor alpha (PPARα) RT-PCR 
A band of 735 bp was observed for PPARα mRNA in all of the cell lines except MCF7.  
PPARα mRNA was expressed in the MCF10A, T47D, ZR-75-1 and MDA-MB-468 cells 
at higher levels than in the MDA-MB-231 and MDA-MB-157 cells.  Only a very weak 
level was detected in the ZR-75-30 cells (Figure 6.6).  PPARα mRNA was confirmed by 
restriction digest with RsaI which generated digested fragments of the correct size (518 bp 
and 188 bp) (Figure 6.7). 
 
 
 
 
 
 
Figure 6.5: Restriction digestion of GCR RT-PCR using AluI.  Lane 1: 1000 bp PCR markers, Lane 2: 
undigested product, Lane 3: digested product. 
Figure 6.6: PPARα RT-PCR.  Lane 1: 1000 bp PCR markers, Lane 2: negative control, Lane 3: 
MCF10A, Lane 4: MCF7, Lane 5: T47D, Lane 6: ZR-75-1, Lane 7: ZR-75-30, Lane 8: MDA-MB-231, 
Lane 9: MDA-MB-157, Lane 10: MDA-MB-468.   
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6.3.2 Induction of CYP4Z1 mRNA by the agonists of candidate nuclear receptors 
In Chapter 4, CYP4Z1 mRNA was expressed in three out of the seven breast cancer cells 
(i.e. T47D, MDA-MB-468 and ZR-75-1) and also in the normal breast MCF10A cells 
(Figure 4.13).  To determine which nuclear receptors were involved in regulating the 
expression of CYP4Z1, agonists against the PGR, GCR and PPARα were used.  The panel 
of all eight cell lines were used in this investigation and were exposed to the individual 
agonists over a period of 21 hours.  This time period was selected as it was successfully 
used in a previous study by Savas and colleagues (Savas et al. 2005) who investigated 
CYP4Z1 regulation in the T47D and MCF7 cells.  All cDNA samples were verified by the 
housekeeping β2-microglobulin RT-PCR (319 bp).  Little variation of β2-microglobulin 
expression was observed between untreated and treated cells in the MCF7 (Figures 6.8A), 
MDA-MB-231 (Figures 6.9A) and MCF10A cells (Figures 6.10A).  However, β2-
microglobulin mRNA in the treated cells in the MDA-MB-468 (Figure 6.11A, lane 6), 
T47D (Figure 6.12A, lane 4) and ZR-75-1 cells (Figure 6.13A, lane 5) was slightly weaker 
than the other lanes which was taken into account when interpreting the result. 
 
In the non CYP4Z1-expressing cell lines, there was no detectable cDNA product size 
corresponding to CYP4Z1 mRNA (159 bp or ~250 bp) either in the MCF7 (Figure 6.8B) 
or MDA-MB-231 cells following exposure to the respective agonists (Figure 6.9B).   
 
Figure 6.7: Restriction digestion of PPARα RT-PCR using RsaI.  Lane 1: 1000 bp PCR markers, Lane 2: 
undigested product, Lane 3: digested product. 
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In the CYP4Z1-expressing cell lines, the induction of CYP4Z1 mRNA in the normal breast 
MCF10A cell line was barely detectable (Figure 6.10B).  However, it is important to note 
that the presence of a ~250 bp fragment was only found in the cells treated with 
dexamethasone and a band of 159 bp was not detected.  In the MDA-MB-468 cells, it was 
found that CYP4Z1 mRNA was slightly altered by the three nuclear receptor agonists in 
comparison to the untreated and vehicle control cells (Figure 6.11B).  In addition, CYP4Z1 
mRNA in the T47D cells was induced only by dexamethasone (Figure 6.12B) whereas, 
CYP4Z1 mRNA in the ZR-75-1 cells was elevated by either dexamethasone or pirinixic 
acid (Figure 6.13B). 
 
 
 
 
 
 
 
(B) 
 
(A) 
Figure 6.8: Induction of CYP4Z1 in the MCF7 cells.  (A) β2-microglobulin RT-PCR.  (B) CYP4Z1 RT-PCR.  
Lane 1: 1000 bp PCR markers, Lane 2: negative control, Lane 3: untreated cells, Lane 4: 0.1% (v/v) 
ethanol, Lane 5: progesterone (2 µM), Lane 6: dexamethasone (1 µM), Lane 7: pirinixic acid (50 µM). 
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(B) 
 
(A) 
Figure 6.9: Induction of CYP4Z1 in the MDA-MB-231 cells.  (A) β2-microglobulin RT-PCR.  (B) CYP4Z1 
RT-PCR.  Lane 1: 1000 bp PCR markers, Lane 2: negative control, Lane 3: untreated cells, Lane 4: 0.1% 
(v/v) ethanol, Lane 5: progesterone (2 µM), Lane 6: dexamethasone (1 µM), Lane 7: pirinixic acid (50 
µM). 
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(B) 
 
(A) 
Figure 6.10: Induction of CYP4Z1 in the MCF10A cells.  (A) β2-microglobulin RT-PCR.  (B) CYP4Z1 RT-
PCR.  Lane 1: 1000 bp PCR markers, Lane 2: negative control, Lane 3: untreated cells, Lane 4: 0.1% (v/v) 
ethanol, Lane 5: progesterone (2 µM), Lane 6: dexamethasone (1 µM), Lane 7: pirinixic acid (50 µM). 
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(B) 
 
(A)
A) 
Figure 6.11: Induction of CYP4Z1 in the MDA-MB-468 cells.  (A) β2-microglobulin RT-PCR.  (B) CYP4Z1 
RT-PCR.  Lane 1: 1000 bp PCR markers, Lane 2: negative control, Lane 3: untreated cells, Lane 4: 0.1% 
(v/v) ethanol, Lane 5: progesterone (2 µM), Lane 6: dexamethasone (1 µM), Lane 7: pirinixic acid (50 
µM). 
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(B) 
 
(A) 
Figure 6.12: Induction of CYP4Z1 in theT47D cells.  (A) β2-microglobulin RT-PCR.  (B) CYP4Z1 RT-PCR.  
Lane 1: 1000 bp PCR markers, Lane 2: negative control, Lane 3: untreated cells, Lane 4: 0.1% (v/v) 
ethanol, Lane 5: progesterone (2 µM), Lane 6: dexamethasone (1 µM), Lane 7: pirinixic acid (50 µM). 
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(B) 
 
(A) 
Figure 6.13: Induction of CYP4Z1 in the ZR-75-1 cells.  (A) β2-microglobulin RT-PCR.  (B) CYP4Z1 RT-
PCR.  Lane 1: 1000 bp PCR markers, Lane 2: negative control, Lane 3: untreated cells, Lane 4: 0.1% (v/v) 
ethanol, Lane 5: progesterone (2 µM), Lane 6: dexamethasone (1 µM), Lane 7: pirinixic acid (50 µM). 
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6.3.3 Evaluation of transcriptional and translational regulation of CYP4Z1 
To investigate whether the nuclear receptor agonists are able to increase de novo CYP4Z1 
mRNA synthesis, expression of CYP4Z1 mRNA was investigated in the T47D and ZR-75-
1 cells and this was found to increase following exposure to the nuclear receptor agonists.  
These experiments were performed in the presence or absence of 10 µg/mL actinomycin D 
(an RNA synthesis inhibitor) for 30 minutes, which prevents the induction of CYP4Z1 
mRNA, followed by exposure to the agonists (i.e. PGR, GCR and PPARα) for 21 hours.  If 
CYP4Z1 mRNA expression was increased due to de novo RNA synthesis, a decrease in the 
level of CYP4Z1 mRNA following exposure to actinomycin D would be expected (Figure 
6.14). 
 
To examine whether de novo protein synthesis is required for the induction of CYP4Z1 
mRNA, the experiments were performed in the presence or absence of 10 µg/mL 
cycloheximide (a protein synthesis inhibitor) for 30 minutes, followed by treatment with 
the nuclear receptor agonists (i.e. PGR, GCR and PPARα) for 21 hours.  If CYP4Z1 
mRNA was regulated through de novo protein synthesis, an increase in the accumulation of 
CYP4Z1 mRNA after treatment with cycloheximide would be observed (Figure 6.14). 
 
The effect of the RNA and protein synthesis inhibitors on β2-microglobulin expression and 
CYP4Z1 mRNA induction by the nuclear receptor agonists in the ZR-75-1 and T47D cells 
is shown in Figures 6.15 and 6.16 respectively.  This data is representative of triplicate 
experiments.  The differences in β2-microglobulin mRNA expression observed in the 
samples were taken into account by normalising the CYP4Z1 mRNA levels in each 
treatment against the equivalent β2-microglobulin.  This data is presented in Figures 6.17, 
6.18 and 6.19.  There were no significant differences (p value > 0.05) in CYP4Z1 mRNA 
between the untreated cells and cells treated with vehicle control 0.1% (v/v) ethanol, 
suggesting that 0.1% (v/v) ethanol has no effect on CYP4Z1 mRNA expression.
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In the T47D cells, a significant increase of CYP4Z1 mRNA expression was observed in 
cells treated with either progesterone (p value < 0.05, Figure 6.17A) or dexamethasone 
alone (p value < 0.001, Figure 6.18A), when compared with the vehicle control data.  The 
ZR-75-1 cells showed a significant increase of CYP4Z1 mRNA when induced by either 
dexamethasone (p value < 0.01, Figure 6.18A) or pirinixic acid alone (p value < 0.001, 
Figure 6.19A). 
 
Co-treatment of the T47D cells with actinomycin D and the individual nuclear receptor 
agonists resulted in a significant decrease of CYP4Z1 mRNA for progesterone (p value < 
0.001, Figure 6.17A), dexamethasone (p value < 0.001 Figure 6.18A) and pirinixic acid (p 
value < 0.01, Figure 6.19A) when compared with cells induced by the nuclear receptor 
agonist alone.  A significant decrease in CYP4Z1 transcription was found when the ZR-75-
1 cells were treated with actinomycin D following either dexamethasone (p value < 0.001, 
Figure 6.18A) or pirinixic acid (p value < 0.01, Figure 6.19A). 
 
Pre-treatment of the T47D cells with cycloheximide followed by one of the individual 
nuclear receptor agonists resulted in a significant decrease of CYP4Z1 mRNA in the cells 
co-treated with progesterone (p value < 0.001, Figure 6.17A), dexamethasone (p value < 
0.001, Figure 6.18A) or pirinixic acid (p value < 0.05, Figure 6.19A).  A significant 
 Figure 6.14: A schematic view of the effect of actinomycin D and cycloheximide on mRNA expression. 
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increase of CYP4Z1 mRNA was observed in the ZR-75-1 cells when the cells were pre-
treated with cycloheximide following treatment with progesterone.  Cells co-treated with 
cycloheximide following treatment with either dexamethasone or pirinixic acid showed a 
significant decrease of CYP4Z1 mRNA. 
 
Considerable variation was observed with the expected CYP4Z1 product size of 159 bp 
during these experiments and this was also found with the alternative splice variant ~250 
bp fragment (CYP4Z1~250 bp).  However, the difference between the variations in the 
expression of two bands was observed.  A significant increase of CYP4Z1~250 bp mRNA 
was found in the T47D cells treated with dexamethasone alone (p value < 0.001, Figure 
6.18B) and in the ZR-75-1 cells induced by either dexamethasone (p value < 0.05, Figure 
6.18B) or pirinixic acid alone (p value < 0.001, Figure 6.19B) as compared with vehicle 
control data.   
 
There were no significant differences (p value > 0.05) in CYP4Z1~250 bp mRNA when 
T47D cells were co-treated with actinomycin D and progesterone or pirinixic acid.  
However, a significant decrease of the CYP4Z1~250 bp fragment was found when the 
cells were treated with actinomycin D followed by dexamethasone (p value < 0.001, Figure 
6.18B), compared with cells treated with dexamethasone alone.  Pre-treatment of the ZR-
75-1 cells with actinomycin followed by one of the individual nuclear receptor agonists 
resulted in a significant decrease of CYP4Z1~250 bp in the cells co-treated with either 
dexamethasone or pirinixic acid (p value < 0.001) was compared with cells treated with the 
nuclear receptor agonist alone (Figures 6.18B and 6.19B).   
 
A significant increase of CYP4Z1~250 bp was found in the ZR-75-1 cells treated with 
cycloheximide followed by progesterone (p value < 0.001, Figure 6.17B), compared to 
cells treated with vehicle control or progesterone alone.  Pre-treatment of the T47D cells 
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with cycloheximide followed by dexamethasone resulted in a significant decrease of 
CYP4Z1~250 bp (p value < 0.001, Figure 6.18B) compared to cells treated with 
dexamethasone alone. 
 
Tables 6.1 and 6.2 summarise the results for the T47D and ZR-75-1 cells demonstrating 
differences in expression of CYP4Z1 (159 bp and ~250 bp) mRNA against β2-
microglobulin expression following co-treatment with either the nuclear receptor agonists 
plus or minus actinomycin D or cycloheximide using Tukey’s test. 
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(B) 
 
 
(A) 
Figure 6.17: Effect of RNA and protein synthesis inhibitors on CYP4Z1 induction in the T47D cells.  (A) 
β2-microglobulin RT-PCR.  (B) CYP4Z1 RT-PCR.  Lane 1: 1000 bp PCR markers, Lane 2: negative 
control, Lane 3: untreated, Lane 4: VC, Lane 5: PG, Lane 6: ACTD+PG, Lane 7: CHX+PG, Lane 8: DEX, 
Lane 9: ACTD+DEX, Lane 10: CHX+DEX, Lane 11: PNX, Lane 12: ACTD+PNX, Lane 13: CHX+PNX. 
Abbreviations: VC; 0.1% (v/v) ethanol, PG; progesterone (2 µM), DEX; dexamethasone (1 µM), PNX; 
pirinixic acid (50 µM), ACTD; actinomycin D (10 µg/mL), CHX; cycloheximide (10 µg/mL). 
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(B) 
 
 
(A) 
Figure 6.18: Effect of RNA and protein synthesis inhibitors on CYP4Z1 induction in the ZR-75-1 cells.  (A) 
β2-microglobulin RT-PCR.  (B) CYP4Z1 RT-PCR.  Lane 1: 1000 bp PCR markers, Lane 2: negative 
control, Lane 3: untreated, Lane 4: VC, Lane 5: PG, Lane 6: ACTD+PG, Lane 7: CHX+PG, Lane 8: DEX, 
Lane 9: ACTD+DEX, Lane 10: CHX+DEX, Lane 11: PNX, Lane 12: ACTD+PNX, Lane 13: CHX+PNX. 
Abbreviations: VC; 0.1% (v/v) ethanol, PG; progesterone (2 µM), DEX; dexamethasone (1 µM), PNX; 
pirinixic acid (50 µM), ACTD; actinomycin D (10 µg/mL), CHX; cycloheximide (10 µg/mL). 
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(B) 
 
(A) 
Figure 6.19: Effect of RNA and protein synthesis inhibitors on progesterone-mediated increase in CYP4Z1 
mRNA in the T47D and ZR-75-1 cells.   (A) CYP4Z1 (159 bp).  (B) CYP4Z1 (250 bp).  Data represent the 
mean± SEM of three independent experiments for each treatment showing the relative intensity of CYP4Z1 
normalised against β2-microglobulin mRNA.  *p<0.05, **p<0.01, ***p<0.001 compared with VC.  
♦p<0.05, ♦♦p<0.01, ♦♦♦p<0.001 compared with PG. 
Abbreviations: VC; 0.1% (v/v) ethanol, PG; progesterone (2 µM), ACTD; actinomycin D (10 µg/mL), 
CHX; cycloheximide (10 µg/mL). 
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(B) 
 
(A) 
Figure 6.20: Effect of RNA and protein synthesis inhibitors on dexamethasone-mediated increase in 
CYP4Z1 mRNA in the T47D and ZR-75-1 cells.   (A) CYP4Z1 (159 bp).  (B) CYP4Z1 (250 bp).  Data 
represent the mean± SEM of three independent experiments for each treatment showing the relative 
intensity of CYP4Z1 normalised against β2-microglobulin mRNA.  *p<0.05, **p<0.01, ***p<0.001 
compared with VC.  ♦p<0.05, ♦♦p<0.01, ♦♦♦p<0.001 compared with DEX. 
Abbreviations: VC; 0.1% (v/v) ethanol, DEX; dexamethasone (1 µM), ACTD; actinomycin D (10 µg/mL), 
CHX; cycloheximide (10 µg/mL). 
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(B) 
 
(A) 
Figure 6.21: Effect of RNA and protein synthesis inhibitors on pirinixic acid-mediated increase in CYP4Z1 
mRNA in the T47D and ZR-75-1 cells.   (A) CYP4Z1 (159 bp).  (B) CYP4Z1 (250 bp).  Data represent the 
mean± SEM of three independent experiments for each treatment showing the relative intensity of CYP4Z1 
normalised against β2-microglobulin mRNA.  *p<0.05, **p<0.01, ***p<0.001 compared with VC.  
♦p<0.05, ♦♦p<0.01, ♦♦♦p<0.001 compared with PNX. 
Abbreviations: VC; 0.1% (v/v) ethanol, PNX; pirinixic acid (50 µM), ACTD; actinomycin D (10 µg/mL), 
CHX; cycloheximide (10 µg/mL). 
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Table 6.1: Summary of results for the T47D cells illustrating differences in expression of CYP4Z1 (159 bp and ~250 bp) mRNA/β2-microglobulin following co-treatment with either the 
nuclear receptor agonists plus or minus actinomycin D or cycloheximide using Tukey’s test.  
 
 Untreated VC PG ACTD+PG CHX+PG DEX ACTD+DEX CHX+DEX PNX ACTD+PNX CHX+PNX 
 159bp 250bp 159bp 250bp 159bp 250bp 159bp 250bp 159bp 250bp 159bp 250bp 159bp 250bp 159bp 250bp 159bp 250bp 159bp 250bp 159bp 250bp 
Untreated     NS NS NS NS ↑*** NS NS NS ↓*** ↓*** ↑** NS ↑** NS NS NS  ↑*** NS  ↑*** NS 
VC NS NS     ↓* NS ↑*** NS NS NS ↓*** ↓*** ↑* NS ↑** NS NS NS  ↑*** NS  ↑** NS 
PG NS NS ↑* NS     ↑*** NS ↑*** NS ↓*** ↓*** ↑*** NS ↑*** NS ↑** NS  ↑*** NS  ↑*** NS 
ACTD+PG ↓*** NS ↓*** NS ↓*** NS     ↓* NS ↓*** ↓*** NS NS NS NS ↓** NS   NS NS   NS NS 
CHX+PG NS NS NS NS ↓*** NS ↑* NS     ↓*** ↓*** NS NS NS NS NS NS  ↑* NS   NS NS 
DEX ↑*** ↑*** ↑*** ↑*** ↑*** ↑ *** ↑*** ↑*** ↑*** ↑***     ↑***  ↑*** ↑***  ↑*** ↑***  ↑***  ↑*** ↑ ***  ↑*** ↑*** 
ACTD+DEX ↓** NS ↓* NS ↓*** NS NS NS NS NS ↓*** ↓***     NS  NS NS NS   NS NS   NS NS 
CHX+DEX ↓** NS ↓** NS ↓*** NS NS NS NS NS ↓*** ↓*** NS NS     NS NS   NS NS   NS NS 
PNX NS NS NS NS ↓** NS ↑** NS NS NS ↓*** ↓*** NS NS NS NS      ↑** NS  ↑* NS 
ACTD+PNX ↓*** NS ↓*** NS ↓*** NS NS NS ↓* NS ↓*** ↓*** NS NS NS NS ↓** NS       NS NS 
CHX+PNX ↓*** NS ↓** NS ↓*** NS NS  NS NS NS ↓*** ↓*** NS NS NS NS ↓* NS   NS  NS     
Abbreviations: VC; 0.1% (v/v) ethanol, PG; progesterone (2 µM), DEX; dexamethasone (1 µM), PNX; pirinixic acid (50 µM), ACTD; actinomycin D (10 µg/mL), CHX; cycloheximide 
(10 µg/mL), ↓; decreasing, ↑; increasing, NS=not significant, *p<0.05, **p<0.01, ***p<0.001 
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Table 6.2: Summary of results for the ZR-75-1 cells illustrating differences in expression of CYP4Z1 (159 bp and ~250 bp) mRNA/β2-microglobulin following co-treatment with either the 
nuclear receptor agonists plus or minus actinomycin D or cycloheximide using Tukey’s test.  
 
  Untreated VC PG ACTD+PG CHX+PG DEX ACTD+DEX CHX+DEX PNX ACTD+PNX CHX+PNX 
  159bp 250bp 159bp 250bp 159bp 250bp 159bp 250bp 159bp 250bp 159bp 250bp 159bp 250bp 159bp 250bp 159bp 250bp 159bp 250bp 159bp 250bp 
Untreated     NS NS NS NS NS NS ↓** ↓*** ↓** ↓* NS NS NS NS ↓** ↓*** NS  NS ↓* ↓*** 
VC NS NS     NS NS NS NS ↓** ↓*** ↓** ↓* NS NS NS NS ↓*** ↓*** NS  NS ↓* ↓*** 
PG NS NS NS NS     NS NS ↓* ↓*** ↓** NS NS NS NS NS ↓** ↓*** NS  NS NS ↓*** 
ACTD+PG NS NS NS NS NS NS     ↓** ↓*** ↓** ↓** NS NS NS NS ↓** ↓*** NS  NS NS ↓*** 
CHX+PG ↑** ↑*** ↑** ↑*** ↑* ↑*** ↑** ↑***     NS ↓* ↑*** ↑*** NS ↑*** NS ↓*** ↑*** ↑*** NS ↓** 
DEX ↑** ↑* ↑** ↑* ↑** NS ↑** ** NS ↓*     ↑*** ↑** ↑* NS NS ↓*** ↑*** ↑** NS ↓*** 
ACTD+DEX NS NS NS NS NS  NS NS NS ↓*** ↓*** ↓*** ↓**     NS NS ↓*** ↓*** NS NS ↓** ↓*** 
CHX+DEX NS NS NS NS NS NS NS NS NS ↓*** ↓* NS NS  NS     ↓* ↓*** NS NS NS ↓*** 
PNX ↑** ↑*** ↑***  ↑***  ↑** ↑*** ↑** ↑*** NS ↑*** NS ↑*** ↑*** ↑*** ↑* ↑***      ↑*** ↑*** NS NS 
ACTD+PNX NS NS NS NS NS  NS NS NS ↓*** ↓*** ↓*** ↓** NS NS NS NS ↓*** ↓***     ↓** ↓*** 
CHX+PNX ↑* ↑*** ↑* ↑*** NS ↑*** NS ↑*** NS ↑** NS ↑*** ↑** ↑*** NS ↑*** NS  NS ↑**  ↑***     
Abbreviations: VC; 0.1% (v/v) ethanol, PG; progesterone (2 µM), DEX; dexamethasone (1 µM), PNX; pirinixic acid (50 µM), ACTD; actinomycin D (10 µg/mL), CHX; cycloheximide 
(10 µg/mL), ↓; decreasing, ↑; increasing, NS=not significant, *p<0.05, **p<0.01, ***p<0.001 
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6.4 Discussion 
The results presented in this chapter provide an in depth look at the mRNA expression 
profile of candidate nuclear receptors (i.e. PGR, GCR and PPARα) in the test cell lines.  
This should facilitate a better understanding of the association between expression of those 
receptors and CYP4Z1 mRNA.  The CYP4Z1 mRNA was not induced in response to the 
nuclear receptor agonists (i.e. PGR, GCR and PPARα) in the non CYP4Z1-expressing cell 
lines (i.e. MCF7 and MDA-MB-231).  In addition, CYP4Z1 mRNA in the CYP4Z1-
expressing cell lines, particularly the T47D and ZR-75-1 breast cancer cells, seems to be 
preferentially induced by different substrates and the pattern of expression differs between 
the cells lines. 
 
The expression of nuclear receptors PGR, GCR and PPARα in the cell lines was 
demonstrated and confirmed (Figures 6.2-6.7).  The relationship between the basal 
expression of CYP4Z1 and those receptors is presented in Table 6.3.  It is important to note 
that a positive correlation between CYP4Z1 mRNA and PPARα expression was found in 
the T47D, ZR-75-1 and MDA-MB-468 breast cancer cells.  However, an inverse 
relationship between CYP4Z1 expression and PPARα mRNA was observed only in the 
normal breast MCF10A cells.  PPARα is involved in the metabolism of endogenous (i.e. 
fatty acids) and xenobiotic compounds (i.e. fibrate drugs, long-chain polyunsaturated fatty 
acids) (Hihi et al. 2002) and is highly expressed in the liver (Motojima and Hirai 2006).   
In mouse mammary gland, PPARα expression has been shown to be associated with the 
regulation of steroid hormones during pregnancy and lactation, suggesting that PPARα 
may play a role in mammary gland physiology and pathophysiology.  The expression of 
PPARα mRNA and protein was found to occur in normal breast and breast tumours 
(Roberts-Thomson 2000). 
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Table 6.3: The basal mRNA of interest genes 
 
 
Gene Name 
 
 M
C
F1
0A
 
  M
C
F7
 
  T4
7D
 
  ZR
-
75
-
1 
  ZR
-
75
-
30
 
  M
D
A
M
B-
23
1 
  M
D
A
-
M
B-
15
7 
  M
D
A
-
M
B-
46
8 
 
 
CYP4Z1 
(Figure 4.13) 
Faint - ++ + - - - +++ 
 
PGR 
(Figure 6.2) 
- ++ +++ + - - ++ - 
 
GCR 
(Figure 6.4) 
Faint - - ++ - - Faint Faint 
 
PPARα 
(Figure 6.6) 
++/ 
+++ 
- ++ 
++/ 
+++ 
Faint Faint + +++ 
Note: +: indicates the level of intensity of the cDNA product by comparing in each gene. 
 
In human breast cancer cell lines, Suchanek and colleagues reported that a higher level of 
PPARα mRNA expression was found in the breast cancer ER-negative MDA-MB-231 
cells than in the breast cancer ER-positive MCF7 cells (Suchanek et al. 2002).  In addition, 
a previous study used quantitative real-time RT-PCR to demonstrate a relationship 
between ER mRNA and PPARα expression in the breast cancer ER-positive ZR-75-1, 
T47D, MCF7 and BT-483 cells.  The findings showed a significant (p value < 0.001) 
inverse relationship between these genes, a high level of ER expression was correlated 
with a low level of PPARα mRNA (Faddy et al. 2006).  In the current study, the presence 
of PPARα mRNA in MDA-MB-231, T47-D and ZR-75-1 is in agreement with the 
previous studies at a qualitative level (Suchanek et al. 2002, Faddy et al. 2006).  However, 
the current project did not detect the expression of PPARα mRNA in the MCF7 cells and 
this does not correlate with the previous two studies.  It should be noted that the lack of 
PPARα mRNA in the MCF7 cells was correlated with the absence of CYP4Z1expression 
in this cell line as shown in Figures 4.13 and 6.6 respectively.  This suggests that the 
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regulation of CYP4Z1 mRNA may have a link with the expression of PPARα mRNA.  
These results are the first to show a positive relationship between CYP4Z1 expression and 
PPARα mRNA. 
 
The highest level of PPARα mRNA was detected in the MDA-MB-468 cells and moderate 
to low levels of PPARα expression were found in the MCF10A, ZR-75-1 and T47D cells.  
However, the induction of CYP4Z1 mRNA by PPARα agonists was clearly shown only in 
the ZR-75-1 cells (Figure 6.13), not in the MDA-MB-468, T47D or MCF10A cells.  These 
results may suggest that the presence of PPARα was not directly associated with the 
induction of CYP4Z1 mRNA. 
 
PPARα needs to form a dimerisation with RXR to activate transcription and a 
PPARα/RXR heterodimer binds to PPAR response elements (PPREs) in the regulatory 
region of target genes.  Transcriptional activation or repression of target gene requires 
recruitment of co-activators or co-repressors respectively to the ligand binding domain of 
the gene.  RXR is a heterodimerisating partner for several members of the nuclear receptor 
super family such as PPARα, PXR, CAR, VDR and RAR (Rastinejad 2001).  It should be 
noted that these nuclear receptors play a crucial role in the regulation of several 
cytochrome P450 enzymes (i.e. PPARα for CYP4A, CAR for CYP2B6, PXR for CYP3A, 
VDR for CYP24A1 and RAR for CYP26).  Crosstalk between PPARα and other members 
of the nuclear receptor may occur at an intracellular level, as they share DNA response 
elements in the regulatory region or ligands (i.e. steroid hormones and some xenobiotic 
compounds) in target genes (Motojima and Hirai 2006).   
 
Evidence of crosstalk between the PPARα signalling pathway and nuclear hormone 
receptor signalling pathway has been reported.  Keller and colleagues (Keller et al. 1995) 
 Regulation of CYP4Z1 gene 
 239 
demonstrated inhibitory crosstalk between the ER signalling pathway and expression of 
PPARα.  Due to competition for oestrogen response element (ERE) binding between 
PPARα /RXR and oestrogen receptor, transcriptional activation of PPARα /RXR 
heterodimerisation is inhibited by ER in target genes.  These observations support the 
findings of Faddy and co-workers (Faddy et al. 2006) who demonstrated an inverse 
relationship between PPARα and ER expression in breast cancer cell lines.   
 
In addition, a previous study reported that PPARα mRNA was induced by glucocorticoids 
in rat hepatocyte cultures, suggesting that the transcriptional activation of PPARα was 
mediated through GCR (Lemberger et al. 1994).  In this research, there was a lack of GCR 
mRNA (Figure 6.4, lane 5) in the T47D cells but when the cells were induced by the GCR 
agonist dexamethasone, an increase in CYP4Z1 mRNA was observed (Figure 6.12).  A 
moderate level of PPARα mRNA expression was detected in the T47D cells (Figure 6.6, 
lane 5).  These findings may suggest that CYP4Z1 induction by the GCR agonist in the 
T47D cells is mediated through the PPARα signalling pathway.  However, information on 
protein-protein interaction of the PPARα signalling pathway with other hormone nuclear 
receptor signalling pathways would be necessary to identify the regulation of CYP4Z1 
expression in breast cancer cells. 
 
To determine whether the nuclear receptor agonists’ effect on CYP4Z1 mRNA is at the 
transcriptional or post-transcriptional level, CYP4Z1 mRNA was further investigated in 
the T47D and ZR-75-1 cells.  These two cell lines were selected as they showed increased 
CYP4Z1 mRNA expression following treatment with the nuclear receptor agonist for 21 
hours.  Pre-treatment of the T47D and ZR-75-1cells with the RNA synthesis inhibitor 
actinomycin D followed by one of the individual nuclear receptor agonists resulted in a 
significant decrease in CYP4Z1 mRNA levels, and inhibition of CYP4Z1 induction by 
 Regulation of CYP4Z1 gene 
 240 
either progesterone, dexamethasone or pirinixic acid (Figures 6.17, 6.18 and 6.19).  This 
indicates decreased transcription of CYP4Z1 and/or reduced stability. 
 
Moreover, the induction of CYP4Z1 mRNA by all three agonists in the ZR-75-1 cells was 
not prevented by the protein synthesis inhibitor cycloheximide, ruling out the possibility 
that protein synthesis is required for CYP4Z1 mRNA induction.  These findings suggest 
that the pre-existing expression of PGR, GCR or PPARα mediated the progesterone, 
dexamethasone or pirinixic acid respectively for CYP4Z1 mRNA induction.  Unlike the 
ZR-75-1 cells, CYP4Z1 mRNA induction by all three nuclear agonists in the T47D cells 
was significantly inhibited by cycloheximide (Figures 6.17, 6.18 and 6.19), suggesting that 
specific proteins are involved in the transcription or stability of CYP4Z1 mRNA by these 
nuclear receptor agonists. 
 
This research demonstrated that a significant increase of CYP4Z1 mRNA in T47D cells is 
induced by progesterone and dexamethasone but not pirinixic acid.  These observations are 
in agreement with those of Savas and co-workers who demonstrated CYP4Z1 mRNA 
induction in the T47D cells by either progesterone or dexamethasone, and suppression of 
CYP4Z1 induction by RU486 (the antagonist of PGR and GCR) (Savas et al. 2005).  
However, the present study is the first to show that progesterone or dexamethasone affect 
CYP4Z1 mRNA at a pre-translational level.  The CYP4Z1 mRNA induction profile has 
not been previously reported.  This research demonstrated that CYP4Z1 mRNA in the ZR-
75-1 cells is significantly elevated by either dexamethasone or pirinixic acid.  These two 
agonists affect CYP4Z1 mRNA transcription and/or stability, and protein synthesis is not 
required. 
 
CYP4Z1 mRNA in the ZR-75-1 cells was inducible by either dexamethasone or pirinixic 
acid, which is similar to CYP4A11 expression in the human hepatoma HepG2 cell line 
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(Savas et al. 2003).  A study by Savas and colleagues (Savas et al. 2005) also demonstrated 
that CYP4X1 mRNA was induced by pirinixic acid.  The CYP4Z1 gene is located in a 
cluster that contains CYP4A11 and CYP4X1 genes on chromosome 1p33 (Rieger et al. 
2004).  CYP4Z1 shares 54% and 52% sequence homology with CYP4X1 and CYP4A11 
respectively (Savas et al. 2005).  Comparative genomics of CYP4Z1 between human and 
rodent in a study by Nelson and colleagues (Nelson et al. 2004) has indicated that there are 
no orthologs expressed in mouse or rat, and CYP4Z1 may be human or primate specific.  
This could suggest overlapping substrate specificity among these genes, and CYP4Z1 
could be responsive to peroxisome proliferator chemicals including the PPARα mediated 
pathways.  PPARα is activated by a variety of fatty acids and previous studies 
demonstrated that high-fat diets are associated with an increase in breast cancer incidence 
(Lu et al. 1995).   
 
In the T47D and ZR-75-1 cells, considerable variation was observed with the expected 
product size of 159 bp as well as with the alternative splice variant (~250 bp) (Figures 6.15 
and 6.16), and there were differences in the induction profile with some treatments.  
However, this research has demonstrated that higher levels of CYP4Z1 mRNA induction 
were observed with the fragment of 159 bp than with the fragment of ~250 bp, particularly 
in the T47D cells (Figures 6.17, 6.18 and 6.19).  As shown in Figure 6.1, removal of 
introns from pre-mRNAs is an essential process in eukaryotic gene expression.  Alternative 
splicing of pre-mRNA generates the production of multiple mature mRNAs obtained from 
a single gene encoding different protein.  Alternative pre-mRNA splicing and its regulation 
has an important role in human diseases including cancer and this observation is being 
exploited to identify novel targets for cancer therapeutics and diagnostic markers (Ben-
Dov et al. 2008).  Alternative splicing events can cause down regulation of a gene by 
producing a pre-mature stop codon in the mRNA, promoting the degradation of mRNA 
(Fedor 2008).  
 Regulation of CYP4Z1 gene 
 242 
In conclusion, this chapter provides evidence of potential nuclear receptors regulating the 
CYP4Z1 gene, and the inducibility of CYP4Z1 in non CYP4Z1-expressing and CYP4Z1 
expressing cell lines.  Differential regulation of the PCR products in different cell lines and 
in response to different nuclear receptor agonists suggests alternative splicing may be 
under specific controls.  Further investigation into protein expression in these cell lines, 
both the wild-type and alternative splice variant, is warranted as this may provide a novel 
target for cancer therapy. 
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Chapter 7 
General Discussion 
 
7.1 Introduction 
The work presented in this thesis represents the first large scale study to characterise 
cytochrome P450 mRNA and cytochrome P450-regulatory nuclear receptor mRNA 
expression in a wide range of human breast cancer cell lines and compare this profile with 
a normal breast cell line.  The relationship between cytochrome P450 profile and specific 
tumour characteristics (i.e. oestrogen receptor status, invasive phenotype and ethnicity) 
was investigated in Chapter 4.  Of particular interest in the profile obtained was the 
CYP4Z1 gene as findings from the validation (Chapter 3) and its expression in a panel of 
the cell lines (Chapter 4) raised the possibility of alternative splicing.  The results in 
Chapter 5 demonstrates intron retention at the boundary of exon 5 and exon 6 in the 
CYP4Z1 gene using specific primer sets within the regions of both intron and exon.  In 
addition, this study has established in vitro models for the study of regulatory mechanisms 
of the CYP4Z1 gene using the T47D and ZR-75-1 cells to determine whether the CYP4Z1 
gene is regulated at a transcriptional or translational level.  Alteration of the CYP4Z1 
expression pattern after induction and combination treatment with RNA or protein 
synthesis inhibitor was also determined with regard to the presence of intron retention 
(Chapter 6). 
 
7.2 Profile of cytochrome P450 mRNA in breast cancer cell lines 
As mentioned previously, the results in Chapter 4 provide detailed information on 
differential expression of cytochrome P450s in human breast tumour cultured cells of 
different tumour origins.  Results showed that mRNA from six cytochrome P450s, 
CYP1B1, CYP2D6, CYP2J2, CYP2R1, CYP2U1 and CYP4X1, was found in all normal 
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breast and breast cancer cell lines.  However, the CYP2J2 and CYP2U1 mRNA expression 
profiles are probably the most exciting as lower levels of mRNA expression were observed 
in the normal breast cells than in almost all of the breast cancer cells.  If their protein 
expression shows the same trend as their mRNA expression, this may suggest that CYP2J2 
and CYP2U1 exhibit tumour-specific expression in breast cancer cells and they can be 
used as prognostic biomarkers.  This research also suggests that CYP2J2 and CYP2U1 
may represent new targets for the development of cancer therapeutics.  To date, the 
physiological role of CYP2J2 and CYP2U1 in anticancer drug metabolism remains 
unknown. 
 
Although no difference in cytochrome P450 mRNA expression was observed between the 
different ethnic groups used in this study.  Some trends were suggested in particular a 
potential inverse relationship of cytochrome P450 mRNA (i.e. CYP2A6, CYP2C8, 
CYP2C18, CYP2F1 and CYP4Z1) between ER status and ethnic groups (i.e. ER-positive 
Caucasian and ER-negative Afro-Caribbean) was highlighted.   In addition, CYP2A6 and 
CYP2C8 mRNA were found to be primarily expressed in the non-invasive Caucasian and 
invasive Afro-Caribbean breast cancer cells in these preliminary studies.   
 
CYP2A6 and CYP2C8 are involved in the inactivation of anticancer drugs letrozole and 
paclitaxel respectively.  The potent aromatase inhibitor letrozole is used as adjuvant 
hormonal therapy for postmenopausal women with ER-positive tumours (Goldhirsch et al. 
2006).  Paclitaxel is widely used as adjuvant chemotherapy in first-line treatment in 
women with ER-negative tumours (Goldhirsch et al. 2007).  In the current investigation, 
CYP2A6 mRNA was not detected in the ER-positive Afro-Caribbean breast cancer cells 
and no CYP2C8 mRNA was found in the ER-negative Caucasian breast cancer cells.  This 
variability in letrozole and paclitaxel metabolism between different ethnic groups may help 
to explain unpredictability of clinical outcome.  This research suggests potential 
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similarities in the ER-positive Caucasian and ER-negative Afro-Caribbean breast cancer 
cell lines which warrants further investigation.  
 
It is known that the hepatic CYP2B6 enzyme plays an important role in the conversion of 
anticancer prodrug cyclophosphamide to its active form (phosphramide mustard and 
acrolein) which is then delivered to tumour cells via blood circulation (Stoff-Khalili et al. 
2006).  Cyclophosphamide is one of the drugs in the TAC regimen which is commonly 
used for women with metastatic breast cancer who have ER-negative tumours (Ahluwalia 
et al. 2005).  To minimise toxic effects to normal cells, MetXia which encodes human 
CYP2B6 activating cyclophosphamide in tumours, is injected directly into the malignant 
cells prior to treatment with cyclophosphamide (Braybrooke et al. 2005).  In the present 
study, it was surprising that CYP2B6 mRNA was detected in the ER-positive Caucasian/ 
Afro-Caribbean and the ER-negative Afro-Caribbean breast cancer cells but not in the 
invasive ER-negative Caucasian MDA-MB-231 breast cancer cell line.  Future studies 
should investigate CYP2B6 protein expression in breast cancer cell lines presenting 
CYP2B6 mRNA. This preliminary study highlights the possibility that if the expression of 
protein correlates well with mRNA expression, a clinician in future may have to adjust the 
dosage of cyclophophamide/MetXia. 
 
7.3 Characterisation of CYP4Z1 
Results in Chapter 5 indicate the possibility of intron retention between exon 5 and exon 6 
in the CYP4Z1 gene.  A similar pattern of expression of CYP4Z1 (i.e. 159 bp and ~250 bp) 
was found in all four cell lines.  As described previously, the purified DNA of these 
fragments was analysed by restriction digest and DNA sequencing to confirm that the 
additional band was not a PCR artefact.   
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Alternative splicing is associated with alterations of transcriptional regulation for a certain 
gene.  Alternative splice variants of genes can be found in a specific type of tissue and may 
play a crucial role in transcriptional regulation of certain proteins.  Variability in drug 
metabolising enzymes including cytochrome P450s in a specific tissue has major clinical 
consequences, and has been associated with adverse drug side effects and susceptibility to 
cancer (Stamm et al. 2005).  A study by Christmas and colleagues (Christmas et al. 2001) 
demonstrated intron and exon splice junctions in the CYP4F3 gene in the liver and 
neutrophils.  These findings indicate tissue-specific splicing expression (Christmas et al. 
1999), and an alteration in the regulation of CYP4F3, affecting its substrate specificity.  
This may also occur in other members of the cytochrome P450 family 4, including the 
CYP4Z1 gene, given that they have at least 40% amino acid sequence homology and 
overlapping properties (Nebert et al. 1989). 
 
The current investigation demonstrated the presence of CYP4Z1 mRNA in the ER-positive 
Caucasian ZR-75-1 and the ER-negative Afro-Caribbean MDA-MB-468 breast cancer 
cells and those are novel observations.  Particularly as CYP4Z1 mRNA expression appears 
to be specific to the non-invasive phenotype in both ethnic groups.  These preliminary 
findings may also suggest a relationship between CYP4Z1 and ethnic differences with 
regard to ER status and stage of breast cancer.   
 
7.4 Regulation of CYP4Z1 
As mentioned in Chapter 6, this project is the first study to establish in vitro cell models for 
study of the regulatory mechanisms of CYP4Z1.  Breast cancer T47D and ZR-75-1 cell 
lines were used to evaluate whether CYP4Z1 mRNA induction is regulated at 
transcriptional or translational level, because CYP4Z1 mRNA in these cells was highly 
inducible by the nuclear receptor agonists according to results from induction experiments.  
In T47D, a significant increase of CYP4Z1 mRNA was observed in either the cells induced 
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by progesterone (p value < 0.05) or dexamethasone alone (p value < 0.001).  ZR-75-1 
showed a significant increase of CYP4Z1 expression in the cells treated with either 
dexamethasone (p value < 0.01) or pirinixic acid (p value < 0.001).  These findings suggest 
that there are different receptor mechanism involved in CYP4Z1 mRNA induction in T47D 
and ZR-75-1.   
 
In conjunction, pre-treatment of these two cell lines with the RNA synthesis inhibitor 
actinomycin D followed by the nuclear receptor agonists resulted in a significant decrease 
in (p value < 0.05) CYP4Z1 mRNA levels and inhibited CYP4Z1 induction by either 
progesterone, dexamethasone or pirinixic acid, indicating that these nuclear receptor 
agonists have effects on CYP4Z1 mRNA stability.  In contrast, the protein synthesis 
inhibitor cycloheximide did not inhibit CYP4Z1 mRNA induction by these agonists in the 
ZR-75-1 cells so protein synthesis is not involved.  These results suggest that CYP4Z1 
mRNA induction in T47D and ZR-75-1 is mediated through differential cell type specific 
regulatory mechanisms.  The detection of CYP4Z1 induction in the T47D cells is in 
agreement with a study by Savas and colleagues (Savas et al. 2005).  The results in the ZR-
75-1 cells are a novel observation, suggesting that the ZR-75-1 cells are suitable to use as a 
model to investigate the regulation of CYP4Z1.   
 
In terms of alternative splicing in CYP4Z1, comparative analysis of CYP4Z1 mRNA 
between the fragments of 159 bp and ~250 bp was performed to clarify whether this event 
changes the regulation of the gene or not.  A difference in the induction patterns was 
observed between two bands.  These observations suggest that the alternative splice variant 
of CYP4Z1 may have a different regulation mechanism.  It is essential to further 
investigate CYP4Z1 protein expression in these cells to clarify the mechanisms involved. 
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7.5 Conclusions 
The main points emerging from the current study are:  
(a) The relationships between cytochrome P450 mRNA expression profile and specific 
tumour characteristics are observed in the current study: 
 CYP2B6 which plays a crucial role in the activation of cyclophosphamide was not 
detected in the invasive ER-negative Caucasian breast cancer cells. 
 Some of the findings in this study are of a preliminary nature and warrant further 
investigation particularly as to whether the individual cytochrome P450 protein is 
expressed.  But also as to whether the trends observed in this thesis are confirmed 
in clinical patient samples (at both mRNA and protein level). The trends in 
cytochrome P450 expression suggested in this thesis are detailed as follows:   
• An inverse relationship of CYP2A6, CYP2C8, CYP2C18, CYP2F1 and CYP4Z1 
mRNA between ethnicity and ER status (ER-positive Caucasian and ER-negative 
Afro-Caribbean breast cancer cell lines). 
• An inverse relationship of CYP2A6 and CYP2C8 mRNA between ethnicity and 
invasive phenotype (Caucasian non-invasive and Afro-Caribbean invasive breast 
cancer cell lines). 
• CYP4Z1 and CYP2F1 mRNA were specific for non-invasive phenotype. 
(b) Two distinct bands obtained from the CYP4Z1 PCR product were elucidated by 
specific primer sets, and this project does suggest potential intron retention at the 
boundary of exon 5 and exon 6 in the CYP4Z1 gene. 
(c) Two out of the four CYP4Z1-expressing cell lines, T47D and ZR-75-1, seem to be 
preferentially induced by different substrates and the pattern of expression differs 
between the cells lines: 
 CYP4Z1 mRNA in T47D was induced only by the PGR or GCR agonist whereas 
CYP4Z1 mRNA in ZR-75-1 was elevated by either the GCR or PPARα agonist. 
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(d) CYP4Z1 induction by progesterone, dexamethasone or pirinixic acid is inhibited by 
actinomycin D, suggesting that these agonists have effects on CYP4Z1 mRNA 
transcription or stability.  However, CYP4Z1 induction in the ZR-75-1 cells is not 
prevented by cycloheximide, indicating that CYP4Z1 mRNA induction by these 
agonists is unlikely to involve protein synthesis.  These suggest that the inducibility of 
CYP4Z1 mRNA is mediated through differential cell type specific regulatory 
mechanisms and there is evidence for differential regulation of the splice variants 
(CYP4Z1~250 bp).  
 
7.6 Future work 
This investigation has provided comprehensive information on the differential cytochrome 
P450 mRNA expression among breast cancer cell lines with different characteristics, the 
exploration of alternative splicing in CYP4Z1, and clarification of the regulatory 
mechanism of the CYP4Z1 gene in the breast cancer cell lines.  These findings raise a 
number of questions though, and further study in these areas is likely to lead to a better 
understanding of the role of cytochrome P450 enzymes in breast cancer cell. 
 
The expression of CYP2A6, CYP2B6, CYP2C8, CYP2J2, CYP2F1, CYP2U1 and 
CYP4Z1 mRNA should be investigated by looking at their protein expression in test cell 
lines using western blotting or immunocytochemistry (ICC) followed by cytochrome P450 
expression in clinical samples.  It is known that mRNA expression does not always 
correlate with protein expression, for example the expression of CYP1B1 in normal tissues 
(i.e. breast, brain and testis) (Murray et al. 1997).  Therefore, a demonstration of protein 
expression in these cell lines is required.  If protein expression is detected in these cell 
lines, they could be established as a model system for the development of novel cancer 
therapeutics.  Alternatively, they could be of benefit in the design of more effective drug 
regimens for breast cancer patients.
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The data presented here provides a clearer understanding of the presence/absence of 
cytochrome P450 mRNA using qualitative and semi-quantitative RT-PCR.  The use of a 
quantitative PCR method would be useful in further investigations as it would increase the 
sensitivity of the method. 
 
Detection and evaluation of an intron retention event in the CYP4Z1 gene could be 
achieved through the establishment of a specific cell line stably expressing the human 
CYP4Z1 gene, identification of specific region of intron retention and investigation of 
protein expression.  This would provide a better understanding of the presence of abnormal 
transcripts and a functional gene of CYP4Z1.  
 
In order to investigate whether alternative splicing in CYP4Z1 is specific for breast cancer 
or other types of cancer, determination of this event in a variety of tumour cell lines would 
allow a clearer understanding of the involvement of CYP4Z1 expression in the 
carcinogenic process. 
 
The regulation of CYP4Z1 in the T47D and ZR-75-1 cells is mediated through different 
receptors.  The current study was carried out using a single set of concentrations of nuclear 
receptor agonists and a 21-hour of treatment as described previously by Savas and co-
workers (Savas et al. 2005).  Varying concentrations of agonists and incubation time would 
be a useful approach to elucidate the regulatory mechanisms of CYP4Z1.  The present 
study employed semi-quantitative RT-PCR method; it would be more accurate if 
quantitative real-time PCR was instead used to determine mRNA level.  Correlation 
between mRNA and protein expression would be required to explain the mechanism of 
regulation in breast cancer cells. 
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Transcriptional regulation of CYP4Z1 by nuclear receptors requires further examination to 
clarify the factors involved in the regulatory mechanisms and establish whether CYP4Z1 
induction is connected with the expression of PGR, GCR or PPARα.  Identification of a 
molecular mechanism of functional cross-talk between nuclear receptors would provide a 
theoretical basis for development of novel therapeutic strategies and design of novel 
compounds for treatment of breast cancer.
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Table A.1: List of chemicals and reagents. 
 
Supplier 
 
 
Chemical/reagent (Catalogue number) 
 
Fisher Scientific Ltd. 
(Leicestershire, UK) 
 
 Agarose (BPE1356-100) 
 Ethylenediaminetetraacetic acid (EDTA) (BPE120-500) 
 Tris base (T/P/630/53) 
Invitrogen Ltd. 
(Paisley, UK) 
 0.4% (w/v) trypan blue stain (15250-061) 
 DMEM/Ham’s F12 with GlutamaxTMI (31331-093) 
 Dulbecco’s Modified Eagle’s Medium (DMEM) with GlutamaxTMI 
(61965-026) 
 Epidermal growth factor (13247-051) 
 Foetal bovine serum (FBS) (10108-165) 
 Horse serum (26050-070) 
 Insulin, human recombinant Zinc (12585-014) 
 Leiboitz’s (L15) with GlutamaxTMI (31415-086) 
 Low melting point agarose gel (15517-014) 
 Mixtures of enicillin (10,000 U/mL) and streptomycin (10,000 
µg/mL) solution (15140-122) 
 RPMI 1640 with (61870-010) 
 Sodium pyruvate MEM (11360-039) 
 Trypsin-EDTA (0.05% w/v trypsin with 0.53 mM EDTA●4Na) 
(25300-054) 
Promega Ltd. 
(Southamton, UK) 
 PCR markers 50-1000 bp (G3161) 
Qiagen Ltd. 
(Crawley, UK) 
 RNeasy Plus Mini Column kit (74134) 
Quadratech Diagnosis Ltd. 
(Surrey, UK) 
 Cholera toxin (101B) 
Roche Diagnostics Ltd. 
(Lewes, UK) 
 Taq DNA polymerase (11418432001) 
 Deoxynucleotide triphosphates (dNTPs) (11581295001) 
 High pure PCR product purification kit (11732668001) 
Sigma Aldrich Ltd. 
(Poole, UK) 
 3 M sodium acetate buffer solution (S7899) 
 Actinomycin D (A9415) 
 Boric acid (B6768) 
 Cycloheximide (C1988) 
 Dexamethasone (D4902) 
 Diethyl pyrocarbonate (DEPC) (D5758) 
 Dimethylsulphoxide (DMSO) (D5879) 
 Ethanol (E7023) 
 Ethidium bromide (E1385) 
 Hydrocortisol solution (H6909) 
 Isopropanol (I9516) 
 Moloney Murine Leukemia virus (M-MLV) reverse transcriptase 
(M1302) 
 Phosphate buffered saline (PBS) tablets (P4417) 
 Pirinixic acid (C7081) 
 Restriction endonuclease: AluI (R6885), EcoRI (R6265), HaeIII 
(R56280), MspI (R4506), PstI (R7023), RsaI (R4756), SspI (R6759) 
and XhoI (R6379) 
 β-mercaptoethanol (M6250) 
 Progesterone (P8783) 
Sigma-Genosys Ltd. 
(Haverhill, UK) 
 All the specific oligonucleotide primers 
 Oligo P(dT)13 primers 
 
 
  
Appendices 
284 
Appendix B 
B.1 Preparation of RNase-free solution 
Ribonuclease (RNase) is a major concern in molecular biology experiments as it is a 
nuclease that catalyses the hydrolysis of RNA into smaller components, leading to a 
short lifespan for any RNA.  Diethyl pyrocarbonate (DEPC), a histidine-specific 
alkylating agent, is an effective nuclease inhibitor.  DEPC treated (RNase-free) solution 
is routinely used for handling RNA, effectively reducing the risk of RNA being 
degraded by environmental RNases.  Typically a 0.1% solution is used to inactive the 
environmental RNases by the covalent modifications of the histidine residues. 
 
All solutions used in this study for PCR or molecular biology techniques were pre-
treated 0.1% (v/v) DEPC.  A 0.1 mL aliquot of DEPC was added into 100 mL of the 
solution to be treated.  As DEPC is extremely viscous so the mixture was stirred for 2 
hours to bring the DEPC into solution prior to autoclaving for 15 minutes at 15 lb/in2 to 
inactivate traces of DEPC 
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Table C.1: Components of the digestion buffers. 
 
Buffer for restriction enzymes 
 
Component (1x) 
 
 
Buffer SA 
(For AluI) 
 
 33 mM Tris-acetate 
 66 mM Potassium acetate 
 10 mM Magnesium acetate 
 0.5 mM dithiothreitol (DTT) 
 pH 7.9 
 
 
Buffer SB 
(For BamHI) 
 
 10 mM Tris-HCl 
 100 mM NaCl 
 5 mM Magnesium chloride 
 1 mM 2-Mercaptoethanol 
 pH 8.0 
 
 
Buffer SH 
(For EcoRI, PstI and SspI) 
 
 50mM Tris-HCl 
 100 mM NaCl 
 10 mM MgCl2 
 1 mM dithioerythritol 
 pH 7.5 
 
 
Buffer SL 
(For RsaI and MspI) 
 
 10 mM Tris-HCl 
 10 mM MgCl2 
 1 mM dithioerythritol (DTE) 
 pH 7.5 
 
 
Buffer SM 
(For HaeIII) 
 
 10 mM Tris-HCl 
 50 mM NaCl 
 10 mM MgCl2 
 1 mM dithioerythritol (DTE) 
 pH 7.5 
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Figure D.1: Sequence alignment of the CYP2S1 PCR product against NM_030622 (published human 
CYP2S1 mRNA) [a 100% homology (183 nucleotides)]. 
Figure D.2: Sequence alignment of the CYP4Z1 PCR product (159 bp) against NM_178134 
(published human CYP4Z1 mRNA) [a 94% homology (118/125 nucleotides)]. 
Figure D.3: Sequence alignment of the CYP4Z1 PCR product (250 bp) against NM_178134 
(published human CYP4Z1 mRNA) [a 98% homology (77/78 nucleotides)]. 
Figure D.4: Sequence alignment of the ERα PCR product (208 bp) against NM_000125 (published 
human ERα  mRNA) [a 92% homology (69/75 nucleotides)]. 
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